Molecular genetic investigation of autosomal dominant hemifacial microsomia by Watt, Rebecca
Edith Cowan University 
Research Online 
Theses: Doctorates and Masters Theses 
1-1-2004 
Molecular genetic investigation of autosomal dominant 
hemifacial microsomia 
Rebecca Watt 
Edith Cowan University 
Follow this and additional works at: https://ro.ecu.edu.au/theses 
 Part of the Medical Sciences Commons 
Recommended Citation 
Watt, R. (2004). Molecular genetic investigation of autosomal dominant hemifacial microsomia. 
https://ro.ecu.edu.au/theses/787 
This Thesis is posted at Research Online. 
https://ro.ecu.edu.au/theses/787 
Edith Cowan University 
  
Copyright Warning 
  
 
  
You may print or download ONE copy of this document for the purpose 
of your own research or study. 
 
The University does not authorize you to copy, communicate or 
otherwise make available electronically to any other person any 
copyright material contained on this site. 
 
You are reminded of the following: 
 
 Copyright owners are entitled to take legal action against persons 
who infringe their copyright. 
 
 A reproduction of material that is protected by copyright may be a 
copyright infringement. Where the reproduction of such material is 
done without attribution of authorship, with false attribution of 
authorship or the authorship is treated in a derogatory manner, 
this may be a breach of the author’s moral rights contained in Part 
IX of the Copyright Act 1968 (Cth). 
 
 Courts have the power to impose a wide range of civil and criminal 
sanctions for infringement of copyright, infringement of moral 
rights and other offences under the Copyright Act 1968 (Cth). 
Higher penalties may apply, and higher damages may be awarded, 
for offences and infringements involving the conversion of material 
into digital or electronic form.
EDITH COW/U>J UNIVERSITY 
LIBRARY 
MOLECULAR GENETIC INVESTIGATION OF 
AUTOSOMAL DOMINANT HEMIFACIAL 
MICROSOMIA 
Rebecca Watt BSc -
Principal Supervisor - Dr Mel Ziman 
Associate Supervisor - Dr Richard Brightwell 
This thesis is presented for the degree of Masters of Science by Research 
at Edith Cowan University, 
2004 
Copyright Declaration 
This copy is the property of Edith Cowan University. However the literary rights of 
the author must also be respected. If any passage from this thesis is quoted or 
closely paraphrased in a paper or written work prepared by the user, the source of 
the passage must be acknowledged in the work. If the user desires to publish a 
paper or written work containing passages copied or closely paraphrased from this 
thesis, which passages would in total constitute and infringing copy for the purpose 
of the Copyright Act, he or she must first obtain the written permission of the 
author to do so. 
Abstract 
The overall purpose of this project was to explore the underlying 
pathogenesis of Hemifacial microsomia (HFM), investigate treatment and 
management options, identify likely candidate genes and screen candidate 
genes for mutation(s) causing the form of HFM segregating on chromosome 
11 in a West Australian family. 
Hemifacial microsomia is a congenital malformation arising from the 
derivatives of the first and second bronchial arches. It is both clinically 
and genetically heterogeneous, and can occur sporadically or segregate 
within families in an autosomal fashion. HFM is characterised by significant 
undergrowth to one side of the face and is a common birth defect with an 
estimated incidence of 1 in 1,000 to 1 in 5,600 births 
Most HFM cases are sporadic, but there are rare familial cases that 
exhibit autosomal dominant inheritance. These families present the best 
opportunity for locating and identifying HFM mutations. Two autosomal 
dominant forms of this disease have been located; one to a 10.7 million DNA 
base region on chromosome 14 and the other to an 18.8 million base region 
on chromosome 11. The identification and cooperation of a large West 
Australian family with HFM has allowed the phenotypic and genotypic study 
of the disorder presented in this thesis. 
Candidate genes were identified from the Draft Human Genome 
through genome mining and bioinformatics tools. This essentially involved 
cross-tabulating the genes and predicted genes in the two known hemifacial 
ii 
microsomia candidate regions and by comparison of gene: names, aliases, 
acronyms, functions, disease associations (particularly with axial 
asymmetry), timing of expression and trinucleotide repeat expansions 
( chromosome 11 hemifacial microsomia appears to show anticipation). The 
chromosome 11 linkage region was also investigated for homologies to the 
Completed Mouse Genome. 
This project, based on the anticipation described in the family under 
investigation, and the autosomal dominant nature of this disorder identified 
four candidate genes at the chromosome 11 linkage locus, three of which 
were successfully sequenced and eliminated as candidates in this linkage 
region. Furthermore the sequencing results obtained from this project, 
together with marker analysis reduced the overall region to be analysed by 
355,995 bases. 
This project has greatly contributed to the fundamental 
understanding of this disease and its phenotype and provides a basis for 
further studies aimed at better diagnosis, treatment and identification of 
causative genes and other factors. 
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Chapter 1: Introduction 
1 
1. 0 Introduction 
1.1 Thesis Overview 
The subject of this thesis is the review of current literature 
surrounding hemifacial microsomia (HFM) and determination of the 
genetic cause of one form of autosomal dominant hemifacial microsomia, 
segregating on chromosome 11 in a West Australian family. Fundamental 
aspects of this study include that: 
a) HFM is a congenital defect; 
b) at the commencement of this thesis a large West Australian family 
was known to segregate this disease on chromosome 11; and 
c) at the commencement of this thesis, a gene had not been identified 
for the form of HFM linked to chromosome 11. 
The research in this thesis involved searching for the gene causing 
HFM segregating in this West Australian family and, in doing so develop 
opportunities for further research into the developmental pathways 
involved in its manifestation. 
This thesis will: 
1) Introduce HFM and its correlation with the Human Genome Project 
(HGP); 
2) Review what was known about HFM preceding the commencement of 
this thesis; 
3) Describe the molecular techniques and bioinformatics used 
throughout this project; 
4) Present results of molecular investigations obtained during this 
project; 
5) Describe what is now known about HFM; 
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6) Discuss avenues for further study; and 
7) Discuss treatment avenues based on an increased understanding of 
the disease. 
1.2 Hemifacial microsomia (HFM) 
HFM involves malformations of first and second branchial arch 
derivatives (Cousley, Naora, Yokoyama, Kimura & Otani, 2002; Sze, 
Paladin, Lee & Cunningham, 2002; Kelberman et al., 2001; Silvestri, Natali 
& Iannetti, 1996; Rodgers, Eppley, Nelson & Sadove, 1991; Converse, 
Coccaro, Becker & Wood-Smith, 1973). During embryonic development of 
higher vertebrates, six transient (branchial) arches are formed, all of 
which gives rise to specialized structures in the head and neck. In HFM, 
any derivative of the first and second branchial arches may be affected. 
Consequently the clinical phenotype of those affected by HFM is highly 
variable (Appendix 1). 
The incidence of HFM is uncertain; it is estimated to affect 1 in 
5600 births (Cousley & Calvert, 1997; Cohen, 1991; Gori in, Cohin & Levin, 
1990; Grabb, 1965). Most cases are sporadic (Kearns, Padwa, Mulliken & 
Kaban, 2000), however the recurrence rate in first-degree relatives is 
estimated to be between 2-3% (Rollnick & Kaye, 1983). HFM is 
considered the second most common birth defect worldwide (Monahan et 
al., 2001; Gorlin et al., 1963). 
HFM is a complex deformation displaying a spectrum of anomalies 
that revolve around its universal feature of axial asymmetry. Despite 
often being unapparent in children due to excess tissue, this asymmetry 
is present throughout embryonic development. In addition to craniofacial 
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anomalies, there may be cardiac, vertebral (Gorlin et al., 1963) and 
central nervous system defects (On-line Mendelian Inheritance in Man-
164210 (OMIM-164210), 1998). HFM deformity affecting only one side 
of the body (unilateral deformity) includes: abnormality in external ear 
size and shape; rudimentary nodules and tags of ear tissue located 
anterior to the ear often containing a core cartilage (preauricular nodule 
or tag); and the closure (atresia) or absence (anotia) of the auditory 
canal. Nodule and tag differentiation is merely one of size, nodules being 
smaller than tags. Eye defects associated with HFM may involve small 
cysts containing skin or structures connected with skin, upon the eyeball 
(epibulbar dermoids). Furthermore, absence of the upper eyelid 
(coloboma) is frequent. Preauricular tags are also displayed in Goldenhar 
syndrome (OMIM-164210, 1998). Goldenhar syndrome is classified as the 
same disease as chromosome 14 HFM, hence both have the same 
Mendelian Inheritance in Man (MIM) number of 164210. 
Accurate assessment of (facial) anomalies for effective diagnosis 
and treatment of HFM is crucial (Causley & Calvert, 1997). Numerous 
classification systems have been devised to facilitate the classification 
of HFM, none of which have been universally adopted. The two most 
predominant classification systems include Orbital distortion, Mandibular 
hypoplasia, Ear anomaly, Nerve Involvement and Soft tissue deficiency 
(OMENS) and SAT (S = skeletal, A = auricle, T = soft tissue) (cited in 
Rodgers et al., 1991). 
The pathogenesis and genetic predisposition to HFM is currently 
the subject of extensive investigation. Little success has been achieved 
in identifying genetic, clinical or teratological information (Causley & 
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Wilson, 1992). HFM appears to be caused by a range of factors, including 
defective genes, teratogenic substances and/or vascular anomalies. 
Pathogenetic theories are numerous and range from neural crest cell 
involvement to a deficiency in the development of the bronchial arch and 
head mesoderm. Due to the complexity of its phenotype and inheritance 
pattern, a variety of genetic models have been described. The reduced 
penetrance of an autosomal dominant gene may explain some reported 
pedigrees (Gibson, Sillence & Taylor, 1996; Cousley & Wilson, 1992), 
although alternatively polygenetic inheritance has also been proposed to 
explain the genesis of HFM (Cousley & Wilson, 1992). More so, HFM has 
been associated with trisomy 18, trisomy 7 and 9 mosaicism and cri du 
chat syndrome (Horgan et al., 1995). To date, linkage regions have been 
identified on chromosomes 11 and 14, by Chandler (2001) and Kelberman 
et al., (2001) respectively. 
Currently, those affected with significant facial asymmetry are 
confronted with multiple surgical interventions (Kelberman et al., 2001). 
Effective management of HFM must take into account the variability in 
phenotype specific to the individual (Cousley & Calvert, 1997). Much 
debate surrounds the appropriate time at which to initiate surgical 
intervention. Effective treatment appears more successful through an 
interdisciplinary approach to affect a long-term coordinated treatment 
plan. 
The overall purpose of this project was to explore the underlying 
pathogenesis of HFM, investigate treatment and management options, 
identify likely candidate genes and the mutation(s) causing the form of 
HFM segregating on chromosome 1 1  in a West Australian family. 
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Outcomes of this project may significantly advance investigations into 
the molecular pathology of hemifacial microsomia providing those 
affected with chromosome 11 HFM some hope of better diagnosis, 
prognosis, prevention and treatment in the future. 
1 .3 The West Australian Chromosome 1 1  HFM Family 
11:1 11:t 
111:1 111:t 
11:3 11 :4 
Ul:3 
11:S 11:6 11:7 11:8 
0 11ale 
IH:4 IU:S 
Q lt1Nale • aftcted 
Figure 1 :  West Australian Pedigree. 
11:9 11:10 
Ul:6 IH:7 111:8 
Diagram of a pedigree family - affected individuals are depicted by darkened circles and squares. 
Of a family of 20 people, 9 are affected with the form of HFM that has been linked to 
chromosome 11. 
(Singer et al. 1994). 
Studies described in this thesis were conducted in a West 
Australian family afflicted with hemifacial microsomia. Singer, Haan, 
Slee and Goldblatt (1994) first described this pedigree in 1994 (Figure 1, 
p6). This family afflicted with HFM, is one of the few families large 
enough to provide useful genetic linkage analysis to allow identification 
of a linkage region on chromosome 11, as identified by Chandler (2001). 
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The symptoms of the nine affected ind ividuals in  this family are 
presented in Table 1 .1  (p7) . 
Table 1 . 1  Clinical pathologies for West Australian HFM family 
(modified from Chandler, 2001) 
Pedigree Preauricular Preauricular Epibulbar Hemifacial Macrostomia Other ear 
number nodules tags dermoid microsomia (increase in defects 
mouth width) 
1 1 :2  Right 
1 1 :4 Left Left 
1 1 : 7  Bilateral Bi lateral 
1 1 : 9  Right Mild (right) 
1 1 1 :3  Right Right Right Right 
1 1 1 :4 Bilateral Right Right 
1 1 1 :6 Unilateral Right 
1 1 1 :7  Unilateral Right Right 
1 1 1 :8  Bilateral 
There are nine affected individuals in this family, inheriting varying 
symptoms ranging from pre-auricu lar nodules and sl ight asymmetry of 
the jaw, to pre-auricular tags and hemifacial microsomia. The presence 
of epibulbar dermoids in two ind ividuals (II:4 and III:3)  indicates a 
possible overlap of chromosome 11  HFM and Goldenhar syndrome, simi lar 
to the chromosome 14 l i nked form of HFM (Singer et al. , 1994). 
In 1994 individual II:4 had an affected chi ld,  III: 3 who has an 
epibulbar dermoid and is more severely affected than his mother. 
General ly the severity and number of symptoms increase through 
succeeding generations, thereby indicating some degree of genetic 
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anticipation. This is most clearly evident in the 'hemifacial microsomia ' 
column of Table 1. 1 (p7), where the most pronounced feature of this 
disease, the under-development of one side of the face, becomes evident 
in generation III. 
Table 1 .2  Diagnostic criteria for HFM i n  WA family 
(Cousley & Calvert, 1997) 
I Ipsilateral (one side) mandibular and ear (external/middle) 
defects 
II Asymmetrical mandibular or ear (external/middle) defects in 
association with two or more indirectly associated anomalies or a 
positive family history of hemifacial microsomia 
1.4 Diagnostic criteria used to diagnose this family with HFM 
The fundamental diagnostic criteria presented in Table 1.2 (p8) 
were used to diagnose the West Australian family. Presently, there is no 
agreed minimum diagnostic criterion for HFM however (pre)auricular 
abnormalities such as nodules or tags are noted as possibly the mildest 
manifestation of the disease (Rollnick, 1983) and these were found 
present in the majority of affected family members. Moreover, 
characteristic unilateral facial anomalies are present in the third 
generation patients in this family indicating increased severity (Gorlin, 
1990). The term 'HFM' is generally used to describe disorders where the 
most predominant feature is asymmetric hypoplasia, or under­
development of one side of the face (Cousley & Calvert, 1997). 
Mandibular deformations are also present and were a prime criterion 
used to assess the family under investigation. 
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1.  5 Haplotypes 
The West Australian family under investigation comprises 20 
members, 8 unaffected and 9 who are diagnosed as HFM positive. Dr 
David Chandler (2001) showed linkage of this family's hemifacial 
microsomia disease gene to a region on chromosome 11, between the 
markers D1151883 and D115937. Haplotypes for chromosome 11 are 
available from D11S1765 to D11S876 for both affected and unaffected 
individuals within this family (Chandler, 2001) (Figure 2, pl0). From the 
haplotypes it is clear that a proposed linkage region for HFM exists 
between markers D1151883 to D115911, approximately 18.ScM in length 
(Figure 3, pll). 
1.  5 . 1  Refinement of the Chromosome 11 Linkage Region which 
predisposes the West Australian family to HFM 
The region on chromosome 11 which is linked to HFM in the WA 
family was refined by Chandler (2001) using 152 polymorphic markers, 
and initially, through exclusion mapping, a Lod score of 2.1  (at theta=0) in 
an affected individual only analysis was obtained. Genotyping of a further 
10 markers between D1151985 and D1151396 showed no recombinants 
between these two markers (Chandler, 2001). A possible recombination 
was suggested through the negative scores of markers D11S1765 (3'), 
D11S1883 (3'), D115937 (5') and D11S1362 (5'). Markers D115987, 
D11S4207 and D115916 derived the highest two-point Lod score of 2.11. 
This was the highest possible Lod score achievable with this family in an 
affected-only analysis (Figure 4, p12). 
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Figure 2 :  Haplotypes of the West Austral ian hemifacial 
microsomia family 
I 
' 
Between markers D11S1765 to D11S876. Red bars des ignate the putat ive 
affected haplotype (Adapted from Chand ler,  2001) 
10 
3 
3 
4 
1 
2 ' 
3 
1 
5 
5 
2 
4 
1 
3 
ll:10 
llt:8 
2 
3 
3 
4 
1 
I 
8 " 
3 
5 
2 
2 
3 
3 
D11S1985 
D11S1765 
D11S1883 l 
D11S987 
D11S -!178 
D11S -!136 
DllS -1139 HIM linbge Region 
D11S131 4 
J D11S 4t07 D11S916 D11S911 
D11S937 
D11S 4166 
D11S1362 
D11S1396 
D11S876 
I Marker ,ositions Chromosome 11 
Figure 3 :  Position of markers on Chromosome 1 1  
Excluding individual III: 1 ,  multi-point analysis of the haplotype 
region assuming 100% penetrance yielded Lod scores as high as 3 . 3  near 
markers D1154139 and D11513 14 (Figure 3 ,  p . 12)  (Chandler , 2001) .  With 
an assuming 80% penetrance these values did not diminish below 3 .0 
inferring a high probability of this region containing the disease gene. 
Genes in the region between markers D1151883 and D115911  were 
accordingly investigated for any functional link to the disease phenotype. 
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Figure 4 :  Multi -point Lod score graph 
The conserved HFM hap lotype reg ion for the West Austral ian fam i ly assum ing 70 , 
80, 90 and 100% penetrance levels .  Data from i nd ividual III : 1  was exc luded thereby 
provid i ng a max imum Lod score of 3 .30 at D1 154207 {Adapted from Chand ler,  
2001). 
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1.6 Identifying potential chromosome 11 HFM disease genes 
Dysmorphology can be caused by mutations in several genes. To 
identify candidate genes associated with HFM in this family, three major 
approaches were adopted. Firstly, each gene present in the chromosome 
1 1  HFM linkage area between D11S1883 and D11S911, was investigated 
for embryonic expression and association with axial (a)symmetry. 
Moreover, genes were assessed for trinucleotide repeat regions. 
Trinucleotide repeats are a form of mutation associated with expansion 
in copy number of a sequence of three nucleotides (Cummings, 2000). 
The expansion of trinucleotide repeats situated in or near a gene is 
strongly correlated with the severity of a disease (Jorde, Carey, 
Bamshad & White, 2000). If chromosome 11 HFM is indeed displaying 
anticipation, as suggested by the increasing severity in family members 
of subsequent generations, it may be associated with trinucleotide 
repeat expansions (Brook, McCurrach, Harle et al. , 1992). Screening for 
these repeats was an additional filtering process for candidate gene 
selection. 
Secondly, regions of the mouse genome homologous to the 
chromosome 11 HFM linkage area were identified and genes within these 
regions were investigated for the same criteria. Homologies were 
determined for three of the five chosen candidate genes; WNTJJ, GARP 
and CLNSJA demonstrated homology to regions on mouse chromosome 7. 
Thirdly, as HFM was additionally linked to chromosome 14, a 
comparison of the genes in the chromosome 11  and 14 HFM linkage 
regions was undertaken in regard to the same criteria. 
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In the congenital disorder HFM, as with many malformation 
syndromes, there are progressive symptoms that may be attributed to 
normal growth patterns of malformed tissue or continual incorrect 
expression of a disease gene (characteristics of a likely disease gene 
were investigated as described above). Advances in gene technology as a 
result of the Human Genome Project have resulted in availability of a 
variety of tools which can be implemented to identify candidate genes: 
these include advanced linkage analysis software, automated genotyping 
protocols, comprehensive genomic and cDNA databases with full public 
access (Table 3.1, p82). 
As the volume of online data and sophisticated web interfaces 
increased, the accessibility of powerful linkage and sequence analysis 
software also increased and hence added to the variety of tools available 
to be used in this project. 
1. 7 Candidate Genes (Genome mining) 
Identification of candidate genes in the chromosome 11 HFM 
linkage area was achieved using the aforementioned approaches: 
1. Each gene present in the chromosome 11 HFM linkage area was 
inspected for three criteria, a) embryonic expression, b) association with 
trinucleotide repeats, and c) association with axial (a)symmetry. 
Eleven genes out of a total of 131 genes were identified as potential 
candidates. In order of likelihood of possessing the mutation responsible 
for HFM, thereby fulfilling the criteria listed above, they are UVRAG, 
ARIX, WN T11, GARP, CLNSJA, PKRIR, CAPN5, LGAL S12, 
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DKFZP564M082 and OMP. Of these eleven genes, three were identified 
as prime candidates, UVRAG, WNTJJ and A RIX These particular three 
genes were selected as they were located within the linkage region, 
despite re-mapping of markers on numerous databases and complied with 
the selection criteria. Furthermore they demonstrated some association 
with craniofacial development and/or malformation. Chandler (2001) and 
Kaledijiva (2002) (personal communication) had previously selected the 
developmental gene WNTJJ as a candidate for HFM and sequenced this 
gene in both an unaffected and an affected individual from the West 
Australian chromosome 11 HFM pedigree. The affected and unaffected 
sequences did not vary significantly from each other or from the 
published sequence and as no mutations were found, this gene was 
eliminated as a candidate. GA RP and CLNSJA are genes lying within this 
HFM candidate region and according to Ensembl may be possible 
candidate genes and for this reason both will be tested along with 
UVRAG and ARIX (Specific information on each of the genes is 
described in chapter 2.11.2, p 64). 
2. Regions of the mouse genome homologous to the human 
chromosome 11 HFM linkage region were identified through web­
searches. Genes lying within homologous regions were inspected for the 
same three criteria; embryonic expression, association with trinucleotide 
repeats and association with axial asymmetry. Moreover genes 
associated with HFM in a number of animal models were investigated for 
homology with chromosome 11 genes. Significant insight into craniofacial 
development has been recently unveiled through generation of transgenic 
mouse mutants. These mice are engineered with mutations in genes 
responsible for craniofacial development and the resultant craniofacial 
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syndromes are assessed and compared by classical comparative 
embryological approaches in a range of species (Jones & Trainor, 2004). 
Evidence from two mouse models supports genetic involvement in HFM. 
Hemifacial maxillary malformation in heterozygotes with incomplete 
penetrance has been observed to result from alteration in the genetic 
background of the mouse far (first arch), a recessive lethal mouse 
mutant (Juriloff et al., 1987). The second mouse model is an autosomal 
dominant insertional mutation on mouse chromosome 10 which produces a 
Hfm phenotype in hemizygous mice which resembles HFM in humans, 
including microtia, low set ears and an abnormal bite resulting from 
hypoplasia of the second bronchial arch accompanied by local 
haemorrhage (Naora et al., 1994). 
3. A comparison of all the genes in the chromosome 11 and 
chromosome 14 HFM linkage regions was undertaken and all were 
interrogated in regard to the same three criteria; embryonic expression, 
association with trinucleotide repeats and association with axial 
asymmetry. Genes sharing homology in both HFM linkage regions would 
become prime HFM candidates, particularly when they fulfilled the three 
aforementioned criteria. Since the chromosome 14 region has been 
definitively linked to autosomal dominant HFM (Kelberman et al.) this 
experiment would provide useful information on genes likely to be 
responsible for chromosome 11 HFM. 
1 .8  Project Feasibility 
This project was an attempt to discover a mutation in a region of 
DNA approximately 18.ScM in length between markers D1151883 and 
D115911 on chromosome 11. The difficultly of this task is highlighted by. 
16 
the fact that the mutation could be as smal l  as one altered DNA base. 
The fact that the causative gene is expressed embryonical ly further 
complicates this task as it denies the opportunity to observe the first 
stages of the disease. Nevertheless this project was thought feasible 
and involved selection of candidate genes using methods described above 
and their interrogation by standard laboratory techniques available at 
Edith Cowan University. 
Laboratory methods included the polymerase chain reaction (PCR) 
of coding regions (exons) of HFM candidate genes, sequencing of these 
exons (Sanger, 1981), and the comparison of 'affected sequences', 
'unaffected sequences' and publ ished sequences. Such methodologies 
could reveal DNA sequence alterations segregating within affected 
ind ividuals. 
The Draft Human Genome was inspected across several genome 
databases to monitor the location of the HFM flanking makers, D11S911 
and D11S987 on chromosome 11. By doing this on a regular basis, the 
length of the chromosome 11 HFM candidate region 
(http:/ /www.ncbi.nlm.nih.gov/genome/guide/human] was reduced, as more 
detailed analysis of the genome became avai lable. Moreover the 
candidate genes on chromosome 11 and the chromosome 14 l inkage region 
were compared. This al lowed us to confirm candidature of known and 
predicted genes and to exclude others as HFM candidate genes. This was 
of assistance as genes identified as potential candidates in prel iminary 
investigations were excluded later if they no longer mapped within the 
reduced l inkage regions. 
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Secondly, it was thought that the likelihood of this project 
identifying the causative mutation would be improved through careful 
selection of HFM candidate genes by genome mining. This method could 
assist in identification of candidate genes by cross-tabulating relevant 
details of known and predicted genes in the two HFM candidate regions 
on chromosome 11  and 14. Information on candidate genes was cross­
tabulated with available information in the mouse genome databases. 
Many mouse genes demonstrate high homology to those of humans and it 
was thought a feasible approach to assist in determining gene function 
for the many human chromosome 11 HFM linkage region genes which are 
of unknown function. Criteria relevant to analysis of chromosome 11, 
chromosome 14 and mouse genes included: names, aliases, acronyms, 
functions, disease associations (particularly with axial asymmetry), 
timing and site of expression, and association with trinucleotide repeat 
expansions. 
1 .  9 Originality of this research 
This project is innovative in that it seeks to identify the mutation 
causing the form of hemifacial microsomia segregating on chromosome 
11. If successful, this would be the first identification of a mutation 
responsible for this common congenital disorder. Secondly, the adoption 
of genome mining enhances this project. Genome mining is novel simply 
because it has only recently become possible to attempt such analyses 
with sufficient rigour. Prior to the completion of the Human Genome 
Project in 2004 only moderate-resolution maps of chromosomes 11 were 
available. The publication of the Draft Human Genome, the rapidly 
expanding DNA databases for mouse and man, and the availability of 
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powerful search engines have combined to make such an undertaking 
possible. 
1.10 Overall purpose and significance of this research 
The rationale of this project was that identification of a causative 
mutation responsible for chromosome 1 1  HFM could improve the 
diagnosis, prognosis, prevention, treatment and future research into the 
molecular pathology of autosomal dominant HFM. Although it is 
impossible to predict what molecular connections future research may 
find between the differing forms of HFM, it will become successively 
easier to identify possible causative factors as this and other research 
discoveries emerge. The enhancement of understanding with regard to 
craniofacial developmental deformation will greatly improve future 
prognoses, diagnosis and treatment of such disorders. 
Inevitably, as HFM mutations are discovered, functions of the 
associated gene(s) will become better understood. Studying the effects 
of disease causing mutations is a powerful way of determining the 
biological role of gene products and linking genotype to phenotype. 
1 .11 Conclusion 
This project identified four genes, namely UVRAG, ARIX, CLNSJA 
and GARP from the chromosome 1 1  linkage region as being likely 
candidates for the West Australian family segregating HFM. All four 
genes were thoroughly investigated and the majority of three genes 
were sequenced, by implementation of numerous laboratory techniques. 
In this way this project contributed to enhancing the understanding of 
HFM through the adoption of genome mining and bioinformatics. 
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However sequencing of these three genes in an affected and unaffected 
ind ividual identified no differences from the publ ished sequence. Thus 
the research presented here excludes these genes as candidates for the 
d isease in this fami ly and identifies a potential candidate gene for 
future research. As a result, this project of gene mining for hemifacial 
microsomia, together with advances of the Human Genome Project have 
refined the candidate gene l inkage region associated with HFM on 
chromosome 11. Ultimately, an enhanced understanding wi l l  lead to 
improved treatment strategies. 
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Chapter 2 :  Comprehensive literature overview on HFM 
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2. 0 Comprehensive literature overview on HF M 
This chapter reviews the current literature surrounding hemifacial 
microsomia. It discusses clinical aspects of the disease, assessment and 
classification, malformation causes, laterality defects, specification of axis 
formation and the numerous proposed pathologies surrounding HFM. 
Furthermore, genetics, phenotypic and pathogenetic data will be discussed. 
Candidate genes selected in this project and animal models for HFM will be 
described. 
2 . 1  Nomenclature 
The term ' hemifacial microsomia' ,  was initially coined by Gorlin et al., 
1963 (as cited in Seow et al., 1998) to refer to patients displaying unilateral 
microtia, macrostomia, and hypoplasia of the mandibular ramus and condyle 
(Cavaliere & Buchman, 2002). Alternative terminology used to describe HFM 
includes; first and second bronchial arch syndrome, otomandibular 
dysostosis, lateral facial dysplasia, Goldenhar syndrome, facio-auriculo-
vertebral sequence/ complex, craniofacial microsomia and 
oculoauriculovertebral (OAV) dysplasia/spectrum (Wang, Lin & Yi, 2001; 
Cousley & Calvert, 1997; Jacobsson & Granstrom, 1997; Tiner & Quaroni, 
1996; Johnson, Fairhurst & Clarke, 1995; Kaye et al. , 1992; Boles, Bodurtha 
& Nance, 1987; Mansour, Wang, Henkind, Goldberg & Shprintzen, 1985; 
Yanagihara, Yanagihara & Kabasawa, 1979; Gorlin, Pindborg & Cohen, 1976). 
Numerous authors have found increasing evidence, in the form of 
associated anomalies, supporting the proposition that hemifacial microsomia 
(HFM), Goldenhar syndrome (GS) and oculoauriculovertebral dysplasia 
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(OAV) are part of a spectrum within a single entity (Brady et al., 2002; 
Tiner & Quaroni, 1996; Kaye et al., 1992; Figueroa & Friede, 1985; 
Yanagihara et al., 1979; Gorlin et al., 1976). OAV dysplasia has subsequently 
been changed to OA V spectrum, as dysplasia and syndrome were considered 
inaccurate descriptions (Cousley & Calvert, 1997). Generally, the term HFM 
is widely applied, especially in surgical texts, to illustrate the full clinical 
spectrum of the salient features of facial hypoplasia and axial-asymmetry 
(Cousley & Calvert, 1997). 
2.2 Clinical History 
Hemifacial microsomia (HFM), a complex congenital condition (Cousley 
& Calvert, 1997), is recognized as etiologically and phenotypically 
heterogenous (Cousley, 1993; Cousley & Wilson, 1992; Bassila & Goldberg, 
1989), and has been classified as the second most common birth defect, 
second to cleft lip and palate (Monahan et al., 2001; Fischer & Prahl­
Andersen, 1996; Satoh, Shibata, Tokushige & Onizuka, 1995; Rodgers et al., 
1991). Secondary to underdevelopment, HFM is the commonest 
asymmetrical craniofacial deformity of the craniofacial skeleton and soft 
tissues (Ji, Li, Shamburger, Jin, Lineaweaver & Zhang, 2002; Whyte, 
Hourihan, Earley & Sugar, 1990). Furthermore, HFM involves deformities in 
first and second brachia! arch derivatives (Cousley et al., 2002; Sze et al., 
2002; Kelberman et al., 2001; Silvestri et al., 1996; Rodgers et al., 1991; 
Converse, Woodsmith, McCarthy, Cocaro & Becker,1974; Converse et al., 
1973). As several structures arise from these arches and not all are 
necessarily affected, the clinical presentation may vary considerably . 
During embryonic development of higher vertebrates, six transient arches, 
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also termed pharyngeal or visceral arches, are formed that give rise to 
specialised structures in the head and neck [On-line Medical Dictionary: 
http://cancerweb.ncl.ac.uk/omd/). The skeletal elements of these arches 
are derived from neural crest and lateral plate mesoderm (Appendix 2). 
The estimated international incidence of HFM ranges from 1 in 1000 
births (Horgan et al., 1995), to between 1 in 5600 births (Causley & Calvert, 
1997; Cohen, 1991; Gorlin, Cohin & Levin, 1990; Grabb, 1965;) and 1 in 4000 
births from studies conducted in London (Poswillo, 1973). Although most 
cases are considered sporadic, the estimated recurrence rate in first­
degree relatives is approximately 2-3% (Rollnick & Kaye, 1983). 
HFM is a complex deformation that displays a spectrum of anomalies 
involving soft-tissue and skeletal structures (Carvalho, Song, Vargervik & 
Lalwani, 1999; Causley, 1993). It is characterized by varying degrees of 
facial asymmetry (the general causes of which are outlined in Table 2.1, 
p26) and hypoplasia of the bony and/or muscular and soft tissues of the 
face (Loescher, 1996), auricular anomalies, skin tags, pits and different 
gradations of microtia (Gorlin et al., 1976). Extracraniofacial-associated 
malformations can occur in cardiac, pulmonary, gastrointestinal, renal, and 
central nervous systems (Horgan et al., 1995; Lauritzen et al., 1985). An 
example of the extreme variety of anomalies associated with HFM includes 
the presence of cartilage in cervical appendages (Rollnick & Kaye, 1985). 
The majority of reported cases of HFM are considered sporadic in origin, 
however substantial evidence for genetic involvement has come to light in 
recent years (Causley et al., 2002; Connor, & Fernandez, 1984), including 
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rare familial cases that display autosomal dominant inheritance (Kelberman 
et al., 2001), as is the case in the West Australian family under 
investigation. 
Table 2. 1 Causes of asymmetry in humans 
Causes Examples 
Gene Mutations Kartagener syndrome 
Embryopathies 
Malformations 
Disruptions 
fetopathies 
Deformations 
Hemi-asymmetries 
Hemihyperplasia 
Hemihypoplasia 
Hemiatrophy 
Craniosynostoses 
Hamartoses 
Common and/or well-known 
Infections 
Cysts 
Tumors 
Trauma 
Others 
Adapted from Cohen (1985a) 
2.3 Clinical Ascertainment 
Unilateral cleft lip 
Amniotic band disruption 
Mandibular asymmetry 
Beckwith-Weidemann syndrome 
Hemifacial microsomia 
Romberg syndrome 
Unilateral coronal synostosis 
Sturge-Weber angiomatosis 
facial cellulitis of dental origin 
Lymphoepithelial cyst 
Pleomorphic adenoma of parotid 
Unilateral temporomandibular joint 
ankylosis 
Fibrous dysplasia 
The clinical presentation of HFM generally manifests as one of three 
principal deformities (Silvestri, Natali & Fadda, 1996; Kay & Kay, 1989; 
Mulliken & Kaban, 1987): 1) auricular hypoplasia, 2) mandibular hypoplasia, or 
3) hypoplasia of the soft tissues. The orofacial manifestations of HFM are 
characteristically unilateral, although is has been suggested that bilateral 
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involvement can occur, with more severe expression on one side (Seow et al., 
1998; Kallen, Harris & Robert, 1996; Bassila & Goldberg, 1989; Figueroa & 
Pruzansky, 1982) (Appendix 2). 
A patient displaying HFM in its fullest expression would typically 
exhibit unilateral (rarely bilateral) underdevelopment of the middle and 
external ear, mandible, zygoma, maxilla, temporal bone, facial muscles, 
mastication muscles, palatal muscles, the tongue and parotid gland, as well 
as macrostomia and a first branchial cleft sinus (Grabb, 1965) (Appendix 3). 
Fortunately however, HFM is frequently incompletely expressed. The two 
major features of deformation in HFM are auricular and mandibular 
hypoplasia (Converse, Coccaro, Becker & Wood-Smith, 1973). 
Other variations of HFM may demonstrate predominance of either 
auricular or mandibular dysplasia (Converse, Coccaro, Becker & Wood-Smith, 
1973). In cases exhibiting predominant mandibular dysplasia, additional 
deformities characteristically associated with HFM such as pre-auricular 
tags are less prevalent. 
Anomalies deriving from the variety of malformations of the branchial 
arches in HFM have been reported to include congenital heart disease, 
contracture of a finger, acetabular dysplasia, clubfoot, imperforate anus 
with recto-vaginal-urethral fistula, bilateral failure of rotation of the 
kidneys and hypospadias (Grabb, 1965). Alternatively, maximal auricular 
deformity may be evident while the mandibular deformity may be 
unapparent upon clinical examination. Roentenographic studies (a derivative 
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of radiology) have demonstrated that every case of external auditory canal 
and auricular hypoplasia with middle ear deformation encompasses skeletal 
changes on the affected side, suggesting the severity of ear deformity 
does not parallel that of the mandibular defect (Murray, Kaban & Mulliken, 
1984). 
Mandibular deformation characteristic of HFM may present without 
significant auricular or temporal bone maldevelopment. Differentiation 
between these cases and postnatal deformities caused by injury is difficult, 
although the diagnosis is evident if the deformity was present at birth. 
In HFM there is a specific, but none the less incorrect, tendency to 
consider hypoplasia as predominantly bony. However muscular hypoplasia, 
involving powerful muscles such as the masseter, medial and lateral 
pterygoid and temporalis can emerge which would undoubtedly influence 
skeletal development (Converse, Coccaro, Becker & Wood-Smith, 1973). 
This impairment in muscle function has an apparent impact, not only on the 
developing musculature but also on the morphologic character of the 
attached bones and nerves. Hence paralysis or weakness of the facial 
nerves is an occasional finding. 
Other anomalies associated with HFM may include microtia-atresia; 
mandibular, maxillary and orbital hypoplasia; absence of the parotid gland; 
fistulae, microphthalmia, coloboma of iris and choroid, epibulbar 
lipodermoid, strabismus, macrostomia, conductive or sensorineural hearing 
loss and hypoplastic facial muscles (Converse, Coccaro, Becker & Wood-
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Smith, 1973). It is evident that HFM is an encompassing term that covers a 
variety of congenital defects. Yet the extremely variable phenotype 
revolves around the universal feature of axial asymmetry (Cousley & Wilson, 
1992; Rollnick & Kaye, 1985). In some cases this asymmetry is masked by 
normal adjacent soft tissues. This especially applies to young children whose 
faces are generally more buxom, thereby expressing an incomplete 
phenotype. facial soft-tissue deformities ranges from clinically normal to 
severely deficient on an affected side(s) (Murray, Kaban & Mulliken, 1984). 
Patients who exhibit mild involvement typically display minimal deformity, 
including ear tags, slight macrostomia and minimal subcutaneous-muscular 
hypoplasia without auricular or cranial nerve involvement. On the other 
hand, severe soft-tissue deformities refer to patients with major contour 
deficiency, neuromuscular weakness and major soft tissue deficiency 
associated with ear distortion, nerve deficits and/or clefts of the face or 
lips (Satoh et al., 1995; Mulliken & Kaban, 1987; Murray, Kaban & Mulliken, 
1984). Between these two extremes, patients are classified as moderate. 
Both HFM and the branchio-oto-renal syndrome (BOR) are associated 
with malformations of the external ears, preauricular tags, pits, or sinuses 
and conductive or mixed hearing loss (Abdelhak et al., 1997; J acobsson & 
Granstrom, 1996; Sensi, Cocchi, Martini, Garani, Trevisi, & Calzolari, 1996; 
Rollnick & Kaye, 1985). However, both sensorineural hearing loss and facial 
nerve dysfunction are common features specific to HFM (Brady et al., 
2002; Carvalho et al., 1999; Cousley, 1993). 
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2 .4 Classification 
HFM is typically not diagnosed until late infancy or early childhood, as 
recognizable features such as facial asymmetry are subtle in newborn 
infants (Carvalho et al., 1999; Marsh, Baca, & Vannier, 1989). Accurate 
facial anomaly assessment is essential for effective diagnosis, classification 
and management of HFM (Causley & Calvert, 1997; Converse, Wood-Smith, 
McCarthy, Coccaro & Becker, 1974). 
The spectrum of anomalies consistent with HF M has made systematic 
and inclusive classification difficult (Vento, LaBrie & Mulliken, 1991: Bassila 
& Goldberg, 1989). Subsequently, numerous systems have been devised to 
facilitate the classification of individualized components of this complex 
condition (Polley, Figueroa, Liou & Cohen, 1996; Rodgers et al. , 1991), 
although a system suitable for universal adoption is yet to be devised 
(Polley et al., 1996; Figueroa & Pruzansky, 1982). Classification systems 
categorizing patients as HFM type I, type II etc. are not recommended 
since they are solely based on mandibular deformation, thereby neglecting 
the multitude of other anomalies associated with HFM (Mulliken & Kaban, 
1987; Figueroa & Pruzansky, 1982; Swanson & Murray, 1978). 
Keusch, Mulliken and Kaplan (1990) recommend the distinction between 
malformation and deformation when referring to congenital structural 
anomalies. Malformations specifically incorporate errors of morphogenesis 
in which intrinsically abnormal structures develop throughout gestation, 
whereas deformations result from abnormal mechanical forces on 
presumably intrinsically normal structures. Although effective in 
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categorising the origin for a predominant congenital anomaly, this 
classification system oversimplifies a complex disorder (Keusch et al., 
1990). 
The most favourable systems of classification used in HFM diagnosis 
are (1) the Skeletal, Auricle and Soft-tissue (SAT) multisystem 
classification, proposed in 1987 by David and colleagues, and (2) the 
Orbital distortion, Mandibular hypoplasia, Ear anomaly, Nerve involvement 
and Soft tissue deficiency (OMENS) classification system, proposed by 
Vento, LaBrie and Mulliken (1991). The SAT system allows each component 
addressed (S = skeletal, A = auricle, T = soft tissue) to be graded according 
to the severity of involvement (Appendix 4). Similarly, the OMENS system 
permits grading according to the severity of involvement of each 
component. The differentiation between key phenotypic elements will lead 
to improvements in diagnosis, prognostic predictions, treatment planning, 
data evaluation and case correspondence (Causley & Calvert, 1997). Both 
these systems are useful in HFM classification as they allow bilaterally 
affected patients to be classified by analysis of each affected side 
separately. The SAT system is perhaps less comprehensive than the 
OMENS system as it does not provide a separate grading category for 
nerve involvement. Neither system allows for cardiac, renal, nervous system 
or other anomalies that have been associated with HFM (Rodgers et al. , 
1991). Another flaw of the OMENS system is that the categorisation of the 
five major factors (O.M.E.N.S) displays bias as the authors themselves have 
decided what is to be considered 'major'. Yet there is well established 
evidence to support the inclusion of cardiovascular anomalies as part of the 
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oculoauriculovertebral spectrum (Casey, Braddock, Haskins, Carey & 
Morales, 1996; Cohen, 1991). The diagnostic criteria used to assess the WA 
family under investigation by Singer et al. (1994) for degree of deformation 
is tabulated in Table 1 .2 (p8). 
Three other classification systems deserve brief mention for their 
contribution to the classification of HFM and associated anomalies: the 
Pruzansky classification system, Tenconi and Hall's phenotypic classification 
system and Munro and Lauritzen's system (all cited in Rodgers et al., 1991). 
These are alternative classification systems devised to guide treatment 
planning and diagnosis of HFM, although they are not as widely accepted as 
the SAT and OMENS classification systems. 
The Pruzansky classification system is particularly effective in 
describing mandibular deformities characteristic of HFM, however this 
system has two primary disadvantages, namely failing to include the absence 
of condylar description and to address the variety of other anomalies 
frequently observed in HFM (Pruzansky, 1969). 
A disadvantage of the Tenconi and Hall phenotypic classification 
system is that nerve involvement is not acknowledged and ear abnormalities 
are not addressed, despite being a frequent feature of HFM. 
Munro and Lauritzen's system is unique in that it is an "anatomical­
surgical" classification system. The various categories are distinct, 
reproducible and thorough however this system does not account for nerve 
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involvement, which becomes increasingly evident with deformation severity 
(Rodgers et al., 1991). 
Through reviewing the numerous classification systems in existence to 
date and considering the inherent variability of deformities of HFM, a 
multi-system classification seems justified (David, Mahatumarat & Cooter, 
1987). In reference to problems associated with HFM classification, it is 
the proximity of the structures deriving from the bronchial arches that 
complicates classification, as many of the structures affected are 
comparable to Goldenhar syndrome, rather than specifically to a diagnosis 
of hemifacial microsomia alone (Converse, Coccaro, Becker & Wood-Smith, 
1973). This is evident in the WA family under investigation. In an ideal 
situation, the anatomical structure, aforementioned deriving from the first 
two bronchial arches, would not overlap and would be clearly defined. This 
would encourage more accurate identification of abnormal anatomical 
structures and thereby support a precise method for classification and 
diagnosis. 
2. 5 Causes of Malformations 
Teratogens and genetic factors are two predominant factors known to 
cause malformations. Their effects play an important role in development, 
for example susceptibility or resistance to certain teratogens may be 
provided by genetic factors, thereby complicating interpretation. The 
determination of the relative importance of genetic and environmental 
effects as a cause of malformation is made challenging by the overlap 
between these factors. Independent consideration can be artificial but 
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expedient in circumstances where either an environmental factor or 
specific genetic problem is presumably the sole cause of malformation. 
Teratogens have been subject to considerable research as they are a 
potentially preventable cause of malformation. 
Alternatively numerous studies have confirmed genetic involvement in 
malformation, including recurrence rate of common malformations such as 
cleft lip or neural tube defects in family studies (Clayton-Smith & Donnai, 
1997) as well as the existence of rare, Mendelian inherited malformations 
(Wilkie, 1994). With regards specifically to HFM, Otani et al. (1991) 
demonstrated the involvement of both teratogens and genes by determining 
that hypoplasia of the branchial arch was not the primary cause but a 
result, and that vasculature served as a threshold for the defective gene or 
drug effect. 
2. 6 Molecular basis of dysmorphology 
2. 6 .1 Embryology 
Pre-implantation involves ovulation, fertilisation and cleavage, 
blastocyst formation and zygote implantation. Genetically normal sperm and 
ova are evidently crucial for the initiation of this process. Aside from non­
fatal genetic defects, errors occurring during pre-implantation usually 
result in early pregnancy termination rather than malformation (Martini, 
Ober, Garrison, Welch & Hutchings, 1998). 
Proliferation and condensation of mesenchyme to form somites, 
alongside marked ectodermal activity is the primary embryologic change 
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inaugurating auricle formation in the fourth and sixth weeks of embryonic 
development (Stark & Saunders, 1962). Patterns formed during these initial 
stages of development form the template for the future body plan. 
Pharyngeal arches are formed during the fourth week of embryonic 
development and can be likened to the gills of fish. They reflect the fact 
that that the development of an individual (ontogeny) resembles the species 
evolution (phylogeny) and are important in appreciating the final structure 
and innervation of the head and neck (Zillmusom, 2003). Initially the 
bronchial arches consist of a mesodermal core surrounded by epithelium 
(Shanahan, 2004). The mesenchyme will form muscles, arteries, connective 
tissue, cartilage and parts of the skeleton. Each of these arches contains a 
cartilaginous core, an aortic arch and a cranial nerve which eventually 
supplies the structures that develop from the mesenchyme of the arch 
(Marino, 2004). Structures derived from the bronchial arches are outlined 
in Table 2.2 (p35). 
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Table 2 .2  Structures derived from bronchial arches 
Arch/ Skeletal Ligaments Muscles Pouch 
Nerve 
First (V) 1. Mal leus 1. Anterior l igament 1. Muscles of mastication 1. Auditory tube 
2. Incus of malleus 2 .  Tensor tympani 2. Tympanic cavity 
2. Sphenomandibular 3. Tensor palati 
l igament 4. Anterior belly of 
Digastric 
Second 1. Stapes Stylohoid l igament 1. Muscles of facial expression Lining (crypts) of 
(VII) 2. Styloid 2. Stapedius palatine tonsils 
process 3. Stylohoid 
3. Hyoid bone-
lesser horn, 
upper half of 
body 
Third Hyoid bone- Digastric 1. Inferior 
(VIII) greater horn Stylopharyngeus parathyroid gland 
lower half of 2. Thymus 
body 
Fourth Car ti lag es of 1. All muscles of larynx 1. Superior 
(X) larynx 2 .  Al l  muscles of pharynx parathyroid gland 
(except stvlopharynqeus) 2. C-cells of thyroid 
Sixth (XI) 1. Sternocleidomastoid 
2. Trapezi us 
Adapted from Zil lmusom (2003) 
Patterning genes are responsible for governing cell differentiation in 
regions of overlapping gradients along rostro-caudal, dorso-ventral and 
medial-lateral axes across the embryo (Gavalas, Davenne, Lumsden, 
Chambon, & Rijli, 1997). Through the development of the body pattern, cells 
migrate to their assigned positions and differentiate into specific tissues. 
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Gene expression coding for transcription factors, adhesion factors, 
receptors and structural proteins permit the complex signalling systems 
between cells, the extracellular matrix and soluble factors that brings 
about co-ordinated development of the embryo. 
At the region of the mid- and hind-brain, patterns of gene expression 
are transferred from the neuroectoderm to the oral ectoderm derived 
epithelia which in turn form a number of tissues, including cartilage, bone, 
tooth and tongue. It has been suggested that co-ordinated HOX genes, 
growth factors and receptors orchestrate the timing and positional 
information for the distribution, determination and demarcation of these 
tissues. 
2. 6. 2 Genes involved in Dysmorphology 
Birth defects are caused by mutations in a variety of genes including 
transcription and growth factors, receptors and signal transduction 
molecules, enzymes, transporters and structural proteins (Table 2.4, p40). 
DNA disruptions too small to distinguish using cytogenetic techniques are 
known to cause over 1750 inherited malformations (Wilson, 1992). Of these, 
disorders, over 1000 are multiple defect syndromes. By 1997, 38 genes had 
been found and a further 20 mapped by positional cloning (Winter, 1998). 
The following year, more than 3000 non-chromosomal developmental 
syndromes were reported, of which 2000 seemed to involve single gene 
aetiology. Genes associated with 200 of these syndromes have been located 
and a further 120 syndromes mapped (Winter, 1998). Evidently, the pace of 
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gene discovery for malformations has increased alongside the pace of 
discovery of all human genes. 
2. 7 Developmental genetics 
The neural crest is an embryonic cell population that originates at the 
border of the neural plate and prospective epidermis (Basch, Garcia-Castro 
& Bronner-Fraser, 2004) and throughout the period of embryonic neural 
tube closure, neural crest cells emigrate from the neural tube, migrate 
along defined paths and differentiate into a range of derivatives, including 
the craniofacial skeleton, pigment cells and the peripheral nervous system. 
Many of the more common craniofacial birth defects are a corollary of 
abnormal neural crest development, a proposed pathological cause of HFM. 
Despite the extensive research on the migration and differentiation of the 
neural crest, research is reasonably new in investigations of how the tissue 
originates. Due to the fact that craniofacial abnormalities account for a 
third of all human congenital defects, it is essential to strive for 
understanding of the patterning mechanisms responsible for controlling 
head development, in particular the neural crest cell derivatives and their 
contribution to connective tissue, bones and nerves (Trainor & Krumlauf, 
2000). 
The migration of neural crest cells occurs in three stages; initiation, 
dispersion and cessation of migration. Initiation involves the process by 
which the neural crest cells undergo an epithelial to mesenchymal transition, 
thus causing the cells to break free from the neural tube. Results of this 
process include an increase in intercellular space and increased motility in 
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the neural crest cells. In chick embryo's, slug, a transcription factor is 
thought to be responsible for initiating these factors (Stark & Saunders, 
1962). The second migratory stage, dispersion, involves the migration of 
cells to their final destinations where they proliferate. Two mechanisms are 
thought to guide the control by which the cells migrate, namely contact 
inhibition and contact guidance. And finally, cessation of migration involves a 
reversal of the mechanisms used to initiate migration (Stark & Saunders, 
1962). 
2 .  8 Axis Specification 
Axes specification and formation are crucial developmental events as 
they determine the body plan orientation. Axial patterning is a critical 
component of ontogeny and the developmental process whereby an embryo 
establishes the orientation of its body axis (or axes) and subdivides the 
axis into distinct regions. Fundamentally, the anterior/posterior axis is used 
to describe the axis between the head and the tail; the dorsal/vental axis is 
used to describe the axis from the back (dorsum) to the belly (ventrum); 
and the medial/lateral axis is used to distinguish between the middle and 
lateral sides of the body. Moreover, the vertebrate body is not symmetrical 
across the L-R axis, instead there are two predominant sides, left and right. 
Generally the heart and spleen are located on the left whereas the liver is 
located on the right. 
In regards to axial skeleton development, the ventral portion of the 
sclerotome surrounds the notochord and forms the rudiment of the 
vertebral body. The dorsal portion of the sclerotome surrounds the neural 
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tube and forms the rudimentary vertebral arches. The primary signal or 
sclerotome induction appears to be a notochord-produced factor, Shh. Pax 
genes are additionally involved in mediating interactions between the 
notochord and the developing sclerotome (Bonaventure, 1998). 
2. 8 . 1  Formation of the Anterior/Posterior (A/P) Axis 
The primitive streak is responsible for determining the A/P axis of a 
developing mammalian embryo. Patterning along the A/P axis is controlled by 
a cluster of genes encoding transcription factors that contain a 60-amino 
acid DNA-binding domain (homeodomain). These genes compose the 
homeotic gene complex (HOM-C) in Drosophila, the organism in which they 
were first isolated through mutation identification (Shankland, 2004). Four 
copies of HOM-C (HOX A through D) are found in the human and the mouse. 
There are 39 HOX genes, each 100kb gene cluster located on different 
chromosomes (Jorde et al., 2000; Bonaventure, 1998). These HOX genes 
act to specify specific regional identities along the AP axis of the 
developing organism (Gilbert, 1998; Finnerty, 1994). 
2. 8 . 1 . 1  Homeobox genes 
Homeobox genes regulate the embryonic pattern along the anterior­
posterior axis. The name 'Homeobox' genes was originally derived from a 
multitude of Drosophila phenotypes termed 'homeotic transformations'. 
Homeotic transformations are mutations that alter the identity of 
particular segments, transforming them into copies of alternate segments. 
Mutations in the drosophila homeotic gene complex (HOMC) account for 
dysmorphic phenotypes (Gellon & McGinnis, 1998). HOMC contains a cluster 
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Table 2.4 Genes involved in dysmorphology 
Class of gene 6ana Disorder Reference 
Transcription factors 
PAX PAX3 , PAX 6 Waardenburg syndrome Hoth et al., 1993 
(WS1), WS2 , WS3 Jordan et al, 1992 
Aniridia 
HOX HOXD13 Synpolydactyly Muragaki , Mundlos, Upton & 
Olsen, 1996 
MSX MSX2 Craniosynstosis Li et al, 1993 
Zinc fingers GLI3/GCPS Postaxial polydactyly Radhakrishna, Wild ,  
Grzeschik & Antonarakis, 
1997 
� ZIC3 Visceral heterotaxy Gebbia et al, 1997 
HMG domain SOX9 Campomelic Dysplasia Foster et al., 1994 
Helix-loop helix / MITF WS2A Tassabehji ,  Newton & Read, 
Leucine z ipper 1994 
POU domain POU3F4 Mixed deafness de Kok, 1995 
SffllC'tual proteins 
Collagen COL1A1 Osteogenesis imperfecta de Vries & de Wet, 1986 
Fibril lin FBN2 Congenital contractural Putnam, Zhang, Ramirez & 
Camptodactyly Milewicz , 1995 
Enzymatic deficiencies 
Lysosomal enzymes alpha-1-iduronidase 
Peroxisomal enzymes Actl-CoA oxidase 
Receptor/Signal transducers 
Growth factor receptors FGFRl 
FGFR2 
FGFR3 
Hormone receptors PTH-PTHrP 
Receptor 
Hurler/Scheie syndrome 
Pseudonatal 
Adrenoleukodystrophy 
Pfeiffer syndrome 
Crouzon syndrome 
Achondroplasia 
Metaphyseal 
chondrodysplasia 
Other receptors. can adhesion molecules and gap Junctions 
Endothlin receptors EDNRB Hirschsprung disease 
Adhesion molecules KAL Kallmann syndrome 
GEFs 
G proteins 
Connexin 43 Cardiac Malformations 
FGDl 
LI51/MDCR 
GNA51 
Aarskog-Scott syndrome 
Lissencephaly 
A lbright heridatary 
Osteodystropathy 
Adapted from Chandi.... 2001 
Moskowitz , Tieu & Neufeld, 
1993 
Fournier et al, 1994 
Muenke et al, 1994 
Reardon et al, 1994 
Shiang et al, 1994 
Shiapani, Kruse & Juppner, 
1995 
Puffenberger et al, 1994 
Bick et al, 1992 
Britz-Cunningham, Shah, 
Zuppan & Fletcher, 1995 
Pasteris et al., 1994 
Chong et al, 1996 
Patten et al, 1990 
of eight homeobox genes. Every gene in the HOMC cluster contains a region 
known as a 'homeobox ' ,  which codes for a 60 amino acid part of protein 
termed the 'homeodomain ' .  Homeodomains are DNA binding domains of 
proteins that enhance gene expression of genes to which the protein is 
bound. HOMC gene expression and mutation effects suggest the 
involvement of genes of the HOMC, in regulation of segmentation along the 
developing embryo' s  anterior/posterior (AP) axis. Interestingly, the 
homeobox sequence is exceptionally conserved throughout phylogeny 
(Russell, 2002; Gellon & McGinnis, 1998). Insect HOMC expression variation 
has been suggested as partially responsible for body form variation. In all 
vertebrates, there are four groups of HOX genes (HOXA-D) on four 
different chromosomes (Krumlauf, 1993; Acampora et al., 1989). It has 
been postulated that increasing numbers of HOX genes would accommodate 
the increasing complexity of the vertebrate body form (Acampora et al., 
1989). 
HOX genes are expressed along the dorsal axis from the anterior 
boundary of the hindbrain to the tail, certain derivatives are expressed in 
specific body parts such as the head, thorax and abdomen (Gilbert, 1998). 
3' HOX genes are expressed earlier (temporal collinearity during pattern 
formation along the primary and secondary axes of vertebrates) than and 
anterior to the 5' HOX genes (Bonaventure, 1998). The overlapping domains 
of HOX gene expression generate combinations of codes that specify the 
positions of cells and tissues along the AP axis of the trunk and limbs 
(Jorde et al., 2000). 
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2.8.2 Specification of the t>- V axis in the developing embryo 
(Embryonic patterning) 
D-V axis asymmetry is generated through a cascade of signalling 
molecules, beginning with asymmetric expression of Sonic hedgehog ( Shh) 
from the ventral side and BMPs from the dorsal surface. Furthermore, Shh 
together with BMPs are responsible for dorsal/ventral patterning of the 
central nervous system, induction of the neural plate, patterning of the 
limbs and establishment of the embryonic L/R axis (axis specification). It is 
also a key mediator of the polarizing activity that regulates patterning 
along the anterior-posterior (AP) axis and has been observed to influence 
the signalling pathways regulating calvarial growth and cranial suture 
morphogenesis (Ingham & McMahon, 2001; Bonaventure, 1998). Ingham and 
McMahon (2001) observed expression of genes by Shh in three key 
signalling centres in the vertebrate embryo; the notochord, a mesodermal 
rod that underlies the ventral neural tube, the floor plate, a specialized 
population of support cells at the ventral midline of the developing central 
nervous system, and the zone of polarizing activity (ZPA), a population of 
apical, posterior mesenchyme cells in the limb bud. The notochord is 
responsible for expression of Shh which is both necessary and sufficient 
for the introduction of distinct ventral cell identities in the spinal cord 
(Ingham & McMahon, 2001). Cell-autonomous activation or inhibition of Shh 
signalling within the neural tube indicates that the protein acts both 
directly and at long range to specify cell fate (Ingham & McMahon, 2001). 
Both Pax and a diverse group of homeodomain-containing transcriptional 
regulators provide the initial response to Shh signalling (Ingham & 
McMahon, 2001; Lacombe, 1989). 
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The TGF- � supergene family comprises a large group of structurally 
related genes that encode proteins that form homodimers or heterodimers. 
Members of the TGF-� superfamily exert a diverse range of biological 
effects on cell growth and differentiation, such as governing embryonic 
axial patterning and restricting Shh expression (Dupont & colleagues, 
2003). Various members of the TGF-� superfamily, including BMPs, 
produced by the dorsal ectoderm and roof plate of the dorsal neural tube 
appear to be the dominant influence in the specification of dorsal cell 
identities (Ingham & McMahon, 2001). 
Wnt is an additional patterning gene family critical in the 
establishment of the primary D/V and A/P axes in vertebrates (Chen & 
Johnson, 2002; Saint-Jennet, He, Varmus and David, 1997; Ekker, 1993) 
and is involved in the induction of head structures (Gilbert, 2000). This 
gene family is responsible for encoding secreted glycoproteins that 
participate in a variety of developmental processes, including specification 
of the dorsal/ventral axis and formation of the brain, muscle, gonads and 
kidney (Jorde et al., 2000). 
2.8 . 3  Formation of the medial-lateral (M/L) and left-Right (L/R) Axes 
The cellular and molecular mechanisms that regulate regional 
specification of the forebrain are largely unknown. Shimamura and 
Rubenstein (1997) identified Shh as the molecular regulator of the medial 
neural and thus medial-lateral asymmetry is embryonically established by 
expression of Shh at the mid-line. In contrast, gene expression in the 
lateral neural plate, (Shimamura & Rubenstein, 1997) is regulated by non-
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neural ectoderm and BMPs. This suggests employment of similar patterning 
mechanisms across both the medial-lateral and dorsal-ventral axes. 
The left and right sides of the embryo and organs must also be 
patterned. Nodal, a member of the TGFB family is responsible, in part, for 
the distinction between the left and the right side and is thus a crucial 
element of left /right axis formation. The mechanisms by which nodal 
expression is activated however, differs among vertebrate classes. As the 
primitive streak reaches maximum length, transcription of Shh gene ceases 
on the right side due to expression on this side of activitin and its receptor. 
The expression of activin blocks the expression of Shh and through a 
cascade of events prevents transcription of caronte genes, the absence of 
which results in BMPs blocking expression of nodal and lefty-2 (Gilbert, 
2000). 
Despite the fact that mechanisms initiating left-right patterning may 
be distinct in different vertebrate classes, the conservation of asymmetric 
gene expression patterns of nodal and lefty in the left lateral plate 
mesoderm has become apparent (Bisgrove & Yost, 2001). 
Further evidence for the role of nodal in L/R axis specification has 
come from the observation that L/R expression of nodal is randomised in a 
naturally occurring mouse mutant that exhibits a form of randomised organ 
asymmetry called inversus viscerum (Jorde et al., 2000; Jurliff & Harris, 
1983). 
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2. 8.  4 Craniof acial development 
Hox genes play a critical and definitive role in the patterning of 
regions within the craniofacial complex. In vertebrates, the Hox genes are 
involved in patterning regions of the hindbrain and second bronchial arch. By 
contrast, the first bronchial arch is patterned by groups of homeobox 
genes distinct from those of the Hox gene clusters. Trainor and Krumlauf 
(2000) argued that Hox gene identity of the neural crest is pre-patterned, 
carrying positional information acquired in the hindbrain to developing 
bronchial arches. More recently, investigations have revealed plasticity of 
Hox gene expression in the hindbrain and cranial neural crest of chick, 
mouse and zebrafish embryos, thus postulating that craniofacial 
development is regulated by a complex integration of cell and tissue 
interaction, rather than neural crest pre-patterning, as once assumed. 
Pharyngeal arch development is a complex process involving a number 
of distinct embryonic populations, the ectoderm, endoderm, neural crest 
and mesoderm, all of which have to be coordinated in order to generate the 
necessary components and identity of each bronchial arch (Graham & Smith, 
2001; Graham, Hixon, Bacino, Daack-Hirsch, Semina, Murray, 1995; Causley 
& Wilson, 1992). In mammalian embryos, neural crest cells from the 
presumptive forebrain and midbrain region give rise to the nasal processes, 
palate, and mesenchyme of the first pharyngeal pouch. This mesenchyme in 
turn forms the maxillar, mandible, incus, and malleus. The neural crest cells 
of the presumptive anterior hindbrain migrate and differentiate to become 
the mesenchyme of the second pharyngeal pouch and the stapes and facial 
cartilage. Cervical neural crest cells produce the mesenchyme of the third, 
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fourth, fifth and sixth pharyngeal arches (in humans, the sixth pharyngeal 
arch degenerates). This mesenchymal tissue becomes the muscle and bone 
of the neck. Bones of the skull are thought to develop directly from 
mesenchyme produced by neural crest cells (Jorde et al., 2000; 
Bonaventure, 1998). 
2. 9 Pathogenesis of HF M 
Theories explaining the pathogenesis of HFM are many and varied. 
Previously, the study of the causative mechanism behind HFM has been 
focused on developmental defects involving the 1st and 2nd bronchial arches 
derivatives. Gorlin et al. (1990) emphasized the potential pathogenic 
significance of abnormalities involving the vasculature that supplies the 
developing embryos cephalic mesoderm, and thus vascular impairment of 
vessels supplying the bronchial arches of the embryo (Satoh, Shibata, 
Tokushige & Onizuka, 1995), could cause a deformity (Robinson, Hoyme, 
Edwards & Jones, 1987). 
Hematoma formation and the consequent tissue destruction that 
follows is an alternative widely accepted mechanism of HFM induction 
(Brown & Salinas, 1984). Theoretically, this could be induced by a 
developmental defect of the stapedial artery, a hypothesis encouraged 
through an appreciation of the early vasculature of the embryonic face 
(Robinson, Hoyme, Edwards & Jones, 1987). Further findings by Robinson et 
al. (1987) support the hypothesis that the developmental pathogenesis of 
some unilateral craniofacial defects, including HFM are secondary to 
interruption in embryonic blood flow (Johnston & Bronsky, 1991; Robinson, 
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Hoyme & Edward, 1987; Poswillo, 1973). Tissue ischemia and necrosis both 
result from an interruption of blood flow to developing facial structures. 
'Catch-up growth' would consequently vary, depending on the extent and 
degree of tissue injury, and would present phenotypically as in HFM 
patients. Louryan, Heymanns and Goffard (1995) opposed this theory by 
arguing that the stapedial artery did not play a direct role in the genesis of 
bronchial and particularly ossicular, abnormalities. Yet both latter theories 
were supported by Kearns et al. (2000) as they were consistent with the 
variable and asymmetric nature of HFM. However, neither theory explains 
the progressive nature of deformation following birth. Furthermore, 
craniofacial defects can appear on the side opposite to a possible 
haematoma. Hematoma formation can explain some HFM cases, it can not 
explain them all. 
Evidence for an alternative developmental mechanism is provided 
through the stimulation of facial and asymmetric brain development 
following evidence of acute maternal teratogen exposure during 
gastrulation. Acute ethanol exposure for example can compromise 
embryonic development (Brown & Salinas, 1984). Poswillo's work (1973) 
further illustrates this by using triazine in a pregnant rat and thalidomide in 
a pregnant monkey. Within mere days of administering the treatment, 
haemorrhage and hematoma formation resulted in the areas of stapedial 
artery distribution. Interestingly, asymmetric craniofacial defects in the 
region of the 1st and 2nd bronchial arches were observed in the treatment 
group but not in controls for those animals delivered at term. Furthermore, 
premature accutane (13-ds-retinoic acid) administration can destroy neural 
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crest cells thereby interfering with their normal migratory patterns, and 
results in characteristic HFM deformities. In general, there is a lack of 
understanding surrounding the ramifications of embryonic neural crest cell 
destruction on structure development and long-term growth potential of 
the affected derivatives of the first and second bronchial arches. 
It appears that HFM could result from a variety of causal factors 
including defective genes, vascular anomalies and/or teratogenic materials, 
which either singularly or collectively incur disruption of the developing 
(pre-osteogenesis) facial skeleton (Kearns, Padwa, Mulliken & Kaban, 2000; 
Cousley & Calvert, 1997; Cousley & Wilson, 1992). Johnston and Bronsky 
(1991) argued that although HFM is considered to be at least partly caused 
by mutations in patterning genes (Rollnick & Kaye, 1983), the craniofacial 
and cardiovascular features of this complex syndrome suggest additionally 
primary crest cell involvement. A deficiency in the development of the 
bronchial arch and head mesoderm is assumed to result from failure of the 
neural crest cells to migrate and contribute adequately to the facial 
primordia. This would cause alteration of standard morphogenetic 
interactions through matrix deficiency and consequently encourage 
malformations consistent with HFM (Jacobsson & Granstrom, 1996). Failure 
of neural crest cells to migrate and/or proliferate could be numerous and 
involve genetic, vascular and teratogenic changes. 
2 . 10 Genetics 
Despite the complex nature of HFM, evidence suggests a major 
genetic determinant in some cases of this condition. Rollnick and Kaye 
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(1983) revealed that 45% of 97 participants had a fami ly history of some 
features of the disorder. Ro l lnick and Kaye (1983) further identified first­
degree relatives as being the most frequently affected , often with mild 
phenotypic expression. "Formes fruste" (microforms include those 
d isplaying low penetrance and mild phenotype) are represented by auricular 
abnormalities (Converse, Wood-Smith, McCarthy, Coccaro & Becker, 1974). 
Numerous theories have been proposed to explain the genesis of first 
and second bronchial arch syndromes. Since few congenital disorders fo l low 
strict Mendel ian segregation, a selection of explanatory genetic models has 
been developed. Those commonly appl ied to HFM include the multifactorial ,  
polygenic and single gene (autosomal dominant and recessive) models 
(Cousley & Calvert , 1997; Cousley & Wi lson, 1992; Connor & Fernandez, 
1984). 
Most affected ind ividuals are cytogenetical ly normal,  however a 
number of chromosome abnormalit ies have been reported inc lud ing trisomy 
18 (Greenberg et al. , 1988), deletion chromosome 5p (Neu, Friedman & 
Howard-Peeb les ,  1982), short arm chromosome 4 delet ion (Zel lweger, 
Bardach, Bordwel l & Wi l l iams, 1975), terminal deletion (22q) Hathout et al. , 
1998; Herman et al. , 1988), monosomy chromosome 6q (Greenberg et al. , 
1988), chromosome Sq deletion (Townes & White, 1978), ring chromosome 
21 (Greenberg et al. , 1988), recombinant chromosome 18 (Sujansky & Smith , 
1981), trisomy 22 (Kobrynski et al. , 1993), chromosome 22q deletion 
(Greenberg et al. , 1988), cri du chat (5p-) syndrome (Neu, Friedman, 
Howard-Peeb les, 1982) and 47 XXY (Klinefelter syndrome) (Garavel l i  et al. , 
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1999; Poonawalla, Kaye, Resonethal & Pruzansky, 1980; Kushnick & 
Colondrillo, 1975). Additionally chromosomal mosaicism has been reported 
including trisomy 7 (Hodes et al., 1981) and 9 (Wilson & Barr, 1983). This 
offers an explanation for localised features and low recurrence risk. A 
number of instances of monozygotic twin discordance exist which 
complicates interpretation of twin studies. However, rare cases of 
concordance with varying expression have been reported (Burck, 1983, Ryan 
et al., 1988). These studies all confirm genetic association for this disease 
and thus support the hypothesis that the West Australian family contain a 
genetic predisposition for this disease. 
A lack of extensive kinships with many affected individuals has 
hampered previous genetic studies. Preliminary studies by Rollnick and Kaye 
(1983) involved sporadic cases and families with small numbers of affected 
individuals. While their results suggested a multifactorial origin for HFM. 
It was agreed that HFM is genetically transmitted (Kaye et al., 1992). 
Subsequent investigations performed by Kaye et al. (1992) involving 
segregation analysis provided evidence for autosomal dominant inheritance 
with incomplete penetrance. Recently, two HFM families have demonstrated 
autosomal dominant (AD) segregation, one linked to chromosome 14 (a 
London family) (Kelberman et al., 2001) and the other to chromosome 11 (a 
West Australian family) (Chandler, 2001), the latter being the family under 
investigation. Moreover, the WA family under investigation appears to be 
indeed demonstrating anticipation with increasing severity of symptoms and 
affected individuals in subsequent generations which supports the 
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presumption that this form of HFM is genetically linked, specifically to 
chromosome 11. 
2 . 11 Haplotypes of the West Australian Family 
This West Australian family of 20 members contains 8 unaffected and 
9 affected members. This family is one of a very few segregating with 
autosomal dominant hemifacial microsomia that is large enough to allow 
genetic linkage analysis to locate the disease gene. Linkage analysis 
performed by Dr David Chandler (2001) using 152 polymorphic markers 
suggested linkage of this family's hemifacial microsomia disease gene to a 
region of chromosome 11, between the markers D11S987 and D11S911. 
D11S911 was located on chromosome 11, position 75,971,191 - 75,971,382, as 
located using the Ensembl database. While D11S916 had been reported to 
be located centromerically on chromosome 11 (Chandler, 2001), this marker 
could not be located by this author at the time of experimentation. A 
comprehensive list of relevant, available markers and their respective 
positions on chromosome 11, deduced from Ensemble can be seen in 
Appendix 5. 
Haplotypes for chromosome 11 are available from D11S1765 to 
D11S876 for both affected and unaffected individuals within this family 
(Chandler, 2001) (figure 2 ,  pll). The two paternal haplotypes were equally 
shared and similar maternal haplotypes were received by all four affected 
individuals in the second generation (i.e. minimal recombination). The 
maternal haplotypes received by affected individuals II:7 (D11S1883) and 
II:9 (D11S4166) demonstrates single recombination (Chandler, 2001). Aside 
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from a double recombination that occurred in individual III:6, Chandler 
(2001) observed no alterations to the grand-maternal haplotypes in third 
generation affected individuals. This author determined that since the 
marker D115911 is non-informative in individual III:6, and marker D115916 
could not be located during experimentation the lower breakpoint is most 
probably at marker D1151396 thereby maximising the distance (9.2cM) over 
which such an infrequent happening could occur (probability of 0.0084) 
(Chandler, 2001). from the haplotypes it is apparent that the linkage region 
for HFM stretches from D1151883 to D115911, approximately 16cM in 
length (figure 2, p 10). It is only in one of the ' unaffected' children (III:1) 
that this (D1151883-D115911) haplotype occurs, although the lower part of 
the haplotype (D1154207 to D115911, 4.6cM) occurs in an unaffected 
sibling, III:2. This could suggest a single recombination at D1151314. Of the 
three unaffected individuals (III:1, III:2 & III:5), none inherited the 
conserved haplotypes. Given that the unaffected individual III:1 possesses 
the non-recombinant grand-maternal haplotype, it seems likely that they 
are a non-penetrant carrier of the disease gene. Thereby, if individual III:2 
is indeed unaffected then the critical region for HFM is reduced to 
between D1151883 and D1154207, 11.5cM. Unfortunately, at the time of 
experimentation marker D1154207 could not be located on Ensembl and so 
genes within the region D1151883 to D115911 (16cM) were mined and 
several genes were identified as potential candidates for HF M in individual 
III:6. 
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2 . 11. 1 Screening for Detected Polymorphisms / Mutation Detection 
The final step of all human disease gene cloning strategies is the 
identification of the mutations on chromosomal DNA within the identified 
linkage regions, contributing to each disease. Mutations can be 
translocations, deletions, duplications, repeat expansions, insertions, splice 
site, mis-sense, frameshift or stop codon mutations. They can affect 
transcribed and non-transcribed portions of the genome. 
Deletions that include markers adjacent to the disease gene can be 
recognised from non-Mendelian and/or homozygosity marker segregation in 
pedigrees for both autosomal dominant and recessive diseases. PCR methods 
detect smaller mutations in cloned DNA lying inside or outside coding 
regions. Commonly used mutation detection methods are listed in Table 2.3, 
p60. Of these mutation detection methods the direct sequencing of 
transcripts is of primary relevance and is discussed further in Chapter 3. 
2 .12 Data Mining 
This project was innovative in that it adopted a novel strategy, genome 
mining with which four hemifacial microsomia candidate genes were 
identified in this project. This process involves cross-tabulating relevant 
details of the genes and predicted genes in the two known hemifacial 
microsomia candidate regions, then cross-tabulating all this information 
with what is available in vertebrate and invertebrate genome databases. 
Bergeron (2003) defined data mining as the "process of automatically 
extracting meaningful patterns from (usually) very large quantities of 
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seemingly unrelated data" (p263). Data mining is not simply about searching 
for every possible relationship in a database, rather it has the ability to 
initiate queries that are not restricted by the user' s  fluency in authoring 
effective database inquiries. Data mining allows the researcher to utilize 
their pattern recognition skills and knowledge of the field of interest, to 
determine which data-mining results warrant further investigation. For 
example, with relation to this project, genes identified in the chromosome 
14 linkage region would warrant further investigation if they were 
expressed embryonically, were associated with axial asymmetry or if they 
contained trinucleotide repeats. Their homology to the chromosome 11 
linkage region would then be investigated. If a gene was found in the 
chromosome 11 linkage region that was homologous with a gene involved in 
axial asymmetry from the chromosome 14 linkage region, it would be 
considered a strong candidate for chromosome 11 HFM. 
Data mining principally involves the identification of patterns and 
relationships in data that is often obscure in complex data sets. Pattern 
recognition is a major part of data mining as is , by extension, pattern 
discovery. Pertaining to bioinformatics, pattern recognition is primarily 
concerned with character sequence classification representative of 
nucleotide bases or molecular structures. For bioinformatics to be a 
beneficial research tool, the sequence and structure of proteins and other 
molecules must be linked to functional genomics. The online bibliographic 
data base PubMed, is a primary resource of this as it stores functional data 
that links clinical medicine, sequence and structure data. It is expected 
that by mining such databases, relationships between structure and 
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function will be revealed. PubMed was used extensively throughout the data 
mining experimental portion of this project. 
Additionally, numerous databases were searched for research articles 
involving HFM were identified in databases. These articles were 
consequently researched for any indication of possible candidate genes or 
their tissue expression, which would highlight genes as potential candidates, 
particularly when homologous to different organisms. Alternatively, the 
candidate genes identified by data mining were looked up in PubMed for any 
indication of their involvement with different diseases. 
Table 2.3 Common PCR Mutation Detection Methods 
Method References 
*Direct Sequencing of Gene/Chromosome Sanger 1981. 
Denaturing Gradient Gel Electrophoresis Fischer & Lerman, 1983. 
RNase Cleavage Myers et al. , 1985. 
Deletion screening ( ' multiplex PCR' ) Chamberlain et al. , 1988. 
Chemical Mismatch Cleavage Cotton et al., 1988. 
DNA Single-strand Conformation 
Polymorphism (SSCP) Orita et al., 1989. 
RNA SSCP (rSSCP) Sarkar et al. , 1992a. 
Dideoxy Fingerprinting Sarkar et al., 1992b. 
Repeat Expansion Detection (RED) Schalling et al., 1993. 
Restriction Endonuclease Fingerprinting (REF) Liu & Sommer, 1995. 
Heteroduplex Cleavage with Bacterial Resolvases Youil et al., 1995. 
* Relevant to this thesis and reviewed on page 57 
2 . 12. 1 Candidate genes; selection strategies 
Aforementioned, the neural crest is a principle cell population that 
participates in craniofacial development (Jones & Trainor, 2004). 
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Additionally neural crest cells constitute the connective tissue-forming 
mesenchyme of the facial skeleton. It is for this reason, as mentioned 
previously, that genes associated with defects in patterning, particularly of 
neural crest cells, were targeted as candidate genes associated with 
craniofacial abnormalities (Jones & Trainor, 2004; Graham & Smith, 2001). 
Key patterning factors include bone morphogenetic proteins (BMPs), 
retinoic acid (RA), fibroblast growth factors (FGFs), WNT and Hedgehog 
proteins (Melton, Iulianella & Trainor, 2004). Of these, WNTJJ, of the 
WNT gene family of patterning genes was identified as a candidate gene 
for HFM in the WA family by gene mining strategies (Chandler, Kaledijiva, 
personal communication, 2002). Although sequencing ruled out WNTJJ as a 
candidate, the identification of WNTJJ as a possible candidate exemplifies 
genome mining as a technique suitable for candidate gene identification and 
was considered a feasible method for use in this project. 
Transcription factors regulate cell development by governing gene 
expression, differentiation and growth (Lacombe, 1999). Transcription 
factors, 'patterning genes', are the most likely to be involved in 
dysmorphism and are hence the most likely candidate genes (Lacombe, 
1999). Of the patterning genes, HOX genes are of interest in the molecular 
dysmorphology field due to their association with dysmorphic Drosophila 
and mouse phenotypes. 
Disrupted HOX genes in transgenic mice were found to generate 
dysmorphic phenotypes (Lufkin et al., 1992; Chisaka & Capecchi, 1991; 
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Balling, Mutter, Gruss & Kessel, 1989). The generated phenotypes of the 
mice were similar to recognized human HFM malformations. Consequently, 
HOX genes were thought to be disrupted in human malformations (Chisaka 
& Capecchi, 1991). 
There are 4 Hox gene clusters: HOXA (formerly HOX1) on 
chromosome 7, HOXB (formerly HOX2) on chromosome 17, HOXC (formerly 
HOX3) on chromosome 12, and HOXD (formerly HOX4) on chromosome 2. 
No Hox gene clusters are located on human chromosome 11, the region 
associated with the WA HFM. Therefore Hox genes were ruled out as 
candidate genes in this family. 
Within the linkage region on chromosome 11, five genes were 
identified as suitable potential candidate genes for the form of HFM 
segregating in the West Australian family under investigation; UVRAG, 
WNTJJ, GARP, CLNSJA and ARIX UVRAG (UV Radiation resistance 
Associated Gene - 11q13.5) is expressed embryonically and has been 
specifically associated with axial asymmetry (LocusLink 7405). 
Aforementioned, WNTJJ (11q13.5) is a patterning gene from the WNT 
family critical to the establishment of the DIV and A/P axes (Saint­
J eannet et al., 1997). Saint-Jeannet et al. (1997) reasoned that the dorsally 
expressed Wnt molecules could play an important role in the regulation of 
neural crest eel I formation. However, sequencing ruled out WNTJJ as a 
candidate (Chandler, Kaledijiva, personal communication, 2002). ARIX 
(Aristaless homeobox - 11q13.2) has been associated with left-right 
asymmetry determination and craniofacial abnormalities (LocusLink 401). 
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Specifically ARIX is expressed in noradrenergic cell types of the 
sympathetic nervous system, brain and adrenal medulla (Johnson, Smith, 
Johnson, Rhodes, Rinchik, Thayer & Lewis, 1996). Johnson et al. (1996) 
determined ARIX to be homologous to a gene on mouse chromosome 7 
(approximately 50cM distal to the centromere of mouse chromosome 7) and 
defined regions of conserved synteny between mouse and human genomes 
Rinchik, Magnuson, Holdener-Kenny, Kelsey, Bianchi, Conti, Chartier, Brown, 
Brown, & Peters, 1992). 
When investigating map locations of both mouse and human ARIX 
genes, Johnson et al. (1996) described it as highly likely that A RIX 
pertained to "inherited developmental disorders linked to human 11q13" such 
as HFM (p527). 
CLNSJA (Chloride channel, nucleotide-sensitive, 1A - 13q13.5-q14) is 
involved in auxiliary transport protein activity, chloride transport, 
circulation, regulation of cell volume and visual perception and has been 
linked to human diseases such as leukemia (Buyse, De Greef, Raeymaekers, 
Droogmans, Nilius & Eggermont, 1996) and human breast carcinoma (Bekri 
and colleagues, 1997) (LocusLink 1207). With regards to auxiliary transport 
protein activity, CLNSJA facilitates the transport across one or more 
biological membranes without participating directing in transport itself. 
Bekri et al. (1997) through experimentation identified CLNSJA, GA RP and 
UVRAG as genes present within the region 11q13.5-q14.1, which they linked 
to estrogen receptor positive breast carcinomas prone to metastasis. Thus 
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these genes have previously been identified as playing a crucial role in 
human disease associated with aberrant cell proliferation and migration. 
The functions of GARP (Garpin complex) include receptor interactions, 
enzyme inhibition, cell adhesion and cellular trafficking. Pruitt, Katz, 
Sicotte and Maglott (2000) revealed its involvement in early mammalian 
development, neural development, cell polarization, regulation of gene 
expression and apoptosis signalling. furthermore GARP plays a critical role 
in the morphology and dynamics of the cytoskeletal framework. Pruitt et al. 
(2000) also identified GARP as having homology with the Drosophila 
Aristaless gene. Similar to the human gene ARIX (identified as a candidate 
gene in this project) the Drosophila Aristaless gene is specifically 
expressed in noradrenergic cell types of the sympathetic nervous system, 
of the brain and adrenal medulla of Drosophila. 
2 . 13 Animal Models 
Significant insight into craniofacial development has been recently 
unveiled through generation of transgenic mouse mutants. These mice are 
engineered with mutations in genes responsible for craniofacial development 
and the resultant craniofacial syndromes are assessed and compared by 
classical comparative embryological approaches in a range of species (Jones 
& Trainor, 2004). These studies (Jones & Trainor, 2004), have emphasised 
the importance of developmental transcription factors (patterning genes) in 
craniofacial development. 
60 
Moreover, evidence from two mouse models supports genetic 
involvement in HFM. Hemifacial maxillary malformation in heterozygotes 
with incomplete penetrance has been observed to result from alteration in 
the genetic background of the mouse far (first arch}, a recessive lethal 
mouse mutant (Juriloff et al., 1987). 
This mutation was first discovered as an autosomal recessive disorder 
that caused bilateral facial deficiencies in homozygotes. Transfer of the 
mutation to a different strain produced hemifacial deficiencies in 
heterozygotes. Juriloff, Harris and Froster-Iskenius (1987) proposed that 
bilateral and unilateral abnormalities of tissue derived from the first 
branchial arch may be due to a defect in a single gene and suggested that 
the first branchial arch syndromes in mice, which include tissue 
derangements and deficiencies in the maxillary prominence-derived tissues 
may be analogous to those in HFM of the human. 
The second mouse model is an autosomal dominant insertional mutation 
on mouse chromosome 10 which produces a phenotype in hemizygous mice 
which resembles HFM in humans, including microtia, low set ears and an 
abnormal bite resulting from hypoplasia of the second branchial arch 
accompanied by local haemorrhage (Naora et al., 1994). The mutation was 
caused by the insertion of multiple, tandem copies of a myelin basic protein 
during the creation of transgenic mice. Of 21 transgenic mice with the same 
transgene randomly inserted, only one displayed facial deformities 
suggesting that the site of the transgene insertion was responsible for the 
phenotype, rather than the transgene itself (Otani, Manzoku, Shibaski & 
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Nomachi, 1978). In situ hybridization, performed on transgenic mice by 
Naora et al. (1995), identified chromosome 10 as the locus of integration 
and therefore of association with the Hfm phenotype in mice. At the time 
of this study, no naturally occurring mutations were mapped to this locus in 
mice. further investigation of this Hfm model revealed that integration of 
the transgene was accompanied by a 23kb deletion of genomic DNA. 
Evolutionary conserved sequences were identified within and beside the 
deleted region, suggesting that they may correspond to either a gene(s) or 
a regulatory structure(s) that is associated with the Hf M phenotype. No 
mouse without the transgene but containing the 23kb deletion was 
described. The absence of homozygous mice in the offspring of hemizygous 
males and females suggests that the homozygous is lethal during the 
prenatal period. 
Naora et al. (1994) noted that in terms of pathogenesis, the far and 
Hfm mutations were at different loci and supported different aetiologies 
of human HfM, those of vascular abnormality (Hfm) (Causley & Wilson, 
1992) and those pertaining to cartilage perturbation ( far) (Juriloff et al., 
1987). The region of mouse chromosome 10 has syntony to a portion of 
human chromosome 6q24; there are no known genes in this region that are 
obvious candidates for Hf M. Although there is no known region of human 
synteny for the far mouse mutant, this homologous region cannot be 
excluded as containing candidate genes for HfM in the human (Chandler, 
2001). 
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Further potential candidate loci have been derived through 
experimentation in the mouse. Inactivation of FGFB, located on human 
chromosome 10q25, in the first bronchial arch resulted in a failure to 
develop cartilaginous and skeletal first bronchial arch derived structures 
(Trumpp, Depew, Rubenstein, Bishop & Martin, 1999). Mice with 
heterozygous disruption of FGFB in the first bronchial arch, demonstrated 
a less severe phenotype observed on only one side of the head (Trumpp et 
al., 1999). 
Another mouse mutation that deserves mention is the Msxl knockout 
mouse, Msxl being a homeobox gene expressed in numerous tissues in the 
developing foetus including the limb buds and bronchial arches. Satokata 
and Mass (1994) identified the expression of genes of the Msx class in the 
epithelial or mesenchymal components of disparate tissues undergoing 
morphogenesis and observed bilateral facial malformation. Msxl appears to 
be inherited in a recessive fashion. Satokata and Mass (1994) further 
discovered that the phenotype in Msx knockout mice was mainly restricted 
to the first pharyngeal arch, despite strong evidence for a role for Msxl in 
limb pattern formation. Juriloff, Harris & Froster-Iskenius (1987) proposed 
that this may be modified by genetic background, although transfer of the 
mutation to different strains of mice to test this proposition has not yet 
been done. Despite none of the five candidate genes displaying homology to 
known mouse mutants this process assisted through eliminating mouse 
homology as a technique for candidate gene selection in the genome mining 
process. 
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Table 2 .5 Chromosomal abnormalities responsible for HFM 
Chromosome abnormality Reports Candidate Reference 
invl 1 236 
del5p 3 237, 238 
Monosomy 6q 1 239 
del6q 1 239 
tri7 mosaicism 1 HOXD 235 
Duplication7q 1 240 
del8q 1 241 
tri9 mosaicism 1 242 
tri 18 mosaicism 1 243 
Tri 18 2 239, 244 
Recombinant 18 1 245 
del18q 1 246 
del 22q 2 239,247 
49 XXXXY 1 248 
47 XXY 1 249 
49 xxxxx 1 250 
47 XXX 1 251 
Adapted from Chandler (2001) 
2 . 14 Bioinformatics 
As a result of the Human Genome Project, there are a number of 
freely available tools which can be implemented to identify candidate genes: 
advanced linkage analysis software, automated genotyping protocols, 
comprehensive genomic and cDNA libraries in a variety of vectors, and 
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public access to genetic databases. Combinations of these tools were used 
to 'data mine' the genes present in the chromosome 11 linkage area. 
2 . 15 Candidate genes; Selection by association studies 
Taking into account the complexity of HFM classification, it would be 
unwise to assume that the syndrome is caused by a defect in a single gene. 
It is more likely, as pointed out by Mulvihill (1995) that differing mutations 
in multiple but related genes could produce the range of phenotypes 
displayed in HFM. As yet, the only region linked by family studies with West 
Australian families segregating HFM are the chromosome 11 and 
chromosome 14 studies. Alternate chromosomal abnormalities responsible 
for HFM are listed in Table 2.5, p70. Although the report by Hodes et al. 
(1981) of a HFM patient with a trisomy seven suggests linkage of the 
disorder to chromosome 7 is not localised enough to define a candidate 
gene. The only other indications of candidate genes come from the animal 
models described above. 
Primarily, through bioinformatics this project researched the 
chromosome 14 linkage region for any indications of homology to the 
chromosome 11 linkage region. Using data mining techniques (2.14), a gene 
list from markers D1451142 to D14526 7 (Kelberman et al., 2001) was 
created for chromosome 14 (Appendix 16). Each gene in this linkage region 
was researched and documented under headings including alternative 
symbols, alias names, expression, tissue specificity, family from which the 
gene was derived, function, locus link reference number, position in the 
linkage region and homologs (Appendix 6 & 8). This linkage region on 
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chromosome 14 identified by Kelberman et al. (2001) harbours the 
Goosecoid gene, a candidate for the chromosome 14 linked HFM based on 
mouse expression and phenotypic data. 
2 . 16 Conclusion 
Hemifacial microsomia is a common birth defect involving first and 
second bronchial arch derivatives. It is a complex deformity that displays a 
spectrum of anomalies involving soft-tissue and skeletal structures. 
Additionally it can involve deformation of the cardiac, pulmonary, 
gastrointestinal, renal and central nervous systems. The majority of 
reported cases are considered sporadic in origin, however substantial 
evidence supporting genetic involvement has evolved. 
Substantial debate has surrounded the cause and pathogenesis of HFM. It 
appears HFM results from a culmination of causal factors, including 
defective genes, teratogenic substances or vascular anomalies. Theories 
attempting to explain the pathogenesis of HFM are numerous and range 
from neural crest cell involvement to a deficiency in the development of the 
bronchial arch and head mesoderm. 
As any structure deriving from the first or second bronchial arch may 
be affected, the clinical picture can vary considerably. Of significance is 
the universal demonstration of axial asymmetry. Predominant features of 
HFM include progressive underdevelopment of the mandible, zygoma, 
external and middle ear. 
66 
Accurate assessment of facial anomalies is essential for effective 
diagnosis, classification, treatment and management plans. The most recent 
systems of classification pertaining to diagnosis include the Skeletal, 
Auricle and Soft-tissue (SAT) multisystem classification and the Orbital 
distortion, Mandibular hypoplasia, Ear anomaly, Nerve involvement and Soft 
tissue deficiency (OMENS) classification system. Alternative systems, 
including the Pruzansky classification system, Teconi and Hall ' s  phenotypic 
classification system and Munro and Lauritzen' s  system were alternative 
classification systems devised to guide treatment planning and diagnosis of 
HFM, although not as widely accepted as the SAT and OMENS 
classification system. Involvement of facial soft tissue can be mild or 
severe and needs to be thoroughly assessed prior to surgical intervention 
and treatment strategies. 
The term hemifacial microsomia was initially coined by Gorlin, Jue, 
Jacobson and Goldschmidt in 1963 to refer to patients displaying unilateral 
microtia, macrostomia and hypoplasia of the mandibular ramus and condyle 
(Politi, Sembronio, Robiony & Costa, 2002). The variable expressivity of an 
autosomal dominant gene may explain the variability in the phenotype of 
HFM in two reported HFM pedigrees. No genes had as yet been identified 
for the WA family, although several likely candidate genes were selected, 
as a result of careful selection criteria. 
Despite analysis of genes in the chromosome 11 linkage region, known 
mouse mutants, and genes identified in the chromosome 14 linkage region no 
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homologies were discovered and thus this project implemented PCR and 
sequencing to assess candidate genes. 
2 .17 Aims 
1. To identify HFM candidate genes in one WA family clearly 
segregating with HFM 
2. To find mutations in these genes on chromosome 11 as would cause 
HFM 
To accomplish these aims, a combination of sophisticated genetic techniques 
was utilised, including bioinformatics, mutation detection by PCR and 
sequencing, and data mining. 
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Chapter 3 :  Research Methods 
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3 .  0 Introduction 
This chapter contains in-depth details of experimental protocols. It 
also includes details of software used to obtain and analyse data for this 
thesis. Protocols have been adapted from a number of sources, all of 
which are referenced within the text. It is through methodology 
detailed in this chapter that candidate genes were selected and 
sequenced for this project. 
3 .1 Online Databases 
Table 3 .1 - Web-based databases used to obtain and analyse data 
Database Web address (URL) 
PubMed www.ncbi.nlm.nih.gov/entrez/guery.fcgi 
Draft human sequence www.genome.cse.ucsc.edu 
ENSEMBL www.ensembl.org 
Online Mendelian Inheritance in Man (OMIM) www.ncbi.nlm.gov/OMIM 
GenBank www.ncbi.nlm.nih.gov 
The Genome Database (GDB) www. db.or 
To identify literature and data relevant to this project, searches 
were performed under (a combination of) the following headings 
' hemifacial microsomia' ,  ' malformation' ,  ' congenital disorders ' ,  ' birth 
defects ' ,  ' axial asymmetry ' ,  ' trinucleotide repeat ' ,  ' Goldenhar 
! syndrome ' ,  ' branchial arch derivatives ' ,  ' oculo-auriculo-vertebral 
I spectrum' ,  otomandibular dysostosis ' ,  ' lateral facial dysplasia ' ,  
I 
craniofacial microsomia' in a number of databases (Table 3.1, p70). 
l 
3 .1 .1 Draft Human Genome Sequence and ENSEMBL 
The Draft Human Genome Sequence and ENSEMBL are two 
different interfaces that have been developed for accessing the draft 
human sequence. Both databases were initially released in June 2000 and 
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have since been regularly upgraded. Each interface is searchable by 
marker, gene name, clone name and/or base pair number along a 
chromosome. Moreover, both sites incorporate a variety of features 
including positioning of l inkage markers, gaps, known and predicted genes 
and the position and types of repeats. 
The physical size of the chromosome 11  region in l inkage with 
hemifacial microsomia in the West Austral ian fami ly was estimated from 
the sequence of the Human Genome Working Draft avai lable at UCSC 
genome website (http:/ /www.genome.ucsc.edu/) on Apri l  2001. This was 
achieved by mapping out the positions of the markers flanking the 
chromosome 11 HFM candidate region, namely D11S1883 and D11S911 as 
the gene responsible for chromosome 11 HFM is expected to l ie within 
this region. Markers refer to polymorphisms such as microsatel l ite 
repeats that are l inked to a disease locus (Jorde et al., 2000). This 
estimation of the l inkage region was updated in September 2001, 
December 2001, Apri l 2002 and September 2002 , during the initial 
stages of this thesis (See Haplotypes, Figure 2). 
The UCSC (University of Cal ifornia, Santa Cruz) database was used 
to search for these same flanking markers, namely D11S1883 and 
D11S911, to obtain a complete map of the region and associated genes 
(http:/ /www.genome.cse.ucsc.edu). By c l icking on the l inkage region a 
complete l ist of genes within this region was displayed. 
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3 . 1 . 2  Onl ine Mendelian inheritance in man (OMIM) 
(http://www. omim .com/) 
OMIM is a database containing a definitive col lection of human 
genes and associated genetic disorders. Cytogenetic maps of diseases 
(morb id map) and genes (gene map) are avai lable from this site. 
Figure 5 Chromosome 1 1  
Linkage region ident if ied in  red 
Adapted from data presented in uses (http: //www.genome.ucsc .edu) 
A l ist of genes with in  th is  region is depicted in Append ix 9 
From these cand idate genes were selected by data min ing as descr ibed in  Section 3.4 
In particular this database was used to identify the markers 
flanking the region of interest on chromosome 11 ,  locate each of the 
candidate genes on chromosome 11 ,  and identify their nuc leotide posit ion 
in  relation to other genes present with in the region. Furthermore OMIM 
was used to obtain information on each of the genes selected as 
cand idates for chromosome 11 HFM. The OMIM databases provided l i nks 
to the NCBI interface which within itself offered links to over 1 1  
databases (Tab le 3 .2 ,  p75). Each link unraveled new databases associated 
with the gene in question and thereby generated a cascade of 
information on each gene with in  the chromosome 1 1  linkage reg ion.  Based 
on information retr ieved from these databases , four cand idate genes 
were selected with the aid of str i ct selection criter ia given in Section 
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3.6. Relevant information obtained through bioinformatics investigations 
is displayed in Appendix 15. 
3 . 1. 3  GenBank (http: //www.ncbi. nlm . nih .gov) 
GenBank at the National Institutes of Health, USA, contains DNA 
sequences from all species tested. This database was used by the author 
of this project to obtain the sequences of known genes located in the 
linkage regions for hemifacial microsomia. GenBank searches for 
candidate gene sequences were performed by BLAST using a GenBank 
accession number or, if this number was not known, a partial DNA 
sequence of the chromosome 1 1  HFM linkage region, obtained from the 
Draft Human Sequence, was used. GenBank was also used to confirm 
primer design for PCR and sequencing reactions and as the source of 
'normal' sequence for comparative analysis with sequence generated from 
the DNA of the patient affected with HFM. 
Aforementioned, the NCBI database comprises a number of 
databases, the majority of which were used. These are alphabetically 
listed and briefly described in Table 3.2 (p75). More specifically, the 
database 'Books' was used for general information on a gene, primarily 
expression and/or association with a disease. 'Genome' was used 
extensively to map the genes within the chromosome and obtain genomic 
sequences. OMIM was specifically used for information on genes and 
associated pathologies, as was PubMed, which was further used to 
identify syntony to other genes within the human genome. 
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3 .  2 Online Analysis Software 
3 .  2 . 1  Basic local alignment sequence tool (BLAST) 
(http: //www. ncbi. nlm. nih .gov/BLAST) 
The BLAST program enables a given DNA sequence to be compared 
with all sequences in GenBank in both forward and reverse orientation. 
BLAST uses algorithms to identify optimal sequence alignments, and 
search results are typically displayed as a series of statistical analyses 
of the comparisons (Fassler, Nadel, Richardson, McEntyre, Schuler, 
McGinnis, Pongor & Landsman, 2000). The database provides a list of 
sequences as pair wise comparisons between the test sequence and each 
related identified sequence (Fassler et al. , 2000). BLAST was used to 
compare sequences generated from PCR products of candidate genes in 
patient DNA against the wild type sequence of that gene in GenBank. 
Mismatches indicate a possible mutation. Should a difference 
between the known published 'normal' unaffected sequence and the HFM 
affected sequence be noted, further investigation would ensue to 
determine the specific mutation from which HFM could derive. 
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Table 3 . 2  Databases included in NCBI Entrez 
Database 
3D  domains 
Books 
Description 
Protein domains from NCBI' s Conserved Domain Database 
A biomedical book col lection 
Genome Views of genomes, chromosomes, sequence maps, and 
integrated physical and genetic maps 
Nucleotide Nucleotide sequence data from GenBank, the European 
Molecular Biology Laboratory (EMBL) and the DNA database of 
Japan (DDBJ), the Genome Sequence Database (GSDB) and 
patent sequences from US Patent and Trademark Office (USPTO) as 
wel l as other international patent off ices 
OMIM Human genes and genetic disorders 
PopSet Nucleotide and protein sequence data that has been aligned and 
submitted as a set resulting from a population, phylogenetic or 
mutation studies 
Probeset Hybridization array and Gene Expression Omnibus (GEO) 
Protein Protein Information Resource (PIR) (vertebrate protein sequences) 
SWISS-PROT, Protein Research Foundation (PRF) and 
Protein Databank (PDB), and from the coding sequences that have 
been translated from GenBank, EMBL and DDBJ DNA sequences 
PubMed Biomedical l iterature 
Structure Protein Databank (PDB) derived experimental data from 
crystal lographic and NMR structure determinations 
Taxonomy Names of al l the organisms represented in NCBI' s genetic 
database 
Adapted from Bergeron (2003) 
3. 3 Sequence Maps 
Similar to the use of flow diagrams being used to portray content 
and describe the organization of various components within a program, 
gene maps provide a sophisticated view of a gene and the location of its 
nucleotide sequence within a chromosome (Bergeron, 2003). The Web­
based Map Viewer is a fundamental application used to map genes within 
the genome giving its chromosome location (Figure 5). The Map Viewer is 
part of NCBI' s  integrated Entrez system and provides a composite 
interface with access to various online databases. Through these 
programs, homologous genes can be located in the genomes of different 
species. Furthermore it visually demonstrates the distance between 
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genes in a chromosomal region and information on the sequence of a gene 
in the critical region of a chromosome. Graphs are typically used to map 
the collated sequences from the sequential databases of NCBI and 
relevant links are supplied corresponding to associated databases that 
relate to specific diseases and sequences of the genes themselves 
(Fassler et al. , 2000). The gene list obtained from the Map Viewer 
program (Appendix 1 1) was a starting point for the bioinformatics 
methods used to identify candidate genes present in the chromosome 11  
linkage region as it is from this database that the original list of genes 
was derived [http:/ /www.ncbi.nlm.nih.gov/genome/guide/human/] 
(Appendix 9). Each specific gene was then researched for criteria 
relating to candidate gene selection (Appendix 7 & 12). 
The Map Viewer was monitored regularly to check the positions of 
the flanking markers and the genes within the linkage region. As more of 
the Draft Human Genome was completed markers within and flanking the 
linkage region were not always mapped at previous locations. It 
therefore became essential to continually monitor the marker positions 
to ensure the identified candidate genes remained within the linkage 
region - Map Viewer was used for this purpose. This is explained further 
in 4.1. 
3 .4 Data Mining 
This project adopted a strategy known as 'genome mining' (Houle, 
Cadigan, Henry, Pinnamaneni & Lundahl, 2001) to identify hemifacial 
microsomia candidate genes. This strategy involved obtaining all relevant 
data on the genes from available databases, cross-tabulating relevant 
details of the genes and predicted genes in the two known hemifacial 
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microsomia candidate regions on chromosome 11 and 14, and then cross­
tabulating relevant information with available information on vertebrate 
and invertebrate genomes from appropriate databases. Information 
obtained from databases for each gene included: names, al iases, 
acronyms, functions, disease associations (particularly with axial 
asymmetry), and association with trinucleotide repeat expansions. 
Appropriate analytic methodology incorporating data mining, continual 
investigation of the l inkage region using numerous databases and 
thorough evaluation of a l l  the genes present in the chromosome 11 
l inkage region enabled identification of candidate genes. 
The s ize and complexity of current genomic databases assisted with 
data mining as it was possible to acquire sufficient information on gene 
sequence, structure and function. This was particularly relevant to this 
project, as novel strategies such as data mining have not only become 
possible through the introduction and expansion of various web 
databases but have become an eminent research tool, as d isplayed in this 
project. 
3 .  5 Data Collection / Storage 
3 .5.1 Pedigree data 
Pedigree data includes previously col lected cl inical and personal data 
for patients affected with chromosome 11 HFM. Cl inical ascertainment 
was conducted by Professor Jack Goldblatt from King Edward Memorial 
Hospital (KEMH). Information provided by the fami ly was coded to 
ensure confidential ity. DNA of one affected patient was provided by 
Professor Goldblatt, Royal Perth Hospital (RPH) for use in this project. 
Prior to the col lection of DNA, the patient was required to sign a 
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consent form, a copy of which is given in  Appendix 13. This DNA sample 
was coded with a unique identifier using the DNA Daybook system 
employed by the Department of Neuropathology, RPH. This code was 
annoted to the HFM pedigree under investigation. The only information 
provided for the genetic investigations reported in this thesis was an 
annoted pedigree with HFM status indicated. Patient (III:6, DOB 
05.01. 1981) is affected with HFM as previously identified by Singer et 
al. (1994). This patient demonstrated microtic right ear with ipsi lateral 
macrostomia. On a previous occasion, this was surgical ly repaired 
postnatal ly with simultaneous excision of a right pre-auricular skin tag. 
This patient had a right deviated chin point and upper right occlousal 
plane. Soft tissue was hypoplastic and overlay both the right infraorbital 
and ramus region. Singer et al. (1994) describes that upon oral 
examination this patient was found to have a "Class 1 malocclusion in the 
mixed dentition characterized by the d isplacement of the upper and 
lower centre l ines to the right" (p287). On opening, the mandible 
deviated to the right despite no history of temporomandibular joint 
dysfunction. No teratogenic exposure or parental consanguinity was 
identified (Singer et al., 1994). This patient is an excel lent sample for 
DNA mutation analysis because the patient is in the III generation and 
displays a moderately severe phenotype of HFM. 
3. 6 Identification of Candidate Genes 
Mutations in different genes, perhaps numerous genes, are l i kely to 
cause dysmorphology. As mentioned in the introduction, prime candidate 
genes from the chromosome 11 HFM l inkage region were identified by 
adopting specific selection criteria, described below, fol lowed by 
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comparison with mouse dysmorphology genes and chromosome HFM 14 
genes. 
Firstly, each and every gene located in the chromosome 11  HFM 
linkage area was inspected for three selection criteria; (1) candidate 
genes should be expressed embryonically as HFM is a congenital 
disorder. (2) Candidate genes would be expected to be associated with 
axial asymmetry, a definitive and unique feature of hemifacial 
microsomia and (3) genes should be associated with trinucleotide 
repeats. Trinucleotide repeat expansions are important to research as 
they are a form of mutation associated with expansion in copy number of 
a sequence of three nucleotides, situated in or near a gene (Cummings, 
2000). Trinucleotide repeats, alternatively termed microsatellites, are 
well documented as being unstable and have been strongly correlated 
with disease severity (Jorde, Carey, Bamshad & White, 2000). These 
repeats are particularly relevant to this study as the chromosome 11  
form of HFM appears to be more severe with succeeding generations. If 
chromosome 11  HFM is indeed displaying anticipation, the appearance of 
more severe symptoms at earlier ages in succeeding generations would be 
expected (Cummings, 2000) and this was indeed observed (Table 1. 1, p7); 
such anticipation could be associated with trinucleotide repeats (Brook, 
McCurrah, Harle et al., 1992). 
Several diseases have been documented in which the number of 
trinucleotide repeats increases with successive generations, accompanied 
by increasing severity of the disorder. This phenomenon is particularly 
evident in cases of myotonic dystrophy and Huntington Disease and 
Fragile X (Brook, McCurrah, Harle et al., 1992). Typically, in disorders 
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representative of varying degrees of anticipation, any initial alteration in 
the number of copies of a repeat sequence, either within or near a gene, 
would increase the probability that further modification in repeat 
numbers will occur. 
This in turn generates alleles with full mutations. For example, in 
regions of the genome containing trinucleotide repeats, this event 
increases the chance of and promotes further expansion and subsequent 
development of the disease phenotype (Cummings, 2000). Inheritance of 
such disorders might be explained through forms of genome instability 
as opposed to simple Mendelian inheritance (single gene mutation 
inheritance), as once assumed (Cummings, 2000; Jorde, Carey, Bamshad 
& White, 2000). Genome instability is an abnormal condition in which 
there is a substantial increase in mutations throughout the genome and 
includes the widespread mutations, chromosome breaks and aneuploidy 
(Jorde, Carey, Bamshad & White, 2000). Screening for these repeats 
would be an additional filtering process for candidate gene selection. To 
do this, the entire genomic sequence for a particular gene was copied 
onto a word document and then each possible trinucleotide combination 
AAC, ACT, GCC, GCG etc. within the entire chromosome 11 linkage region 
was identified using the 'find' function in Microsoft Word (Appendix 10). 
Using the methods described above, eleven genes out of a total of 
131 genes were identified as potential candidates. In order of likelihood 
of possessing the mutation responsible for HFM, they are UVRAG, ARIX, 
WNTJJ, GARP, CLNSJA, PKRIR, CAPN5, LGAL S12, DKFZP564M082 and 
OMP. UVRAG (UV Radiation resistance Associated Gene - 11q13.5) is 
expressed embryonically (Perelman et al. , 1997) (Locuslink 7405), is 
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associated with axial (a)symmetry and contains two trinucleotide 
repeats, AAC at 74,105,973-74,105,987 and at 74,272,958-74,272,978 
(Ensembl gene ID ENSG00000137493). 
ARIX (Aristaless homeobox - 11q13.2) has been associated with 
left-right asymmetry determination and craniofacial abnormalities 
(Pattyn, Morin, Cremer, Goridis & Brunet, 1997) (LocusLink 401) and is 
situated near two GTT trinucleotide repeats (75,904,244-75,904,267 
and 75,934,321-75,934,344) (LocusID 1 16648). Aforementioned, ARIX 
is specifically expressed in noradrenergic cell types of the sympathetic 
nervous system, brain and adrenal medulla (Johnson, Smith, Johnson, 
Rhodes, Rinchik, Thayer & Lewis, 1996). Johnson et al. (1996) determined 
ARIX to be homologous to the mouse chromosome 7 (Phox2). Using 
backcross analytical techniques, Johnson et al. (1996) mapped ARIX to 
mouse chromosome 7, approximately 50 cM distal to the centromere, in a 
region showing conservation of synteny with human chromosome 11. This 
author's research also identified such regions of conserved synteny 
between mouse and human genomes and confirms the selection of ARIX 
as a candidate gene for "inherited developmental disorders linked to 
human 1 1q13" such as HFM (Johnson et al., 1996, p,527). 
WNTJJ is a patterning gene from the WNT family critical to the 
establishment of the D/V and A/P axes. As previously discussed, this 
gene family is specifically expressed along the D/V axis of the 
developing neural tube (Saint-Jeannet et al., 1997). This gene family 
consists of structurally related genes encoding secreted signalling 
proteins that have been implicated in oncogenesis and in several 
developmental processes, including regulation of cell fate and patterning 
81  
during embryogenesis (LocusLink 7481). The dorsally expressed Wnt 
molecules play an important role in the regulation of neural crest cell 
formation (Saint-Jeannet et al., 1997) and in anterior-posterior 
patterning of the limb. WNTis expressed both embryonically and fetally 
and is located near a CAG trinucleotide repeat (73,925,066-73,925,080) 
and near two GTT repeats (73,869,466-74,369,532 and 73,881,196 -
73,881,210) (Ensembl gene ID ENSG00000085741). 
CLNSJA (Chloride channel, nucleotide-sensitive, 1A - 11q13.5-q14 is 
involved in auxiliary transport protein activity, chloride transport, 
circulation, regulation of cell volume and visual perception and has been 
linked to human diseases such as leukemia (Buyse et al., 1996) and human 
breast carcinoma (Bekri et al., 1997) (LocusLink 1207). With regards to 
auxiliary transport protein activity, CLNSJA facilitates the transport 
across one or more biological membranes without participating directing 
in transport itself. Bekri et al. (1997) identified CLNSJA, GARP and 
UVRAG as genes present within the region 11q13.5-q14.1, which is linked 
to estrogen receptor positive breast carcinomas prone to metastasis. 
The functions of GARP (Garpin complex) includes receptor 
interactions, enzyme inhibition, cell adhesion and cellular trafficking. As 
previously discussed Pruitt, Katz, Sicotte and Maglott (2000) reveal its 
involvement in early mammalian development, neural development, cell 
polarization, regulation of gene expression and apoptosis signalling. 
Furthermore GARP may play a critical role in the morphology and 
dynamics of the cytoskeletal framework. This author also identifies 
GARP as having homology with the Drosophila Aristaless gene and to the 
human gene ARIX The ARIX gene is specifically expressed in 
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noradrenergic cell types of the sympathetic nervous system, brain and 
adrenal medulla in mice and Drosophila (Pruitt et al., 2000). With specific 
regards to the selection criteria primarily used to identify candidate 
genes in this project both CLNSJA and GARP are located near two 
trinucleotide repeats (GTT repeats near GARP at 73,512,866-
73,512,889 and CLNSJA at 76,696,182-76,696,199) (Ensembl gene ID 
ENSG00000137507 and Ensembl gene ID ENSG00000074201 
respectively). 
PRKRIR (protein-kinase, interferon-inducible double stranded RNA 
dependent inhibitor, repressor of (P58 repressor) - 11q13.5) and CAPN5 
(Calpain 5 - 11q14) are both expressed embryonically (Gale et al., 1998; 
Dear, Matena, Vingron & Boehm, 1997) and are located near trinucleotide 
repeat expansions (PKRIR - (CGG) 73,782,820-73,782,834; (CAG) 
73,925,066-73,925,080; (GCG) 73,782,819-73,782,833 (AAC) 
73,741,283-74,047,866 and 73,677,006-73,677,020 CAPN5 - (CTT) 
73,125,943-73,125,963) (Ensembl gene ID ENSG00000137492 and 
Ensembl gene ID ENSG00000149260 respectively). 
Similarly L GAL S12 (lectin, galactoside-binding, soluble, 12 (galectin 
12) - 11q13) and OMP (olfactory marker protein - 11q13.5) are fetally 
expressed (Yang, Hsu, Yu, Ni, Liu, 2001; Evans et al., 1993 respectively) 
(PMID 9302557, Ensembl gene ID ENSF00000009799 respectively). 
The OMP gene structure and protein sequence are highly conserved 
between mouse, rat and human (Ricnchik et al., 1992). DKFZP564M082 
(DKFZP564M082 protein - 11q13.4) is homologous to mouse chromosome 
7 and is phenotypically known to produce congenital abnormalities 
(LocusID: 25906). 
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Of these eleven genes, due to their compliance with the selection 
criteria and specific association with craniofacial deformation and axial 
development, three were identified as prime candidates, UVRAG, WN TJJ 
and ARIX Chandler (2001) and Kaledijiva (2002) (personal 
communication) had previously selected the developmental gene WN TJJ 
as a candidate for HFM due to its involvement in embryonic axial 
patterning, and sequenced this gene in an unaffected and an affected 
individual from the West Australian chromosome 11 HFM pedigree. The 
WN TJJ sequences for the HFM affected individual and the unaffected 
individual did not vary significantly from each other or the published 
sequence, and as no mutations were found, this gene was eliminated as a 
candidate. 
Due to the properties of GARP, namely its homology to Drosophila 
ARIX and its involvement in cytoskeletal framework and neural 
development, it was chosen as a possible candidate gene and was 
sequenced for mutations in the HFM patient, along with UVRAG and 
ARIX, as will CLNSJA. 
Regions of the mouse genome homologous to the human chromosome 
11 HFM linkage region were identified through web-searches and genes 
lying within homologous regions were inspected for the same three 
criteria; embryonic expression, association with trinucleotide repeats 
and association with axial asymmetry (Appendix 15). 
Genes in the chromosome 11 and chromosome 14 HFM linkage 
regions were compared in regard to the same three criteria; embryonic 
expression, association with trinucleotide repeats and association with 
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axial asymmetry. Genes that satisfied these criteria and shared 
homology with both HFM linkage regions would become prime HFM 
candidates. This comparison was essential as the chromosome 14 region 
has been definitively linked to autosomal dominant HFM (Kelberman et 
a/.) and could thus provide crucial information on genes likely to be 
responsible for chromosome 11 HFM. 
3 .  7 Sequencing of Candidate Genes to Identify Mutations 
The four candidate genes, UVRAG, ARIX, CLNSJA and GARP were 
analyzed for mutations by standard PCR methodology. Exonic sequences 
of each of three candidate genes in an affected patient were sequenced 
and compared with normal gene sequence, obtained from the NCBI 
database. Several attempts to sequence the fourth gene (ARIX) were 
unsuccessful. 
3 .7.1 UVRAG (Candidate gene 1) 
The UVRAG gene is 328,418 bases in length, including both exonic 
and intronic sequence and spans base numbers 74,047,885 to 74,376,860 
on chromosome 11q13.5 (as at April 2002). UVRAG contains 15 exons. The 
number of bases in each exon and their positions on chromosome 11  are 
depicted in Table 3.3 (p86), to clarify the nucleotide positions and 
regions of UVRAG to be sequenced. 
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Table 3 . 3  UVRAG exons and positions on chromosome 11 
Exon Position (bases) No . bases 
1 74,049 ,885-7 4,050,179 294 
2 74,086 ,537-74,086 ,655 118 
3 74,096 ,400-7 4,096 ,435 35 
4 74,114,532-74,114,694 162 
5 74,123,482-74,123,557 75 
6 74,146,607-74,146,693 86 
7 74,196,098-74,196,204 106 
8 74,218,041-74,218,168 127 
9 74,238,659-74,238,744 85 
10 74,242 ,188-74,242 ,276 88 
11 74,243,461-74,243 ,522 61 
12 74,251,469-74,251,635 166 
13 74,300 ,364-7 4,300,486 122 
14 74,350 ,578-7 4,350,670 92 
15 (i) 74,375,366 - 74 375 968 602 
15 (i i) 74,375 ,842-7 4,376 ,425 583 
15 (ii i) 74,376 ,320-74,376 ,860 540 
15 (iv) 74, 376,238-74,376 ,502 464 
Given the enormous size of exon 15 (Appendix 14), and for purposes 
of experimentation, the exon was divided into four parts, and PCR 
primers were chosen to span both halves so that the entire exon could 
be analyzed by sequencing, exon 15(i) spanned 602 bases, exon 15(ii) 
spanned 583 bases, exon 15(iii) spanned 540 bases and exon 15(iv) 
spanned 464 bases. 
3 .7.2 ARIX (Candidate gene 2) 
The ARIX gene is 4,426 bases in length, including both intronic and 
exonic sequence and spans from base numbers 75,883,451 to 75,887,841 
on chromosome 11 (as at April 2002). The ARIX gene contains 3 exons. 
The number of bases in each exon and their positions on chromosome 11  
are as depicted in Table 3.4 (p87), to indicate regions of the gene to be 
sequenced. 
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Table 3 .4 ARIX exons and positions on chromosome 1 1  
Exon 
1 
2 
3 
Span 
75,883 ,451-75 ,883 ,803 
75,886,282-75,886,470 
75,887,370-78,887,820 
3 .  7. 3 GARP ( Candidate gene 3) 
No. bases 
352 
188 
450 
The GARPgene is 12,322 bases in length, including both intronic and 
exonic sequence and spans from base numbers 74,891,183-74,903,592 on 
chromosome 11 (as at Apri l 2002). The GARP gene contains three exons. 
The third exon is 5,097 bases in length and was divided into eight parts 
for choice of PCR primer positions so that the entire exon could be 
analyzed by sequencing. The number of bases in each exon and their 
positions on chromosome 11 are depicted in Table 3.5 (p87), to indicate 
nucleotides that require sequencing for mutations in  affected and 
unaffected samples. 
Table 3 .  5 GARP exons and positions on chromosome 1 1  
Exon Span No. bases 
1 74,891 ,183- 74,891,371 188 
2 74,894,952-74,895,264 88 
3 (i) 74,899 ,273-7 4,899,971 699 
(ii) 74,899,814-74,900,391 578 
(ii i) 74,900,281-74,900,911 630 
(iv) 74,900,591-74,901,191 600 
(v) 74,901,257-74,901,866 609 
(vi) 74,901,773-74,902,343 570 
(vi i )  74,902 ,297-74,902,898 601 
(vi i i)  74,902,782-74,903,490 708 
3 .7.4 CLNSJA (Candidate gene 4) 
The CLNSIA gene is 21,648 bases in length, includ ing both intronic 
and exonic sequence and spans base numbers 75,889,882 to 75,937,186 
on chromosome 11. The CLNSJA gene contains 7 exons. The number of 
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bases in each exon and their positions on chromosome 11  are depicted in 
Table 3.6 (p88), to indicate regions of the gene to be sequenced. 
Table 3 .6  CLNS1A exons and positions on chromosome 11 
Exon Span No. bases 
1 75,889,882-75,890,095 213 
2 75,897,788-75,897,925 137 
3 75 ,901,868-75 ,901,970 102 
4 75,902,616-75,902,724 108 
5 75,905 ,005-75 ,905 ,179 174 
6 75 ,907,980-75 ,908 ,070 90 
7(i) 75,910 ,899-75 ,911,371 472 
7(ii) 75,911,312-75,911 ,704 392 
Given the size of exon 7, and for purposes of experimentation, the 
exon was divided into two overlapping parts, exon 7(i) spanned 472 bases 
(92 intronic region bases, 380 exonic bases) (75,910,899-75,911,371), 
exon 7(i i) spanned 392 bases (75,911,312-75,911,704). For exon 7(i) 
intronic sequence was used to facil itate primer binding in the PCR 
reaction. The intronic primer position was considered to be the best 
choice according to the primer design programs, indicated and explained 
further in Section 3.9.1.2. 
3 . 8  Molecular Methods 
3 . 8 .1 Markers 
Individuals of the WA family had been previously genotyped for 
l inkage analysis using a variety of markers identified from a number of 
genetic maps (Chandler, 2001; Figure 2, p10 and Appendix 5). A total of 
152 polymorphic markers with an average intermarker distance of 20cM 
were analysed for the WA fami ly. These markers were chosen from a 
variety of sources including Genethon and CHLC and genotyped at ANRI. 
Chandler (2001) performed a two-point analysis and obtained a 2.11 Lod 
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score for markers D11S987 and D11S916 on 11q13-23 (See section 2. 10). 
Therefore the linkage region was defined as being within this area. 
3 .  9 Mutation Detection / Sequencing 
3 .  9 .1 The polymerase chain reaction (PCR) 
The polymerase chain reaction (PCR) can be performed in vitro and 
uses heat stable DNA polymerases to amplify a region of isolated DNA 
that is selected and bound by two short strands of complementary DNA 
sequences (the primers), chosen specifically to select the DNA regions 
of interest. DNA polymerase then copies the two strands by inserting 
complementary bases as it reads both strands of the DNA in a 3' to 5' 
direction from the bound initiating primers, producing two new strands 
of double stranded DNA. The original target sequences as well as the 
copies are then replicated repeatedly in subsequent tandem reactions 
resulting in an exponential increase in the number of copies of the region 
(Figure 6). In general the size of the region that can be amplified by this 
method does not exceed 2000 base pairs. 
The reaction mix contains individual nucleotides together with 
primers, template DNA and Taq polymerase. Taq DNA polymerase 
amplifies template DNA by attaching nucleotides to the 3' hydroxyl 
group of the primer and extends along each template strand by adding 
complementary nucleotides. DNA synthesis proceeds in a 5' to 3' 
direction while template DNA strands are 'read' in a 3' to 5' direction. 
This ultimately gives rise to multiple copies of double stranded DNA. 
Exponential amplification is obtained by cycling of the above conditions 
for 20-40 cycles. 
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PCR amplifies short sequences of DNA approximately one billion 
times. Thus in a standard PCR, picograms of template DNA can be 
amplified to produce micrograms of DNA product. The resultant product 
will be multiple copies of a selected DNA region that can be routinely 
sized by comparison with known size markers using agarose gel 
electrophoresis. 
Electrophoresis is a separation technique based on the movements 
of charged molecules in an electric field. Molecules of different lengths 
move at different rates and the different sized components of a 
mixture will be separated when an electric field is applied. Several 
factors have important effects on the mobility of DNA fragments in 
agarose gels and can be used to advantage, as in this study, to optimize 
separation of DNA fragments, including agarose concentration (2%) and 
voltage (100W). hydrogen bonds 
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Figure 6 Schematic representation of the polymerase chain reaction 
(PCR) 
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3. 9 . 1 . 1  Primers 
Primers are chemically synthesised oligonucleotides, usually 20-25 
nucleotides in length obtained commercially from several Biotechnology 
companies such as Geneworks, Research Genetics and Applied 
Biosystems. For this project, primers were designed to be 
complementary to both the 5' and 3' ends of the intronic sequences 
surrounding each exon under examination (Figure 7), as identified in 
GenBank. They were designed using primer design programs to comply 
with the criteria outlined in Section 3.9. 1.2. Oligo's were suspended in 
water to a concentration of 100ng/µL and a working solution of 50ng/µL 
was prepared for each PCR reaction. 
3. 9 . 1. 2 Primer design 
The primer annealing temperature varies according to the primer 
melting temperatures (TM). The annealing temperature is the 
temperature at which the primers will anneal with single strand DNA 
sequences and this is based on their length and G/C content. Those 
primers with the same annealing temperatures could be run at the same 
time in a thermocycler, so for the sake of time efficiency, primers for a 
single reaction were designed to have similar annealing temperatures. 
Similar annealing temperatures can be achieved by designing primers 
that are the same length and display similar G/C base content. Generally 
primers that are complementary to sequences displaying lower G/C 
content can be compensated for by an increase in length. Primers ideally 
comprised 40-60% G/C content. The approximate annealing temperature 
was calculated as follows; TA(°C) = [2(A+T) + 4(G+C)] - 5 (Rozen & 
Skaletsky, 1996). 
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UVRAG Exon 2 
Forward Primer � 
tctggctcaataaataaatgactgagacaacttattacatttcatttttg 
aactgcaacttccagaaaattttataggaggaaaaatctgaatgccttct 
cttttttgttgttatttttcagCGGCGTCTTCGACATCTTCGGA 
ACATTGCTGCCCGGAACATTGTTAATAGAAATGGCCA 
TCAGCTCCTTGATACCTACTTTACACTTCACTTGTGTA 
GTACTGAAAAGATATATAAAGgtaaggggatctgtggcctta 
ctacccacagattgttatatttttattttttttgtaacacaagtgattctca 
gtgcctcctgcttttgtggcttctcggaaacctaaattgttatgctgtc 
Forward Primer: 
Reverse Primer: 
� Reverse Primer 
3 '  - tctggctcaataaataaatgact - 5 '  
3 '  - ctttggatttaacaatacgacag - 5 '  
Figure 7: An example of Primers Designed to amplify a n  exon of 
interest 
UVRAG exon 2 sequence from GenBank. Primers were designed to be complementary to 
intronic sequences l00bp on either side of the exon. Primers are depicted in bo ld case. 
Exonic sequence is depicted in uppercase, intronic sequence is in lower case. 
Primers were designed to be approximately 22 bases long and 
complementary in sequence to intronic sequences located within 100 
bases on either side of the exonic sequence. Furthermore, to reduce the 
chance of primer-dimer formation, primers themselves did not contain 
any sequences that were complementary to sequences within the primer 
or its partner; these include complementary triplets or complementary 
sequences within or between primer pairs particularly at the 3'-end of 
each primer. The 3'-end of each primer was designed so as to avoid 
ending with a 'T as this increases the chance of mismatch as it does not 
bind with sufficient strength to complementary DNA. Furthermore, the 
forward and reverse primers were designed to be as similar in annealing 
temperature as possible. In specific instances where this was not 
possible, an average annealing temperature was used in the PCR. Again, in 
certain instances where this approach was not successful, either forward 
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or reverse primers were chosen from exonic sequences and designed to 
have a similar annealing temperature to that of the intronic primer of 
the pair. Where the exons were very large, primers were designed to 
amplify adjacent, overlapping exonic sequences, such as in UVRAG exon 
15 where the exon was too large to sequence using one set of exclusively 
intronic primers (Appendix 16). 
Primers were also run through the BLAST program on GenBank to 
check the complementarity to other known gene sequences, particularly 
at the 3'-end of each primer. This ensured that the designed primers 
would not anneal elsewhere in the genome. 
3. 10 PCR Thermocycling 
The thermocycling of a polymerase chain reaction (PCR) comprises 
three components; denaturing, annealing and extension. The denaturing 
step consists of 10-30 seconds at 94°C and is responsible for the 
separation of all double-stranded DNA. The annealing step generally 
varies between 10-30 seconds although this is dependant on the size of 
the DNA region to be amplified and the primer sequence. As previously 
described the annealing temperature is deduced from the melting 
temperature of the primer. The extension step involves 1 minute at 72°C, 
the optimal synthesis temperature for many thermostable polymerases. 
For this project, PCR cycling conditions were generally as follows: 
initial denaturing step of 5 minutes at 94°C followed by 30 cycles of 
94°C for 15 seconds, 55°C (TA) for 30 seconds, 72°C for 1 minute 
followed by a chasing step of 72°C for 10 minutes (Table 3.7, p94). The 
cycle primer annealing, DNA amplification and denaturation steps were 
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repeated, anywhere up to 40 times following the initial denaturation. 
This yields continuous denaturing and amplification of the template DNA, 
producing new products that act as templates for the following cycle. 
Copies of template DNA flanked by the primers multiply exponentially 
providing a final mix of multiple copies of double stranded DNA of a 
defined length and sequence. DNA synthesis occurs at a rate of 
approximately 1000 bases/min thereby achieving a billion fold increase in 
template DNA following 30-35 PCR cycles. 
Table 3 .  7 Typical PCR Thermocycling Conditions 
Steps 
Temperature 
Initial denaturation 
Amplification cycle X 30 cycles 
2 :15 
Initial denaturation 45sec 
Annealing 
Extension 
3 . 11 PCR Reaction 
60sec 
60sec 
l0min 
Time 
94°c 
94°c 
* 
12°c 
PCR reactions generally comprised 2.0µL of 10 X Qiagen 
amplification buffer, 0.3µg of each dNTP, lµL of each primer at 50ng/µL, 
0.lµL of Taq DNA polymerase (at 5u/µI), 5µL of target DNA (at lng/µI) in 
a total volume of 20µL (Table 3.7, p94). "HotStar" Taq DNA polymerase 
was used to amplify exons which could not be amplified using standard 
Taq DNA polymerase. HotStar reactions contain 250 units of Taq 
polymerase, l0mM of each dNTP, 5x Q-solution, 25mM MgCl2 and l0X 
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PCR Buffer per reaction, premixed in a 10µL HotStar master mix, lµL 
each of 50ng/µI.. primers, 3µL ddH2O and 5µL template DNA at lng/µI 
(Table 3.8, p95). 
HotStar Taq DNA polymerase is suppl ied as an enzyme antibody 
complex that exhibits no polymerase activity unti l  heated at 95°C for 15 
minutes which denatures the antibody and activates the HotStarTaq 
DNA Polymerase (Table 3.9, p95). This ensures high ly specific 
ampl ification by preventing mispriming at non-specific sites which tends 
to take place at lower temperatures i .e. preventing extension of non­
specifical ly annealed primers and primer-dimer extensions which 
characteristical ly form during the reaction setup and initial heating 
period. 
Table 3 .  8 Hot Star PCR 
Reaction Mix 
10µL Hot Star master mix 
lµL forward / reverse primer 
3µL ddH2O 
5µL template DNA 
20µL PCR reaction 
Table 3. 9 Hot Star PCR 
Thermocycling conditions 
Steps 
Hot Star 
Ampl ification cycle 
Time 
14:30 
Initial denaturation 30 sec 
Anneal ing 60 sec 
Extension 60 sec 
Final Extension 10 min 
Storage infinity 
30 times 
Temperature 
94°c 
94°c 
* 
12°c 
12°c 
4°c 
* anneal ing temperature, approximately 60°C 
Table 3.8 depicts a typical Hotstar PCR reaction that was used to ampl ify DNA regions 
that could not be ampl ified using standard Taq DNA polymerase. 
Table 3.9 depicts Thermocycl ing conditions for Hotstar PCR. 
3 .12 Electrophoresis 
Al l  Ampl ification products were visual ized by electrophoresis on a 
2% agarose gel .  DNA grade agarose powder was added to 1X TAE Buffer 
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to ach ieve a concentration of 2% .  The solut ion was shaken and melted i n  
a 700W microwave unt i l  the DNA grade agarose powder was completely 
d issolved . The gels  were poured in  open-ended hori zontal trays , with 
wel ls formed at one end of the gel by a suspended comb inserted i nto 
the gel . 
Agarose gels were run under 1 X TAE buffer i n  hori zontal tanks , 
with DNA loaded i nto the submerged wel ls  us ing a h igh density l oad ing 
dye contai n ing bromophenol b l ue and f icol l .  A 100V current was app l i ed 
across the tank for 60 minutes. The DNA moved through the gel towards 
the pos it ive e lectrode (cathode) due to the negative charge carr ied by 
phosphate groups in DNA alongside a lkB+ ladder (Figure 8) .  
hp  
12 ,000 -
5,000 -
2,000 -
1 ,650 -
1 .000 -
850 -
650 -
500 -
400 
300 -
200 
1 00 -
Figure 8 1 Kb Plus Ladder 
900ng/lane; 0.9% agarose gel stained with eth id ium bromide 
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DNA in the agarose gel was visualized by staining the gel in 100ml of 
ethidium bromide solution (1µg/100mL) for 10 minutes and gels were 
then photographed over UV light on a transilluminator. Alternatively, 
EtBr was added to the melted agarose (lµL EtBr was added per 100mL 
agarose). PCR products, visualized by gel electrophoresis, were assessed 
for size and purity by reference to a DNA size ladder as well as to 
positive and negative PCR controls. 
3 .13 Purification of PCR Products 
To purify PCR products for subsequent sequencing reactions, 
QiaQuick buffers and spin-columns (Qiagen) were used (protocol 
summary, Table 3.10, p99). The QiaQuick PCR purification kit separates 
DNA strand by size and allows the efficient binding of double stranded 
PCR products as small as 100bp to a silica membrane on a spin column 
while allowing (99.5%) of primers up to 40 nucleotides to pass through 
the column. During the DNA absorption step, unwanted primers and 
impurities, such as salts, enzymes, unincorporated nucleotides, agarose, 
dyes, ethidium bromide, oils and detergents which do not bind to the 
silica membrane, flow through the column and are discarded. Salts are 
quantitatively washed away by the ethanol-containing buffer PE. Any 
residual buffer PE, which may interfere with subsequent enzymatic 
reactions, is removed by additional centrifugation steps. 
A volume of Buffer PB supplied by the manufacturer was added to 
each completed PCR reaction in the ratio 5: 1 Buffer:PCR volume. This 
mixture was then loaded onto a spin-column placed in a collection tube 
and centrifuged at 13 000 rpm for 30-60 seconds. Any flow-through 
following centrifugation was discarded, as DNA binds to the spin-column 
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matrix. 700µL of 20% PE buffer (in ethanol), supplied by the 
manufacturer, was dispensed onto each spin  column and these were 
similarly centrifuged for 30-60 seconds. The flow-through was again 
discarded and the columns centrifuged for a further 30-60 seconds to 
collect and discard any remaining PE buffer. 
Spin-columns containing bound DNA were transferred into clean 
labeled 1.5ml eppendorf tubes. Depending on the quantity of DNA, as 
assessed by PCR product band intensity, 30µL elution buffer (for lower 
DNA concentrations) or 50µL ddH2O (for higher DNA concentrations) 
was added to the center of each spin-column. The columns were 
centrifuged for the final time at 13 000 rpm for 30-60 seconds. DNA 
bound to the spin-column matrix dissolves in either elution buffer or 
ddH2O and moves through the column into the supporting eppendorf tube 
in the final centrifugation. This purification method removes all PCR 
reagents and DNA fragments smaller than 100 bases in length providing 
pure template DNA for sequencing reactions. 
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Table 3 .10 QiaQuick protocol Summary 
i) 5 volumes of buffer PB were added to 1 volume of PCR sample & mixed 
i i) A spin column was added into a 2ml col lection tube 
i i i)  To bind DNA, the sample was appl ied to the QiaQuick column and centrifuged at 
13 000rpm for 30-60 seconds 
iv) Flow-through was discarded and the QiaQuick column was replaced in the same 
tube 
v) To wash, 0.75ml Buffer PE was added to QiaQuick column and centrifuged at 13 
000rpm for 30-60 seconds 
vi) Flow-through was discarded and the QiaQuick co lumn was placed back into the 
same tube. Columns were centrifuged for an additional 1 minute at max speed 
(13 000rpm) 
vii) QiaQuick column was placed in a clean 1 .5ml centrifuge tube 
vii i) To elute DNA, 50µL Buffer EB or ddH2O was added to the centre of the 
QiaQuick membrane and centrifuged at 13 000rpm for 1 minute. 
Alternatively, for increased DNA concentration, 30µL elution buffer was 
added to the centre of the QiaQuick membrane, the column was left to stand 
for 1 minute then centrifuged at 13 000rpm for 1 minute. 
ix) Isolated DNA was stored frozen prior to being sequenced. 
3 .14 Mutation Detection 
The ideal outcome of a positional cloning project is the 
identification of the disease-causing mutation(s). The most suitable 
methods available for detecting a mutation in a short DNA strand include 
[ sequencing of a PCR product to detect small mutations, such as single 
r base deletions, insertions or substitutions (such as trinucleotide repeat 
amplifications). 
3 .14.1 Heterozygote sequencing 
In an autosomal dominant disorder, such as HFM, the presence of 
one copy of the mutated gene may cause the disease phenotype. 
Detection of a disease mutation in a candidate gene is complicated in 
these cases primarily because the sequencing reaction is performed on a 
combination of both alleles at a locus and the mutated allele will be 
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partially masked by the normal sequence of the normal allele. The 
fluorescent detection system most commonly used for sequencing in 
modern molecular biology can only distinguish a heterozygote by 
identifying a position at which the computer cannot distinguish whether 
the signal is due to one base or another at which point an N (unknown) is 
inserted into the sequence. This is complicated further by the 
consistency of the signal which depends not only on the dye being 
detected, but also on the surrounding sequence. A considerable effort 
has been made to reduce this noise from surrounding sequences by 
creating dye terminator and specialist dye systems (ABI Prism Big Dye 
Terminator Cycle Sequencing Ready Reaction Kits). The accuracy of 
heterozygote mutation detection is thus now greatly increased. 
3 . 15 Sequencing Reactions 
An ABI 373 DNA Sequencer was used for all sequencing. Generated 
sequences were analysed using the Sequence Navigator program. The 
analysed sequences were stored as data files on a G4 Macintosh 
computer in the Centre for Human Genetics, Edith Cowan University, in a 
file only accessed by this researcher so as to conform to ethical 
requirements. 
3 . 16 Sequencing 
Since the advent of thermostable polymerases, efficient 
fluorescent labeling systems and high throughput gel and capillary 
electrophoresis, sequencing is now done almost exclusively using the 
dideoxy method (Sanger, Nickl en & Coulson, 1977). Two variations of the 
dideoxy method are in general use, dye-terminator and dye-primer 
sequencing. The procedures vary in  that the fluorescent label is 
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attached to either the dideoxy nucleotides (dye terminator) or the 5' 
end of the sequencing primer (dye primer). 
Dye terminator sequencing is usually the method of choice for one­
off sequencing of PCR products, and was the method employed in this 
project. 
3 .16.1 Direct sequencing of transcripts 
Each dideoxy sequencing reaction contains a mixture of both 
deoxynucleotide triphosphates, dNTPs and dideoxynucleoside 
triphosphates (ddNTPs), dideoxy-adenosine triphosphate (ddATP), 
dideoxythymidine triphosphate (ddTTP), dideoxyguanosine triphosphate 
(ddGTP) and dideoxycytidine triphosphate (ddCTP) each ddNTP labelled 
with a different fluorophore. Also present in the reaction are a single 
forward or reverse primer, MgCl2, 10X buffer and Taq DNA polymerase. 
Chain termination occurs when ddNTPs are incorporated into the growing 
chain because they lack a hydroxyl group at the 3 '  end of the carbon 
atom of the ribose sugar and therefore no subsequent nucleotides can be 
joined onto the growing chain. The concentration of ddNTPs is much 
lower than that of the dNTPs, consequently chain termination occurs 
randomly ultimately producing a series of products, each one nucleotide 
longer than the next. During electrophoresis of the sequenced products, 
a monitor records the four different fluorophore signals as they pass a 
detector. Data is recorded electronically as a chromatographic intensity 
profile with A, T, G, and C translation into a detailed chromatogram 
(Appendix 17). 
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3 . 16 .  2 Dye terminator sequencing reaction 
Sequencing reactions were performed in 0.2ml microtubes, as per 
ABI protocol. Each tube contained 2-4µL purified PCR template dsDNA 
(at lng/µL), 1-3µL ddH2O, 4µL Big Dye Terminator Mix and lµL (of 
50ng/µI) of the forward or reverse primer appropriate for the DNA 
template (Table 3.11, p102). The volume of template DNA and ddH2O 
added to each sequencing reaction was adjusted according to initial DNA 
concentrations. When necessary, purified DNA PCR product was 
concentrated by vacuum centrifugation to a minimum volume of 10µL. The 
reaction mix was cycled on a thermocycler (Table 3.12, p102). 
Table 3 .11 Sequencing Reaction 
2µL BigDye V3.1 
lµL BigDye Buffer (10X) 
0.5µL forward / reverse primer (50ng/µI) 
2-4µL template DNA(10ng/µI) 
4.5-2.5µL ddH2O 
10µL total volume 
Table 3.11 summarizes the composition of a typical sequencing reaction 
Table 3 .12 Thermocycling Conditions for a Typical  Sequencing 
Reaction 
Step 
Initial denaturation 
Amplification cycle X 25 times 
Stora e 
Time 
1 min 
30 sec 
30 sec 
4 min 
infinit 
Temperature 
96°C 
50°c 
60°C 
4°c 
Table 3.12 indicates the cycles used for a sequencing reaction 
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3 . 16.  3 DNA sequencing reaction cleanup protocol 
Unincorporated ddNTPs, enzymes and salts were extracted from 
sequencing reaction products by ethanol / sodium acetate precipitation 
as follows; 2µL of 3M sodium acetate (pH 4.6) and 50µL of 95% ethanol 
were added to each completed sequencing reaction. Tubes were shaken 
and left to stand at room temperature for 5 minutes, then centrifuged 
for 45 minutes at 13 000 rpm. Supernatants were discarded and 150µL 
of 70% ethanol added to each pellet. Tubes were again centrifuged for a 
further 10 minutes at 13 000 rpm. Supernatants were discarded and the 
pellets briefly dried at 65°C. These were forwarded to the Australian 
Neuromuscular Research Institute (ANRI) for sequencing on an ABI 373 
Automated DNA Sequencer. 
3 . 16 .  4 Analysis of sequence data 
Sequencing results and chromatograms received from ANRI were 
imported into and analysed using computer softwares SeqEd, Version 
1.0.3 and Sequence Navigator. Sequencing results were compared with 
the equivalent normal sequence, both manually and by computer analysis 
using BLAST analysis online available at NCBI on GenBank. Any base 
discrepancies are evaluated as polymorphisms or as potential disease 
causing mutations by comparison with coding and non-coding sequences 
and translated amino acid sequences. 
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Chapter 4: Results: Identif ication, Ampl if ication and 
Sequencing of Candidate Genes for Hemifacial 
M icrosomia 
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4. 0 Introduction 
Identification of markers and candidate genes in the chromosome 11 
linkage region thought to be associated with HFM in the West Australian 
family are discussed. Moreover the results of sequencing of four candidate 
genes in the chromosome 11 linkage region will be presented. 
4 .1 Marker Analysis to Refine the Chromosome 11 Linkage Region 
The major result of this project has been to reduce the size of the 
chromosome 11 HFM region, linked to HFM in the WA family under 
investigation (Chandler, 2001) (Table 4.3, p108). Through the redefinition of 
marker positions and the employment of genome mining methodology, the 
chromosome 11 candidate region has been reduced in size from an estimated 
18.8 million DNA bases to 13.5 million DNA bases. This considerable 
reduction in size of 5.3 million bases will simplify future studies. By 
regularly monitoring the positions of the markers in the Draft Human 
Genome, the candidate region was reduced by 28.2%. Essentially this 
involved continual inspection of the 5' and 3' chromosome 11 marker 
positions in the human genome sequence, the draft of which was regularly 
updated, thereby resulting in reorganization of markers and their positions 
on the genome in databases such as Ensembl. The sequencing of the genes 
themselves further reduced the linkage region by another 355,995 bases. 
More specifically, the linkage region was assumed to be between bases 
66,988,646-83,391,363 in September 2002 (D1151883-D115911), according 
to data from ENSEMBL. Yet, in August 2001, the marker D1151883, the 5' 
limit of the HFM linkage region was located on the draft human genome 
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sequence at position 70,661,457-70,754,563. Furthermore, in December 
2001 the same marker on the same database was positioned at 72,543,444-
73,659,301 and in April 2002 was between 64,433,363-66,012,757. 
Alternatively, D1154207, the 3' limit of the HFM linkage region was located 
in the draft human genome at position 84,621,967-84,822,321 (August 
2001). Again, in December 2001, the marker was relocated to position 
74,683,628-74,883,976. Due to inconsistency in the marker positions in 
April 2002 the locations of markers achieved in December 2001 were 
assumed to be correct at the commencement of experimentation, confirmed 
by Ensembl. Consequently, the linkage region was reduced to a length of 
14,160,864 bases and the linkage region was amended to be Chrll: 
64,533,373 - 75,971,382. 
This was an extremely significant result and proved useful in reducing 
the region to be sequenced. As a consequence 100 known and predicted 
genes were excluded as potential candidate genes for HFM, since genes 
I previously located within the chromosome 11 HFM linkage region were 
excluded, thus reducing the number of potential candidate genes in this 
region. The next step, the choice of candidate genes by genome mining, was 
therefore simplified by reducing the number of possible candidates in the 
linkage region between the markers D1151883 and D115911. 
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Table 4 . 1  Icelandic Map Chromosome 11 Marker positions 
4th September 2002 
D11S1765 66,988,646 
D11S1883 (not currently mapped) 
D11S987 77,403,003 
D11S4178 77,801,817 
D11S4136 79,387,634 
D11S4139 (not currently mapped) 
D11S1314 82,286,854 
D11S4207 (not currently mapped) 
D11S916 83,161,640 
D11S911 (not currently mapped) 
D11S937 89,391,363 
The Icelandic Map (Weber, 2002) is based on the genotyping of 5,136 
microsatellite polymorphisms in 146 nuclear families, all from Iceland, 
containing 1,257 meioses and is considered to be of substantially improved 
resolution compared to previous human genetic maps. The Icelandic Map on 
the 4th September 2002, was explored for the aforementioned genetic 
markers (Table 4.1, p107). Four of the markers previously mapped on the 
Ensembl database, namely D1151883, D1154139, D1154207 and D115911 
were not found on the Icelandic Map. The D115911 marker was of particular 
relevance as it is the 3' marker flanking the HFM linkage region. 
Nevertheless the genes between markers D1151765 and D115916 were 
consistent with those identified by Ensembl on December 2001 and thus 
selection of candidate genes was confirmed. 
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The positions of the markers on chromosome 14 surrounding the 
chromosome 14 HFM linkage region markers were assessed in July 2002 
(Table 4.2, p 108) and found to be consistent with previous marker positions 
for chromosome 14 identified on Ensembl thereby indicating that changes 
were minimal and therefore that chromosome 11 markers may have 
stabilised. 
Table 4.2 Chromosome 14 markers and their positions on ENSEMBL as 
at 22 July 2002 
Marker 
D1451142 
D1451143 
GATA168F06 
D145987 
D14565 
D145267 
Position 
92 880 607 - 92 880 769 
93 119 794 - 93 119 956 
93 507 497 - 93 507 718 
95 080 876 - 95 081 183 
96 108 679 - 96 108 841 
96 108 697 - 96 108 847 
97 711 801 - 97 712 038 
97 711 831 - 97 712 043 
Consequently, the positions of markers for the chromosome 11 HFM 
linkage region on the draft human genome were mapped in July 2002 (Table 
4.3, p 110) and the linkage region for chromosome 11 was amended to be 
Chrll: 64,533,373 - 75,971,382 (Table 4.3, p109) as the final positions. 
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Table 4 . 3  Chromosome 11 Genetic markers and locations as at 3rd July 
2002 
D11S1883 
D11S987 
D11S4178 
D11S4136 
D11S4139 
D11S1314 
D11S4207 
D11S911 
(64,533,373 - 64,533,624) 
(not currently mapped) 
(not currently mapped) 
(69,221,479 - 69,221,668) 
(69,946,835 - 69,946,983) 
(not currently mapped) 
(not currently mapped) 
(75,971,191 - 75,971,382) 
The final positioning of the above markers were assumed to be correct and 
were used in candidate qene selection and experimentation 
4.  2 Genome Mining Results 
Genes in the chromosome 11 linkage region were subsequently 
identified using the NCBI database. The sequences of these genes were 
then compared to sequences from genome databases in GenBank and GDB. 
Using databases such as NCBI, GenBank and GDB a list of 131 genes was 
compiled for the chromosome 11 HFM linkage region (Appendix 9). Specific 
information on each of these genes was then obtained through sequence and 
database analysis from data on PubMed and LocusLink (Appendix 12). 
Candidate genes were selected based on their compliance with selection 
criteria. The more criteria a particular gene fulfilled, the more its 
candidate status was enhanced. From this information, four genes were 
identified as prime candidates, based on selection criteria outlined in 
Section 3.6. 
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4.  3 Sequencing of UVRAG, ARIX, CLN51A and GARP 
Four genes, namely UVRAG, ARI)(, CLNSJA and GARP, were chosen as 
the most likely candidate genes based on their compliance with the three 
selection criteria, of embryonic expression, association with axial 
asymmetry and possession of / association with trinucleotide repeats. 
4 .  3 . 1  UVRAG (UV Radiation Resistance Associated 6ene) 
UVRAG was selected as the prime candidate gene for chromosome 11 
HFM. It is located in position 74,047,886-74,376,304 on chromosome 
11q13.5 (Map Viewer, Appendix 11). This gene fulfilled all three components 
of the selection criteria (see Section 1.5, p8). UVRAG is expressed 
embryonically and is associated with axial asymmetry (Ensembl gene ID 
ENSG00000137493) (Perelman et al., 1997). Furthermore UVRAG contains 
two (aac) trinucleotide repeats and an (oat) trinucleotide repeat (positions 
Chrll:74,105,993-74,106,007, 74,272,978-74,272,998 & 74,287,745-
74,287,759 respectively) (Figure 9), thereby making it a prime candidate 
for chromosome 11 HFM. 
�------ UYRAO Oene ----------, 
?4.047.886 W?6J04 
------®-----®-@------
Figure 9 Position of trinucleotide repeats in relation to UVRAG 
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4. 3. 2 ARD< (Aristaless homeobox) 
ARIX is located on chromosome 11 at position 75,883,451-75,887,841 
(Map Viewer, Appendix 11). ARIX gene ontology, according to LocusLink 
suggests regulation of downstream target gene expression, morphogenesis 
and differentiation (Johnson et al., 1996) (LocusID 116648). It is a DNA 
binding protein involved in neuronal development, neurotransmitter 
synthesis and storage. More specifically it was identified as a candidate 
gene for chromosome 11 HFM as it is associated with left-right asymmetry 
determination and craniofacial abnormalities (Pattyn et al., 1997). 
Specifically ARIX is expressed in noradrenergic cell types of the 
sympathetic nervous system, brain and adrenal medulla (Johnson, Smith, 
Johnson, Rhodes, Rinchik, Thayer & Lewis, 1996). Furthermore two (gtt) 
trinucleotide repeats (positions Chrll:75,820,692-75,820,715 & 
75,934,321-75,934,344 respectively) are situated on either side of the 
gene (Figure 10) and these repeats could be in regulatory regions of the 
gene which normally lie 5' and 3'. Regulatory regions may be located in close 
proximity to the gene and others may be several kilobases away from the 
actual gene. 
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Figure 10 Position of trinucleotide repeats in relation to ARD< 
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4.3 .3  CLNSJA (Chloride channel, nucleotide-sensitive, lA) 
CLNSJA is located on chromosome 11, position 75,889,882-75,911,533 
(Map Viewer, Appendix 11). Gene ontology for CLNSJA as indicated in 
Ensembl suggests involvement in vision, circulation, small molecule transport 
and photoreception (Ensembl gene ID ENSG00000074201) (Bekri et al., 
1997; Buyse et al., 1996). It encodes an integral membrane protein and the 
gene is alternatively referred to as CLCJ, ICLN, IC/n or CLNSJB. More 
specifically CLNSJA contains an (att) trinucleotide repeat and a (gtt) 
trinucleotide repeat at positions Chrll: 75,893,893-75,893,916 and 
75,900,770-75,900,787 respectively (Figure 11). These repeats may lie in 
regulatory regions generally located 5' and 3' of the gene . 
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Figure 11 Position of trinucleotide repeats in relation to CLNSJA 
4.  3. 4 GARP (Garpin complex) 
The GARP gene is located on chromosome 11 at position 74,891,183-
74,903,592 (Map Viewer, Appendix 11). Gene ontology according to Pruitt, 
i Katz, Sicotte and Maglott (2000) proposes that GARP encodes an integral 
� plasma membrane protein. GARP is situated near an aat and a gat 
[ 
l trinucleotide repeat (position Chrll: 74,858,600-74,858,623 & 74,909,997-
74,910,011 respectively (Figure 12). 
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Figure 12 Position of trinucleotide repeats in relation to GARP 
As mentioned previously, the functions of GARP are diverse and 
include receptor interactions, enzyme inhibition, cell adhesion and cellular 
trafficking. It has been reported to be involved in early mammalian 
development, neural development, cell polarization, regulation of gene 
expression, the cytoskeletal framework and apoptosis signalling (Pruitt, 
Katz, Sicotte & Maglott, 2000). Pruitt et al (2000) also identified the 
homologous relationship between GARP and the Drosophila Aristaless gene 
and the human gene ARIX Human GARP and A RIX genes are specifically 
expressed in noradrenergic cell types of the sympathetic nervous system, 
brain and adrenal medulla (Pruitt et al, 2000), so alterations to these genes 
may affect craniofacial development by affecting neural function. 
4.  4 Results of Homology Investigations 
Despite homologies of ARIX and GARP to regions on mouse 
chromosome 7, no genes associated with characteristics pertaining to HFM 
were identified on the mouse chromosome at these regions. No other 
candidate genes on chromosome 11 showed homology to relevant mouse 
genes (Appendix 15). 
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A number of animal models have been described, including far and Hfm 
but other genes are homologous to the genes identified on chromosome 11 
and both present different aetiologies to that of human HFM (Naora et al. 
1994). These models therefore, were not responsible for additional 
candidate gene identification in this project. None of the genes within the 
chromosome 11 linkage region demonstrated homology to the genes within 
the chromosome 14 linkage region although this was considered an essential 
step in the identification of candidate genes for HFM. No relevant data was 
obtained using this method so PCR and sequencing of the three candidate 
genes was adopted as the most sensitive. 
Despite no homologies being identified through these comparative 
methods, they were nonetheless considered relevant analytical techniques 
for candidate gene identification and selection. 
4.5 Sequencing of HFM candidate genes in DNA from a HFM patient 
, .  
i A search of NCBI Genome Browser identified genomic sequence for 
I each of these genes. Primers were specifically chosen to amplify the 
intronic and exonic regions of all these genes and were designed in 
accordance with parameters detailed in Section 3.9.1.2, p91 (Appendix 7). 
Primers were designed to amplify the exons including all intron/exon 
boundaries (Figure 6, p90) so that any mutations at intron/exon boundaries, 
likely to cause splicing errors and thus errors in the final gene product, 
would also be identified along with mutations in the coding exonic regions. 
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The patient tested in this project is individual D02-517 (III:6). The 
patient phenotype was described in Section 3.5.1 (p77) as characteristic of 
an affected member of the WA family (see WA pedigree - Figure 1). This 
patient was diagnosed with HFM and therefore the DNA from this patient 
was isolated from blood and utilised to find mutations in the chromosome 11 
linkage region. Furthermore the DNA of this patient was already accessible 
for research purposes. Primers were then designed and used to sequence 
the exons of the four candidate genes in to identify possible mutations in 
the HFM linkage region. 
4.  6 PCR amplification of UVRAG and sequencing results 
4 .6 .1  Exon 1 - Amplification and sequencing 
Forward primer 74 049 814F 5'-CTAAGCCAATGAGCGCTCC-3' 
Reverse primer 74 050 433R 5'-AGCTGGCTGGCTGCTTGTC-3' 
An annealing temperature of 55°C with 30 cycles successfully 
amplified this exon from DNA of an unaffected and affected patient. PCR 
products incorporating Q-solution were electrophorised at 100V for 1hr. 
The PCR products were then QIAquicked and eluted with 50µL ddH2O. PCR 
products were sequenced using 3.5µL template DNA. No mutations were 
detected in affected or unaffected DNA, when assessed by comparison of 
sequences between each sample and GenBank {See Appendix 17 for 
sequencing chromatogram). 
4.6.2 Exon 2 - Amplification and sequencing 
Forward Primer 74 086 399F 5'-GAGACTGGGTTATGGTTTCTGG-3' 
Reverse Primer 74 086 741R 5'-AAGCAGGAGGCACTGAGAA TCA-3' 
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An annea l ing temperature of 6 1°C with 35  cyc les successfu l ly amp l ified 
th is exon from DNA of an unaffected and affected pat ient. PCR products 
incorporat ing Q-solut ion were electrophorised at B0V for l hr20min (F igure 
13) .  In an attempt to c leanup the PCR product another PCR was ran using an 
annea l ing temperature of 6 1°C with 25 cyc les. This was a lso successfu l and 
these PCR products were consequent ly QIAquicked and eluted with 30µL 
elut ion buffer. Sequenc ing using 2µL temp late DNA was successfu l .  
However no mutations were detected i n  affected or  unaffected DNA when 
sequences were assessed relat ive to each other and GenBank. (See 
Append ix 17 for sequencing chromatogram). 
Q-solution Non Q-solution 
Ex2F Ex2F 
Ex2R Ex2R 
Figure 1 3  - UVRAG exon 2 PCR Ampl ification 
visual ized on 2% EtBr stained agarose gel 
4. 6 .  3 Exon 3 - Ampl ification and sequencing 
Forward Primer 74 095 976F 
Reverse Primer 74 096 685R 
5 '  -cactagcaaccaggtaacctaca-3'  
5- 'gtatacatgtgccatgtcggtgtg-3 '  
1 16 
Due to amplification difficulties, an alternative technique was used to 
amplify this exon. Three differing concentrations of template DNA were 
used in three separate PCR reactions: lµL, 1/l00µL and 1/l000µL. Higher 
concentrations (1µ1) of template DNA gave the best result when cycled at 
68°C for 45 cycles. However sequencing was unsuccessful, therefore new 
primers were designed using Web-based primer design program 
[http://seq.yeastgenome.org/tmp/sorted.tmp.26024.html]. 
Forward primer 74 094 747F 5'-TGAGTTTTGTGACCTTTTCCA-3' 
Reverse primer 74 096 084R 5'-TTCTTTGTTTTCAACACAGCC-3' 
Using these new primers, a PCR reaction was performed and an 
annealing temperature of 47°C with 30 cycles proved unsuccessful as 
assessed by electrophoresis at 100V for 1hr, consequently a HotStar PCR 
was prepared using control DNA (unaffected/unrelated male and female 
DNA) (Figure 14). Interestingly, the control DNA amplification was 
successful when amplified. Similar conditions to these were used for the 
affected DNA (i.e. HotStar Taq DNA polymerase). PCR amplification was 
achieved by running a Hot Star PCR at 50°C for 30 cycles (Figure 14). Thus, 
the PCR was successfully amplified for affected and unaffected DNA and 
the PCR fragment sequenced and analyzed but it revealed no mutations in 
affected or unaffected DNA when sequences were compared relative to 
each other and GenBank. 
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lkb+ Ladder Exon 1 1  Exon 9 Exon 7 Exon 5 Exon 3 
Contro l B lank ExonlO Exon 8 
Figure 14  - PCR ampl ification using a 2% agarose gel of UVRAG exons 3 - 1 1  
S i nce a l l  gel pi ctures are s im i lar , the gel p i ctures shown are used as typical example of gels obtai ned 
through experi mentation  throughout th is  project 
4 . 6 . 4  Exon 4 - Ampl ification and sequencing 
Forward Pr imer 74 1 14 287F 
Reverse Pr imer 74 1 14 840R 
5'-ccatgtaagtgagtgatagg-3 '  
5'-catcaaggtctctcttagtg-3 '  
A Hot-Start PCR using an anneal ing temperature of 53°C for 25  cyc les 
successfu l ly ampl if ied th is exon from DNA of an unaffected and affected 
pat ient. PCR products without Q-so lut ion were electrophor ised at 100V for 
1hr. PCR products were QIAqu icked and eluted with 40µL ddH2O. PCR 
products were sequenced using 2µL temp late DNA but again no mutations 
were detected in affected or unaffected DNA when sequences were 
assessed relat ive to each other and GenBank. 
1 1 8  
4.6.5 Exons 5- 14 Amplification and sequencing 
Conditions for PCR amp I if ication and sequencing cleanup reactions for 
exons 5-14 are displayed in Table 4.4, p119. All PCR reactions were 
performed as for standard PCR reactions as described in 
Sections 3.9 and 3.10. PCR products were electrophorised at 100V for 1hr 
(Figure 14). PCR products were then QIAquicked and eluted with volumes 
given in Table 4.4, p119. PCR products were sequenced using 3µL template 
DNA. For all these exons, no mutations were detected in affected or 
unaffected DNA when sequences were assessed relative to each other and 
GenBank (see Appendix 17 for chromatograms). 
Table 4 .4 Amplification and Sequencing of UVRAG exons 5- 14 
Primer Primer sequence Annealing Number Elution 
Tem rature of C cles 
Forward - 74 123 374F 57°C 30 30µL 
Reverse - 74 123 748R buffer 
Forward - 7 4 146 376F 60'C 45 30µL 
Reverse - 74 146 915R buffer 
Forward - 74 196 035F 53'C 30 30µL 
Reverse - 7 4 196 397R buffer 
elution 
elution 
elution 
Forward - 74 217 800F 58'C 30 40µL ddH2O 
Reverse - 74 218 291R 
Forward - 74 238 567F 63'C 30 30µL elution 
Reverse - 74 238 924R buffer 
Forward - 74 242 073F 54°c 30 40µL ddH2O 
Reverse - 7 4 242 494R 
Forward - 7 4 243 311F 55°c 30 25µL elution 
Reverse - 74 243 678R buffer 
Forward - 74 251 478F 55°c 30 40µL ddH2O 
Reverse - 74 251 635R 
Forward - 74 300 291F 61 °C 30 30µL elution 
Reverse - 7 4 300 550R buffer 
Forward - 74 350 386F 61
°C 30 50µL ddH2O 
Reverse - 7 4 350 755R 
119 
4.6.6 Exon 15 - Amplification and sequencing 
Due to the size of UVRAG exon 15 (1,940bp) and for ease of 
sequencing, this exon was divided into four sections - UVRAG exon 15(i)-(iv) 
by choosing primers suitably located within the exon. Primers were selected 
so that regions to be sequenced overlapped (Figure 15). 
4.6.6.1 Exon 15 (i) Exonic Primers - Amplification and sequencing 
Forward Primer 74 375 366F 5'-gatccagaaggcttacactgag -3' 
Reverse Primer 74 375 968R 5'-CAGAAGAAATCATCGGGCTGGT -3' 
An annealing temperature of 61°C with 30 cycles successfully amplified 
this exon from DNA of an unaffected and affected patient. PCR products 
incorporating Q-solution were electrophorised at 100V for 1hr. These PCR 
products were then QIAquicked and eluted with 40µL ddH2O. Sequencing 
was achieved using 3µL template DNA and was not definitive. Despite 
several attempts to complete sequencing were unsuccessful. The sequence 
contained several repeat nucleotide sequences which are difficult to 
sequence. [No difference in PCR product size was observed when assessed 
by gel chromatography thereby suggesting no obvious deletions or 
insertions]. 
4.6. 6. 2  Exon 15(ii) Exonic Primers - Amplification and sequencing 
Forward Primer 74 375 842F 5' - AATGGCACTCTCCTACCCAG - 3' 
Reverse Primer 74 376 425R 5' -GAGCTTACAGCTCGAGTCACCT- 3' 
An annealing temperature of 60°C with 30 cycles successfully 
amplified this exon from DNA of an unaffected and affected patient. PCR 
products incorporating Q-solution were electrophorised at 100V for 1hr. 
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(i) LIVRAG 74 375 366F 5' - gatccagaaggcttacactgag - 3' 
VVRAG 74 375 968R 5' - ACCAGCCCGATGATTTCTTCTG - 3' 
(i i) VVRAG 74 375 842F 5' - AATGGCACTCTCCT ACCCAG - 3' 
VVRAG 74 376 425R 5' - AGGTGACTCGAGCTGT AAGCTC - 3' 
( i i i) VVRAG 74 376 320F 5' - CAGTGGGCCAAAGTT AGA - 3' 
VVRAG 74 376 860R 5' - TTCATCTAATCTGAGGGCCG -3' 
( iv) LIVRAG 74 376 238 F 5' - AGCTGTGACGTTCCATCTCTTC - 3' 
UVRAG 74 376 502 R 5' - GTCCAGTTGTCATTCCCGCATT - 3' 
tcatgaaatccttctcactgcctcactgagcatgggcaagtcatgtaaattctctgccagatgaggatgcctgcttttcaaagctaaaataaga 
attgaattgaatactaaaacaagaatgagattatggatagcccttcagaaatatgaagttagttatatccttcacatgtttttcttgctagatc 
cagcctgtccagttacttcacctcttccccataggacagggtttctgttccctgccctgccttgggccctcttctctaaatatattgcagtgtg 
tctgtatcctgctggaaggaagctcccaaagttggacccacatacctcatgttgttttttgcattgagacactgcaataactattgtctaagat 
tgattcttatctatttttattagctcagacctaagtatgctgttccctgtctctggatccagaaggcttacactgagttctgaagtccaaagta 
acttcttgtttttgtttctcttctag TGACAGACATCACACCTCCAGTGCAATCCCTGTTCCT AAGAGACAAAGCTCC 
ATATTTGGGGGTGCAGATGTAGGCTTCTCTGGGGGGATCCCTTCACCAGACAAAGGACATCGAAAACGGG 
CCAGCTCTGAGAATGAGAGACTTCAGTACAAAACCCCTCCTCCCAGTTACAACTCAGCATTAGCCCAGCCT 
GTGACCACCGTCCCCTCCATGGGAGAGACCGAGAGAAAGATAACATCTCTATCCTCCTCCTTGGATACCTC 
CTTGGACTTCTCCAAAGAAAACAAGAAAAAAGGAGAGGATCTAGTTGGCAGCTTAAACGGAGGCCACGC 
GAATGTGCACCCTAGCCAAGAACAAGGAGAAGCCCTCTCCGGGCACCGGGCCACAGTCAATGGCACTCTCC 
TACCCAGCGAGCAGGCCGGGTCCGCCAGTGTCCAGCTTCCAGGCGAGTTCCACCCAGTCTCAGAAGCTGAG 
CTCTGCTGTACTGTGGAGCAAGCAGAAGAAATCATCGGGCTGGAAGCCACAGGTTTCGCCTCAGGTGATC 
AGCTAGAAGCATTTAACTGCATCCCAGTGGACAGTGCTGTGGCAGTAGAGTGTGACGAACAAGTTCTGG 
GAGAATTTGAAGAGTTCTCCCGAAGGATCTATGCACTGAATGAAAACGTATCCAGCTTCCGCCGGCCGCG 
CAGGAGTTCCGATAAGTGAAGTGAGCAGGTCAACAGTAGGACTGGGGCAGAAGCTCTGCCTAAAATGAA 
GTGAAAGCTGCACTTAACCCTTTGTGATAATGATGACACAAAATGAATATTAATGGAGGATATTCCTCG 
GAAAAACAGACTTTGGGAATGAAGGAGGGACTCAGGATCATTGTTATCAGTGGGCCAAAGTTAGATTT 
TGCTTTCAAGATTTGCTTTTCGGGCCTGATGATTTTAAAGCAAAAATCACCCTCTAGTTGAAAGAGCTT 
ACAGCTCGAGTCACCTTTTAGCTATTTGTCTGCTTTTTATTTACCCTTGTATGTTATCCTCAGAGGGAAG 
ATGATAATATATAAATAATATAATGAACACACCCTTAGTTTCTCATAAGCATTTGCCCTCACCATGGTT 
TATAAAACTTTGGGAAAACGGAATATTCAGAAATAGGTTTCCGCCATGTACTGAAAGGTCTGTGGCCAT 
CTGTGAGGTAGATGAAGAAGCAGCATAGTGGTCTCCTTACATCTAGGCCTAACTGTCCCTCTTCCTGCCCC 
CGGGTACCACAGTCCACCTTTAGACCCTACTGTCGCCCCATCTTCTCCGTGGATGGGCCATGCGTCCTGAA 
AACAGGACATCAGATTCACTGGTTCTGTAACCCAGTAGCTGTGACGTTCCATCTCTTCTAACCAGCCATG 
GCCTTCCCCTCCTCTGCCATACCCTTAATGCGGCCCTCAGATTAGATGAAAAACTTGCTCCTGGTGGATCC 
CAAGGGACCCTCAAGGACCTCGAGGTTACTGCAGTCAGATGCCATCTCATCCCCTGTGGGGGCCAAAGTTT 
TTATGTGGGCAGATGCTGTGGTCAGGAACTAGGCATGCTTTCTGGCAATGCACTCACCAGACAAAAATCC 
CTTGATGTAAATCCCATGTTAATTTATTAAATTTCAGTCAGAAGGTCAGCATTTACATGACAGAATGTA 
TGTAGAGAGTTGGGGTGTCTGGTAGGCAAACTGCAAGGCAGTTGAGATAGTTGGATTAAGAGGCTAGAC 
GAGACATAGAATACTATTGGTATGTGTGCAATTTCATGAATATTAAATTATGTTTCGAAGTCCAGTTG 
TCATTCCCGCATTCAGATTTCATTTGCTGTTGCTTTATACGTTACGTACCCAAGGACATTGCCTCAGGGT 
TGCAAACTCTTTAAAGGAAAATTTATCCATATATCCATGTATTATATAGAAGAATAAAAATTGAGTTT 
ACTTC 
Figure 1 5  UVRAG Exon 1 5  and positions of primers selected for PCR 
and sequencing reaction 
Forward primers are depicted in red text and reverse in blue text 
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The PCR products were QIAquicked and eluted with 40µL ddH2O. 
Sequencing was achieved using 2µL template DNA and no mutations were 
detected in affected or unaffected DNA when sequences were assessed 
relative to each other and GenBank. 
4.  6. 6. 3 Exon 1 !5 (iii) Exonic Primers - Amplification and sequencing 
Forward Primer 74 376 320F 5'-CAGTGGGCCAAAGTTAGA-3' 
Reverse Primer 74 376 860R 5'-CGGCCCTCAGA TTAGA TGAA-3' 
An annealing temperature of 52°C with 30 cycles amplified this portion 
of exon 15 from DNA of an unaffected and affected patient. PCR products 
incorporating Q-solution were electrophorised at l00V for 1hr. These PCR 
products were QIAquicked and eluted with 40µL ddH2O. PCR products were 
sequenced using 3µL template DNA. Again sequencing analysis was 
unsuccessful, and despite numerous attempts this portion of exon 15 was 
unable to be excluded as a causative sequence for HFM. However it was 
noted that there were no differences apparent on gel chromatography 
therefore suggesting no obvious deletions or insertions on this portion of 
the exon. 
4. 6. 6.4 Exon 1!5 (iv) Exonic Primers - Amplification and sequencing 
Forward Primer 74 376 238F 5'- AGCTGTGACGTTCCATCTCTTC -3' 
Reverse Primer 74 376 502R 5'-AATGCGGGAATGACAACTGGAC-3' 
An annealing temperature of 61°C with 30 cycles amplified this portion 
of exon 15 from DNA of an unaffected and affected patient. PCR products 
incorporating Q-solution were electrophorised at l00V for 1hr. These PCR 
products were QIAquicked and eluted with 40µL ddH2O. PCR products were 
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sequenced using 3µL template DNA. Again sequencing analysis was 
unsuccessful, and despite numerous attempts this portion of exon 15 was 
unable to be excluded as a causative sequence for HFM. However it was 
noted that there were no differences apparent on gel chromatography 
therefore suggesting no obvious deletions or insertions on this portion of 
the exon. 
To summarize, 14.5 out of 15 exons for this gene was sequenced, and 
no mutations were detected in affected or unaffected DNA when 
sequences were assessed relative to each other and GenBank. Therefore 
sequencing of this gene has reduced the region to be assessed for future 
studies of chromosome 11 HFM mutation analysis. 
4.7 PCR amplification of ARIX and sequencing results 
4. 7 . 1  Exon 1 - Amplification and sequencing 
Forward Primer 75 883 245F 5'-ccacacctctgagccctaagacg-3' 
Reverse Primer 75 883 905R 5'-cattggagggtctggccaaggca-3' 
The PCR was thermocycled using an annealing temperature of 69°C for 
30 cycles. The annealing temperature was reduced to 68°C to improve 
quality of amplification but with little success. New primers were designed 
and ordered. 
Forward Primer 75 883 245F 5'-ccacacctctgagccctaaga-3' 
Reverse Primer 75 883 915R 5'-tctggccaaggcaggaat-3' 
The PCR was thermocycled using an annealing temperature of 56°C for 
30 cycles, without success. A HotStar was prepared and ran at 50°C for 30 
cycles. A HotStar PCR reaction was prepared using control (unaffected, 
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unrelated male and female) DNA. This too was unsuccessful, implying that 
the primers were not annealing successfully. Primers were redesigned in the 
exonic sequence at the beginning and end of the exon. Those primers were 
manually designed and then compared with on-line databases as to 
specificity of region to be sequenced. Moreover, their design complied with 
suggested parameters for success (See section 3.9.1.2). 
Forward Primer 71 676 429F 5'-CTGAGTGCGGCCGCGAC-3' 
Reverse Primer 71 676 808R 5'-GCGCTCACCTGCCGAGT A-3' 
The PCR was thermocycled using an annealing temperature of 55°C for 
30 cycles, without success. Control DNA and the affected DNA were used. 
The control DNA yielded multiple bands while the affected DNA did not 
amplify. Despite numerous attempts this exon was unable to be excluded as 
a candidate for chromosome 11  HFM. 
4.7.2 Exon 2 - Amplification and sequencing 
Forward Primer 75 886 137F 5'-ggctgccgggaccaagacga-3' 
Reverse Primer 75 886 575R 5'-gccttcgggctgcatctgcc-3' 
The PCR was thermocycled using an annealing temperature of 63°C for 
30 cycles. Multiple bands were evident but faint. Two separate PCR 
reactions were prepared and run, one at 62°C with 30 cycles, and the other 
at 64°C with 30 cycles. The former proved to be more successful and a 
sequencing reaction using 4µL template DNA was prepared and run. This was 
not accurate enough to definitively compare the affected sequence to the 
sequence available on GenBank. Consequently primers were redesigned and 
ordered. 
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Forward Primer 75 886 107F 
Reverse Primer 75 886 709R 
5' -ttgagtaatagggaggacgct-3' 
5'-tcggaactttctgccctaaga-3' 
The PCR was thermocycled using an annealing temperature of 57°C for 
30 cycles. PCR reaction without Q-solution was superior in its amplification 
however all PCR products were faint. A new PCR was prepared and run at 
52°C for 30 cycles. This was unsuccessful and the annealing temperature 
was dropped to 50°C for 30 cycles. A HotStar PCR reaction was prepared,. 
Again, efforts were fruitless. Control DNA was used to prepare two 
separate reactions, a standard PCR reaction and a HotStar PCR reaction, 
both of which were run at 50°C for 30 cycles. This too was unsuccessful. 
Exonic primers were redesigned and ordered. These primers were manually 
designed and then compared to on-line databases as to specificity of region 
to be sequenced. Moreover their design complied with suggested 
parameters for success (See section 3.9.1.2). 
Forward Primer 71 679 299F 5'-TGCCCTACAAGTTCTTC-3' 
Reverse Primer 71 679 486R 5'-CTGCACGCGAGCCTCA-3' 
The PCR was successfully thermocycled using an annealing temperature 
of 48°C for 30 cycles. PCR reaction without Q-solution was superior in its 
amplification. PCR products were QIAquicked and eluted with 40µL ddH2O. 
Sequencing however was not clean enough to compare with sequences 
available on GenBank and therefore this region cannot be excluded as a 
candidate region for HFM. The PCR reaction amplified by electrophoresis 
displayed no size difference and hence suggests no obvious changes (see 
Appendix 17 for chromatograms). 
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4.  7. 3 Exon 3 - Amplification and sequencing 
Forward Primer 75 887 278F 5'-tccgaaccaggatctcactcgag-3' 
Reverse Primer 75 887 995R 5'-gagtggccctgacttggtctcc-3' 
The PCR was thermocycled using an annealing temperature of 67°C 
with 30 cycles. The annealing temperature was reduced to 65°C without 
success. New primers were ordered. 
Forward Primer 75 887 280F 5'-cgaaccaggatctcactcga-3' 
Reverse Primer 75 887 982R 5'-ttggtctccaaagttgggga-3' 
Two PCRs were thermocycled using annealing temperatures of 65°C 
and 66°C for 30 cycles. This proved unsuccessful so a PCR was run at 50°C 
for 30 cycles. The PCR reaction without Q-solution added was superior in 
its amplification although multiple bands were evident. A HotStar PCR was 
prepared and run at 50°C for 30 cycles. Given the difficulties with the first 
and second exon of this gene, exonic primers were designed and ordered. 
Forward Primer 71 680 387F 5'-AGGTCTGGTTCCAGAACCG-3' 
Reverse Primer 71 680 843R 5'-GCAGCTAGAAGAGATTGGTC-3' 
The PCR was thermocycled using an annealing temperature of 55°C for 
30 cycles successfully. PCR reaction with Q-solution added was superior in 
its amplification. The PCR products were QIAquicked and eluted with 25µL 
ddH20. Similarly to exon 2, sequencing was unsuccessful and we were unable 
to analyze this exon accurately enough to definitively claim this exon does 
not contain a mutation. 
To summarize, sequencing was not definitive with the three exons of 
ARIX. Therefore this project is unable to exclude ARIX as a candidate 
gene for chromosome 11 HFM. It is important to note however that PCR 
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reactions amplified by electrophoresis displayed no size difference and 
hence suggests no obvious changes. 
4. 8 PCR amplification of GARP and sequencing results 
4 .8. 1 Exon 1 - Amplification and sequencing 
Forward Primer 74 891 069F 5'-taagtcagctgaggccgagag-3' 
Reverse Primer 74 891 257R 5'-ctccagcacatgctgagccg-3' 
An annealing temperature of 61°C with 30 cycles successfully amplified 
this exon from DNA of an unaffected and affected patient. PCR reactions 
with Q-solution were electrophorised at 100V for 1 hr. These PCR products 
were QIAquicked and eluted with 30µL elution buffer. Sequencing was 
achieved using 2µL template DNA and no mutations were detected in 
affected or unaffected DNA when sequences were assessed relative to 
each other and GenBank (see Appendix 17 for chromatograms). 
4.8 .2 Exon 2 - Amplification and sequencing 
Forward Primer 74 894 838F 5'-ttccagctccagccgtgctc-3' 
Reverse Primer 7 4 895 150R 5'-cctgactcttctaacttctggc-3' 
An annealing temperature of 61°C with 30 cycles successfully amplified 
this exon from DNA of an unaffected and affected patient. PCR products 
with Q-solution were electrophorised at 100V for 1 hr. These PCR products 
were QIAquicked and eluted with 30µL elution buffer. Sequencing was 
achieved using 4µL template DNA and no mutations were detected in 
affected or unaffected DNA when sequences were assessed relative to 
each other and GenBank (see Appendix 17 for chromatograms). 
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4.8 .3  Exon 3 - Amplification and sequencing 
4 .  8.  3 . 1  Exon 3 (i) Exonic primers 
Forward primer 74 899 173F 5'-ccttcatcgagttccttcctt-3' 
Reverse primer 7 4 899 598R 5'-TA TGCAGGTCAAGCTGCTCCA-3' 
An annealing temperature of 51°C with 30 cycles was unsuccessful in 
amplification of this exon. A Hot Star PCR using control 
(unrelated/unaffected male and female) DNA was thermocycled using an 
annealing temperature of 50°C with 30 cycles. This identified the primers 
as being unable to anneal and thus new exonic primers were chosen that 
were more complementary to sequences at the beginning and end of the 
exon. 
Forward primer 74 891 334F 5'-gGTGGACAAGAAGGTCTCGTG-3' 
Reverse primer 74 891 794R 5'-CTATGCAGGTCAAGCTGCTCC-3' 
An annealing temperature of 61°C with 30 cycles was unsuccessful and 
despite numerous attempts this exon was unable to be excluded as a 
causative sequence for HFM. However it was noted that there were no 
differences apparent on gel chromatography suggesting no obvious deletions 
or insertions in this portion of the exon. 
4.8 .3 .2  Exon 3 (ii) Exonic primers 
Forward Primer 74 899 713F 5'-CCTTCATCGAGTTCCTTCCTT-3' 
Reverse Primer 74 900 289R 5'-TATGCAGGTCAAGCTGCTCCA-3' 
An annealing temperature of 58°C with 30 cycles successfully 
amplified this exon from DNA of an unaffected and affected patient. PCR 
products without Q-solution were electrophorised at 100V for 1 hr. These 
PCR products were QIAquicked and eluted with 40µL ddH2O. Sequencing 
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was achieved using 3µL template DNA and no mutations were detected in 
affected or unaffected DNA when sequences were assessed relative to 
each other and GenBank 
4.8.3. 3  Exon 3 (iii) Exonic primer 
Forward Primer 74 900 181F 5'-AGGACAGCAAGGGCATCC-3' 
Reverse Primer 74 900 809R 5'-CCTCCAAGGAGGCCTCC-3' 
An annealing temperature of 53°C and 55°C with 30 cycles were both 
unsuccessful in amplification of this exon. Alternative exonic primers were 
ordered. 
Forward primer 74 900 181F 5'-AGGACAGCAAGGGCATCCA-3' 
Reverse primer 74 901 326R 5'-TCCCGGCTTCTTTAGGCTTTA-3' 
An annealing temperature of 52°C with 30 cycles was unsuccessful and 
despite numerous attempts this exon was unable to be excluded as a 
causative sequence for HFM. However it was noted that there were no 
differences apparent between gel chromatography therefore suggesting no 
obvious deletions or insertions on this portion of the exon. 
4. 8. 3. 4 Exon 3 (iv) Exonic primers 
Forward Primer 74 901 157F 5'-GAGCCACGTGCGTCCTGAGGAC-3' 
Reverse Primer 74 901 764R 5'-CGGGGCCTGCCGAGCTCTGGA-3' 
An annealing temperature of 69°C with 30 cycles successfully 
amplified this exon from DNA of an unaffected and affected patient. PCR 
products with Q-solution were electrophorised at 100V for 1 hr. These PCR 
products were QIAquicked and eluted with 40µL ddH2O. Sequencing was 
achieved using 3µL template DNA and no mutations were detected in 
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affected or unaffected DNA when sequences were assessed relative to 
each other and GenBank. 
4.8 .3.5 Exon 3 (v) Exonic primers 
Forward primer 74 901 457F 5'-CCTGCTGCATCAGTGGGTGA-3' 
Reverse primer 74 902 423R 5'-TTCCTGTCCACTTAACGGCCT-3' 
An annealing temperature of 59°C with 30 cycles successfully 
amplified this exon from DNA of an unaffected and affected patient. PCR 
products without Q-solution were electrophorised at 100V for 1 hr. These 
PCR products were QIAquicked and eluted with 40µL ddH2O. Sequencing 
was achieved using 3µL template DNA and no mutations were detected in 
affected or unaffected DNA when sequences were assessed relative to 
each other and GenBank (see Appendix 17 for chromatograms). 
4.8. 3.6 Exon 3 (vi) Exonic primers 
Forward Primer 74 902 197F 5'-TAGGAGAGAGTGCTGCAGAG-3' 
Reverse Primer 74 902 796R 5'-CAGACACAAGGCTTGGATTCA-3' 
An annealing temperature of 57°C with 30 cycles successfully 
amplified this exon from DNA of an unaffected and affected patient. PCR 
products without Q-solution were electrophorised at 100V for 1 hr. These 
PCR products were QIAquicked and eluted with 30µL ddH2O. Sequencing 
was achieved using 2µL template DNA and no mutations were detected in 
affected or unaffected DNA when sequences were assessed relative to 
each other and GenBank. 
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4.8 .3 .7  Exon 3 (vii) Exonic primers 
forward Primer 74 902 297f 5'-GCACCCAGCTTGGCAGATGTG-3' 
Reverse Primer 74 902 898R 5'-AGAGAGGACATCACTCTGGTCC-3' 
An annealing temperature of 63°C with 30 cycles successfully 
amplified this exon from DNA of an unaffected and affected patient. PCR 
products without Q-solution were electrophorised at 100V for 1 hr. These 
PCR products were QIAquicked and eluted with 30µL ddH2O. Sequencing 
was achieved using 2µL template DNA and no mutations were detected in 
affected or unaffected DNA when sequences were assessed relative to 
each other and GenBank. 
4.8 .3 .8  Exon 3 (viii) Exonic primers 
forward Primer 74 902 782f 5'-CTGAGGCTTAGGAAGAGAATG-3' 
Reverse Primer 7 4 903 490R 5'-tgccatgatgattgaacgacc-3' 
An annealing temperature of 57°C with 30 cycles successfully 
amplified this exon from DNA of an unaffected and affected patient. PCR 
products without Q-solution were electrophorised at 100V for 1 hr. These 
PCR products were QIAquicked and eluted with 30µL ddH2O. Sequencing 
was achieved using 2µL template DNA and no mutations were detected in 
affected or unaffected DNA when sequences were assessed relative to 
each other and GenBank (see Appendix 17 for chromatograms). 
To summarize, the first two exons and the majority of exon three 
(75%) for this gene was sequenced, and no mutations were detected in 
affected or unaffected DNA when sequences were assessed relative to 
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each other and GenBank. Therefore sequencing of this gene further 
reduced the region to be assessed for chromosome 11 HFM linkage. 
4.9  PCR amplification of CLNSJA and sequencing results 
4.  9 . 1  Exon 1 - Amplification and sequencing 
Forward Primer 75 889 781F 5'-tccacacgttcttagccgacctc-3' 
Reverse Primer 75 890 255R 5'-gagccttccacccgctacaggta-3' 
An annealing temperature of 67°C with 30 cycles successfully 
amplified this exon from DNA of an unaffected and affected patient. PCR 
products without Q-solution were electrophorised at 100V for 1 hr. These 
PCR products were QIAquicked and eluted with 50µl. ddH2O. Sequencing 
was achieved using 3µl. template DNA and no mutations were detected in 
affected or unaffected DNA when sequences were assessed relative to 
each other and GenBank (see Appendix 17 for chromatograms). 
4. 9 .  2 Exon 2 - Amplification and sequencing 
Forward primer 75 897 695F 5'-gtggtcttacatgaggatttac-3' 
Reverse primer 75 898 022R 5'-gattacaggcgtgagccac-3' 
An annealing temperature of 57°C with 30 cycles successfully 
amplified this exon from DNA of an unaffected and affected patient. PCR 
products with Q-solution were electrophorised at 100V for 1 hr. These PCR 
products were QIAquicked and eluted with 30µl. ddH2O. Sequencing was 
achieved using 4µl. template DNA and no mutations were detected in 
affected or unaffected DNA when sequences were assessed relative to 
each other and GenBank. 
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4. 9.  3 Exon 3 - Amplification and sequencing 
Forward Primer 75 901 707F 5'-ctaggatgctcactgtataatc-3' 
Reverse Primer 75 902 094R 5'-caatagaatggaggtaatggtg-3' 
An annealing temperature of 57°C with 30 cycles successfully 
amplified this exon from DNA of an unaffected and affected patient. PCR 
products with Q-solution were electrophorised at 100V for 1 hr. These PCR 
products were QIAquicked and eluted with 50µL ddH2O. Sequencing was 
achieved using 3µL template DNA and no mutations were detected in 
affected or unaffected DNA when sequences were assessed relative to 
each other and GenBank. 
4. 9. 4 Exon 4 - Amplification and sequencing 
Forward Primer 75 902 472F 5'-gcttcaaccgctttcaag-3' 
Reverse Primer 75 902 813R 5'-gaactataatcctctaccc-3' 
An annealing temperature of 51°C with 30 cycles successfully amplified 
this exon from DNA of an unaffected and affected patient. PCR products 
with Q-solution were electrophorised at 100V for 1 hr. These PCR products 
were QIAquicked and eluted with 30µL ddH2O. Sequencing was achieved 
using 2µL template DNA and no mutations were detected in affected or 
unaffected DNA when sequences were assessed relative to each other and 
GenBank (see Appendix 17 for chromatograms). 
4. 9. 5 Exon 5 - Amplification and sequencing 
Forward Primer 75 904 858F 5'-gtgccaccacgcctggctaa-3' 
Reverse Primer 75 905 214R 5'-gtgctcatctgactgttcacac-3' 
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An annealing temperature of 61°C with 30 cycles successfully amplified 
this exon from DNA of an unaffected and affected patient. PCR products 
with Q-solution were electrophorised at 100V for 1 hr. These PCR products 
were QIAquicked and eluted with 35µL ddH2O. Sequencing was achieved 
using 3µL template DNA and no mutations were detected in affected or 
unaffected DNA when sequences were assessed relative to each other and 
GenBank (see Appendix 17 for chromatograms). 
4. 9.  6 Exon 6 - Amplification and sequencing 
forward Primer 75 907 890F 5'-cactagcttccttctggtaga-3' 
Reverse Primer 75 908 195R 5'-atgccactgcactgtagcct-3' 
An annealing temperature of 57°C with 30 cycles successfully 
amplified this exon from DNA of an unaffected and affected patient. PCR 
products without Q-solution were electrophorised at 100V for 1 hr. These 
PCR products were QIAquicked and eluted with 30µL ddH2O. Sequencing 
was achieved using 3µL template DNA and no mutations were detected in 
affected or unaffected DNA when sequences were assessed relative to 
each other and GenBank (see Appendix 17 for chromatograms). 
4. 9.  7 Exon 7 - Amplification and sequencing 
4. 9.  7 .1 Exonic Primer (i) 
Forward Primer 75 910 899RF 
Reverse Primer 75 911 374R 
5' -ggcact cgtgactaggcatt-3' 
5'-TGGTAA A ACA TGGCGAAAGG-3' 
An annealing temperature of 55°C with 30 cycles was unsuccessful and 
despite numerous attempts this exon was unable to be excluded as a 
causative sequence for HFM. However it was noted that there were no 
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differences apparent between gel chromatography therefore suggesting no 
obvious deletions or insertions on this portion of the exon. 
4.  9 .  7. 2 Exonic Primer (ii) 
Forward Primer 75 911 301F 5'-GCACAGGAGCTTGGT AG-3' 
Reverse Primer 75 911 691R 5'-gccttactaaatacttgcc-3' 
An annealing temperature of 49°C with 30 cycles was unsuccessful and 
despite numerous attempts this exon was unable to be excluded as a 
causative sequence for HFM. However it was noted that there were no 
differences apparent between gel chromatography therefore suggesting no 
obvious deletions or insertions on this portion of the exon. 
To summarize, 6 out of 7 exons for this gene was sequenced, and no 
mutations were detected in affected or unaffected DNA when sequences 
were assessed relative to each other and GenBank. Therefore sequencing of 
this gene has reduced the region to be assessed for chromosome 11  HFM 
linkage. 
In those genes sequenced, no sequence variations were detected in 
exonic sequences of affected or unaffected individuals (Appendix 18). 
4 . 10 Summary 
To summarize, although no mutations were found, sequencing of these 
genes has contributed significantly in reducing the region to be analyzed by 
355,995 bases. Unfortunately no further results could be achieved with the 
time available for this project, however, publication of these results (paper 
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in preparation) will markedly improve available data for HFM. These 
sequencing results, together with marker analysis, reduced the overall 
region to be analyzed by 355,995 bp. 
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Chapter 5: Discussion 
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5.0 Discussion 
The overall purpose of this project was to explore the underlying 
pathogenesis of HFM, investigate treatment and management options, 
identify likely candidate genes and screen candidate genes for mutation(s) 
causing the form of HFM segregating on chromosome 11 in a West 
Australian family. Outcomes of this project have significantly advanced 
investigations into the molecular pathology of hemifacial microsomia and will 
provide those affected with chromosome 11 HFM some hope that a genetic 
mutation may be found in the near future which could lead to better 
diagnosis, prognosis, prevention and treatment. 
Hemifacial microsomia (HFM) is a congenital developmental disorder 
involving malformation of the first and second bronchial arch derivatives. 
Variable axial asymmetry is the characteristic feature of this disorder with 
craniofacial malformations as the phenotypic manifestation of the disease. 
As any derivative of the bronchial arches may be affected, the clinical 
picture varies considerably. 
Embryologically, asymmetry is a relatively common occurrence in 
nature. Examination of frog embryos has indicated that a cascade of 
signaling molecules is responsible for the generation of asymmetry, 
beginning with the asymmetric expression of Shh along the dorsal-ventral 
axis and FGF and RA along the rostro-caudal axis and forms part of the 
normal specification and formation of axes, crucial developmental events, 
for determining the orientation of the body plan. However, left-right 
asymmetry is essential for formation of the two sets of a symmetrical body 
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plan and is generated by signaling molecules and genes (lefty and nodal). 
Asymmetry across the left-right axis leads to abnormalities which have 
fatal consequences if they severely affect organ and skeletal structures. 
HFM is a relatively mild manifestation of left-right asymmetry. 
The aetiology of HFM has been subject to much debate and is yet to 
be sufficiently explained. Literature surrounding this phenomenon has 
suggested that HFM results from a culmination of causal factors, including 
defective genes, teratogenic substances or vascular anomalies. This leads to 
the conclusion that within the HFM spectrum there is an amalgamation of 
both incidental and inherited disorders without any true prediction of the 
pathogenesis of the syndrome that results. Alternatively, variable 
expression of an autosomal dominant gene may explain the reported HFM 
pedigrees as it could also account for the range of deformities associated 
with HFM. Numerous chromosomal abnormalities have been associated with 
HFM and studies involving both mutant and transgenic mice have been 
discovered that appear to be models of HFM. 
This project, based on the anticipation described in the family under 
investigation, and the autosomal dominant nature of this disorder, 
identified and sequenced four candidate genes at the chromosome 11 
linkage locus, previously identified by Dr David Chandler (2001). Despite 
unsuccessful attempts at mutational analysis both here and previously, 
performing this study has greatly added to the general understanding of 
this disease and its phenotype, and provides a basis for further studies 
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aimed at better diagnosis, treatment and identification of causative genes 
and other factors. 
5 .1 Diagnosis recommendations 
HFM is typically not diagnosed until late infancy or early childhood, as 
recognizable features such as facial asymmetry are subtle, in newborn 
infants. Accurate facial anomaly assessment is essential for effective 
diagnosis, classification and treatment of HFM. The two most common 
classification systems adopted to analyse HFM are the SAT and OMENS 
classification systems. Alternative systems, including the Pruzansky 
classification system, Teconi and Hall ' s  phenotypic classification system and 
Munro and Lauritzen ' s  system were alternative classification systems 
devised to guide treatment planning and diagnosis of HFM, although not as 
widely accepted as the SAT and OMENS classification system. This author, 
through review of the classification systems determined that SAT and 
OMENS are the two classification systems of preference however 
individual phenotypes must be taken into account to support accurate 
treatment and management. A combination of the two is recommended for 
future studies. 
5. 2 Treatment and Management Suggestions 
Treatment has historically concerned the jaw or ear, the choice being 
dependant on the patient, family concerns and the surgeon's expertise and 
experience. Every facial structure affected in patients with HFM shows 
evidence of bilaterally diminished growth potential. This is a key feature of 
HFM and worthy of consideration in treatment regimes. Giving 
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t consideration to the fact that the inborn morphogenetic error cannot be 
treated, the more appropriate approach is to create an environment where 
normal facial growth is encouraged and secondary distortion is minimised 
(Kearns, Padwa, Mulliken & Kaban, 2000; Murray, Kaban & Mulliken, 1984). 
Determining a patient's degree of skeletal deformation is one of the first 
steps in treating a patient with HFM. The severity of the defect can be 
appreciated and the progression rate predicted through the investigation of 
mandibular reconfiguration. This project has contributed by providing an 
overall literature review on treatment strategies, as well as comparing the 
benefits and risks associated with early or late surgical intervention and 
pulication of this material as a result may assist with diagnosis in the 
future. 
Reconstruction of the mandible is one of the key elements in the 
skeletal rehabilitation of patients with HFM (Polley, Figueroa, Liou & Cohen, 
1996). Aforementioned, severe grades of HFM present with significant 
dysplasia of both skeletal and soft tissues, posing challenging problems for 
the surgical reconstructive team (Polley & Figueroa, 1997). Central skeletal 
deformity usually centers on the temporomandibular region. A variety of 
orthodontic regimes have been recommended for treating HFM, including 
functional appliances, used singularly, or in conjunction with surgery (Chate, 
1995). 
The question of facial growth potential in HFM is important when 
developing treatment strategies for patients (Cobourne, 2000). This is 
central to timing of surgical intervention which has been subject to much 
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debate (Cousley & Calvert, 1997; Kaban, Moses & Mulliken, 1988; Murray, 
Kaban & Mulliken, 1984). In general, the treatment plan is considered most 
beneficial if formulated once the soft-tissue and skeletal deformities are 
classified and the mandibular type and anatomy are appropriately analysed 
(Cousley & Calvert, 1997). To date, there is no universal protocol to be 
followed when treating patients with HFM. 
Despite the deformation of other structures aside from facial 
asymmetry it is the face that is considered of prime aesthetic importance. 
Hence, many treatment reviews have concentrated on improving the 
symmetry of the mandible and its associated deformities. 
5. 2 . 1  Arguments Supporting Early Intervention and Recommendations 
Based on this author's review of the literature and treatment, it is 
suggested that early intervention is recommended in terms of psychological 
benefit to the patient however it is apparent that a long-term management 
plan, possibly involving further surgical intervention, may be required as 
skeletal structures develop and deformation becomes more apparent. 
Through clinical observation Murray, Kaban and Mulliken (1984) 
deemed the mandible responsible for growth restriction of the maxilla, 
zygoma and orbits. Early mandibular elongation therefore provides more 
symmetrical growth of the midface and subsequent psychological benefit to 
the young patient (Kaban, Moses & Mulliken, 1988). This author deemed the 
most beneficial approach to treatment involves mandibular repositioning in a 
more physiological position which will trigger the growth potential of 
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adjacent structures. Results of this strategy have included minimised 
secondary deformity, improved function and appearance of the mandible and 
a greater benefit of the patient's skeletal and psychological growth (Kearns, 
Padwa, Mulliken & Kaban, 2000). As a result of continual asymmetric growth, 
the clinical defects worsen, even though the morphogenetic damage within 
the first and second bronchial arches occurs in utero. The earliest skeletal 
manifestation characteristic of HFM is mandibular hypoplasia which 
compromises otherwise normal downward growth of the maxilla. Thus 
mandibular distortion worsens with asymmetric skeletal growth and can 
cause secondary deformation of the mid-face. 
Operations involving bone or cartilage transplantation can be used to 
enhance facial symmetry. Despite the aesthetically pleasing results, 
transplanted bone is not expected to grow or improve the facial contour 
(Polley & Figueroa, 1999; Kazanjian, 1939). Mechanical devices used to 
control normal mandible movements must take into consideration the 
patients age and the substitution of temporary teeth with permanent ones. 
Following on from the proposition that the affected side of a patient 
exhibits diminished growth potential, it can be argued that with time the 
skeletal defect would progressively worsen. A more extensive mandibular 
procedure, maxillary osteotomy, is frequently required by adult HFM 
patients, proceeded by several bone grafts, whereas in the developing child 
the operative correction can be limited to the mandible. 
Those children suffering from severe HFM are most likely to benefit 
psychologically from early intervention and treatment (Poole, 1989). Reports 
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are insufficient on the long-term result of major facial osteotomies, 
although several authors have observed the preservation of symmetry up to 
6 years post-op. Moreover appropriately timed mandibular construction 
and/or elongation in children with HFM is safe and effective (Polley & 
Figueroa, 1997). The optimized facial growth eventuates from the reduction 
in secondary deformity on the affected side. 
There are several advantages associated with advocating early skeletal 
correction in children with HFM. Primarily, the mandibular procedure is 
easier for the patient and the surgeon. Secondly, children seem to benefit 
from an improved self-image while growing, thereby diminishing the 
psychological trauma of their asymmetrical deformity (Kaban, Moses & 
Mullike, 1988; Stark & Saunders, 1962). While difficult to measure, the 
psychological benefits are imperative to both the patient and their family. 
Finally, in early operative intervention, complications are few. 
Consequently, early intervention/operation is advisable to assist in 
maintaining normal soft tissue development on an affected side, since the 
bone defect cannot be completely or permanently rectified at the operative 
stage (Stark & Saunders, 1962). However, those who advocated early 
surgery recognised that further definitive correction was required at the 
end of growth (Poole, 1989; Vargervik, 1983a,b). 
5. 2. 2 Arguments Supporting Late Intervention and suggestions 
Surgery prior to the conclusion of adolescence has been criticised 
because of morbidity; potential growth disruption from the operation and 
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subsequent scarring; the underlying asymmetry of the soft tissue functional 
matrix; the effects on patient compliance and the need for post-growth 
corrections (Renzi, Carboni, Perugini & Becellim, 2002; Poswillo, 1974). 
Consequently it has been argued that definitive soft tissue reconstruction 
should be delayed unti I after the completion of both growth and skeletal 
surgery (Cousley & Calvert, 1997). Ultimately it can be reasoned that 
complete correction can be successfully carried out in the adult patient 
with one major skeletal operation (Kaban, Moses & Mulliken, 1988). 
Kaban, Moses and Mulliken (1988) acknowledged concerns regarding 
surgical intervention in children, primarily that young patients severely 
affected by HFM would require numerous operations throughout the course 
of facial growth. Therefore until full growth is acquired, changes in the 
contour of the face would be constantly taking place (Kazanjian, 1939). This 
author also acknowledged that premature surgical treatment could 
accentuate a deformity by decreasing already compromised growth 
potential. This would be compounded if multiple procedures were required 
due to repeat tissue damage and scar formation. Similarly Murray and 
colleagues (1984) advocated late intervention in patients with HFM. 
There are two opposing views in the literature concerning the 
progressive nature of facial asymmetry in HFM patients. Both Rune et al. 
(1981) and Polley et al. (1997) emphasized that asymmetry did not evolve in 
HFM patients and that the deformity changes in proportion to the child ' s  
overall size but that it did not become increasingly severe with time. 
Therefore, it is recommended that the facial asymmetry be addressed, at 
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the completion of growth, by surgical correction of the end-stage 
deformity. Similarly Rune et al. (1981) and Polley et al (1997) concluded 
that growth on the affected side parallels that of the non-affected side 
with the degree of mandibular asymmetry remaining relatively constant 
throughout craniofacial development. However, several authors suggest 
alternatively that mandibular asymmetry is progressive and patients exhibit 
increasing vertical mandibular asymmetry with growth (Kearns, Padwa, 
Mulliken & Kaban, 2000; Padwa, Mulliken, Maghen & Kaban, 1998; Polley & 
Figueroa, 1997; Polley, Figueroa, Liou & Cohen, 1996; Rune et al. , 1981). 
HFM patients are best treated in multidisciplinary centres by 
competent specialists with the necessary experience and skills. This 
effectively involves individual patient assessment in relation to 
reconstructive surgery (Guichard & Arnaud, 2001), orthodontics (Chate, 
1995), otolaryngology, audiology, speech and language therapy, opthalmology, 
paediatrics, genetics and psychology (Poole, 1989). 
Prevention of craniofacial malformations is unlikely, based on 
knowledge of their etiology or pathogenesis, although identification of 
causal mechanisms may play a role in the future clinical management. The 
ultimate goal of treatment of HFM is to improve facial symmetry and 
mandibular function upon completion of craniofacial growth. More 
specifically, the objectives of treatment include optimizing function 
(hearing, speech, mastication, swallowing and respiration) and aesthetics 
(symmetry and balance) (Cousley & Calvert, 1997). The need to recognise 
hearing loss early and provide for a sensory prosthesis and auditory training 
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where indicated, is a matter of early priority in patient care (Figueroa & 
Pruzansky, 1982). However, recognition that a child's psychosocial 
confidence may suffer from an obvious abnormality is important (Causley & 
Calvert, 1997; Dryland, 1996). The decision whether to perform surgery or 
not should only be dictated by the possibility of an optimal long-term result. 
Despite the varying methods of treatment available diagnosis and 
treatment of HFM will be greatly enhanced by discoveries of genetic 
mutations linked to the disease. Treatment and management of HFM 
essentially relies on an increased understanding of the pathogenesis of 
HFM. Insufficient numbers of severe HFM patients have been observed 
over the long-term to growth completion to predict with certainty how many 
will require maxillary osteotomy. This is an important consideration when 
analysing treatment and management modalities. Additionally, there is a lack 
of understanding surrounding the ramifications of embryonic neural crest 
cell destruction on structure development and long-term growth potential 
of the affected derivatives of the first and second bronchial arches. 
Additional assessment of the probands' family members for defects 
associated with the HFM complex is essential. Chromosome analysis and 
genetic counselling can be offered, where appropriate (Causley & Calvert, 
1997; Epstein, Curry, Packman, Sherman & Hall, 1979). 
Previously, linkage studies were hampered by the lack of large families 
with HFM, despite the identification of numerous small families. Non­
penetrance and the difficulties associated with classifying HFM make it 
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both unnecessary and unwise to combine small families for the purpose of 
I inkage studies. 
5.  3 Mutation analysis in this thesis 
The identification and co-operation of a large West Australian family 
with HFM has allowed the phenotypic and genotypic study of the disorder 
presented in this thesis. Phenotypic analysis demonstrates that Goldenhar 
and HFM symptoms are both present in this family, indicating that these 
two disorders may be caused by mutations in a single gene (J acobsson & 
Granstrom, 1996; Kaye et al., 1992; Yanagihara, Yanagihara & Kabasawa, 
1979). Although large, this family does not have sufficient affected 
individuals to provide significant linkage in an affected-person only analysis. 
It was however large enough to give significant linkage using all members of 
the pedigree and to exclude a large portion of the genome as being in 
linkage with HFM (Chandler, 2001; this thesis). 
Professor Robin Winter' s  group in London, has performed a genome 
screen on another large family with HFM. This yielded a Lod score of 3.00 
on chromosome 14 in the vicinity of markers D14526 7 and D14S987. Typing 
of the Western Australian family for these markers showed that the West 
Australian family does not link to this region. Conversely, work on the 
English family for markers in the chromosome 11  linkage region for the 
West Australian family excluded the English family from being linked to a 
region on chromosome 11. This confirmed the probability of different 
genetic loci associated with these disorders in two separate families and 
heightens the possibility of genetic association with an autosomal dominant 
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disease gene. Moreover, these results provide a clue to the suspected 
genetic heterogeneity for this disorder, based on phenotypic heterogeneity 
thereby emphasising the importance of careful and accurate phenotypic 
classification. 
Once a linkage had been established and phenotype carefully assed, 
this project adopted a novel strategy known as 'genome mining' (Houle, 
Cadigan, Henry, Pinnamaneni & Lundahl, 2000) to identify hemifacial 
microsomia candidate genes. This technique was successful and identified 
four genes, namely UVRAG, ARIX, CLNSJA and GARP from the chromosome 
11 linkage region as being likely candidates for the West Australian family 
segregating HFM. All four genes were thoroughly investigated (for 
association with known HFM regions in patients and animal models) using 
several databases. Moreover, the majority of three genes were sequenced. 
Despite the implementation of numerous laboratory techniques sequencing 
of all for genes could not be completed. Nonetheless, this project has 
contributed to enhancing the understanding and assessment of HFM 
through the adoption of novel strategies; genome mining and bioinformatics. 
While data-mining and sequencing of these three genes in an affected and 
unaffected individual identified no differences from the published 
sequence, these results assist future studies by minimising the regions and 
genes required to be sequenced. Furthermore, results presented here 
exclude UVRAG, CLNSJA and GARP as candidates for the disease in this 
family and suggests further sequencing of ARIX as it is a strong candidate 
for future research and experimentation. 
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[ Within the chromosome 11 linkage region, there are 131 known genes. 
r From genome mining studies performed for this study, we have reduced this 
list to the most promising candidate genes. In this way, genome mining 
further reduced the list of candidate genes and provides a useful resource 
for future studies aimed at identifying likely candidate genes for HFM. 
5. 3 .1 Triplet repeat expansion 
The observation that anticipation may be involved in this family in the 
inheritance of HFM prompted the investigation of triplet repeats for a 
disease causing expansion. Future examination of candidate genes should 
take into account the possibility of a perhaps small repeat expansion either 
in or near the gene as a causative mutation. A full list of repeat regions in 
or near genes is provided in Appendix 10 and is a useful resource for future 
genome mining studies of this region. 
5.4 Contribution of this study to the treatment and diagnosis of 
dysmorphology 
An important aim of this project was to add to the understanding and 
concepts and aid in decisions that optimise treatment. The identification of 
disease genes is crucial for the understanding and treatment of the 
disease. Moreover optimal management of HFM is dependant on appreciation 
of the complete genotype and phenotype. In this thesis, I provide a 
comprehensive appraisal of genetic and interdisciplinary approaches along 
with long-term coordinated treatment planning. Aforementioned, this 
author endorses a co-ordination of both early and late intervention and 
management. I also indicate effective treatment strategies specific to the 
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individual that can be formulated once the soft-tissue and skeletal 
deformities are classified. The use of bioinformatics to assess genetic 
information has also proven to be partially successful and provides a 
framework for future studies. 
5.5 Future Research 
Through identification of genes associated with HFM, it will be 
possible to accurately diagnose, treat and manage patients with HFM, 
providing them with optimal life expectancies and better quality of lie. 
Results presented in this thesis contribute to this cause. 
It is implausible to test every gene in this linkage region for this 
project. Foremost, further familial studies are necessary in order to 
confirm this linkage region on chromosome 11 as associated with HFM and so 
as to refine the linkage region. From studies presented here, it becomes 
evident that the intricacy of the developmental system implies that many 
molecules will be involved in HOX code communication to the myriad of 
tissues and organs reliant on positional and patterning information. Through 
future studies on the interaction of nuclear proteins with the HOX 
transcription factors, a number of genes, including the zinc-finger genes, 
will prove to play a role in craniofacial development. Should these or related 
genes, be discovered in the linkage region previously described, they should 
become prime candidates and tested accordingly in the affected family to 
determine if they are in fact mutated. Furthermore, ARIX has been 
identified by this project as a prime candidate for chromosome 11 HFM. 
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Due to time restraints and lack of success in sequencing, this project has 
identified ARIX as a candidate for future testing. 
5.  6 Concluding Comments 
A model of human development will in time be built through the 
discovery of inherited malformations. In turn this will assist in the 
understanding of causative factors of randomly occurring malformations. 
The knowledge and scope of dysmorphology has greatly expanded over the 
last decade through the identification and localization of disease genes. 
Every gene discovery is another stich in the intricate tapestry that is the 
development of the human body. This thesis has helped by contributing 
strategies and sequencing information that will assist in the search for 
genes associated with hemifacial microsomia. 
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Bronchial arch derivatives affected in HFM 
AURICLE 
MUSCULATURE 
BONES 
First arch anterior helix 
tragus 
Second arch helix 
First arch 
Second arch 
First arch 
Second arch 
antihelix 
lobule 
muscles of mastication 
tensor palatine 
muscles of facial expression 
maxilla 
zygoma 
palatine bone 
mandible 
malleus 
incus 
stapes 
Hyoid (lesser cornu) 
Table to illustrate the derivatives of the first and second bronchial 
arches that can be affected in HFM (Adapted from Figueroa & 
Pruzansky, 1982). 
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APPENDIX 2 
C l i n ical  presentation of an affected individual 
(Right) PA cephalometr ic rad iograph 
trac ing of affected i ndiv idual (r ight).  
Right-sided mand ibular hypoplasia. 
Maxi l la shows hypoplasia also. Lower and 
centre l i ne disp lacement. Occlusal p lane 
t i l ts to the r ight .  
Adapted from Singer , Haan, S lee & Go ldblatt (1994 ) .  
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(Left) Front view of 
affected ind ividua l .  Note 
the r ight-s ided facia l  
hypoplasia of the 
skeleton and soft t issue. 
Add it iona l ly ,  the ch in  
deviates to the r ight.  
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APPENDIX 3 
Spectrum of congenital malformations which comprise the first and 
second bronchia l  arch syndrome 
underdev 
ouncle 
c:left sinus 
absence of 
parotid 9/ond 
and duc t  
underdeveloped 
muscles or 
mast1cat1on 
mocrostom,a 
underdeveloped 
foc,al muscles 
,,,,.�/' :p
::
·o;::,¾, unaeraey·eloped 
zyqoma 
� 
The above i l lustrations depict the spectrum of congenital malformat ions which comprise 
HFM (fi rst and second branchia l  arch syndrome). A patient d isplaying HFM in  its ful lest 
expression would exh i b it uni lateral underdevelopment of the external ear , middle ear , 
mandib le ,  zygoma, max i l la ,  temporal bone, facial , mastication and palatal muscles, tongue 
and parotid gland . In add ition, macrostomia and a f irst bronch ial cleft sinus. 
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APPENDIX 4 
Malformation classification in patients with HFM 
SKELETAL CATEGORIES 
Sl - Smal l  mandible with normal shape 
S2 - Condyle, ramus, and sigmoid notch identifiable but grossly 
distorted; mandible strikingly different in size and shape from 
normal 
S3 - Mandible severely malformed, ranging form poorly 
identifiable ramal components to complete agenesis of ramus 
S4 - An S3 mandible plus orbital involvement with gross posterior 
recession of lateral and inferior orbital rims 
S5 - The S4 defects plus orbital dystopia and frequently 
hypoplasia and asymmetrical neurocranium with a flat temporal 
fossa. 
AURICLE CATEGORIES 
Al - Normal 
A2 - Smal l ,  malformed auricle retaining characteristic features. 
A3 - Rudimentary auricle with hook at cranial end corresponding to 
the helix 
A4 - Malformed lobule with rest of pinna absent 
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SOFT TISSUE CATEGORIES 
Tl - Minimal contour defect with no cranial nerve involvement. 
T2 - Moderate defect 
T3 - Major defect with obvious facial scoliosis, possibly severe 
hypoplasia of cranial verves, parotid gland, muscles of mastication; 
eye involvement; clefts of face or lips 
(Adapted from Rodgers, Eppley, Nelson & Sadove, 1991 & Silvestri, 
Natali & Iannetti, 1996). 
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APPENDIX 5 
Markers for Chromosome 11  candidate region 
[)11S1883 (64,533, 373 - 64,533, 624) 
SYNONYMNS - RG74478, 3 1183, w6333, stSG34793, stSG34794, 
stCP2122, AFMB072WE5, D11S4146, SHGC-20653, AFMb072we5, 
253263, RH3 1164, AFN039XG3, AFM039xg3, STS1041, D11S1883, 
039xg3, DBSTS:46439, DBSTS:31183, b072we5, HSB072WE5, 
RH74477 
PRIMERS - 5' AACACGAGGTTAAGCAGAG 
3' GAATGAAGAATTTTCCAAACT AC 
[)11S987 (Not currently mapped in Ensembl) 
SYNONYMS - AFMa131ye5 
PRIMERS - 5' GACTCCAGTCTGGGCAATAAAAGC 
3' GGTGGCAGCATGACCTCTAAAG 
[)1154178 (Not currently mapped in Ensembl) 
SYNONYMS - DBSTS:46486, AFMB358XA9, D11S4178, AFMb358xa9, 
HSB358XA9 
PRIMERS - 5' cgtgtccagatgaaagtg 
3' caggcccagtctcttg 
[)1154136 (69, 221,479 - 69, 221, 668) 
SYNONYMS - RH84412, AFMB032ZG5, RH15566, AFMb032zg5, 
STS16665, b032zg5, RH86312, DBSTS:31083, HSB032ZG5, stCP2113, 
D11S4136, 253163, gbd:602708, SHGC-20680 
PRIMERS - 5' GAA TCGCTTGAACCCAG 
3' CCAGGTGGTCTT AACGG 
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D1154139 (69, 946, 835 - 69, 946, 983) 
SYNONYMS - RH86094, AFMB038YB9, 253184, SHGC-22368, 
DBSTS:46488, STS59405, AFMb038YB9, b038yb9, RH84110, 
HSB038YB9, stCP2116, D11S4139 
PRIMERS - 5' 
3' 
TATAGACTTCAGCCCTGCTGC 
CCTCTGTAGGATGCAGTTGG 
Dl 1S1314 (Not currently mapped in Ensembl) 
SYNONYMS - SU1353, SHGC-2065, RH13524, 1549, D11S1314, 
AFM212xe3, RH37073, 223617, RH973 
PRIMERS - 5' ACAGACAGATCAAAAGGCAA 
3' GAAATGTGACCTCCTTCACC 
Dl 154207 (Not currently mapped in Ensembl) 
SYNONYMS - AFMA1032F9, AFMa103zf9, a103zf9, HSA1032F9, 
DBSTS:46492, D11S4207 
PRIMERS - 5' 
3' 
gctgggtgttacacaggac 
gagatcccgttcgacttg 
D11S911 (75, 971, 191 - 75, 971, 382) 
SYNONYMS - RH822, RH52094, AFM155XH10, STS15702, 
AFM155xh10, RH3099, 675, D11S911, DBSTS:675, gdb:593659, SHGC-
780, RH13281, STS9925, RH72807, 155xh10, 216690, HS155XH10, 
stCP1913 
PRIMERS - 5' 
3' 
CTTCTCATGCTTGACCATTT 
CTTCTGAACAATTGCCACAT 
Above information was taken from ENSEMBL database (June 2002) 
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APPENDIX 6 
Bioinformatics relating to genes identified on chromosome 14 between 
markers D14S1442 - D14S26 7 
1. KIAA1622 
Alternate Symbols - HEAT-like repeat-containing protein, isoform 
1/2 
Alias - MGC4163 protein 
Function - Gene ontology 
known / inferred 
Locus Link - 57718 
Span - 93,917,777-94,023,200 
Homologs - T2230 (Caenorhabditis e/egans - CE) 
NE (%) Tissue 
34.81 testis, cell line 
14.54 germ cell 
13.00 muscle 
10.49 pool, lung, testis and b-cell 
8.86 pool, melanocyte, heart and uterus 
7.03 breast 
6.95 eye 
3.22 uterus 
1.08 brain 
2.  SERPINA 10 
Alternate Symbols - PZI, ZPI 
Alias - protein Z-dependent protease inhibitor precursor 
Function - Gene ontology 
Blood clotting, serpin, Plasma protein, 
inhibitor/repressor 
Locus Link - 51156 
Span - 94,026,778-94,036,489 
Homologs - AA238242 (Mus musculus - MM) 
U55765 (Rattus norvegicus - RN) 
T47462 (Arabidopsis thaliana - A  7) 
T16119 (CE) 
1617172A (MM) 
JC4841 (RN) 
186 
Tissue 
liver 
NE (%) 
42.11  
26.26 
25.69 
5.96 
corresponding non-cancerous liver tissue 
hepatocellular carcinoma 
pool, liver and spleen 
3 .  SERPINA6 
Alternate Symbols - CBG, CBG decreased in, CBG elevated, 
corticosteroid-binding globulin precursor 
Alias - corticosteroid-binding globulin, alpha-1 antiproteinase, 
antitrypsin, serpina6 corticosteroid-binding globulin deficiency, 
transcortin deficiency 
Family - Serpin family 
Mouse Homology Maps 12 51.00cM 
Function - Gene ontology 
12 950.75cR 
12 953.79cR 
12 20157.15cR 
Steroid binding, serpin, inhibitor / repressor 
Locus Link - 866 
Span - 94,047,714-94,066,801 
Homologs - X70533 (MM) 
BF388405 (RN) 
T02362 (A 7) 
T16119 (CE) 
Q06770(MM) 
P31211  (RN) 
Disease associations - defect in CBG (leuven) is linked with reduced 
cortisol binding affinity 
Tissue Specificity - plasma, synthesized in liver, also identified in a 
number of glycocorticoid responsive cells 
NE (%) Tissue 
60.90 hepatocellular carcinoma 
2 1.77 corresponding non-cancerous liver tissue 
4.91 whole embryo 
3.18 pool, liver and spleen 
2.50 liver 
2.45 
1.65 
0.92 
colon, 2 pooled adenocarcinomas 
pancreas 
kidney 
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0.59 
0.51 
4. SERPINA2 
heart 
eye 
Alternate Symbols - ATR, PIL, ARGS, alpha-1-antitrypsin-related 
gene sequence, al pha-1-antitrypsi n-related protein precursor 
Alias - Protease inhibitor 1-like, protease inhibitor 1 (alpha-
1-antitrypsin)-like 
Family - Serpin family 
Function - Gene ontology 
Serine protease inhibitor / repressor 
Locus Link - 5299 
Span - 94,107,179-94,110,163 
NE (%) Tissue 
100 testis 
5. SERPINA1 
Alternate Symbols - PI, AAT, PI1, AlAT, alpha-1-antiproteinase, 
PRO0684/PRO2209, alpha-1 protease inhibitor, alpha-1-antitrypsin 
precursor 
Alias - Protease inhibitor (alpha-1-antitrypsin), protease inhibitor 1 
(anti-elastase), alpha-1-antitrypsin, serpinAl alpha-1-antitrypsin 
deficiency, autosomal recessive 
Family - Serpin family 
Mouse Homology Maps 12 51.00cM 
Function - Phenotype 
emphysema, emphysema-cirrhosis, hemorrhagic 
diathesis due to 'antithrombin' Pittsburgh 
Gene ontology 
Serine proteinase inhibitor, plasma glycoprotein, 
inhibitor / repressor, proteinase inhibitor, connective 
tissue development and maintenance, gas exchange, 
extracellular matrix maintenance, serpin acute phase 
response 
Locus Link - 5265 
Span - 94,121,848-94,126,716 
Homologs - U78975 (B n 
AB019366 (RN) 
T00972 (A n 
T16119 (CE) 
1617172A (MM) 
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ITRT (RN) 
Tissue Specificity - plasma 
NE (%) Tissue 
19 .62 gall bladder 
14.35 liver 
12.11  liver, hepatocyte 
10.11  corresponding non-cancerous liver tissue 
9.96 uterus, endometrium 
8.80 hepatocellular carcinoma 
4.77 thymus 
3.65 marrow 
2.96 pool, liver and spleen 
2.26 spleen 
6 .  SERPINA4 
Alternate Symbols - KAL, KST, P14, KLST, kallistatin precursor 
Alias - protease inhibitor 4 (kallistatin), tissue kallikrein inhibitor 
Family - Serpin family 
Function - Gene ontology 
Serine protease inhibitor / repressor, plasma protein, 
protein binding 
Locus Link - 5267 
Span - 94,306,957-94,313,069 
Homologs - T00972 (A 7) 
T25504 (CE) 
S23675 (MM) 
P35577 (RN) 
Tissue specificity - secreted from liver cell lines 
NE (%) Tissue 
21.93 ovary 
15.89 pool, liver and spleen 
13.27 spleen 
11.09 liver 
8.99 pancreas, exocrine 
6.91 corresponding non-cancerous liver tissue 
5.90 pool, melanocyte, heart and uterus 
3.66 whole embryo 
3.38 colon 
3.27 mixed 
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7. SERPINA5 
Alternate Symbols - PCI, PAI3, PROCI, PLANH3, acrosomal serine 
protease inhibitor 
Alias - protein C inhibitor, protein C inhibitor (plasminogen activator 
inhibitor-3), protein C inhibitor (plasminogen activator inhibitor-III), 
plasma serine protease inhibitor precursor 
Family - Serpin family 
Mouse Homology Maps 12cM 
Function - Phenotype 
Protein C inhibitor deficiency 
Gene ontology 
Peptidase, plasma glycoprotein, protein degradation, 
serine protein inhibitor, extracellular (excluding cell 
wall) 
Locus Link - 5104 
Span - 94,330,818-94,335,707 
Homologs - NM_008785 (MM) 
AB013128 (RN) 
T00972 (A n 
T25504 (CE) 
P70458 (MM) 
P09006 (RN) 
Tissue Specificity - synthesised in liver, secreted in plasma 
NE (%) Tissue 
29.97 uterus, endometrium 
8.46 adrenal cortico adenoma for Cushing's syndrome 
7.52 hepatocellular carcinoma 
5.70 pheochronocytoma 
5.16 adrenal gland 
3.90 ovary, epithelium 
3.71 testis, cell line 
3.68 pool, liver and spleen 
3.67 gall bladder 
2.92 pancreas, exocrine 
8 .  SERPINA3 
Alternate Symbols - ACT, AACT, alpha-1-antichymotrypsin precursor 
Alias - actichymotrypsin, alpha-1-antichymotrpsin, antichmotrypsin 
alpha-1 
Family - Serpin family of serine protease inhibitors 
Mouse Homology Maps 12 52.00cM 
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Function - Phenotype 
12 957.87cR 
16 509.87cR 
Alpha-1-antichymotrypsin, cerebrovascular disease, 
occlusive 
Gene ontology 
Serine protease inhibitor, plasma protein, proteinase 
inhibitor, acute-phase response 
Locus Link - 12 
Span - 94,357,899-94,367,522 
Homologs - T00972 (A 7) 
T25504 (CE) 
JH0494 (MM) 
P09006 (RN) 
Disease associations - chronic obstructive pulmonary disease / 
occlusive 
cerebrovascular disease 
Tissue Specificity - plasma 
NE (%) Tissue 
17.84 prostate, stroma 
17.53 gall bladder 
11.58 uterus, epithelium 
10.83 brain, pituitary 
6.4 liver 
5.36 pancreas, islet 
3.31 blood cd34+/cd38- hematopoietic 
2.82 hepatocellular carcinoma cells 
2.76 
2.68 
9 .  KIAA0928 
sciatic nerve 
choroid 
Alternate Symbols - HERNA, K12H4.8-LIKE 
Alias - helicase-moi, dicer drosophila homolog of, helicase with 
RNAase motif 
Family - dead box helicase family, deah subfamily 
Function - Gene ontology 
ATP binding, DNA helicase 
Locus Link - 23405 
Gene lynx - 9775 
Span - 94,833,138-94,885,433 
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Homologs - T48946 (A 7) 
S44849 (CE) 
NE (%) 
12.83 
12.17 
11.87 
9.04 
7.06 
5.15 
5.06 
4.06 
3.51  
2.73 
P40562 (Sacharomyces cerevisiae - St) 
Tissue 
whole embryo, mainly head 
pancreas, islet 
tongue 
colonic mucosa with ulcerative colitis 
pheochromocytoma 
human skeletal muscle 
hypothalamus 
prostate, metastatic prostate bone lesion 
brain 
macular retina 
10. calmin 
Alternate Symbols - FLJ12383, KIAA1188, calponin like 
transmembrane domain protein 
Alias - hypothetical protein FLJ12383 
Family - 130p family of ribosomal proteins 
Mouse Homology Maps 12cM 
Function - unknown 
Locus Link - 79789 
Span - 94,935,243-94,947,905 
Homologs - P14148 (MM) 
NE (%) 
26.30 
16.77 
1 1.86 
9.55 
6.44 
2.72 
2.52 
2.82 
2.07 
1.90 
JC4320 (RN) 
Tissue 
mammary gland 
ovary, tumor tissue 
melanoma (neuro cell line) 
human eye anterior segment 
oesophagus 
corresponding non-cancerous liver tissue 
muscle 
breast 
prostate epithelium 
eye, retina 
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1 1 .  FLJ21276 
Function - unknown 
Locus Link - 79686 
Span - 95,152,296-95,154,718 
NE (%) Tissue 
35.95 subcondral bone 
12.28 CNS, ms lesions 
10.39 human fetal eyes 
9.48 tonsil, enriched for germinal centre B-cells 
6.58 kidney 
4.42 pool, melanocyte, heart and uterus 
4.27 muscle 
3.93 chondrosarcoma 
3.85 bone 
3.56 foreskin melanocyte 
1 2 .  FLJ20034 
Function - unknown 
Locus Link - 54792 
Span - 95,205,402-95,209,243 
1 3 .  LOC51218 
Alternate Symbols - PRO1238 
Alias - clone FLB4739, PRO1238 
Family - cyclic nucleotide-gated cation channel family, 
Mouse Homology Maps 12103.20cR 
Function - unknown 
Locus Link - 51218 
Span - 95,289 ,008-95 ,289 ,648 
Tissue specificity - rod cells in the retina and inner medulla of kidney 
NE (%) Tissue 
20.48 connective tissue 
14. 13 testis, epididymus 
12. 71 thymus 
7.75 muscle, leg skin muscle 
3 .19 bone 
2.80 hepatocellular carcinoma 
2. 70 thyroid 
2.48 bone, mixed marrow stroma 
2.40 human fetal eye 
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2.11 
lps 
human lung, epithel ial cel l  l ines in treated lps 6hr to 
14. TCL6(i) 
Alternate Symbols - TNG1, TNG2, T-cel l leukemia / lymphoma 6 
A l ias - TCL1-neighbouring gene 1 / 2, T-cel l  leukemia / lymphoma 6, 
isoform TCL 
Fami ly - dead box hel icase fami ly, deah subfami ly 
Function - Gene ontology 
Known I inferred 
Locus Link - 27004 
Span - 95,408,286-95,416,877 
NE (%) Tissue 
25.25 leukopheresis 
18.91 placenta, human 8wk 
16.29 placenta 
5.40 tonsi l, enriched for germinal centre b-cel ls 
5.11 b-cel ls germinal 
4.16 lymph 
3 .79 pool, l iver and spleen 
3 .74 aorta 
3 .43 b lood, lymphocyte 
3 .13 chondrosarcoma 
15. TCL6(ii) 
Alternate Symbols - TNG1, TNG2 
A l ias - TCL1-neighbouring gene 1 / 2 
Function - Gene ontology 
Known I inferred 
Locus Link - 27004 
Span - 95,396,208-95,416,877 
16. TCL6(iii) 
Alternate Symbols - TNG1, TNG2 
A l ias - TCL1-neighbouring gene 1 / 2 
Function - Gene ontology 
Known I inferred 
Locus Link - 27004 
Span - 95,408,286-95,418,482 
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17. TCL6(iv) 
Alternate symbols - TNG1, TNG2 
Alias - TCL1-neighbouring gene 1 I 2 
Function - Gene ontology 
Known / inferred 
Locus Link - 27004 
Span - 95,396,208-95,418,482 
18 . TCL6(v) 
Alternate symbols - TNG1, TNG2 
Alias - TCL1-neighbouring gene 1 I 2 
Function - Gene ontology 
Known / inferred 
Locus Link - 27004 
Span - 95,408,286-95,424,863 
19 . TCL6(vi) 
Alternate symbols - TNG1, TNG2 
Alias - TCL1-neighbouring gene 1 I 2 
Function - Gene ontology 
Known / inferred 
Locus Link - 27004 
Span - 95,408,286-95,424,863 
20. TCL1B 
Alternate Symbols - TMLl/SYN-1/syncytio trophoblast-specific 
protein, T-cell leukemia / lymphoma protein 1B, TCL1B oncogene 
Alias - Leukemia 1B/T-cell lymphoma 
Expression - mouse embryonic expression 
Family - tell family 
Function - Gene ontology 
Oncogenesis, cell growth and/or maintenance 
Locus Link - 9623 
Span - 95,431,471-95,437,658 
Homology - P56844 (MM) 
NE (%) Tissue 
66.89 lymph 
16.18 tonsil, enriched for germinal centre B-cells 
8.16 germ cell 
5.42 pool, lung, testis and B-cells 
3.36 colon 
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2 1. TCLlA 
Alternate Symbols - TCLl / TCLl-PEN 
Alias - T-cell lymphoma-1 / T-cell leukemia/lymphomalA, T-cell 
lymphoma-IA, lymphoma/leukemia T-cell, P14TCL1 protein, TCL-1 
protein, TCLl oncogene 
Family - TCLl family 
Function - Phenotype 
Leukemia / lymphoma, T-cell 
Developmental process 
microsome 
Differentiation 
Cell growth and/or maintenance 
Locus Link - 8115 
Span - 95,454 ,995-95 ,459 ,139 
Homologs - IJNP (MM) 
Tissue specificity - restricted in the T-cell lineage to immature 
pharmocytes and activated peripheral lymphocytes. Preferentially 
expressed early in T- and 8- lymphocyte differentiation 
NE (%) Tissue 
60.49 lymph, b-cell 
15.67 lymph 
15.62 b-cells 
2.45 b-cells from Burkitt lymphoma 
1.41 muscle 
0.95 blood, lymphocyte 
0.94 testis, cell-line 
0.59 leukocyte 
0.45 tonsil, enriched for germinal centre b-cells 
0.35 pool, liver and spleen 
22. DKFZp761F2014 
Alternate Symbols - DKFZP761F2014 
Function - Gene ontology 
unknown 
Locus Link - 5696 7 
Span - 95,835,457-95,838,917 
Homologs - T19201 (CE) 
S71512 (MM) 
A57514 (RN) 
S78475 (St) 
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NE (%) 
23.93 
17.49 
17.19 
10.96 
4.03 
3.39 
3.31 
3.06 
3.01 
2.24 
Tissue 
tongue 
brain, hippocampus 
whole embryo, mainly body 
brain, cerebellum 
human fetal eye 
uterus, epithelium 
normal lung tissue epithelial cells 
rpe and choroid 
brain 
eye, retina 
23. BDKRB2 
Alternate Symbols - B2R, BK3, BKR2, BRB2, B2 Bradykinin receptor, 
BK-2 receptor, Brady Kin receptor 2 
Family - family 1 of g-protein coupled receptors 
Mouse Homology Maps 12 53.00cM 
12 968.0lcR 
Function - Gene references into function 
Two cysteine residues located in the carboxyterminal 
domain of the bradykinin B2 receptor are 
palmitocylated & play a crucial role in the response of 
the repressors to ligand binding 
Gene ontology 
Virulence, circulation, invasive growth, plasma 
membrane, sensory perception, Bradykinin receptor, 
smooth muscle contraction, integral plasma membrane 
protein, cytostolic calcium ion concentration 
elevation, cell surface receptor linked signal 
transduction, phosphatidylinositol-4 ,5 bi phosphate 
hydrolysis, G-protein linked receptor protein tyrosine 
kinase signalling pathway 
Locus Link - 624 
Span - 95,949,888-95,989,480 
Homologs - T30999 (CE) 
NE (%) 
28.86 
22.17 
JC7209 (DM) 
P32299 (MM) 
P25023 (RN) 
Tissue 
lung, cell line 
thyroid gland 
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20.69 colonic mucosa with ulcerative colitis 
5.29 placenta human full-term 
3.91 lung metatastic chondrosarcoma 
3.47 kidney 
3.10 pool, melanocyte, heart and uterus 
2.88 germ cell 
2.77 prostate, epithelium 
1.29 mixed 
24. BDKBRl 
Alternate Symbols - BIBKR, BIR, BKR1, BRADY Bl, BK-1 receptor 
Alias - Bradykinin receptor Bl, Bl Bradykinin receptor 
Family - Family 1 of g-protein coupled receptors 
Mouse Homology Maps 12cM 
Function - Gene ontology 
G-protein linked/coupled receptor, plasma membrane, 
bradykinin receptor, integral plasma membrane 
protein, cytostolic calcium ion concentration 
elevation, inflammatory response, pain sensation, 
endoplasmic reticulum, G-protein coupled / linked 
receptor protein signalling pathwat 
Locus Link - 623 
Span - 96,008,705-96,009,786 
Homologs - NM_007539 (MM) 
AJ132230 (RN) 
T30999 (CE') 
JC7209 (DM) 
JC4681 (MM) 
P97583 (RN) 
Tissue NE (%) 
65.85 
15.50 
7.30 
6.89 
4.46 
chondrosarcoma 
unclassified 
stomach 
kidney 
skin 
25. FLJ10242 
Family - Mouse Homology Maps 
Function - unknown 
Locus Link - 55102 
Span - 96,029 ,77 4-96 ,054 ,546 
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12 1003.20cR 
Homologs - T16637 (CE) 
S63208 ( SC) 
Tissue NE (%) 
27.08 
17.33 
9.16 
7.33 
6.35 
4.81 
4.30 
4.06 
3.52 
2.67 
whole embryo, mainly head 
foveal and mucular retina 
small intestine 
placenta, human full-term 
human feta I eye 
kidney 
pool, melanocyte, heart and uterus 
adrenal gland 
eye, retina 
uterus, epithelium 
26 . HSPC210 
Family - Mouse Homology Maps 12cM 
Function - unknown 
Locus Link - 51527 
Span - 96,127 ,276-96 ,130 ,759 
Homo logs - T26857 ( CE) 
NE (%) Tissue 
11.02 human optic nerve 
6.70 pancreas, islet 
6.02 human lens 
5.35 leukopheresis 
4.53 human skeletal muscle 
4 .40 human feta I eye 
4.29 parathyroid 
3.72 bone marrow 
3.70 colon 
3.41 pancreas, exocrine 
27.MGC5378 
Alternate Symbols - PAPOLA 
Alias - poly (A) polymerase alpha 
Family - poly {A) polymerase family 
Function - mRNA processing, transcription, nucleus, RNA binding 
Locus Link - 84 718 
Span - 96,247,453-96,277,724 
Homologs - T10692 (A n 
T22140 (CE) 
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NE (%) 
23.78 
10.79 
9.37 
4.97 
3.67 
3.23 
2.64 
2.52 
2.44 
2.43 
28 . VRK1 
S19031 ( St) 
Tissue 
brain, frontal lobe 
blood, white cells 
testis cell line 
human eye, anterior segment 
human skeletal muscle 
ear, cochlea 
umbilical cord, endothelium 
CNS, ms lesions 
human lens 
placenta human 8wks 
Alternate Symbols - Vaccinia virus BIR-related kinase 1 
Alias - Vaccinia-related kinase-1 
Expression - fetal 
Family - Ser/Thr family of protein kinases 
Mouse Homology Maps 12cM 
Function - Gene ontology 
Protein  phosphorylation, protein serine/threonine 
kinase, transferase, ATP binding 
Locus Link - 7443 
Span - 96,542,405-96,626,629 
Tissue Specificity - expressed in photoreceptor cells of the eyes as 
well as the region situated between the optic lobe and the 
central brain 
Homo logs - BC0166 76 (MM) 
H359602 (RN) 
C71405 (A 7) 
T16194 (CE) 
076324 (DM) 
S29522 ( St) 
1CKJ (RN) 
S47616 (MM) 
Tissue NE (%) 
27.34 normal gingiva (cell live from immortalised 
keratinocytes) 
12.70 
10.11  
7.84 
nose, olfactory epithelium 
bone marrow 
blood 
200 
6.34 
4.12 
3.24 
2.83 
2.65 
2.24 
bladder 
whole embryo, mainly head 
lung epithelial cells tissue 
testis 
bone, mixed marrow stroma 
cervix 
NE% - Normalised expression (%) 
Indicators used to assess homology with chromosome 11 genes 
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APPENDIX 7 
cDNA / Exonic Primers for Candidate Genes 
UVRAG ct>NA/Exonic Primers 
Amplicon Primers Primer Sequences 
(Base numbers) 
1 74 049 814F 5 ' -cagtaatgccagcgatggacag-3 '  
74 050 433R 5' -tgagctggctggctgcttgtc-3' 
2 74 086 399F 5' -gagactgggttatggtttctgg-3' 
74 086 741R 5' -aagcaggaggcactgagaatca-3' 
3 74 094 747F 5 ' -cactagcaaccaggtaacctaca-3' 
74 096 084R 5' -gtatacatgtgccatgtcggtgtg-3' 
4 74 114 287F 5'-ccatgtaagtgagtgatagg-3' 
74 114 840R 5'-catcaaggtctctcttagtg-3' 
5 74 123 374F 5' -gccggtttctcagtattgaag-3' 
74 123 748R 5-atggactggatggttatgtgc-3' 
6 74 146 376F 5'-gctccttctccactcttgtcag-3' 
74 146 915R 5'-ttctctcccactgtccagag-3' 
7 74 196 035F 5'-ctgaggctctttgttgag-3' 
74 196 397R 5' -gcaggcacttcatgcgttac-3' 
8 74 217 800F 5' -ttgtgtagtgtctgttgggtc-3' 
74 218 291R 5' -ccctgtcattaagtgatgtgtg-3' 
9 74 238 567F 5'-ctctcacagtcagggatttggc-3' 
74 238 924R 5' -tggcacagtgcatgacacacag-3' 
10 74 242 073F 5'-ctgtggcctattacagacag-3' 
74 242 494R 5'-tgatgagtgcatcccacca-3' 
11  74 243 311F 5' -caccatgtactcatcatccagc-3' 
74 243 678R 5'-atctcccatcaaggcgtctg-3' 
203 
12 74 251 478F 5'-ggacatagtaagagttcttgc-3' 
74 251 635R 5'-aatgaggcactctacaaagg-3' 
13 74 300 291F 5'-gcctctgttgacaacttggag-3' 
74 300 550R 5'-aaatgcgagggtcaactgcag-3' 
14 74 350 386F 5'-gtgtgcatactcatacacgtgc-3' 
74 350 755R 5'-tgtggagcaatgtggaagtcag-3' 
15 (i) 74 375 366F 5'-gatccagaaggcttacactgag-3' 
74 375 968R 5'-CAGAAGAAATCATCGGGCTGGT -3' 
15 (ii) 74 375 842F 5'-AATGGCACTCTCCTACCCAG-3' 
74 376 425R 5'-GAGCTTACAGCTCGAGTCACCT-3' 
15 (iii) 74 376 320F 5'-CAGTGGGCCAAAGTTAGA-3' 
74 376 860R 5'-CGGCCCTCAGATT AGATGAA -3' 
15 (iv) 74 376 238F 5'-AGCTGTGACGTTCCATCTCTTC-3' 
74 376 502R 5'-AATGCGGGAATGACAACTGGAC-3' 
UVRAG exonic base numbers used to identify primers. Lower-case 
identifies 5'-UTR and 3'-UTR primer sequences identified from GenBank 
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GARP cDNA/Exonic Primers 
Amplicon Primers Primer Sequences 
1 -114F 5'-taagtcagctgaggccgagag-3' 
74R 5'-ctccagcacatgctgagccg-3' 
2 3655F 5'-ttccagctccagccgtgctc-3' 
3967R 5'-cctgactcttctaacttctggc-3' 
3 7976F 5'-tccacccatggaaccttcatcga-3' 
8639R 5'-GGGTGAGGCGAG TCAGACTG TT-3' 
9235F 5'-gGTGGACAAGAAGGTCTCGTGC-3' 
8530F 5'-TGGACCTGTCTGGGAACA-3' 
9106R 5'-ATCCAGA TTCAAGAGCTGG-3' 
8998F 5'-AGGACAGCAAGGGCATCC-3' 
9626R 5'-CCTCCAAGGAGGCCTCC-3' 
9635F 5'-ACTGACTGAGCTGGACC-3' 
10060R 5'-GGCAGAGACCAGTATGAA-3' 
9974F 5'-GAGCCACGTGCGTCCTGAGGAC-3' 
10581R 5'-CGGGGCCTGCCGAGCTCTGGA-3' 
10489F 5'-TAGGAGAGAGTGCTGCAGAG-3' 
11057R 5'-CAGACACAAGGCTTGGATTCA-3' 
11014F 5'-GCACCCAGCTTGGCAGATGTG-3' 
11619R 5'-AGAGAGGACATCACTCTGGTCC-3' 
11499F 5'-CTGAGGCTTAGGAAGAGAA TG-3' 
12307R 5'-tgccatgatgattgaacgacc-3' 
5' GARP exonic base numbers used to identify primers. Lower-case 
identifies 5'-UTR and 3'-UTR intronic primer sequences. Uppercase 
identifies exonic primer sequence 
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CLNSJ A cDNA/Exonic Primers 
Amplicon Primers Primer Sequences 
1 -101F 5' -tccacacgttcttagccgacctc-3' 
373R 5'-gagccttccacccgctacaggta-3' 
2 7740F 5'-ctcagtttccactactgaa-3' 
8140R 5'-gattacaggcgtgagcca-3' 
7810F 5'-gcataaaggtgtccaagc-3' 
7848F 5'-gtggtcttacatgaggatttac-3' 
8191R 5'-ctcgatctcctgaccttgtg-3' 
3 11825F 5'-ctaggatgctcactgtat-3' 
12208R 5' -agaatggaggtaatggtg-3' 
4 12590F 5' -gcttcaaccgctttcaag-3' 
12931R 5' -gaactataatcctctaccc-3' 
5 14976F 5' -gtgccaccacgcctggctaa-3' 
15332R 5' -gtgctcatctgactgttcacac-3' 
6 18008F 5' -cactagcttccttctggtaga-3' 
18313R 5'-atgccactgcactgtagcct-3' 
7(i) 2 1001F 5'-tacctaagtcctctggca-3' 
21492R 5'-ctaccaagctcctgtgc-3' 
7 (ii) 2 1419F 5'-gcacaggagcttggtag-3' 
21809R 5'-gccttactaaatacttgcc-3' 
5' CLNSJA exonic base numbers used to identify primers. Lower-case 
identifies 5'-UTR and 3'-UTR primer sequences. 
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ARIX cDNA/Exonic Primers 
Amplicon Primers Primer Sequences 
1 -170F 5'-ccacacctctgagccctaagacg-3' 
490R 5'-cattggagggtctggccaaggca-3' 
-170F 5'-ccacacctctgagccctaaga-3' 
421R 5'-tctgcaggaat-3' 
lf 5'-CTGAGTGCGGCCGCGAC-3' 
379R 5'-gcgctcacCTGCCGAGTA-3' 
2 2722F 5'-ggctgccgggaccaagacga-3' 
3160R 5'-gccttcgggctgcatctgcc-3' 
2693F 5' -ttgagtaatagggaggacgct-3' 
3293R 5' -tcggaactttctgccctaaga-3' 
2870F 5'-TGCCCT ACAAGTTCTTC-3' 
3057R 5'-CTGCACGCGAGCCTCA-3' 
3 3863F 5'-tccgaaccaggatctcactcgag-3' 
4580R 5' -gagtggccctgacttggtctcc-3' 
3958F 5'-agGTCTGGTTCCAGAACCG-3' 
4414R 5'-GCAGCTAGAAGAGA TTGGTC-3' 
5' ARIX exonic base numbers used to identify primers. Lower-case 
identifies 5'-UTR and 3'-UTR primer sequences. 
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APPENDIX 8 
Gene list derived from location of markers on chromosome 14 D14S1442-
D14S267 
1. SERPINA1 
2. SERPINA4 
3. SERPINA5 
4. SERPINA3 
5. KIAA0928 
6. calmin 
7. FLJ21276 
8. FLJ20034 
9. LOC51218 
10. TCL6 
11. TCL1B 
12. TCL1A 
13. DKFZp761F2014 
14. BDKRB2 
15. BDKRB1 
16. FLJ10242 
17. HSPC210 
18. MGC5378 
19. VRK1 
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APPENDIX 9 
Gene l ist derived from location of Markers on 
chromosome D11S1881-D11S911 (2002) 
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APPENDIX 9 
Gene l ist derived from location of Markers D1151881-D115911 
1. HRASLS3 
2. ESRRA 
3. HSPC152 
4. PRDX5 
5. PLCB3 
6.  BAD 
7. LOC56834 
8. KCNK4 
9. LRP16 
10. FLRT1 
11. STIP1 
12.  HSPF2 
13. MGC13045 
14. MGC11134 
15. MGC10966 
16. COX8 
17. FLJ13848 
18. FLJ20113 
19. HRLP5 
20. LGALS12 
21. RARRES3 
22 .  HRASLS2 
23 .  DKFZp434G0920 
24. RPS6KA4 
25.  SLC22A11 
26. NRXN2 
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27. RASGRP2 
28. PYGM 
29. Sfl 
30. MAP4K2 
31. MEN1 
32 .  EHD1 
33. PPP2R5B 
34. GPHA2 
35. NAALADASEL 
36. CAPN1 
37. MRPL49 
38. FAU 
39. C11orf5 
40. TM7Sf2 
41. C11orf2 
42. ZFPL1 
43.  MGC16386 
44. MGC10966 
45. HSU79266 
46. SNX15 
47. ARL2 
48. LOC116071 
49. EMK1 
50. POLA2 
5 1. CEP2 
52.  REQ 
53. FKSG44 
54. SPRY4 
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55. NTKL 
56. LTBP3 
57. SF3B2 
58. GSTP1 
59. NDUFV1 
60. MGC9740 
61. CABP2 
62. DOC-1R 
63. PITPNM 
64. AIP 
65. ALDH3B2 
66. UNC93B1 
67. ALDH3B1 
68. NDUFS8 
69. TCIRG1 
70. CHK 
71. FLJ20039 
72. CGI-85 
73. C11orf24 
74. LRP5 
75. C11orf23 
76. LOC51083 
77. MTL5 
78. CPT1A 
79. IGHMBP2 
80. CCND1 
81. FGF19 
82. FGF4 
2 13 
83. FGF3 
84. FLJ10261 
85. FADD 
86. PPFIA1 
87. EMS! 
88. SHANK2 
89. FLJ10661 
90. FLJ11099 
91. IL18BP 
92. NUMA! 
93. FLJ20625 
94. DKFZP564M082 
95. FOLR3 
96. FOLR1 
97. FOLR2 
98. INNPL1 
99. ARIX 
100. SKD3 
101. SDCCAG28 
102. KIAA0769 
103. P2RY6 
104. KIAA0337 
105. TNRSF19L 
106. PHRET1 
107. PME-1 
108. DKFZP586N2124 
109. FLJ22596 
110. KIAA0102 
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111. NEU3 
112. SLC21A9 
113. ARRB1 
114. RPS3 
115. PP1665 
116. SERPINH2 
117. FLJ22644 
118. DGAT2 
1 19. UVRAG 
120. WNT11 
121. PRKRIR 
122. C11ORF30 
123. GARP 
124. E2IG4 
125. PHCA 
126. CAPN5 
127. OMP 
128. MYO7A 
129. PAK1 
130. CLNS1A 
131. HBXAP 
Bold text depicts those genes identified in this thesis as candidate genes for 
chromosome 11  HFM. 
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APPENDIX 10 
List of trinucleotide repeats present on chromosome 11 between markers 
D11S1881-D11S911 and identified in this project 
1. Very large expansions of repeats outside coding sequences . 
(i) Repeat 
Disease; 
MIM No 
Inheritance 
Location 
Stable Repeat 
Unstable Repeat 
(CGG}n 
Fragi le-X site A (FRAXA) 
309550 
X-linked 
Xq27.3 I 5'UTR 
6-54 
200-1000 
CGGACACCCCGTTCTCCTGGTGCCCAGCGCGGGGGCCCCCCTACCTGCAGGCTGTCGGCGCAT 
GGCTGCGGCGGCGGCGGCGGCTCGTCCGGCTTGAGGAAGACCTGCTGGCCCCGCCTGAGGAA 
TTGGACAACAGCGATGAGGATGTGGTGCAGCACCAGGACCATGCTCGCAG 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
76,256,733 - 76,256,747 
5 
PDE2A 
CGGGCGTCAGGGTGCATTGTGGGAAGGAGGCGGCAGCGTCTCGGGCGGGC 
GGGAGGTGCACCAGCGGCGGCGGCGGCGGTAAATCCTCCCGGCCGCTCAC 
AGCACTGTGGAGCCGCGTCCCCAGCCCGGCCTCGGACCGCGGCACCCCTC 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
82,148,443 - 82,148,457 
5 
Between GL002 & PRKRIR 
CAGACTCAGGACCAGCGGACCCTGTGGCGGGGGGAGTCTCCTCACCGGTGAGCAGCTGCAG 
GCGAAAACGGCGGCGGCGGCGGCTGAGGCGGCGATGCCCTTGTCTTCTCCGGAGGCTACGG 
CGGCGACGCTCTCGCCCGTGTCCAGTAGGGTGGC 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
(ii) Repeat 
Disease; 
MIM No 
Inheritance 
84,487,220 - 84,487,234 
5 
Between FLJ14993 & PHRETI 
(CCG}n 
Fragi le-X site E (FRAXE) 
309548 
X-linked 
2 17 
Location 
Stable Repeat 
Unstable Repeat 
Xq28 promoter 
6-25 
200+ 
GTCCGGGTCTCTGGGCGAAGTGACTGAGGCGGTCGCGCCGCGAGAGAACAACAGTCCCAGA 
TGTCTGGGTCCTGGCTccgccgccgccgccgccgcccgccccgcctacggccccgccccgcgccttaggccccgc 
cccttcccgccc TTGCTGA TTT AAGTCCCCGAAGTTCT AGACTGGAGCCCGGGAGCGCGCTCCC 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
75,258,572 - 75,258,589 
6 
Between PME-1 & FLJ10661 
gttctcctcgcaccagtccagcgtggaggtcgtggggccccagtagccctctcggtccgcggccggagccatcacgccgc 
cgccgccgccgcccaggcgctccgctcactgtgccgggttaggctggcgaccaggccggctccggcccag 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
(iii) Repeat 
Disease; 
MIM No 
Inheritance 
Location 
Stable Repeat 
Unstable Repeat 
81,668,555 - 81,668,569 
5 
PHCA 
(GAA}n 
Friederich 's  Ataxia (FA) 
229300 
AR 
9q13-q21.1 intron 1 
7-22 
200-1700 
ccccctaccccgcacatctcgttttccggtgcgacagcaagttcaccgtctccaggacttggctctgctctcacaccttaa 
acccttaaaagaaaaagctaagtttaagctatttgcctttaagtcataaagacaccaaaagtatttaaagtgcagatctag 
aagaagaagaagaacgcctagatcaaactgacccagaagatctcaggctggctctagtcctcctccctcaatcttaaagc 
tacagtaatgtagcaagtagtattaggtgttgta 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
73,965,721 - 73,965,735 
5 
Between HREV107 & MRPL48 
AAGAACAGGAAGCAGTTGTTACTGAAGGGTAGATACGGGAGGAACAAATGTGAGAAAGA 
AGTGATgaaggaaaagaagaagaagaagaagaagaagaagaTGA TGATGA TGGTGATG 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
78,444,113 - 78,444,136 
8 
DLG2 
AGTCACACAAGA TTGTCATGCGAGCTGAAGGGGGCTGAAA TT A TTCCCTCTgaagaagaaga 
agaagaagaaAACATACTGCAGCTCCCGA TTTGGTAAAAAGCCAGTGGCTTGCT 
Base Numbers: 79,541,889 - 79,541,909 
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Number Repeats: 7 
Nearest Gene: DLG2 
AATGATCTGCCTTCTGGCCTAGCAATTTTCCGGAGATACTGTGCAATGTGATTGTTTCTT 
TCCTGAGAAAAATGTTTAAAAAGGCAGCTTATTTAGGTCAAAGGAAGAAGAAGAAGAA 
ATAGGAGAGGTATGAAAGAGAATGAAGATAAAGTTGTGTAGAGAAAAAGAGAGATTAC 
TTGAGTCTTAAGAAAATGTGACTTCTTCCTTCTGCTACTT 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
81,282,464 - 81,282,478 
5 
Between PAK1 & MY07A 
agttgtgggcaGCcatagtggctcacatctgtaatcccagcactttgggaggacgagggacgagatgggaggatcacttg 
tgcccaggaggtcaaggctgcagtgagcttcactccagcctggccaacagaatgagacactgtctcaaaaaaaaaaaaaa 
aaagaagaagaagaaGAAGTTCAAAGAAAAAGAAAGAAAAAGTCACTGAAATTAATGATCAT 
TTTTAatgttgtcaatttgacatacggaatttggtttatttgtttctgttggcatacaattttagatgcctcccatttcc 
tgtctgtcttgattttaactttctgaat 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
85,260,387 - 85,260,401 
5 
PTD015 
attagttgggcatggtggcacatgcctgtaatcccggtactggggaggttggggcacgagaaccacttgaacccaggagg 
tgaaggttgcagtgagttgagatcacaccagtgcattccagcctaggtgacggagtgagaccctgtctcaaagaaacaaa 
aaaaaaaaaacaaaaaaaaAAAAGAAGAAGAAGAAGAAGGAAAAAA TCTTGAA TAT AAA TGGA 
TT AAGTTCTTCAA TT AAAAGGtacactacagcctgggcaacagagagacagacaccctgtctcaaagaaaga 
aaaaaaaaaaaag 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
(iv) Repeat 
Disease; 
MIM No 
Inheritance 
Location 
Stable Repeat 
Unstable Repeat 
Disease; 
MIM No 
Inheritance 
Location 
Stab le Repeat 
Unstable Repeat 
85,356,826 - 85,356,840 
5 
Between PTD015 & MGC16 733 
(CTG}n 
Myotonic Dystrophy (DM) 
160900 
AD 
19q13 3'UTR 
5-35 
50-4000 
Spinocerebel lar Ataxia 8 
606364 
AD 
13q21 untranslated RNA 
16-37 
110-500 
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TACATGCTGAATAGCT6CT6CT6CT6CTGCCAGCTTTTCAGGTCTGGAGAGAAAGGTTAT 
TTCTCATAAGAAGTCACAAGGG 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
(v) Repeat 
Disease; 
MIM No 
Inheritance 
Location 
Stable Repeat 
Unstable Repeat 
73,993,056 - 73,993,070 
5 
MRPL48 
(CCCCGCCCCGCG}11 
Juveni l le Myoclonus Epi lepsy (JME) 
254800 
AR 
21q22.3 promotor 
2-3 
40-80 
TGAGGCGGTCGCGCCGCGAGAGAACAACAGTCCCAGATGTCTGGGTCCTGGCTccgccgccgcc 
gccgccgcccgccccgcctacggccccgccccgcgccttaggccccgccccttcccgcccTTGCTGATT 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
75,258,606 - 75,258,618 
1 
Between PME-1 & FLJ10661 
2 .  Modest expansions of CAG repeats within coding regions . 
Repeat (CAG}11 
Disease; Huntington Disease (HD) 
MIM No 143100 
Inheritance AD 
Location 4p16.3 coding 
Stable Repeat 6-35 
Unstable Repeat 36-100 
Disease; Kennedy Disease (SBMA) 
MIM No 313200 
Inheritance XR 
Location Xq21 coding 
Stable Repeat 9-35 
Unstable Repeat 38-62 
Disease; Spinocerebel lar Ataxia 2 (SCA2) 
MIM No 183090 
Inheritance AD 
Location 12q24 coding 
Stable Repeat 14-31 
2 20 
Unstable Repeat 
Disease; 
MIM No 
Inheritance 
Location 
Stable Repeat 
Unstable Repeat 
Disease; 
MIM No 
Inheritance 
Location 
Stable Repeat 
Unstable Repeat 
Disease; 
MIM No 
Inheritance 
Location 
Stable Repeat 
Unstable Repeat 
Disease; 
MIM No 
Inheritance 
Location 
Stable Repeat 
Unstable Repeat 
32-77 
Machado-Joseph Disease (SCA3,  MJD) 
109150 
AD 
14q32.1 cod ing 
12-39 
62+86 
Spinocerebellar Ataxia 6 (SCA6) 
183086 
AD 
19p13 coding 
4-17 
21-30 
Spinocerebel lar Ataxia 7 (SCA7) 
164500 
AD 
3p12-p21.1 coding 
7-35 
37-200 
Dentatorubral-Pal l idoluysian Atrophy (DRPLA) 
125370 
AD 
12p coding 
3-35 
49-88 
GAAT AATAGGAAAGATGGAA TTCCAAAGAT AATGTAATAAAGGGAGGT ATGAT Aggttag 
gggaattaacaaggaataatgaagcactccggaacccagcagcagcagcagcagcagcagcagcagcaagaaaccttta 
ctatccctaaggattagggcaagagagaagaaatagggagttacagtctgatgagaagaggagccttggaagaagtgttg 
actgacag 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
79,623,417 - 79,623,446 
10 
DLG2 
GAGTGACTATGGATAAAGTCATCATAAAAATAAACTTATATCATCAATCTCCATGATCA 
ATTTCTTTAAAGCAAAATATGATATGCAGCAGCAGCAGCAGAGTACAGAAGGTACACTG 
GTCAGATAACCACAATTTTAAGCTAATTTTGGCCATGTGCTTGCTG 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
79,934,190 - 79,934,204 
5 
Between DLG2 & HT007 
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TTGGCACCCGGGGAAGCATGGCCGGGTTGTCTGGGCCCCACTCACGGCCAGCAGCAGCAGC 
AGGGGCCACGGCATGGTGGGGGCTAGAAAGAGAGCCACAGGTGA 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
81,733,884 - 81 ,733,898 
5 
Between PHCA & E2IG4 
ATCCCTGCCTGAGGTTTGCCCTACTTCATGGGATGCCCTGTGGCCTCCCCGCTCCTGTGTGG 
GTTGGTAGGACAGCAGCAGCAGCAGCTTCTGTGGGGCTCCAGGTCCGACCCAGCCCCAGCCC 
CTCCCTCCCTGGCTCCAGGAAGTCTGGAGCCCCGAG 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
82,290,689 - 82,290,703 
5 
Between PRKRIR & WNTll 
cagttctaactcagtttcctcctgttttagcagtctaagatttggcaagccatgttctctctctgggctttagtcttccatt 
tataaaacaaatggactgaataagatgatatttaaggtccttttcagctacaagagtccatgttccaagaG AAGA T AA 
AAATTGCAGCAGCAGCAGCAGCAATATTCACTGAAGACTTAGCATGTGCCAGAATCTTGC 
TAGGAACCA 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
83,710,316 - 83,710,330 
5 
Between KIAA0102 & FLJ22596 
TGAGATGCTCCAGCAAAAGAACCAGCAGCAGCAGCAGGAAGTTTCAATGGGGCCGGGCAG 
AGCATGCGCCCTGCACCCGCGCGGTGGCCTTATGTGGAAGGAGCA 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
85,227,600 - 85,227,614 
5 
Between RAB6 & THRSP 
3 .  Other short repeats within coding regions . 
Repeat 
Disease; 
MIM No 
Inheritance 
Location 
Stable Repeat 
Unstable Repeat 
(GCG}ri 
Ocu lopharyngeal Muscu lar Dystrophy 
9462747 
AD / AR 
14qll.2 
6 
7-13 
CCGGACACCCCGTTCTCCTGGTGCCCAGCGCGGGGGCCCCCCTACCTGCAGGCTGTCGGCGCA 
TGGCTGCGGCGGCGGCGGCGGCTCGTCCGGCTTGAGGAAGACCTGCTGGCCCCGCCTGAGGA 
ATTGGACAACAGCGATGAGGATGTGGTGCAGC 
Base Numbers: 
Number Repeats: 
76,256,732 - 76,256,746 
5 
222 
Nearest Gene: PDE2A 
AGAGGGCACCCCCGGGCGTCAGGGTGCATTGTGGGAAGGAGGCGGCAGCGTCTCGGGCGGG 
CGGGAGGTGCACCAGCGGCGGCGGCGGCGGTAAATCCTCCCGGCCGCTCACAGCACTGTGG 
AGCCGCGTCCCCAGCCCGGCCTCGGACCGCGGC 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
82,148,442 - 82,148,456 
5 
Between GL002 & PRKRIR 
4.  Triplet repeats without disease associations. 
Repeat (AAC) 
tattccaaaaaattagggaggagggtctcctccctaactcattctattaggccagcttcatcctgataccaaaacctggca 
gagattacaaaaacaacaacaacaacaacaaaaaaacacaaaaacttcaggccaatatctttggtgaatatcaatgcaa 
aaatcctcaacaaaatactggcaaaccaaatccagcagcatatcagaaaaattatccaccatgatcaagt 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
72,956,999 - 72,957,016 
6 
Between HRLP5 & SLC22A8 
gcatgtgcctgtagtcccagctactcagaaagctgaggtggggggatcgcttgaacccaggagattgaggctgcagtgaa 
ctatgaattcaatgaagtgccattgcccttcagccagggtgacagagtgagaccctatctcaaaacaacaacaacaacaa 
attaaaaaaaaaaTTCCCTACCATGTTTCCTAAGAAGCAGA TTT AACCAGGCAAAAGTTTT AC 
TAA i  1 1 1 1  
Base Numbers: 
Number Repeats: 
Nearest Gene: 
73,417,540 - 73,417,554 
5 
Between SLC22A6 & HREV107 
GGGAAGAAGGTAAGGATGAAAATGACCTTACAGATTAACAACAACAACAACAAAATAT 
GAACTTCAGCATGTACTGTGTTAACCCAATTAAAAACCTTTTATCAAAGAA 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
73,506,822 - 73,506,836 
5 
Between SLC22A6 & HREV107 
ggatcgtttgaagtcaggagttccagactaccctgggcaacatagtaagatcctgtctctacaaaaaatacaaaaattagc 
tgggcatggtatgtgcatctgtagccccagctactcgggaggctgaggtgggaggatcttgagcccaggagatggagact 
gcagtgagccatgatcataccactgcactccagcctaggtgacagagtgagaccctgtctcTAAaacagcaacaacaa 
caacaacaataacaacaaGAGTACAGCCTTT ACCTCCCTCAGT AGTTCCCACCTCAGTACAGAGT 
TATCACTCCTTTC 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
74,396,542 - 74,396 ,556 
5 
KIAA0769 
223 
tggcgcatgcctgtaatcccagctacttgggaggctgaggcgggagaatcgcttgaacccaggaggtggaggttgcggtg 
aaccgagattgcaccattgcactccagcctgggcaacaagagtgaaactccatctcaaaacaacaacaacaacaacaac 
aacaacaacaacaacaacaacaaaagcatgtaaagcgcttaggtcagtgcctTCCTTTT AAGGCACTCTGTT 
AATTGTTGTTGTTAATAGGAGAAGGGTTTTCTTGAGAAGGGAGGAAGGGACGCGAAGAG 
GAATGGTC 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
74,397,612 - 74,397,653 
14 
KIAA0769 
ACACA TCCGCA TTT AAAACAA TAGTAggccaggtatggtggctcacgcctgtaatcatagcactttaggag 
gccaagacgggagaatcacttgaggccaggagttcaatatcagcctgggcaacatagtgagaccccatctattaaaaaca 
acaacaacaacaacaacaacaacaaaaaacttcttaaaaataaaccaggcatgatggtacacatctgtagtcctagcta 
cttggaagtctgaggtgggagg 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
74,536,561 - 74,536,587 
9 
KIAA0769 
CCTGTTGGgccgagcatggtgctgtgcacctgtaatcccagcccttcgggaagaccaggtgggaggattgcttaaacc 
caggggtttaaggctgcaggagttTGAGGCTGCACT AAGG I I I I I I GTGTGTCTCAAAAGCAACAA 
CAACAACAACAAAAGTCACTCTGGCCATAGTAAGGGAAAGGATTGGATGGGGAGACTGC 
AGGTCTAGAAGGTGGCCCACAGTGGCAGGAGGGTGGAGGAGTACTAG 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
74,666,789 - 74,666,803 
5 
Between KIAA0769 & UCP2 
AAGGCAGAGGACCAAATTCCCTAGGCTAGGGAATCAGGAAAGTTGCAGTTGGAGCTGGGT 
TCTT AAAGGA T AACT AGGATGTAGA T AAGAAACAAACAACAACAACAACGaaaaatagggaa 
gggcattgtaagtacaaggaagggtatgcaaaggcccagagacagaaatgagtcccacgtgtcttgggaCAA TT AA T 
AGATAGGCTTGGTAAGATGCAGGTCCAAGTTGGAGAAGAAGAAG 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
75,554,480 - 75,554,494 
5 
Between FLJ10661 & FLJ11099 
ggcgtgcctgtaatcccagctactcgggaggctgaggcaccagaatcgcttgaacccaggaagtggaggttgcagtgagc 
tgagatcacgcctctgcattccagcctcggtgacaaagccagactctgtctcaaaaaaacaacaacaacaacaaaaaaa 
aaCTTAGCTGAAGATAAACACTGTAACCTTCTTATCTGTCAGTTGCCAGTAAAAAGAAAT 
TCTAGAG 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
76,125,973 - 76,125,987 
5 
Between S KD3 & PDE2A 
ctgaggcaggagaatggcatgaacccgggagacagagcttgcagtgagccgagatcgtgccactgcactccagcctgggc 
gacagagcaagactccgtctcaaacaacaacaacaacaacaacaaatgatgatagcctcttcctgaaactaaccccctt 
tttgcaaggggaccaaaactgcctttataaaactttataaaactaacaaattgtccataagtttagaattatggcttagaa 
224 
gttatgaagccaaaggtcacaagatttgtaacctccccaattgctcctatagataacaccactattgtaaaacctaagacc 
ggtatttgagatatttttcagaccttgcattctgagg 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
76,182,612 - 76,182,632 
7 
PDE2A 
GAGAAAATATGGAAACTAAAAGTTGAACCTAATCTTTATAGAGAAGTAAATAATAATT 
GAGTGATTAACAACAACAACAACAAAAAGGGACTGTAATACACAGCAAAATAGGCTTAG 
GAACTTGAAAAAGAGTTGTGGCCCAGAGTTTTTCTGAAATGCTGGT 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
76,570,470 - 76,570,484; 76,714,587 - 76,714,601 
5 
Between FOLRl & PRCP 
ctactaaaaatacaaaaaaagaaattagccgggcgtggtggcgggcgcctgtagtcccagctactcgggaggctgaggca 
ggagaatggcgtgaacccaggaggcagagcttgcagtgagtcgagatcacaccactgcactccagcctgggcgacagagc 
gatactctgtctcaaaacaacaacaacaacaacaaaaaaccctgaagtctgaagaccccatgtttggtaattgaagcttc 
cacgagagaaattcctgggaaatggtagggcagaaaTGGCAtttgcctagaactaagggatttcttgttatgtggaact 
tcaacgctaaaactgaaacagtctcaagcaa 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
77,455,596 - 77,455,613 
6 
Between FOLRl & PRCP 
GAAGGATGAGAAGCAAATGTTGTTTCACAGCTTTTAATTCTTTAGCGAAGTCTCAAAAG 
TATCATAGTATAAACATGTCAGGACCATGGTTGAGAAAAGTAACCAGTTGCAGTTAAaac 
aacaacaacaacaacaaAAAA TTTTGGAAAAAAAGGAATGGCAAACTCT AGAAGA TCTCTCCC 
AGAGGCTAATAGAGCAATGATCCCTAAGTACTCATTACTATG 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
77,706,098 - n,706,115 
6 
PRCP 
AA AG A TTCTTTGGAATAAAACAACTACTCAGCAACAACAAcaacaacaacccactgagtgcctgtt 
attggccaggttgtgtgcaaagtac 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
78,276,463 - 78,276,480 
6 
Between MDS025 & DLG2 
gcaccactacactccagcctgggtgaaagagtgagatcccgtctcaaaaacaaaaCT A AACAaacaacaacaacaac 
aacaaAGCATCCCATGTCTACAACAAGCTTTCGTGAACTCGTAGAAGCATGAAGGA I I I I I 
AGCATAGGTGAGGCATCATTTCAACCTTTTACATGAGGAGCATTTAG 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
78,941,556 - 78,941,573 
6 
DLG2 
225 
T ATCCCTT AAGAGAGTTTCATCTGTGGAATcaacaacaacaacaacaacaaAAGT AT A TTGTAA 
AGGATGTTGAATACCCTCATAGGCAATTGGAGGTAGAACAAGACAGTGTAAGACAGGAC 
ATTGGTAGT 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
79,260,026 - 79,260,040 
6 
DLG2 
CTAAAAAGTTT AGGTTTT A TTGTTTTGTCA TTGTATATATAGAAGAGCCCTGaacaacaac 
aacaacaacaaGGACA T AGCCCAGGGA TCTTCAATGAGCTACTAAA TAT A TTGAAT 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
79,565,214 - 79,565,231 
6 
DLG2 
CTGGAGCCTGATCAAGTATGTGTCTGTCCCTTCCAAACCA TT AAAaacaacaacaacaacaacca 
caaaaaccacaacCCACAAACCCA TGTGAGGAGACCAAAGCCAAAGCCAAAGCCAGAGCCAGA 
TTCTCAGTCTT 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
79,687,340 - 79,687,357 
6 
DLG2 
CTCAAAAACTATTTGAGAGTTGAAGAAGTTTCTCAGAAATAATGTTGTAATAAACAACA 
ACAACAACAATACTGTGGCCCTCTCATTGATTCATATTTTCTTATTTATCCCTTCTCCATA 
GAACACTGCAAA 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
79,709,066 - 79,709,080 
5 
DLG2 
gtttgagcccaggagttcgagacctgcctgggcaatatagcgagattcccttccacaaaaaggaagaaaaaacaacaaca 
acaacaacaacaacaacaacaacaacaGATACAGAA TTCACA TTCTGGTAAAGAAAAGCAGAT AT 
AAACATCTCCAAAACAAGGGATATACTAGTGTTACACT 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
79,731,813 - 79,731,848 
12 
DLG2 
gtctaaaaaaaaaaaaacaacaacaacaaccacaacaaaaagtgtcttttacctcctgccatgattctgaggcctccc 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
80,309,449 - 80,309,463 
5 
Between DLG2 & HT007 
atcatgccattgcactccagcctgggcgacagagtgagactctgtctcaaaaacaaaaacaaaaCAACAACAACAA 
CAGAAACCCTTAACTATCCATTCTTCAATCCAAGGAGTGATAAAATTGCTCTTGTAATAA 
TGAGAAAGCTA 
Base Numbers: 81,224,261 - 81,224,275 
226 
Number Repeats: · 5 
Nearest Gene: PAKl 
ggctaacacagtgaaaccccatctctactaaaaatacaaaaacaaaaacaacaacaacaacaaaattagctggatgtgtt 
ggcatgcacctgtagtccccgctactcaagaggctgaggcaagataattgctcctgggaggcagagg 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
81,234,377 - 81,234,391 
5 
Between PAKl & MYO7A 
aagactctgtctcaaaaacaaacagacaaacaaaaaaccaacaacaacaacaacaacaacaaaaaactcccttcaacaa 
ctacatatatctgtgtaaagcctaattttctttaaatacttcaaccaaaacaacagattacaacagattaaa 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
81,632,578 - 81 ,632 ,598 
7 
PHCA 
ATACTATGATGTAAAAA TT ATAGGGCTTaacaacaacaacaacaacaaAGTTTGGAGCAGATC 
ATTTAAAACATATGGTCTTTGTAAGCACAGTTCTAACAAAAACAGCACCAATCC 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
81,697,315 - 81,697,332 
6 
Between PHCA & E2IG4 
caaaataagtaaaacaacaacaacaacaaaaatacaaaAGTCACCCTACagtagagaggacattgaactaggaacc 
aaaagatgagtctcactctgccactaatc 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
82 ,042 ,629 - 82,042 ,643 
5 
Between GL002 & PRKRIR 
aagaggcggaagttgcagtgagccgagattgcgccactgcattccaacctgggcaacagagtgaggctccatctAAAC 
AaacaacaacaacaacaacaaAA TGCTCCAGCCAAAA TTTCA TTTGGCCTTCTCTGCAAGCAAG 
AAGGTTTCTTGC 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
82,106 ,906 - 82,106,923 
6 
Between GL002 & PRKRIR 
CACGAGCCTCATTCAAGTCCTCCAGGGCGacaataacaacaacaacaacaaaaacCTGTGAAAAAA 
ATGTTAATGTAAAATGCCAGCAGCATGCAAGCTGCCCCTAlll fl CCCCCATGATCGAGT 
AAGGAAGTGAC 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
82,471,596 - 82,471,610 
5 
UVRAG 
ccaatgggcaatttttggtcctcctatttgatcactctctcctcttaaaaaaacaagcaaaaagacaaacaacaataacaa 
caacaacaacaacaacaaaaccctttctttctctggactttgagattctacacaaaactttgctctctttcccttgggcc 
acttcttttcagtcatc 
227 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
82,638,581 - 82,638,601 
7 
UVRAG 
gcttgcagtgagccgagatcgcgccactgcattccagcctgggcgacagagtgagagtgaggctttgtctcaaacaacaa 
caacaacaacaaaaaccaaaaacaaaaacaaaacacaaatggctcagatgggttataacacacatcaggctggtcac 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
83,484,106 - 83,484,123 
6 
Between SLC21A9 & NEU3 
ttgcactctagcctgggtgaacagaggaagactccatctcaaaaaacaaacaaacaaacaaacaaacaacaacaacaac 
aaaaaaCAAGCTGACTGGA TTT AGACTAAATACAAATGTAGGCAAATGC 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
83,567,984 - 83,567,998 
5 
Between NEU3 & KIAA0102 
ggagaggaacccttgagctcaggagttcaaggctagcctggggaacatggtgagacctcatctcttaaaaaacaacaac 
aacaacaacaacaacaacaacaaaaaacagaaCagacctgggtcctggaccctgatttgtcacttattggctgtgtgag 
ttgggacagaccacttct 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
83,801 ,002 - 83,801,031 
10 
Between KIAA0102 & FLJ22596 
ggctgagatcacaccactgcactccagcttgggcaacagagtgacatcctgtctcaaacaacaacaacaacaaaaaatg 
tcgtgcttcaaagcacaccatcaagaaagtacaaagacaatccacagaatgggagaaaatttttgcaaataatttttcaat 
cagggtcttgtattcaga 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
83,933,935 - 83,933,949 
5 
Between DKFZP58N2124 & KCNE3 
atcacttgagcctgggaggtcgaggctgcagtgagccgtgactgtgaccaatgcattcaatcctgggcaacagagcaaga 
tcctgtaacaacaacaacaacaacaaaatttaaaaagtaaaaaCGGAAACAatgcagatggaaccatataacgtgta 
gtttttgtgtatgacttct 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
83,953,943 - 83,953,960 
6 
Between DKFZP58N2124 & KCNE3 
actccatcctgggtgacagagtgagactccatctcaacaacaacaacaacaaacaacaa TCTCGTTCTGTT A TT 
TAAAGAAAACACTTCAAACAGTT AGAA A TTTTGA TTGTTtgtggcaggcactgtactgagag 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
84,129,965 - 84,129,979 
5 
FLJ14993 
228 
ACAA TGACCA TTTT ACAaaacaaacaaacaaacaaacaaacaaCAACAACAACAAAAACagaagttaa 
gtgatttgttcaaggtcccatagatagtgggatgccagaaactcaaacctgggtctacagacacaagtccagtgttctttc 
tatgatatcatgctg 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
84,369,995 - 84,370,009 
5 
Between FLJ14993 & PHRETI 
gcttgcagtgagccgagatcgcgccactgcattccagcctgggcgacagagtgagagtgaggctttgtctcaaacaacaa 
caacaacaacaaaaaccaaaaacaaaaaacaaaacacaaatggctcagatgggttataacac 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
84,770,048 - 84,770,065 
6 
Between RA 86 & THRSP 
atcctgtaacaacaacaacaacaacaaaatttaaaaagtaaaaaCGGAAACAATGCAGATGGAACCATAT 
AACGTGTAG I I I I I GTGTATGACTTCtgtttt 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
84,784,898 - 84,784,915 
6 
Between RAB6& THRSP 
cactgcagcctgggcaacaaagcgagatcctgtctcaaaaaaaaaaaaccaaaaaacaacaacaacaacaacaaaaaaa 
CGGAAAACTGCGTGCAGGCATTAATCTACACAAGCATTTCCTTCTGAACAATTGCCACAT 
ACACCATTTT 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
85,145,617 - 85,145,634 
6 
Between RA 86& THRSP 
aggccagcctggccaacatgacgaaatcctgtctctacaacaacaacaacaacaacaacaacaacaacaacaaagcag 
ggtgtggtggcgagcacctgtagtcccaactacttgggaggctgaggtgggaggatcgcttgagtctggga 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
85,584,976 - 85,585,008 
11 
Between MGC2840 & GAB2 
ACA TTCAAAGAGTcaaaaacaacaacaacaacaacaaAACCCAGAATCGAACACA TCA TTTCCCT 
CA TTTCCTCA TTCAGGAAGCTTCGGGTGGACCCTGAACtttttcttttc 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
Repeat 
85,601,890 - 85,601,907 
6 
{GTTI 
ACTTTTGCCTGGTT AAA TCTGCTTCTT AGGAAACATGGTAGGGAA ttttttttttaatttgttgtt 
gttgttgtttgagatagggtctcactctgtcaccctggctgaagggcaatggcacttcattgaattcatagttcactgcag 
cctcaatctcct 
229 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
73,485,410 - 73,485,424 
5 
Between SLC22A6 & HREV107 
CACAGTTTTGTTGGTA I I I I I ATAGGTTCTTTCAGATATTTAtttttgttgttgttgttgtttttgt 
ttttgagagagagacggtcttgcttgtggcccaggcttgagtacagtggcatgatcatagctccctgcagcctcgaactcc 
tgggttcaagc 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
74,026,398 - 74,026,412 
5 
MRPL48 
TCAAGTCTTTACAAAGCAACAAACTTAAtgttgttgttgttgttgttgttgttTTAAATTACCAAGC 
TACCTTCAACAACCAAGGAg 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
74,093,090 - 74,093,113 
8 
Between LOC51287 & SERPINHl 
AAACTTGTTGTTGTTGTTGTTTGTTTGTTTGTTGTTTTGCTTTTCTTAGGCATCTGAAAG 
CACTAGCAATCTAGCAATCTAGGTTCACTTTAATCCAATTTCCAAGCCATCCAAATGAC 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
74,129,041 - 74,129,055 
5 
Between LOC51287 & SERPINHl 
ttgtgatttttgttgttgttgttgttgttgttaaaaactggccatttgaatctaataaggtggtgactctggacatcagatt 
ctccctctttctgaggt 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
74,467,949 - 74,467,969 
7 
Between KIAA0769 & UCP2 
GAGTGAACAA TTTTGTTGTTGTTGTTGTtatttttagtagagacaaggtttcaacatgttgatcaggctgg 
tctt 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
74,577,423 - 74,577,437 
5 
KIAA0769 
aatctcccttgaccaatgtccagaagcatttcccctatgttttcttgtactagttctatgttttcttgtactagttctatag 
tgtgggtgtttttttgttgttgttgttgttgttttctttttttttttttcgagacagggtatcactctgtcacccaggct 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
74,613,714 - 74,613,731 
6 
KIAA0769 
atctcccttgaccaatgtccagaagcatttcccctatgttttcttgtactagttctatagtgtgggtgttTGTttgttgtt 
gttgttgttgttttctttt 
230 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
74,617,478 - 74,617,495 
6 
KIAA0769 
GAAACTTGTTGTTGTTGTTGTTTGTTTGTTTGTTGTTTTGCTTTTCTTAGGCATCTGAAA 
GCACTAGCAATCTAGGTTCACTTTAATCCAATTTCCAAGCCATCCAAATG 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
75,244,782 - 75,244,796 
5 
Between PME-1 & FLJ10661 
cagtagctgtgattaaaggcgcctgccaccatgactggctaattttgttgttgttgttgttgttttgagacggtttcactc 
gtcaccccagctg 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
75,694,752 - 75,694,769 
6 
Between NUMAl & FLJ20625 
GTTGAGATGCAGGAACACTATGATGAA I I I I I I GAGGAgttgttgttgttgttgttgttgtttgagat 
ggagttttgctttgttgcccaggctggagtgcagtggcgctatctcggctcactgcaagct 
Base Numbers: 
- 75,934,344 
Number Repeats: 
Nearest Gene: 
ARIX & SKD3 
75,820,692 - 75,820,715; 75,904,244 - 75,904,267; 75,934,321  
8 
Between FOLR2 & FOLR3; Between ARIX & SKD3; Between 
cCCtgttgttgttgttttttgttgttgttgttgttTGTTTGTTTGTTTT ACCTT AAGATGAAGCTCT AA 
AAGTTTGGGAGGCCCGTGTCTTGAGAATTCCCATGCAGAATCCTTTCCTTCTCTCCTT 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
76,179,326 - 76,179,340 
5 
PDE2A 
CAACAttgttttgttgttgttgttgttgttgAAAGTGACA TTTGAAGGCAGGT AGA TTTT AGTGAA 
AACATGATTAGGAAAGTAAAGTTTCTTCCCAGG 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
76 ,816,361 - 76,816 ,378 
6 
Between FOLRl & PRCP 
attccctgcctctgtcatcaaccctagaaattactgatcatcctcttttctctgtagttctagttttacagaattgcatata 
aatgcaggtgatttgttgttgttgttgttattgttgtgttgttcttgagacggagtttcactcttgtttccca 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
76,935,406 - 76,935,420 
5 
Between FOLRl & PRCP 
ATGTGtttttgttgttgttgttgtttttgagacagtctcacttattgcccaggatggagtgcagtagtgcgatcacaggc 
tcactgcagcctcgacttcctgggctcaag 
231 
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I 
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Base Numbers: 
Number Repeats: 
Nearest Gene: 
77,695,173 - 77,695,187 
5 
PRCP 
TTTCCAAATGCCATCCTGTTGGGTGAC I I I I  I I GTTGTTGTTGTTGTTTTTTAATGGAAG 
CAGGGCACTGAAGACATGGTAAAGTCACATCAATTATATAACTGAAAATT 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
79,247,010 - 79,247,024 
5 
DLG2 
AAGGtgtttttgttgttgttgttgttgttgttgttgttgttttgagacggagtctcagtctatcactcaggctgaagtgc 
aatggcatgatctcagctcactgcaacctccccctccc 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
80,354,060 - 80,354,089 
10 
Between DLG2 & HT007 
accatgaccagctttttgttgttgttgttgctcctgttgttgttgttgttgttgagacagggtctcacaatgttacccaggt 
tggtcttaaactcctggcctcaagtgatcctcccacctc 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
80,404,403 - 80,404,420 
6 
Between DLG2 & HT007 
tttgttgttgttgttgttgttgttcttgctgcttgagaaggagtctcactctgtcacccaggctggagtgcagtggtgcaa 
tgtcggctcactgcaacctttacctcccaggttcaagagattctcct 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
80,618,890 - 80,618,910 
7 
SYTL2 
ttcccatccaagagtatgatgtatctttccatttgttcagatcttgtgttctctttttttgttgttgttgttgttgttgttgt 
ttttgagac 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
81 ,878,489 - 81 ,878,512 
8 
Between E2IG4 & GARP 
tgctaggattacaggtataagccactgcgtcagcctattgtggTTTTttgttgttgttgttgttgttgttgttgtttttg 
agacaggatctcattctgtcacccaggctggagtgcagtggtgggatctcagctcacgatagcctctacctcccagggtc 
aagtgat 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
82,235,089 - 82,235,115 
9 
Between PRKRIR & WNTll 
ttttttgttgttgttgttgtttttttttgaggcagggtctcactctgttgcccaggctggagtgcagtgatatgatgatctt 
ggctcattgcagcctctgcctcccaagcttggctcattgcagcctctgcctcccagcttgaccgatcc 
232 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
82,246,819 - 82,246,833 
5 
Between PRKRIR & WNTll 
tccaggatattatgcaggtattcatataacaagcgatgaaatgtgtttctacaagatatttgttgttgttgttgttgttgtt 
tttagatggaatctcactctgttgcccaggctggagtgcagtggtgcgatctcggctcactgaac 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
82,786,763 - 82,786,783 
7 
Between DGAT2 & FLJ22644 
CGA AA TT AGttttttttgttgttgttgttgttttgagatggagtctcactcgttgccaggctggagtgcagtggtgtg 
atctcggctcactgcaacctccgccccccaggttcaagtgattttcctgcc 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
82,948,435 - 82,948,449 
5 
Between FLJ22644 & SERPINH2 
ccagcc TAT AT AT AT AT A TTttgttgttgttgttgttgttgagatggagtctcactctgttgcccaggctggagtg 
cagtggcatgatggtagtgactgcaacctctgcctgcctgattcaa 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
83,034,549 - 83,034,566 
6 
Between SERPINH2 & PP1665 
acagaactcctcctagcttttatttcctcatttgttgttgttgttgttgtttttgagatggagtctcactcttgttgcccag 
gctggagtgcaatggtgcaatctcggctcactgcagcctct 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
83,374,997 - 83,375,014 
6 
SLC21A9 
TA A ACT ACA TTGAGGAGtttttgttgttgttgttgtttgtctgttctgagaagaggccttgctctgtcacccagg 
ctggagtgcagtggcgctatctcggct 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
83,441,907 - 83,441,921 
5 
Between SLC21A9 & NEU3 
atgctcattatctagaatattacctgatacatgataggtgctcaataagtttgttagatgaatgaatGAtttttgttgttg 
ttgttgttcagatggagtttcgctctgtagcccaggccggagtgcagtggtgcgatcttggctcactgcagcctccacctc 
ccgggttcaagcaattctcctg 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
83,673,371 - 83,673,385 
5 
Between KIAA0102 & FLJ22596 
99agct999attaca99cacccgccagcactcagctgatttttgt9999ttttgttgttgttgttgttttgta 
233 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
83,674,632 - 83,674,646 
5 
Between NEU3 & KIAA0102 
ACATACTTCAACTCAATAGAACA I I I I  I I GTTGTTGTTGTTGTTTTG I I I I IGAAACAT 
A TT A TGttttatgttgttgttgtgt 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
84,570,662 - 84,570,676 
5 
PHRETI 
atggtgtgctttgaagcacagacattttttgttgttgttgttgtttgagacaggatgtcactctgttgcccaagctggagt 
gcagtggtgtgat 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
84,783,053 - 84,783,067 
5 
Between RA 86 & THRSP 
CGTTTTCAGGATttgttgttgttgttgttgtttttaacttctattttaagctcagaagtacatgtgcaggtttgctat 
acaggtgaattgcatgtcacagggcttgggtttacagattattttgtcaccca 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
84,939,354 - 84,939,371 
6 
Between RAB6 & THRSP 
TTCT ACGT A TTGGGAACTGT ACAAGTGGCTTTCATGttttgttttttgtttgtttgactggtttgttgtt 
gttgttgttgttgttgttgttgtttttgagacggagtttcgctcttgttgcccaggctggagtacaatggcgcgatctagg 
ctaccacaacctct 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
84,996,592 - 84,996,621 
10 
Between RAB6 & THRSP 
aattgttgttgttgttgttgttttctagagacagcatttagccatgttgcccagtctggtcctgaactcctgagctcaagct 
atctgcctaccctggcctcctaaagtgttgggattacaagcgtaagccactgcaactggccaagaatagtattttcaacaa 
atcgtgct 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
85,061 ,805 - 85,061,822 
6 
CLNSlA 
GgtttttgttgttgttgttgttgttgttgTTTT AACACAAA TT ATGGCGTGAA TTCACAGGGAAT AG 
GCTCCAGCAACTCAGGCTCCTTCCCACTGGTTCTTACACAGTGTGCTTCTCTGG 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
85,276,822 - 85,276,845 
8 
PTD015 
234 
GCCTTTTGAACATGA TT ACTATCA TTGCT A TTTTGGGTTttgttgttgttgttgttgttgttgttgtt 
tgagacagagtcttgctcttgttgccctggctggagtgcaatggtgcaatctcacagccactgcaacctccgcctcccgg 
gttcaa 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
85,409,013 - 85,409,039 
9 
MGC16733 
AGGCAGTGCCTGCttattttattattttattttattttttgttgttgttgttgttgttgagatggaatcttgctctgtt 
gcccaggcggga 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
85,468,387 - 85,468,404 
6 
Between MGC2376 & PRO2849 
ctacacctagcc TGA TGACT A ttttgttgttgttgttgtttgttttttgagacggagtctcactctgttgccaggctg 
aagtgcagtggt 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
Repeat 
85,577,825 
5 
Between MGC2840 & GAB2 
(AGG) 
GGCCGAGGGCCTGGGGGTCCAGGGGGCT gaggaggaggaggaggaggaagaagaggaggaggaggagggg 
gCCGTGTCCCAGCTTGCCCGCCCAAGGGCCCAGGTAATGCAAATGCAGATTCTGTACAGGC 
AG 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
73,354,938 - 73,354,955; 73 ,354,962 - 73,354,976 
6 , 5 
Between SLC22A6 & HREV107 
gggggaggggacgaggaggaggacccataggaggaggaggaggagtggggtgagcggtggggccagagcaggcggaga 
gggagAGCCGGGCAGTGCTG 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
73 ,356,761 - 73,356,784 
8 
Between SLC22A6 & HREV107 
aaggaggaggaggaggaggagaaggaggaggaggaggaggtggcaactggaggatgaataccagctgagtgaggagga 
ggagaaggaggaggaggaggaggaggCAACTGGAGGATGAAT ACCAGCTGAGTgaagagaaggaggagg 
aggaggcaactggaggatgaataccagctgagtgaagagaaggaggaggaggaggCAACTGGAGGATGAAT A 
CCAGCTGAGTgaagagaaggaggaggaggaggaggggaagaaggagaaggagaaggaggagggcaagaaggagga 
ggaggaaggggaggCGACCGGAGG 
Base Numbers: 73,678,196 - 73 ,678,213; 73,678 ,217 - 73 ,678 ,234; 73,678,234 
- 73 ,678 ,254; 73,678,332 - 73,678,346; 73,678,381 - 73 ,678,395; 73 ,678 ,430 -
73 ,678,447 
Number Repeats: 6, 6 ,  7, 5, 5, 6 
235 
Nearest Gene: Between HREV107 & MRPL48 
T ACCAGCTGAG T gaggaggaggaggagaaggaggaggaggaggaggaggaggaggaggaggaggaggtggcaac 
tggaggatgaataccagctgagtgaggaggaggagaaggaggaggaggaggaggaggaggCAACTGGAGGA TGA 
AT ACCAGCTGA TT gaagagaaggaggaggaggaggcaactggaggatgaataccagctgagtgaagagaaggag 
gaggaggaggCAACTGGAGGA TGAA TACCAGCTGAGTgaagagaaggaggaggaggaggaggggaagaa 
ggagaaggaggagggcaagaaggaggaggaggaaggggaggCGACCGGAGGA TGAA T ACCAGCAA AGCC 
AGGAAAAAGGATACCTCTTCTCAC 
Base Numbers: 73,690,028 - 73,690,066; 73,690,110 - 73,690,133; 73,690,168 
- 73 ,690,182; 73,690,217 - 73,690,231; 73,690,266 - 73,690,283 
Number Repeats: 13, 8, 5, 5, 6 
Nearest Gene: Between HREV107 & MRPL48 
gaagcagaagcagaagaaggagaagaagaaggaggaggaggaggagaaggaggagaaggagaaggaggaggagaagGa 
ggagaaggaggaggaaattgtttt 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
77,535,167 - 77,535,181 
5 
Between FOLR1 & PRCP 
gaaagaaagaaaggaagaaagaaaaataaagaaaaggaggaggaggaggagaaaaacaagaagagggaac 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
79,812 ,611 - 79,812,625 
5 
Between DLG2 & HT007 
CACACTGACGTTTCGAGGGCACTACAGCCCGAGCAATA66A66A66A66A66A66TACAC 
GTGCTGGGTGACTGTACATCCTATCATAATAATCCCACT 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
79,842,296 - 79,842,313 
6 
Between DLG2 & HT007 
gatcatgtcactgtactccagcctgggcaacacagtgagaccctgtctcaagaaggaggaggaggaggaggaggCACA 
Gtgatgatga 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
80,324,986 - 80,325,006 
7 
Between DLG2 & HT007 
AGGGACA66A66A66A66A66CCTGGAGGAGAAGACAGTGCTCTTTTGAAGAAGAGGGT 
GGCCTGGACAAGATAGTGGTTATTTGTGTGTAGAAAGAGAAAGATTATAG 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
81,119,440 - 81,119,454 
5 
Between CL TH & PA Kl 
gagtgagaccctgtcttaaaaaaaaaaaaaaa66A66A66A66A66AGAAA TGGCCTTTTCAGTG TCT 
atttccacctgccagcatctgtaccttttttctcaggacttttggagggaccggggctgtcaacccatgtgtcaggctgga 
236 
catgctggagaattcatatcccccgagcagccctcagccaatgactgactcccctagcccccttgcctctaatgaggggt 
aactctggatgtgtgtt 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
84,013,413 - 84,013,427 
5 
Between DKFZP58N2124 & KCNE3 
gaaaacaaaaggaagaagaaagaaaaaggaggaggagtaggcagaggaaaaggcgggggggaggaggaggaggaggaa 
gaagaAAGAAGAAGAGAAAGGAGGCAAAAAGAAGGAAaaaagaagaaatac 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
Repeat 
84,436,444 - 84,436,458 
5 
FLJ14993 - PHRETI 
(CCT) 
CCTCCGG TCGcctccccttcctcctcctccttcttgccctcctccttctccttcttcccctcctcctcctcctccttct 
cttcACTCAGCTGGTATTCATCCTCCAGTTGcctcctcctcctccttctcttcactcagctggtattcatcct 
ccagttgcctcctcctcctccttctcttcACTCAGCTGG TA TTCA TCCTCCAGTTGcctcctcctcctcctcc 
tcctccttctcctcctcctcactcagctggtattcatcctccagttgccacctcctcctcctcctccttctcctcctcctcc 
tcctccttctcctcctcctcctcACTCAGCTG 
Base Numbers: 73,647,640 73,647,567; 73,647,692 
73,647,706; 73,647,741 - 73,647,755; 73,647,790 - 73,647,813; 
73,647,857 - 73,647,874; 73,647,878 - 73,647,895 
Number Repeats: 6, 5, 5, 8, 6, 6 
Nearest Gene: Between HREV107 & MRPL48 
ctccttcttcccctcctcctcctcctccttctcttcACTCAGCTGGT A TTCA TCCTCCAG TTGcctcctcctc 
ctccttctcttcactcagctggtattcatcctccagttgcctcctcctcctccttctcttcACTCAGCTGGTATTC 
ATCCTCCAGTTGcctcctcctcctcctcctcctcctccttctcctcctcctcactcagctggtattcatcctccagtt 
gccacctcctcctcctcctcctcctcctcctcctcctcctccttctcctcctcctcctcACTCAGCTGG TA TTCA T 
CCTCCAGTTGCCACCACCTCTTCCTTCTCTTCCTCCTCAATGCAG 
Base Numbers: 73,845,263 - 73,845,280; 73,845,315 - 73 ,845,329; 73,845,364 
- 73,845,390; 73,845,413 - 73,845,439; 73,845,483 - 73,845,521 
Number Repeats: 6, 5, 5, 9, 13 
Nearest Gene: Between HREV107 & MRPL48 
CCCCTCCTCTCCGGCCCTCCTCCTCCTCCTGGTCCTTGCTAACGCTGCCGTCGG 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
74,356,049 - 74,356,063 
5 
KIAA0769 
CCTCACCACAGACCAGCCGGAGCCCCTCCTCCTCCTCCTGCCACTTCACCCTCA 
Base Numbers: 
Number Repeats: 
74,679,589 - 74,679,603 
5 
237 
Nearest Gene: Between KIAA0769 & UCP2 
GGCCAATTATTTGTGTATA I I I I l ctcttcctcctcctcctcctcctccACCATCTTC I 1 1 1  I CTGT 
CCCTTAT 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
77,017,352 - 77,017,369 
6 
Between FOLRl & PRCP 
AAAGACTT ACTCTGT AAATTACA TTTCTA TTCATCATAtcctcctcctcctcctttcttctgctcctt 
cttctcctccttct 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
77,376,957 - 77,376,971 
5 
Between FOLRl & PRCP 
TCT ACTGCAA T AAcatcagcagcatcatcgtcatcatcaccatcaccaACTtcctcctcctcctcctcctcctccc 
cctTTCTGCCAAC 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
79,222,004 - 79,222,024 
7 
DLG2 
cctttcacttctctttcttttctttctccttccacatctttgcctcttcttcctcctcctcctcctttatcttttccttctCT 
TGTATTCAGAAGACA 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
79,392,422 - 79,392,436 
5 
DLG2 
ATCTCCTCCTCCTCCTCCTAATTGATTTAATCTTCTCATACCAGAGAGTGGGGCCGGGTTT 
GGGGAGATGGTGTTGATCAGAA 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
83,311,146 - 83,311,160 
5 
Between ARRBl & SLC21A9 
catatagG T AcctgctcctcctcctcctcctcttcctccttctcA TT ACT A TTG TGA TT A TT A TTCTT AA 
ATGAATGTTT AGGA TT ACTGtgtgtttctca 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
83,357,574 - 83,357,588 
5 
SLC21A9 
GCTAATTACCTCCTCCTCCTCCTTCAGACCTCAGAGACACCTTTTACCTCTCTGACTAGGT 
CACATGACCCTGGTACTTCATGCACCTCTCTTG 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
83,676,246 - 83,676,260 
5 
Between KIAA0102 & FLJ22596 
238 
AACCAGATCTCCTCCTCCTCCTCCTAATTGATTTAATCTTCTCATACCAGAGAGTGGGGCC 
GGTTT 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
Repeat 
84,765,219 - 84,765,233 
5 
Between RAB6 & THRSP 
(AAG) 
ACTGAAGGGTAGATACGGGAGGAACAAA TGTGAGAAAGAAGTGATgaaggaaaagaagaagaa 
gaagaagaagaagaagaTGATGATGATGGTGATGatggtagct 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
78,444,111 - 78,444,137 
9 
DLG2 
GTCACACAAGA TTGTCA TGCGAGCTGAAGGGGGCTGAAA TT A TTCCCTCT gaagaagaagaag 
aagaagaaAACA T ACTGCAGCTCCCGA TTTGGT AAAAAGCCAGTGGCTTGCT 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
79,541,890 - 79,541,907 
6 
DLG2 
AATCACTGGATTAAAAAAAAAAAAGAAGAAGAAGAAGGAGGGGGGAATGAGCTCACTC 
AGGAAGGAG 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
79,744,482 - 79,744,496 
5 
DLG2 
ggaggtcaaggctgcagtgagcttcactccagcctggccaacagaatgagacactgtctcaaaaaaaaaaaaaaaaagaa 
gaagaagaaGAAGTTCAAAGAAAAAGAAAGAAAAAGTCACTGAAA TT AA TGA T 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
85,260,385 - 85,260,402 
6 
PTD015 
aaaaAAAAGAAGAAGAAGAAGAAGGAAAAAATCTTGAATATAAATGGATTAAGTTCTTC 
AATTAAAA 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
Repeat 
85,356,824 - 85,356,838 
5 
Between PTD015 & MGC16 733 
(CTT) 
AACATGAAGTTCTCTTTCCT AACtttctttgtttccttatttcttcttcttcttcttctccttcttcttcttctt 
cttcttcttcttcttcttcttcttcttcttcttcctcttcttcttcttcttcttctttcttcttcttctccttctccttttcct 
239 
tcttctttttttgctgagacagggtctcactctgacagtacagtggtgccatcacagctcactgcagcctcgacctccagg 
gctcaagcaatcctcccagctcaccctcccaa 
Base Numbers: 
- 75,732 ,104 
Number Repeats: 
Nearest Gene: 
75,732 ,016 - 75,732 ,030; 75,732 ,033 - 75,732,080; 75,732 ,084 
5, 16, 7, 
Between DKFZP564M082 & FOLR3 
GGCCCAGtcttcttcttcttcttcttcttttttttttgagaccgagtctcattctgtcacccaggctggaatgcaatggc 
acagtctcagctcactgcaacctctgcctcccaggttcaagcgattctcc 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
75,866,488 - 75,866,505 
6 
Between FOLR2 & INPPU 
ctaggatcttcttcttcttcttcttcttcttcttcttcttcttctttttttttttttt 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
76,107,319 - 76,107,357 
13 
Between S KD3 & PDE2A 
CT AT AAAA TT AATCA I I I I I GTTTTGGA TCTCTTGAGAGAGAAT AA TTttttccttcttcttct 
tcttctacttcttcttcttctAAAtagagacagtgttttgctatgttgcccaggctagtcttgaactcctgggctcaa 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
78,909,269 - 78,909,283 
5 
DLG2 
cctcccatatccccctcctccccctcctcctccctcttcccctccccttcccccCtcctcttcttcttcttcttcttctttc 
ttcctttctccttcttcttt 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
81 ,491 ,566 - 81,491 ,586 
7 
Between CAPN5 & PHCA 
CCAGGGCCCAGCATCTTGGT ACAGTCCT AGttcttcttcttcttcttctttttttttgagacagacttttgct 
cttgttgctcaggctagagtgcaatggcacaatctcggctcactgcaacc 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
83,281,737 - 83,281,757 
7 
Between ARRB1 & SLC21A9 
GCCCCTCGACTTCCACGTCATGGGCAATGTTGT ACATGtcttcttcttcctcttcttcttcttcttcctc 
ttcctcttcttcctcttcgtcttcctcttcttcttcttctccttctccttcctcttcctctt 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
83,398,401 - 83,398,415 
5 
Between SLC21A9 & NEU3 
240 
acaattctccataacttcttcttcttcttcttcttcttcttcttcttcttcttcttcttcttattattattattattattatta 
ttagagacagtctcactctgttgcccaggct 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
85,054,880 - 85,054,927 
16 
Between RAB6 & THRSP 
TTTCttcttcttcttctttttttttttttttttgagatggagtcttgctctgtcgcccaggctggagtgcagtggtgcaat 
ctcagct 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
Repeat 
85,461,054 - 85,461,068 
5 
Between MGC2376 & PR02849 
(ATC) 
TA TTTT ACAAAGTGCTACA TAA TGTAATGGATA TTGCCA TA TTCTtcatcatcatcatcatcat 
catcaccatcatcatcatcatcatcaccaccatc TTTCTT AGAGAAGGATGA TAGT AT AATGTCTTGA 
GCT 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
74,476,098 - 74,476,118; 74,476,139 - 74,476,156 
7, 6 
KIAA0769 
ATATCACTACCACCACAATGACTACACAAGGGATCATCATCATCATCATCCTAATATGTA 
AT A AGCTGCTactaatttatccttaaattgttataagataggtactattagtcctactttacaaataaggatagtgta 
tctaagcaaaaataacttgactaagattgcataactaatTT AACA TTT AACTCCTGAGTCTGTGA 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
79,425,063 - 79,425,080 
6 
DLG2 
ACTGGAAATGGAAGAAGATGGTCTCCCTGTTTCTGTATCTCTCATCATCATCATCATCAC 
CGTGTTCTGTCTATACTTCTTATGG 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
81 ,003,400 - 81,003,414 
5 
Between CL TH & PA Kl 
GGCCT AA AG TGACTGCA TCCAGA TTtcatcatcatcatcatcatcgtcatcatcatcatcatcaccatcatc 
a teat AGCA TCTGGCAAATACTCTGTGGCAAGCAGGGTGCTAGG 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
84,327,374 - 84,327,391; 84,327,395 - 84,327,409 
6, 5 
Between FLJ14993 & PHRETI 
caatatagcaagaccccatctcaagaaaaataaaaaaTCATCATCATCATC I I I I I AAATGTCTAAAAC 
TAAAAAATATGGCCACATAC 
241 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
Repeat 
84,475,703 - 84,475,717 
5 
Between FLJ14993 & PHRETI 
(GAT) 
caacagagcgagactctgtctcaaagtaataataataataatgatgatgatgatgata TAGG TGT A TCAGAGA A 
TATCAAGTCCCTAGGAATAAATCTACCAGGTCTTCAAGATCT 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
76,147,185 - 76,147,199 
5 
Between S KD3 & PDE2A 
TAAGTTATATGTTCTAGCATataatgtgatgatgatgatgatgataatataatgaGTAGAATCAATGA 
AATAGGAAAAGATATAAGGCAAATGTTATATACGTTATATGtaa 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
77,952,993 - 77,953,010 
6 
Between RAB30 & PCFll 
TTCTT ATAGTAAATACTGA TTTTtgatgatgatgatgatggtgatgatgacaatgaCAATAGTT AAA 
TAGGACAATGAAAACAATTTCAAG I I I I I CATTGTTCACCAAACTTTGCACAGCCCCTGA 
TGCATAATACACT 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
79,781,848 - 79,781,862 
5 
Between DLG2 & HT007 
GCCAGAACAACCAGCAGGTATGAAG I I I I I I CCTAGAAAA I I I I I IGATGATGATGATG 
ATAAAGACAATA TT AAaatagcaacattagttgagtgtgtttaatgctctaa 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
80,827,894 - 80,827,908 
5 
CLTH 
CAGTGCCACCAGTTTCAGAAgatgaggatgatgatgatgatgatgCTACCCCACCACCAGTGA TTGC 
TCCACGCCCAGAGCACACAAAATCTGTGAGTCTTTGGGGACCTGGCCAGTTTTGTGATTTA 
TTAGAGTAAG 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
81,170,564 - 81 ,170,581 
6 
PAKl 
ctggagtccactgtccagtgggcaagacaaacACGTAAAatgacgacgacaatgatgatgatgatgatgaGGCTT 
GCCTTAgagcacttaccacccgccattgttctgagtgatttacacagtattgactca 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
81 ,905,102 - 81,905,116 
5 
Between GARP & GL002 
242 
gtgggtatgaatcctggctctgctgggtgtcctttggtaagtgggtcaacctctctgtgcttcagagttctcatctataaa 
atggg9at9at9at9atGATACTTtggggatgtaacatggtgcagtcacattggaaaagtttggcagttcctcaaaag 
gttaaacataaaagttaccat 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
83,048,912 - 83,048,926 
5 
Between SERPINH2 & PP1665 
GGGTTGAGGAATGAAATGATGATGATGATGATGACAGCCAACATTAAGCATTTACTGTA 
T ACTAGACTCCAGTATAAAGGCTTT ATCTACATAAGAACCACttatttctactttacagataaggaa 
acccagattaagtaatttgcctaatatcacatggttagtcaggac 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
83,606,605 - 83,606 ,619 
5 
KIAA0102 
TCCTGTAATAGCTACAGTCAAATGGGCAGCTGAAGATGATGATGATGATGATCTTGACAC 
CGAGAAGCAGAAGACCAATGAAGATGACCAGACAGCAAAAAAGGAT 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
Repeat 
85,549,763 - 85,549,780 
6 
MGC2840 
(AAD 
caaaaaataataataataataataataaaataaagatttgatgtcataaagaaattagtgctccccaaacaatctaaaaa 
tccaaatgcaattctaatacaaatcttaatatctggtggtgagaac 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
72,548,177 - 72,548,197 
7 
FLJ23392 
ccagcctgggtaacacagtcagaccccgtctctacaaataataataataatAATA TT ATAT AAAGTA Tggttg 
ggcacagtggctcacgcctgtaatcccagcacttt 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
72,548,535 - 72,548,552 
6 
FLJ23392 
aaaaataataataataataataaaataaagatttgatgtcataaagaaattagtgctccccaaacaatctaaaaatccaa 
atgcaattctaatacaaatcttaatatctggtggtgagaactttgtaagatgac 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
72,632,932 - 72,632,949 
6 
Between FLJ23392 & FLJ20556 
cctgggtaacacagtcagaccccgtctctacaaataataataataataatattatataaG TAT ggttgggcacagtgg 
ctcacgcctgtaatcccagcacttt 
243 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
72,633,287 - 72,633,304 
6 
Between FLJ23392 & FLJ20556 
atcgcgccagtgcactccagcctgggcaacagagcaagactccatctcaaataataataataataataataataataat 
aataataatTA TT A TT A TT A TT A TT Acctatcatctcggcattctgggaagctgagggaagaggatcacctgag 
gccaagagttcgagaccagtctgggcaacacagtgagaccccaactctacaaaaaaaaaaaaaaaT AAT AAT AAT 
AAT AATGtataagtaacaatcatagtatgctaaagacacagggatggg 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
72,633,964 - 72 ,634,002; 72,634,131 - 72 ,634,148 
13, 6 
Between FLJ23392 & FLJ20556 
cctcagaaaaacacccaacAAGCCTATCAACCAAaataataataataataataataataataaATAAATAa 
ataagtaataattttaaaaagcacccaggaccaaacagaatcacagctgaattctactagaag 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
72,956,772 - 72,956,798 
9 
Between HRLP5 & SLC22A8 
cagtatcgcaccattgcactccagcctgggggataagagtgaaacttcgtctcaaaataataataataataataatGag 
ctgggtgtggtggcacatatcccagctacttg 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
73,426 ,246 - 73,426 ,266 
7 
Between SLC22A6 & HREV107 
acctgcctctaaaaaataataataataataacaataataataataaATggccgggcgaggtggctcatgcctgtaatcc 
cagcactttgg 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
73 ,670,696 - 73,670,710 
5 
Between HREV107 & MRPL48 
gggactctgcttcaaaaagaaaaaaagtgagaaaaacaaaT AATAATAAT AAtgttatatataaaatgtttattta 
gaaacagaatacttgttcgtcggtact 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
73 ,696 ,199 - 73 ,696,213 
5 
Between HREV107 & MRPL48 
attgcactccagcctgggggataagagtgaaacttcgtctcaaaataataataataataataatGagctgggtgtggtg 
gcacatatcccagctacttgacttgggaggctgaggcaggagaattgctt 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
73 ,770,597 - 73 ,770,617 
7 
Between HREV107 & MRPL48 
ccagcctgggcaaagaagcaagacctgcctctaaaaaataataataataataacaataataataataaATggccgggcg 
aggtggctcatgcctgtaa 
244 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
73,817,489 - 73,817,503 
5 
Between HREV107 & MRPL48 
tgacaggggggagactttatctcaaaaTAATAAT AATAATATGCCAGGAGCAATCGGCGcgcctgtaat 
cccagcactttgggaggctgaggtg 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
73,980,949 - 73,980,963 
5 
Between HREV107 & MRPL48 
taaaaaaacaaaaataataataataataataattctaaaatgtcagccaccttagtattggcatctacatattgtcattt 
tt 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
74,262 ,573 - 74,262 ,593 
7 
Between SERPINHl & P2RY2 
cggcgaaaccctttctctaaaaaaaaaataataataataatacagaaaaactagctgggcatggtagcacacacctgtag 
tccctgctactcaggaagctgaagtgggaggat 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
74,596,007 - 74,596,021 
5 
KIAA0769 
tccagcctgggcgacagagcgagactctgtctcaaaaataataataaaataataataataataataataataataataa 
taataataatggctggacacagtggc 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
74,773,736 - 74,773,777 
14 
Between KIAA0769 & UCP2 
aacAGCAGAGA TtagtagtagtaataataataatgataataataataataataataataacaatGGA TT A TT A 
GTAC 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
74,969,017 - 74,969,037 
7 
Between UCP3 & PME-1 
aaaacttaaagtataataataataataataataataataaAAGTTTGGGACaaaaaaataaaaaataaataaaatG 
CAGCTT 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
75,141 ,994 - 75,142,017 
8 
Between PME-1 & FLJ10661 
cattaagttacaATTT AATAAT AATAATAATGCTTT AACAAT AATGAAGT AATGTT AT AATC 
TTAATAACAAAAGTA 
------ - ---24§- --- -- ------------':'Ill 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
75,295,962 - 75,295,976 
5 
Between PME-1 & FLJ10661 
agcctgggctacaagagcgaaactccgtctcaaaataataataataataataataaACCACA TCACACCCACCA 
CAAACCAGCTG 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
75,402,505 - 75,402,525 
7 
Between FLJ10661 & FLJ11099 
ggcaacagagcgagactctgtctcaaagtaataataataataatgatgatgatgatgata T AGGTGT A TCAGAG 
AA 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
76,147,170 - 76,147,184 
5 
Between SKD3 & PDE2A 
tctcTA TtaataataatgatgataataataataataataGCAGGGGGTGCAGACTCTGGGGGTGATGTA 
GAGTC 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
76,343,055 - 76,343,069 
5 
Between CENTD2 & FOLRl 
tctacaaaaaatacaaaataataataataataataataacaggcatggtgtcgcatcctgtagtctcagctactca 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
76,452 ,028 - 76,452 ,048 
7 
Between FOLRl & PRCP 
GTT AATCCATAGGAAGTCAGGCtaaaaataataataataataaCCATGCATAGACATCAGGAGCC 
ACAGCAGTTTCTGCAGTTTATGTCTGGACAA 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
76,927,820 - 76 ,927,834 
5 
Between FOLRl & PRCP 
aaacttctaggcttaagcaatcggtctgcctcagccacccaatgtgctgggattacaggcatgagccaccacacccagcc 
aggttcagttttttaatctattaaataggaataataataataATAAAGAATAATAATCTA TT AAATAGA 
AATA 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
77,123,392 - 77,123,406 
5 
Between FOLRl & PRCP 
aggcggagcttacagtgagccaaaatcgcgccactgcactccagcctgggcgacagagcaagattccgtctctaacaata 
ataataataataataagcatttgattaaattcattatatatattcatgataaaatctcctagcaaaccaggaatagagcca 
aatttccaaattt 
246 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
77,156,213 - 77,156,230 
6 
Between F OLR1 & PRCP 
ACAGGAAAGTtaataataataataataataataataataataataatagtaataGCAACTTGCTTCA TTT 
TGGGAGACTAAAAGTAAGCTG 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
77,171,742 - 77,171 ,777 
12 
Between FOLR1 & PRCP 
CTGT AAAACCTGCTCTTGTACACataataataataataataataatataacaataataaATGGAGAAGT 
GGGTAGAATACACCATGTACTTTGTCCCTAACTAGGAA 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
77,830,564 - 77,830,584 
7 
RAB30 
catctcatttaatcctcacaactatgcaatgaggtaataataataataataataaataatgactaccatttattgagcatc 
ttttacatatagactgaacactat 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
78,338,569 - 78,338,586 
6 
DLG2 
ACAGGACCCTCACaataataataataataataaACAAAGTCACAAATGTTACTTTCAGGTTTGAA 
TTCCACTTGAATTCATTGAGTTA 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
78,466,83 2  - 78,466,849 
6 
DLG2 
gaaatcaagtaattaataataataataatgtaggctaatttctataactttggaaggatggaggaggtcccctcacccat 
gctgagaac 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
78,689,106 - 78,689,120 
5 
DLG2 
ATATGGTGTCCTTCA TTtaataataataataataataataaAAGA TTTGCTCTCTGGTAGACAGGA 
GAGCGGTAATTTAGCTACAATTT 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
78,787,761 - 78,787,781 
7 
DLG2 
aacaaatacaataataataataataataataataataataataaccacatgcactagtgcatgcctgtagtcccagcta 
tttgagaggctgagatgggaggatcacttgagccca 
247 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
78,798,119 - 78,798,151 
11 
DLG2 
cgagactccatctcaaaaaaagaaaataataataataataaattaaataaG TCTG TCAGCTTTCTGGCAA AT 
TATCTTCCAGTGTTTCCCCACCCTC 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
78,799,934 - 78,799,948 
5 
DLG2 
gcaacagagtgagattccatctcaaataataataataataatattaaGAAGCAGCA TTCTCAA TT AA TGCT 
ATCTATGTAAAGTGCTAAGTAGCAAAGTTTCTTTGTTTCCTCCAG 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
79,042,516 - 79,042,533 
6 
DLG2 
ttcatctcaaaataacaataataataataataaaataaagtggtaatacatactttgaagtacacatatgaaaattaaata 
atacatgATAATCCTTAACATGTAGTAGTAGTTATCATTTTACTAGTCATAAATGTGGATT 
TGCTC 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
79,159,865 - 79,159,879 
5 
DLG2 
gtaacaaacctgcatgttgtgcacatgtaccctagaacttgaagtattataataataataataataataataataaAGA 
AACTTTGTAAACTTTGTAAACAGATTATATTTCCTGTTTCAGCTCTAA 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
79,362,242 - 79,362,265 
8 
DLG2 
tctgtctcaataataataataataatgaaggaaataaagtcaaggaaataagatgctccaagagagcacaagaa 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
79,375,798 - 79,375,815 
6 
DLG2 
AAGTT AAAAGAGTCAATGTTTTCCaaaataataataataatactataattaaGGAAGTAT AACCAT 
AATTACATGTTGACAATAAATTATGGGACAGTTATAGACATAAAATTG 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
79,403,607 - 79,403,621 
5 
DLG2 
ttgatcagcatagctgacctctgcaaaaaaagaaataataataataataaaaattagctgggtgcagtagcatgcactca 
tag 
Base Numbers: 79,498,775 - 79,498,789 
248 
Number Repeats: 5 
Nearest Gene: DLG2 
TCTGTGATCACAGTATataataacaataataataataataataatTATTATTATTA I I I I I GCCCTT 
AGACTGTATGGGGGCTCTTCCAGG 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
80,504,378 - 80,504,398 
7 
Between D KFZp586C1924 & ZF 
catctctaaaaaaacaaaaataataataataataataattctaaaatgtcagccaccttagtattggcatctacatattg 
tcatttttcatttagtttacaatcttcctggttcttggtatgatgagtgatttattgaaacctggaca 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
80,703,186 - 80,703,206 
7 
Between SYTL2 & CL TH 
TCACTT AGTCTCTTGTACCaaaataataataataattttttaaaGTAAATGATACATATCTGAAGT 
TAAATGTACAAATAACAAAATAAAAAACAAAAGGACATGAAAAAGACATTAACTGTGT 
A 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
80,793,801 - 80,793 ,815 
5 
Between SYTL2 & CL TH 
gctatgattgtgccactgcactccagcttgattgacagaatgagaccatgtctctaataataataataataattttaaaa 
taattaacaagatcataaagggcttcatctaataacataaagaa 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
81 ,048,456 - 81 ,048,473 
6 
Between CL TH & PA Kl 
gactctgtctctaataataataataataatacaaagaatacaaaaaagcatatagaataaagctataaagaaaatattgt 
atagctgtac 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
81,113,532 - 81,113,549 
6 
Between CLTH & PA K1 
tgtatcaaaaTAATAAT AAT AATGTAGCAGCTGCTGAGCTTTGTTTGCTTAGAGGCAGCTAT 
AGGGGCCCA 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
77,745,240 - 77,745,254 ; 81,117,084 - 81,117,098 
5 
PRCP; Between CLTH & PAK1 
ATCAGATACCAAAAACACATCAAGTATGAAT AATAAT AATAATAAtttttttttgagac 
Base Numbers: 
Number Repeats: 
81,237,475 - 81,237,492 
6 
249 
¥ ' 
Nearest Gene: Between PA Kl & MYO7 A 
CT AGGGAAAaataataataataataataataaGgcaaataattcaaaagcacattaaaaggatcattcaccatgat 
caagtaagat 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
81,450,353 - 81,450,373 
7 
CAPN5 
tgggcacaagagcaagactctgtctcaaaaaataataataataataataataataataataatggaaagccaatgaagg 
tttcaccaatagataacatggtcagactcatgtatt 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
81,533,096 - 81,533,128 
11 
Between CAPN5 & PHCA 
tctgcaaaatggagctgctgctaataataataataataataataatatctaccttcttgggtgtag 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
81,853,705 - 81,853,728 
8 
Between E2IG4 & GARP 
ccactgtactccagcctgggcaacaggagtgagaccctgtctcaaaaaataataataataataaaataataataataat 
aataGCAGCACAGAAATGTtaaaacgatgggaaaatatactaggcaaatgctaagcaaaataatgcaatattgac 
agcttttaag 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
82,133 ,197 - 82,133,211; 82,133,214 - 82,133,231 
5, 6 
Between GL002 & PRKRIR 
ggtgacagagcaagactcctctcaaaaataataataataataataataataactaagagtataactggattgtttgtaac 
acaaaggatgaatgcttgaggtgatggatacccatttaccctgatgtgattgctatacattgtatgcc 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
82,135,610 - 82,135,633 
8 
Between GL002 & PRKRIR 
CTCACTGAAAACAACTAAAATGTCAGGtaaaatatttttttaaataataataataatCACCA TT AAC 
ATCAAAGAATTTCCAAACCAAGGAAGAAAGAACCCAGAGAGGTAAGTGGAGATCT 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
82,653,348 - 82,653,362 
5 
UVRAG 
aacacccaagaatgatcaataaaaaaataaataaataaa T AAAT AAT AAT AAT AAT AA A taaaataaaaata 
aaaattagtcagagatg 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
83,120,336 - 83,120,350 
5 
PP1665 
250 
gtgagatcgtatatctaaaaataataataataataaaaattagtcaggcatggtggcccatg 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
83,141,306 - 83,141,320 
5 
Between PP1665 & RPS3 
gccactccactccagcctgggtgacagagcgagactccatctccaaataataataataataatgataataataatCTG 
GGGGAAAAACATCATAAATTGTGTTTTCTACCCAAGACTGTAGGGAGACAGACAGTTTA 
AA 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
83,226,502 - 83,226,519 
6 
Between RPS3 & ARRBl 
ccactgtgcccagcccattgtcttattttaagaaattatctatgtaagtaagaaatgcttctagaaaaataataataataa 
taataataataataatacactaaatcttcagcaaccaccaccctgataagtcagcagtcaccaac 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
83,533,699 - 83,533,728 
10 
Between SLC21A9 & NEU3 
tgggtgacagagtgagactccgtctcaaaaaaaaaaaaataataataataataataataaaaaaaaGA TTCCA TCA 
GTCCCTGGGCAGGTTTTGGCCACATGTTTACTCTGGGCCTCTCTCTCTCCGCTGCCCCCAAC 
TAAGTGCCG 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
83,828,924 - 83,828,944 
7 
Between KIAA0102 & FLJ22596 
gagattgtgccactgcactccagcctgggtgacagagtaagactccatctcaaataataataataataataataataaa 
ataaAGACACCATCAA TT A TTT ACCCTGCCCACATGTACAAATCCTT ATAA TTTCAAAGAT 
GTTTTAATGTCAAT 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
83,834,039 - 83,834,062 
8 
Between KIAA0102 & FLJ22596 
ccagcctgggcaacaagagcttaatccgtctcaaaaaaTAATAATAATAATAGGCCTCTCCAAACCT AG 
GGTTTGTTTTATTGATGGTTATTCACTTCATAGGGGCAAGAGGTACAATAAAA 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
84,425,966 - 84,425,980 
5 
RAB6 
ACCCA TTCCCTCCA TCCCACCACT AGCaaattaataataataataataatttaaataattaaataaaataaaa 
agacaaatcct 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
84,445,679 - 84,445,696 
6 
RAB6 
251 
I' 
I, " 
tttGTTTAaataataataataataataataataataataataataaatgaaataaaaataatagtgtatatctttttt 
aac 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
84,620,594 - 84,620,629 
12 
RAB6 
gggcaacaaaagcgaaaactccatctcaaaaaT AAT AATAAT AATTTT ACCA T ACTGCA T ACTTT AC 
AGTCATATAAAGAACTATAATCCTCTACCCTTAA 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
85,032,972 - 85,032,986 
5 
Between RAB6 & THRSP 
tgggcaacagagagagaccccatttctataaaataataAT AATAATAATCCCT AAA CT AGGA TTT AGAC 
AGCTTCTGAGTTGG 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
85,210,150 - 85,210,167 
6 
Between RA B6 & THRSP 
tgggcaagagcaagactccgtctcaaaataataataataataataataataGCCTT ATAA TT ATGTGTTT AA 
AAACACAGAGTGAAAGAAAATTCCAAAAGGCATTCCCTATCTCTAAAATAAACCAAA 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
85,291 ,221 - 85,291,244 
8 
Between RA B6 & THRSP 
ggcaacagagcgagactccatctcaaaaaataataataataataataataataataataataataataataataataa 
ACAAATAAATACATAAGTAAGGCTGCAGGCTCAATAAACTGAGAA 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
Repeat 
85,364,856 - 85,364,903 
16 
Between RAB6 & THRSP 
(ATT) 
taataataataataataataataataatTATTATTATTATTATTAcctatcatctcggcattctgggaagctga 
gggaagaggatcacctgaggccaagagttcgagaccag 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
72,634,001 - 72,634,018 
6 
Between FLJ23392 & FLJ20556 
CTCATCTTTCAAGACCGAAACAAAAATCTCAGGTGCTCAGGTGCTCTCTTTGACATCACct 
ccagttcatcttctcccattctctctcttttctttattattattattattatttttttaaattttagagatgggtctcac 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
72,642,459 - 72,642,476 
6 
Between FLJ23392 & FLJ20556 
252 
.,, 
�( 
I 
GGGACAAACAGAA TTCAGAAGGTTGattattattattattattatttttgagatggagtcttgctctgtcac 
ccaggctggagtgcaatggcacgatcttg 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
72,769,308 - 72,769,328 
7 
HRLP5 
tataaactgctagttgccatgtattccttttattattattattattattattgttattatttcaatagcttttggggaacag 
gtggtgtttggttacatagataagtcctgtagtgggtgatttctgaga 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
72,845,628 - 72,845,648 
7 
Between HRLP5 & SLC22A8 
T ACTT AAAGattattattattattattattattatcattattttatttttatGctttaagttttagggtacatgtgca 
caatgtgcaggttagttacatatgtatacatgtg 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
72,911,789 - 72,911,812 
8 
Between HRLP5 & SLC22A8 
acttaaaaaataataattaTTATTATTATTTTTAAaaagaaggtcattatgtaattatacagggatccattcagc 
aaggggatataatacttccaaatatatatgca 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
73,194,274 - 73,194,288 
5 
Between HRLP5 & SLC22A8 
T ACTT AAAGattattattattattattattattatcattattttatttttatGctttaagttttaggg 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
73,303,451 - 73,303,474 
8 
Between SLC22A6 & HREV107 
accacacccagctCAtttttattattattattattttgagacgaagtttcactcttatcccccaggctggagtgcaatggt 
gcgatactggctcactgcaacctctgcctcc 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
73,476,694 - 73,476,708 
5 
Between SLC22A6 & HREV107 
ttttctttattattattattattattttttaaattttagagatggggtctcacatgtttcccaggctggccttgaactcttg 
gctcaag 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
73,558,031 - 73,558,048 
6 
HREV107 
tatatataacaTTATTATTAttatttgtttttctcactttttttctttttgaagcagagtccccctttgccgcccagg 
ctggagtgcagtggtgggatcttggctcactgcaacctccacct 
253 
- .L 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
73,668,825 - 73,668,839 
5 
Between HREV107 & MRPL48 
tttctaaataaacattttatatataacaTTATTATTATTAtttgtttttctcacttt 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
73 ,668,825 - 73668,839 
5 
Between HREV107 & MRPL48 
attattattattgttattattattattattttttagaggcaggtcttgcttctttgcccaggctggagtgcagtgtggcaat 
catagctc 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
73,694,328 - 73 ,694,342 
5 
Between HREV107 & MRPL48 
TGCTCAAAAAGTAGCAGCTGtaattattattattattaataCTGCT ACTA TTCCAGAACTGCCTTG 
TATGTC 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
74,018,141 - 74,018,155 
5 
Between MRPL48 & LOC51287 
GA TTCCAACTGGCAatttttgtttttatttttacttatttattattattattattattttatttttgagacagggtct 
cactctgtcactggggctggagggcagtagcgtgatctcagctcactacag 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
74,593,503 - 74,593 ,520 
6 
KIAA0769 
AGCatttaaattattattattattatctttagagacagggtcttgctctgttgcccaggct 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
75,140,272 - 75,140,286 
5 
PME-1 
TCACTT AAGCaaataaaaatattattattattattataGCCT ACTAGG 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
75,172,445 - 75,172,459 
5 
Between PME-1 & FLJ10661 
CAtattattgttattattattattattatttgagacagagtttcactcttgtcacccaggctgg 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
75,515,915 - 75,515,932 
6 
Between FLJ10661 & FLJ11099 
254 
TTTTAattattatcattattattattattatttgagacggagtctcgctctgtcacccaggctggagtgcagtggcgcg 
atctcagc 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
75,751,538 - 75,751,555 
6 
Between FOLR3 & FOLR2 
tatctggtggaagaaatttgtttattattattattattattattattattattattatttttgagatagagtctcactctg 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
75,755,654 - 75,755,689; 76,376,183 - 76,376,218 
12 
Between FOLR3 & FOLR2 
ccactacacctagctaattttttgttattattattattattattatttgggtagagactaggtctcgctatgatgcccaag 
ctggtcgaactcctgggctcaagcagtcctcctgcctcagcctcctaaagtgctgggatta 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
76,090,890 - 76,090,910 
7 
Between S KD3 & PDE2A 
GTT A TGACACT A TttattattattattattattaCTTTTT I I I I TT 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
76,104,755 - 76,104,772 
6 
Between S KD3 & PDE2A 
GCTTCA I I I I I ATT ATT Attattattatactttaagttctggggcacatgtgcagatcgtgcaggtttattacat 
aggtatacatgtgccat 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
76,553,399 - 76,553 ,413; 76,697,516 - 76,697,530 
5 
Between FOLRl & PRCP 
CATTTTCAGGTCAtattattattattattattaATTTTCTTATATTCTTTCTGG 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
76,591,861 - 76,591,878; 76,735,978 - 76,735,995 
6 
Between FOLRl & PRCP 
ttgcaaagttttcagggctttattattattattattattattattattattattattaaataggctttctatgacatctccc 
atctgtaatccttttagcacaatccc 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
76,761,862 - 76,761 ,897 
12 
Between FOLRl & PRCP 
ttacagatgaggaaactgagCCttattattattattattaatattattattaGCTTGCAAA TAAAAATACTGT 
GACTTGAATCCATGTCAGCTTGATAACAAATCTGAATTAA 
255 
ii I 
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Base Numbers: 
Number Repeats: 
Nearest Gene: 
76,766,838 - 76,766,852 
5 
Between F OLRl & PRCP 
TGTGTGTTTttattattattattattattataagttctgggttacatgtgcagaacgtgcaggtttgttacacaggta 
tacacttgcca 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
76,953,222 - 76,953,239 
6 
Between FOLRl & PRCP 
ttttaattattattattattattattattattattattattattttgagacagagtttcgctcttgcccaggctggagtgc 
aatggcgtgc 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
77,326,612 - 77,326,650 
13 
Between F OLRl & PRCP 
tttgcttaaatattttattattattattattattattttgagacagggtctcgctctgttgcccaggctggagtgcagtgg 
tgtc 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
77,757,298 - 77,757,318 
7 
Between PRCP & RA B30 
TGGTCTGattatcattattattattgttattattattattatttgagctggagtctcgctctgtcgcccaggctggagg 
acattggcctaatcttggctcactgccaccttcacctcctgggttcaagcaattcttgtgcttcagcctcc 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
77,851 ,794 - 77,851,808 
5 
Between RA B30 & PCf 11  
TAATTGtattattattattattattattatttttgagaccggatctaactgctggagtgcagtggcacaatcatagc 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
78,862,218 - 78,862,241 
8 
DLG2 
GAA TTT A Tttattttatcatttttattattattattatttgagaccaagtctctgtcaaccaggctgcagtgtagggg 
tgtgatctcggctcactgcaacctcaaccttctgggttcaagtgattctcatgcatcagcctccggag 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
79,060,238 - 79,060,252 
5 
DLG2 
TGA TGTT AGT AAattattattattattattattattactattttgagacaagaccttgttctgtcacccaggatgga 
gtgcagtgt 
Base Numbers: 
Number Repeats: 
79,262,184 - 79,262,207 
8 
256 
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Nearest Gene: DLG2 
TAAGAGTTCACttattattattattattattattattattatGTT AATCAGAAATAA TT AAAAACAG 
TAAATTAGAA 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
79,331,148 - 79,331,174 
9 
DLG2 
ccgggcggcggagcttgcagtgagctgagatcgcgccactgcactccagcctgggcaacaaagcgaggttccgtctcaaa 
a T AA T AA T Aattcttattaataatatattattatatattaataattatatttattaatattttattattatatttattaa 
tatattatattattattattattgttatGGAAGCATGTAACT ATCATGGCCA TTGAAGGTTT A TTTT 
ATTAGGTC 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
79,689,217 - 79,689,231 
5 
DLG2 
cccagcttattattattattatttgttgtagagacagggtctcactatgttgcccacactggttttgaacttctgTTCA 
AAGAACTTTTAAGAG 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
79,822,310 - 79,822,324 
5 
Between DLG2 & HT007 
GTTTTGtactattatttttattattattattattattatactttaagttttagggtacatgtgcacaatgtgctggttag 
ttacatatgtatacatgtgacat 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
80,229,444 - 80,229,461 
6 
Between DLG2 & HT007 
agctcttatgacaacttagtgaggagaaggaattattattattatttcaattttacaaagaaaattgagtcattgagaaat 
cgaatggattgctccaagttgcat cagcagttattggttaagacagCTTG TG T AGA TGTCA T 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
80,230,060 - 80,230,074 
5 
Between DLG2 & HT007 
TCCA TTT AGTTCACAT A TT ATATGGCTTCCATT ATT ATT ATT Atttttttttt 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
80,380,193 - 80,380,207 
5 
Between DLG2 & HT007 
taataataataataatT ATTA TT A TT ATTTTTGCCCTT AGACTGT A TGGGGGCTCTTCCAGGGC 
AGTAA 
Base Numbers: 
Number Repeats: 
80,504,397 - 80,504,411 
5 
257 
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Nearest Gene: Between D KFZp586C1924 & ZF 
gggtgtgggggcaggcgcctataatcccagttactcgggaggctgaggcaggacaatcgcttgaacccaggaggcagagg 
ttgcagtcagccgagaacatgcaactgcactccagcctgggcgacagagcgagattccatctcaaaacaacaacaacaa 
caacaacaacaaaaacCCAgatccacctgccacggcctcccagagtgctgggattacaggtgtgagccaccatgcctgg 
cACAT 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
80,693,536 - 80,693,559 
8 
Between SYTL2 & CL TH 
ATTTAtatcattattattattattattatttgagatggagtcttgctctgtcacccaggctggagtacagtggcatgat 
ctcagctcac 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
80,629,112 - 80,629,132 
7 
SYTL2 
taggtactactatcttttttacaATTATTATTATTATTGATTAATCATCATAATAAATACTTTTC 
ATTTCTACCACAAATGACTATTTCAAAATCAT 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
81 ,444,010 - 81,444,024 
5 
CAPN5 
ccaaactagttattattattattattattattattattattatttctggtagagacagggtctcacA AGAA T CA TTT 
CTttacaaat 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
81 ,519,331 - 81,519,363 
11 
Between CAPN5 & PHCA 
aaatttattatgattattattattatttgagacagagtcttgctctgtcgccaggctggagtgcagtggcgtgatcttggc 
ttactgcgatctccgcc 
Base Numbers: 81 ,569,104 - 81,569,118 
Number Repeats: 5 
Nearest Gene: PHCA 
AA TT ACAGttattattattttattattattattattttgagatggagtctcactctgtctccaggctggagtaca 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
82,017,809 - 82,017,823 
5 
Between GL002 & PRKRIR 
ACTCCCCCATTAAAACAAttattattattattttatttttttatagagatggggtcttgctaccttgaccagtctg 
gtcttgaaccccctggcctcaggagagcttc 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
82,985,014 - 82,985,028 
5 
SERPINH2 
258 
AGCA AA A TGGGAttattattattattattttgagacggagtctcgctcgttgcccagg 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
83,212,431 - 83,212,448 
6 
Between RPS3 & ARRBl 
acccttggctaagtttcttttttattattattattattttttggagagatggggcctcactgtgttgcccaggctggtctc 
aac 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
83,318,873 - 83,3 18,887 
5 
Between ARRBl & SLC21A9 
GGAAATTGCAATTTTCATTATTATTATTATTATTAgagacagggtctcacttatcacacaggcttga 
gtacaggggtgtgattatagctcatt 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
83,401,056 - 83,401,073 
6 
SLC21A9 
ttgaggatttctgcatcaatattcatcagatatattggcctgtattattattattattttatttatttattttattgattttt 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
83,629,311 - 83,629,325 
5 
Between KIAA0102 & FLJ22596 
GGTCAAAGGTttattattattattattattattattattattTTAAATTTTATTTC I I I I I 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
84,290,357 - 84,290,386 
10 
KIAA0337 
ttcaaatttctctacatcctcaacaacccttgttttattattattattattattattatagccatcctat 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
84,321 ,716 - 84,321 ,736 
7 
Between FLJ14993 & PHRETI 
CACCTCTTAAAattataattttattattattattattattTTGgaggcagagtctcactctgtcaccaggctggagt 
gcagtggcacaatctcggctcactgcaacctctgcc 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
84,409,318 - 84,409,335 
6 
Between FLJ14993 & PHRETI 
gttttctccttaagtatattattattattattattattattactattattattatgactcgtggatttaaacatgttttata 
gtaattactgattttcaagtttcctacagtttgaccagtag 
Base Numbers: 
Number Repeats: 
84,601,425 - 84,601,448 
8 
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Nearest Gene: RAB6 
tgcctgactaatttttattattattattatttttagatataggatctcactatgttgcccaggctagtcttgaactcctggc 
ctcaagccatcctcctgccttgacctcccaaagtt 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
84,711,338 - 84,711,352 
5 
Between RAB6 & THRSP 
ttcttcttcttcttcttcttcttcttcttattattattattattattattattagagacagtctcactctgttgcccaggct 
ggagtgcaa 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
85,054,928 - 85,054,951 
8 
CLNSlA 
AATCAGCTGAAACAAACCTCCAAGTT ATT ATT ATT ATT Attttttttt 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
85,305,641 - 85,305,655 
5 
PTD015 
caggctaatttttattttattattattattattatttgagacaagtcttgctctgtcgcccaggctggagtgcagtagtgc 
aatctcagctc 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
Repeat 
85,460,008 - 85,460,025 
6 
Between MGC2376 & PRO2849 
(ACC} 
CAA TT AGAA TTCATGATACCAGTTTCccaccaccaccaccaccaccGTCGCCCTGCCA TTGTT AG 
CAAAACCATCTCTTGAGTGGAG 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
73,959,445 - 73,959,462 
6 
Between HREV107 & MRPL48 
aacaacctaataaatccatctctggcaaagtcacaccaccaccaccaccaccaccacaaactctctcagcctagaccact 
gagatact 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
79,562,544 - 79,562,564 
7 
DLG2 
cattgtcaacaccaccatcactacctttaccatcaccactatcatcactacccacaacactgtcatcaccaccaacaccat 
cactacctccaccatcaccaccaccaccaccatcactaacatcatcCCTACCTCCAAT A TT ACCATAGTCAT 
CA 
Base Numbers: 81,336,257 - 81,336,271 
260 
Number Repeats: 5 
Nearest Gene: Between PA Kl & MYO7A 
cacacagccgtgcgccctcacatacaccacaccaccaccaccaccaccacacacacacacacacacac 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
81,336,257 - 81,336,274 
6 
Between PA Kl & MYO7A 
atagcaaaaactcaatacaaattgaccattTactaccaccaccaccaccaccaccaccaccaccactactacTATTT 
ATGAAG 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
81,683,381 - 81,683,410 
10 
PHCA 
AGCACAGAGCCTGGCACACCACCACCACCACCACAAGGTGCCCGGCGAAAACCAGCCCCTTC 
TTCCTGAATGTGTCAGGCTTCTCCCCTCGAGGGTCGTAACTC 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
83,102 ,606 - 83,102,620 
5 
Between SERPINH2 & PP1665 
AACTTCAAAGACCACAGTGTTGGGAAGGCAACACCACCACCACCACCAACTGGATTCTTG 
ATTCAGTTTCCCACTGGAAAGGCAGATCCAAAAAGAGGTGAGAG 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
83,146,897 - 83,146,911 
5 
Between PP1665 & RPS3 
CGTGcgcacacacgcacaactgcacaaagacgtgcacactcctccatccacaccaatacactccctaatagggcccgca 
cacagccgtgcgccctcacatacaccacaccaccaccaccaccaccacacacacacacacacactctcacacggactcg 
cacgc 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
83,177,504 - 83,177,521 
6 
Between RPS3 & ARRBl 
Tcaccactaccactgtcactgccattaccaccaccaccaccaccgttactgccacctctaccaccaggaccacccctcac 
acttgcagg 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
83,839,223 - 83,839,240 
6 
Between KIAA0102 & FLJ22596 
261 
Repeat (GGT} 
GCGGGTGATCTCCCCCATCCCGCAGCGTGGggtggtggtggtggtggtggAAGCAGCACTAACTGG 
GACCCAGGCGTCCCGAGTGCAGGCCCTGCTCTCTCAATGGAAAGAGCAGCTGTCATCTACC 
A 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
83,214,448 - 83,214,465 
6 
Between RPS3 & ARRBl 
TTTCCAGTGGGAAACTGAATCAAGAATCCAGTTGGTGGTGGTGGTGGTGTTGCCTTCCCA 
ACACTGTGGTCTTTGAAGTTGAGTTGTCTAAACTCTCCAACCT 
Base Numbers: 84,842,518 - 84,842,532 
Number Repeats: 5 
Nearest Gene: Between RAB6 & THRSP 
Repeat (ACG} 
Repeat (CGTI 
Repeat (ACT} 
Repeat (AGTI 
AT AAATAAATATAAGGAAGATAGgtagtagtagtagtagtagaggtagtcttagcagcagcagcagCAA 
GAGTAAAAACATTGGTGTAA I  I I I I I CAACTCTACATGATG 
Base Numbers: 
Number Repeats: 
Nearest Gene: 
79,086,747 - 79,086,761 
5 
DLG2 
As derived from GenBank, BLAST by this author (2002). 
Repeats in bold 
Coding sequence in upper-case 
Non-coding, intronic sequences in lower case 
262 
!I ; 
• I 
�. I 
t! 
ii 
!I-' 
· 11 :  
,:c 
APPENDIX 11 
NCBI Map Viewer 
263 
·.1 .. : ..
. .  
' .  
t 
i '  
!_ 
Homo sapiens Map View BLAST The Human 
Build 34 Version 1 Genome 
Chromosome: 1 2 3 4 5 6 7 8 9 1 0 [ 1 1 J 12 1 3  1 4  1 5  1 6  1 7 1 8  1 9  20 
.il 22 X Y  
Master Map: Genes On Sequence 
Total Genes On Chromosome: 1501 
� IA Region Displayed: 0-134M bp DownloadNiew Sequence/Evidence 
� "i � Genes Labeled: 19 Total Genes in Region: 1501 
F � � � Ideogran Cont.ie HsUniG ftones.soq Symbol Q Cyto 
� � � � U 1"i11.!S • : + KCNOl • l lp15 . 5  
if ;:j � .ij u "1s.4 • _ ....,  i < u ,.u.3 ! 
20 e � ;· •• ZS.. t"a ;i: u,.u.a -cn. IA q 111'16.t • 9: � .:;;, -0 Up1M : -3 � ci , u ,.14.a • : 
t l lp1 5.3 
t l lpl5 .3 
t l lp15 . 1  
Description 
potassium voltage-gated channel, KQT ·like subfamily, member 1 
Cheroot-Marie-Tooth neuropathy 4B2 (autosomal recessive, with myelin outfolding) 
SRY (sex determining region Y)-box 6 
neuron navigator 2 
.[ -� i:::,_· �Q Up14•1 -11,.13 • � _., 1A 3 • t l lpl 5.2-p l 5 . 1  NEL-like 1 (chicken) ::S- 0 -· 11,12 
i i !. � 11,.11.a Q 1.0 1.0 1.0 � � , 11,.1i.1a ('a -+ 11 a u,.11.11 !. ::s- • a 11 <111 _ -+ � � u,u.1 :;s- ...... -0 ,_ -· ::r 11,12.a _,_, � iii. '< u,u.:, "1l ,v IA :C � ;; -· 114113+1 
-· -• C Ii 11"113+2 :::, 3 ., Q -+ t"a t"a ::::s u,1:,.3 
if n  a. a.  :E &. ; �  n. -· g i IA Q. IA -t, _.. a _.. -· 
> � a n C 1,0 -t- �  
i I ! �-= !A :;s- � Q O � 0 :::, :::, -0 ., 
u,u.4 1 1,13.s 11"14+1 -11,14.a 1 1"114+3 1h21 11..u.1 -11,aa.a u .. aa.3 -11,u.1 11<tll3+ll a- n a � 3 :;s- -· � ::.: ci ::t. o· 11 4123.3 ;< 3 g :::, 0 IA -h 
� � � 
� 
114124+1 11 '124•2 11 "124+3 -u,as 
• • 
• 
• 
• 
• 
+ 
Cl lorf25 • l l p14.3 
LOC375992 t l lp12  
• 11q13.5 
t l lq21 
t l lq14.2 
t l l q21 
chromosome 1 1  open reading frame 25 
similar to Trophinin 
tN radiation realatance assodllted gene 
discs, large homo log 2, chapsyn- 1 1 0  (Drosophila) 
glutamate receptor, metabotropic 5 
mastermind,like 2 (Drosophila) 
t l l q21-q22.2 contaotin S 
t l l q22 
GUCY1A2 t l l q21-q22 
t l lq23.2 
DSCAMLl t l l q23 
t l l q24 
t l l q25 
t l l q25 
glutamate receptor, ionotrophio, AMP A 4 
guanylate cyclase 1, soluble, alpha 2 
immunoglobulin superfamily, member 4 
Down syndrome cell adhesion molecule like 1 
NEPH2 
neurotrimin 
opioid binding protein/cell adhesion molecule-like 
3: 
(i' 
)Ii. 
9 m - z � 
t 
.... w w .... 
w 
...... w 
...... 
w 
APPENDIX 12 
Bioinformatics derived from location of Markers 
D11S1881-D11S911 
265 
APPENDIX 12 
Bioinformatics derived from location of Markers D11S1881-D11S911, 
April 2002 Freeze (64,533,373-75,971,382) 
HRASLS3 (64,501,887-64,514, 534) 
HRAS-like suppressor 3, HREV107, HREV107-3, H-REC107-1 
Similar to rat HREV107 
Homologous to mouse chromosome 19 
ESRRA (64,620, 871-64, 628,909) 
Estrogen-related receptor alpha, ERR1, ERRa, ESRL1, NR3B1, 
ERRALPHA, ERRalpha, Estrogen receptor-like 1 
Homologous to mouse chromosome 19 
Gene ontology 
Nucleus 
DNA binding 
Ligand-dependent nuclear receptor 
Pol II transcription 
HSPC152 (64, 628,862-64, 629, 732) 
Gene ontology 
Unknown 
PRDX5 (64, 630, 351-64, 976,461) 
Peroxiredoxin 5, ACR1, B166, PRXV, PMP20, AEOB166, Antioxidant 
enzyme B166 
Homologous to mouse chromosome 18 
Gene references into function 
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Crystal structure at 1.5 angstrom resolution 
Glutaredoxin-dependent peroxiredocin from poplar: protein-protein 
interaction and catalytic mechanism 
Gene ontology 
Peroxisome 
Respiration 
Mitochondrion 
Electron transporter 
Inflammatory response 
Oxidative stress response 
Cell stress 
Oxidoreductase 
Anti-pathogen response 
PLCB3 (64, 631, 222-64,637, 236) 
Homologous to mouse chromosome 19 
Gene ontology 
Phospholipase C 
Tumor suppressor 
BAD (64,639 ,514-64,665,041) 
BCL2-antagonist of cell death, BCL2L8, BCL20-binding protein, BCL2-
binding component 6, BCL-X/BCL-2 binding protein 
Gene references into function 
Expression in normal, hyperplastic and carcinomatous human prostate 
Direct interaction with Bad with pro-survival members of the Bcl-2 
family 
Contributes to the progress of Sindbis virus-induced apoptosis 
267 
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Protein kinase A Rialpha antisense inhibition of PC3M prostate cancer 
cel l growth 
Bcl-2 hyperphosphorylation 
Bax up-regulation 
Bad-hypophosphorylation 
Gene ontology 
Apoptotic program 
LOC 56834 (64,665, 908-64, 667,812) 
Homologous to mouse chromosome 19 
Gene ontology 
Unknown 
KCNK4 (64, 671, 207-64,679 ,037) 
TRAAK, DKFZP566E164, Two pore K+ channel, 2P domain potassium 
channel, tandem pore domain potassium channel TRAAK, potassium 
inward ly-rectifying channel subfami ly K member 4, TWIK-related 
arachidonic acid-stimulated potassium channel protein 
Homologous to mouse chromosome 19 
Gene ontology 
Potassium channel 
Potassium transport 
Channel (passive transporter) 
LRP16 (64, 695, 195-64,865, n4) 
Homologous to mouse chromosome 19 
Gene ontology 
Unknown 
268 
FLRT1 (64, 742, 227-64, 744, 902) 
Expressed in kidney and brain 
STIP1 (64, 757, 292-64, 769, 066) 
HOP, P60, STI1L, IEF-SSP-3521 
Transformation-sensitive, simi lar to Saccharomyces cerevisiae STI1 
Homologous to mouse chromosome 19 
Gene onto logy 
Nucleus 
Stress response 
Golgi apparatus 
HSPF2 (64, n0,494-64, nl , 922) 
MCG18, DANJC4, DNAJC4-PENDING, Heat shock 40kD protein 2 
Homologous to mouse chromosome 19 
Gene ontology 
Membrane fraction 
Heat shock protein 
Unspecified membrane 
MGC13045 (64, n3 , 3 17-64,7n,043) 
Homologous to mouse chromosome 19 
Gene ontology 
Unknown 
MGC11134 (64,7n, 182-64,n9, 533) 
Gene ontology 
Unknown 
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COX8 (64,790,817-64,792,719) 
COX VIII 
Homologous to mouse chromosome 19 
Gene ontology 
Mitochondrion 
Energy pathways 
Cytochrome-c oxidase 
General cellular role 
FLJl 3848 (64, 810, 383-64, 849,174) 
Gene ontology 
Unknown 
FLJ20113 (64,865, 917-64, 875,998) 
Homologous to mouse chromosome 19 
Gene ontology 
Unknown 
HRLP5 (63, 675,029-63,702,058) 
Gene ontology 
Unknown 
LAGALS12 (64, 906, 969-64,917, 653) 
GALECTIN-12, Galactin-12 
Homologous to mouse chromosome 19 
RARRES3 (64,937, 694-64, 947, 344) 
RIG1, TIG3 
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Gene ontology 
Tumor suppressor 
Negative control of cell proliferation 
HRASLS2 (64, 953 ,656-64, 964, 268) 
FLJ20556 
Gene ontology 
Unknown 
DKFZp434G0920 (65, 008369-65,012, 188) 
Gene ontology 
Unknown 
RPS6KA4 (65, 013,825-65, 026, 869) 
MSK2, RSKB, RSK-B 
Ribosomal protein kinase B; mitogen- & stress-activated protein kinase 2 
Homologous to mouse chromosome 19 
Gene ontology 
Nucleus 
Protein kinase 
Protein kinase cascade 
Transferase 
SLC22A11 (65, 210, 571-65, 226, 150) 
HOAT4 
Gene ontology 
Small molecule transport 
Integral plasma membrane protein 
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Sodium-independent organic anion transporter 
Active transporter, secondary 
Major facilitator superfamily 
NRXN2 (65, 260,795-65, 368,621) 
Neurexin 2, KIAA0921, Neurexin II 
Homologous to mouse chromosome 19 
RASGRP2 (65,381, 710-65,400, 252) 
CDC25L, CALDAG-GEFI, Calcium and diacylglycerol-regulated guanine, 
Nucleotide exchange factor I 
Homologous to mouse chromosome 19 
Gene ontology 
Lipid binding 
Calcium binding 
Signal transduction 
Guanyl-nucleotide exchange factor 
Activator 
Inhibitor/repressor 
PYGM (65,401, 354-65,415, 587) 
Phosphorylase, glycogen, muscle 
Homologous to mouse chromosome 19 
Phenotype 
McArdle disease 
Gene references into function 
McArdle disease may be caused by R269X nonsense mutation in this gene 
Gene ontology 
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Glycogen metabolism 
Glycogen phosphoylase 
Muscle action 
Energy storage 
Transferase 
SF1 (65,419,478-65,433, 636) 
Splicing factor 1, ZFMl, ZNF162, D11S636, Zinc finger protein 162 
Homologous to mouse chromosome 19 
Gene references into function 
The KH-QUA2 region of SFl defines an enlarged KH (hn RNP K) fold 
which is necessary and sufficient for intron branched point sequence 
(BPS) binding 
Gene ontology 
Nucleus 
Transcription co-repressor 
RNA polymerase II transcription factor 
RNA splicing 
Inhibitor/repressor 
MAP4K2 (65,444,013- 65,458,059) 
GCK, BL44, RAB8IP, Rab8 interacting protein (GC kinase) 
Homologous to mouse chromosome 19 
Gene ontology 
JNK cascade 
Golgi membrane 
Immune response 
Stress response 
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Soluble fraction 
Hemocyte development 
Protein serine/threonine kinase 
Peripheral plasma membrane protein 
Differentiation 
Transferase 
MENl (65,458, 396-65,465, 594) 
Multiple endocrine neoplasia I, MEAL, SCG2, Menin, Wermer syndrome 
Endocrine adenomatosis, multiple 
Zol l inger-El l ison syndrome, included 
Homologous to mouse chromosome 19 
Phenotype 
Adrenal adenoma, sporadic 
Angiofibroma, sporadic 
Carcinoid tumor of lung 
Hyperparathyroidism, AD 
Lipoma, sporadic 
Multiple endocrine neoplasia I 
Parathyroid adenoma, sporadic 
Prolactinoma, hyperparathyroidism, carcinoid syndrome 
Gene references into function 
Multiple endocrine neoplasia type 1Burin from Mauritius: a novel MEN1 
mutation 
Loss of heterozygosity of the MEN1 gene in  a large series of TSH­
secreting pituitary adenomas 
Gene ontology 
Nucleus 
274 
Protein binding 
Tumor suppressor 
Transcription regulation 
Repression of transcription from Pol II promoter 
Inhibitor/repressor 
EHD1 (65, 507,603-65,533, 576) 
PAST, HPAST, H-PAST 
Testilin 
EH domain containing 1 
Homolog of drosophila past 
Homologous to mouse chromosome 19 
PPP2R58( 65, 579, 835-65, 589, 340) 
Protein phosphatase 2, regulatory subunit B 
Gene Ontology 
Cytoplasm 
Protein phosphatase type 2A regulator 
CNS- specific functions 
Regulatory subunit 
GPHA2 (65, 589,640-65, 590, 327) 
Glycoprotein alpha 2 
Cysteine knot protein 
Gene References into Function 
Capable of mediating the actin of relaxin through an adenosine 3' ,5'­
monophosphate ( cAMP)-dependant pathway 
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NAALADASEL (65, 642, 795-65, 955, 527) 
I100 
CAPN1(65, 668, 883-65, 699 , 003) 
CANP, muCL, CANPL1, muCANP, Calpain, large polypeptide Ll, Calcium­
activated neutral proteinase 
Homologous to mouse chromosome 19 
Gene References into Function 
Calpain (mu-calpain) is a signal transducer and activator of transcription 
(STAT) 3 and STAT5 protease 
Gene Ontology 
Positive control of cell proliferation 
MRPL49 (65, 761, 870-65, 766, 888) 
Mitochondrial ribosomal protein L49 
Gene Ontology 
Unknown 
FAU(65, 767, 036-65, 768, 592) 
FAU1, RPS30, 405 ribosomal protein 530, ubiquitin-like protein fubi, 
ubiquitin-like-530 fusion protein, F AU- encoded ubiquitin-like protein, 
FBR-MuSV-associated ubiquitously expressed gene 
Homologous to mouse chromosome 19 
Gene Ontology 
Ribosome 
Cytoplasm 
Ubiquitin 
RNA binding 
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Protein biosynthesis 
Structural protein of ribosome 
Protein conjugation factor 
C11orf5 (65, 711, 524-65, 772, 819) 
FON, Chromosome 11 open reading frame 5 
Homologous to mouse chromosome 19 
Gene Ontology 
Unknown 
TM7SF2 (65, 772, 992-65, 777, 320) 
ANG1 
Homologous to mouse chromosome 19 
Gene Ontology 
Endoplasmic reticulum 
Integral plasma membrane protein 
C11orf2(65, 777, 514-65, 793, 011) 
ANG2, Chromosome 11  open reading frame2 
Homologous to mouse chromosome 19 
Gene Ontology 
Unknown 
ZFPL1 (95, 800, 822-65, 804, 985) 
MCG4, D11S750, Zinc finger protein-like 1, Zinc-finger protein in MEN1 
region 
Homologous to mouse chromosome 19 
277 
MGC16386 (65, 805, 170-65,811, 765) 
Homologous to mouse chromosome 2 
Gene Ontology 
Unknown 
MGC10966 (64, n9 ,446-64, 784, 078) 
Gene Ontology 
Unknown 
HSU79266 (65, 955, 935-65, 959, 794) 
Homologous to mouse chromosome 19 
Gene Ontology 
Unknown 
SNX15 (65, 960, 192-65, 973, 274) 
Sorting nexin 15, HSAFOO1435, Clone iota unknown protein 
ARL2 (65, 978, 586-65, 986, 574) 
ARLF2, ADP ribosylation factor-like 2 
Homologous to mouse chromosome 19 
Gene References into Function 
C. elegans evl-20 gene encodes a functional homo log of human ARL2. 
Elimination of evl-20 function results in abnormal vulval, gonad, and male 
tail development and disrupts embryonic proliferation, hypodermal 
enclosure and elongation 
Gene Ontology 
GTP binding 
Tubulin folding 
278 
GTPase inhibitor 
Hydro lase 
Inhibitor /Repressor 
GTP-binding protein/GTPase 
LOC116071 (66,010,517-66,012 , 826) 
Gene Ontology 
Unknown 
EMKl (66, 311,572-66, 332 , 557) 
MARK2 ELKL motif kinase 1, ELK motif kinase 1 
Homologous to mouse chromosome 19 
Gene Ontology 
Protein phosphorylation 
Microtubule cytoskeleton 
Protein serine/threonine kinase 
Cell polarity 
Transferase 
Cytosketal 
Tubulin-cytoskeleton associated 
POLA2 (66,448 ,552-66,484, 208) 
Homologous to mouse chromosome 19 
CEP2 (66, 501,451-66, 509,016) 
BORG! 
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REQ (66, 520,465-66, 539 , 575) 
UBID4, MGC10180, Ubi-d4 
Apoptosis response zinc finger protein 
Homologous to mouse chromosome 19 
Gene Ontology 
Induction of apoptosis by extracellular signals 
FKSG44 (66, 573, 293-66, 598, 258) 
Gene Ontology 
Unknown 
SPRY4 (66, 627, 002-66, 629 ,637) 
Gene Ontology 
Known/Inf erred 
NTKL (66, 711, 704-66, 725, 296) 
GKLP, NKTL, P105, TAPK, TRAP, HT019, N-terminal kinase-like protein, 
Teratoma-associated tyrosine kinase, Telomerase regulation-associated 
protein, HT019 protein; telomerase regulation-association protein 
Likely ortholog of mouse N-terminal kinase-like protein 
Hypothetical gene supported by AB047077; AB051427; AB051428; 
AF297709; BC009967; NM_020680 
Homologous to mouse chromosome 19 
LTBP3 (66, 725, 395- 66, 734, 641) 
L TBP2, DKFZP586M2123 
Homologous to mouse chromosome 19 
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SF3B2 (66, 793,585-66, 810,082) 
SF3B, SAP145, SF3B145 
Spliceosome associated protein 145, SF3b subunit 
Homologous to mouse chromosome 3 
Gene ontology 
Spliceosome 
mRNA splicing 
mRNA processing 
pre-mRNA splicing factor 
nuclear 
RNA-binding protein 
GSTP1 (67,064, 303-67,067, 136) 
PO, DFN7, GST3, FAEES3 
Deafness, X-linked 
Fatty acid ethyl ester synthase III 
Homologous to mouse chromosome 19 
Gene references into function 
Expression in nasopharyngeal carcinoma 
GSTP1 gene encodes the pi class glutathione S-transferase 
Genetic determinants of lung cancer short-term survival 
Gene expression level of beta-TUB, Bel-XL and GSTpi was closely related 
with the IC50 for docetaxel 
Data suggest that GST-pi expression in tumor cells are related to drug 
resistance in epithelial ovarian cancer 
Expression in malignant tissue and plasma levels in the human colorectal 
and gastric tumors increased depending on tumor stage 
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Glutathione s.:.transferase Pl and NADPH quinone exidoreductase 
polymorphisms are associated with aberrant promoter methylation of P16 
(INK4a) and 0(6 )-methylguanin-DNA methytransferase in sputum 
The GSTPl gene encodes for an enzyme, glutathione S-transferase pi 
(GSTpi), involved in detocification of carcinogens. An amino-acid 
substitution (I105)V in GSTP 1 produces a variant enzyme with lower 
activity and less capability of effective detoxification 
Gene ontology 
CNS development 
Transferase 
CNS-specific functions 
NDUFV1 (67, 087,479-67, 092, 932) 
UQORl 
Homologous to mouse chromosomes 16 and 14 
Phenotype 
Alexander disease 
Leigh syndrome 
Gene ontology 
Energy pathways 
Membrane fraction 
Mitochondrial inner membrane 
NADH dehydrogenase (ubiquinone) 
General cellular role 
MGC97 40 ( 6 7, 109, 306-6 7, 117,431) 
HCBPl, MGC9740, HCV core-binding protein 
Homologous to mouse chromosome 19 
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CABP2 (67, 195,637-67, 200, 084) 
CaBP2, Calcium binding protein 
Homologous to mouse chromosome 19 
Gene ontology 
Calcium binding 
Signal transduction 
CNS-specific function 
Small molecule-binding protein 
DOC- l R  (67, 210,401-67, 212, 535) 
Homologous to mouse chromosome 19 
Gene ontology 
Tumor suppressor 
PITPNM (67, 223,447-67, 238, 839) 
NIR2, DRES9 
Drosophila retinal degenerationB 
PYK2 N-terminal domain-interacting receptor 2 
Homologous to mouse chromosome 19 
Gene ontology 
Brain development 
Lipid metabolism 
Phototransduction 
Membrane fraction 
Phosphatidylinositol transporter 
AIP (67, 239, 504-67, 243, 610) 
ARA9, XAP2, FKBP37 
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HBV-X associated protein 
Aryl hydrocarbon receptor interacting protein 
Homologous to mouse chromosome 19 
Gene references into function 
Two distince regions of the immunophilin-like protein XAP2 regulated 
dioxin receptor function and interaction with hsp90 
Gene ontology 
Cytoplasm 
Signal transduction 
Transcription co-activator 
Transcription factor binding 
Activator 
Pol II transcription 
Inhibitor/repressor 
ALDH382 (67, 256, 288-67, 267, 245) 
ALDH8, ALDH3B2-PENDING, Aldehyde dehydrogenase 8 
Gene ontology 
Lipid metabolism 
Alcohol metabolism 
Aldehyde dehydrogenase 
UNC9381 (67, 518, 981-67, 531,960) 
Unc93, UNC93B, Unc-93 related protein, Unc93 (C.elegans) homolog B 
Homologous to mouse chromosome 19 
Gene ontology 
Exact function not known 
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ALDH3B1 (67, 538, 223, -67, 557, 147) 
ADLH4, ALDH7, ALDH3B1-PENDING, Aldehyde dehydrogenase 7 
Homologous to mouse chromosome 19 
Gene ontology 
Lipid metabolism 
Alcohol metabolism 
Aldehyde dehydrogenase 
NDUFS8 (67, 558, 515-67, 564, 520) 
NADH dehydrogenase (ubiquinon) Fe-5 protein 8 (23kD) 
NA DH-coenzyme Q 
Phenotype 
Leigh syndrome 
Gene ontology 
Membrane fraction 
Complex I (NADH to ubiquinone) 
NADH dehydrogenase (ubiquinone) 
Iron-sulfur electron transfer carrier 
Energy generation 
Oxi doreductase 
TCIRG1 (67, 566,889-67, 578,n2) 
A3, Stvl, Vphl, ATP6I, OC116, OPTB1, TIRC7, ATP6N1C, ATP6N1D, OC-
116kDa, T-cell, immune regulator, V-ATPase 116-kDa isoform a3, ATPase 
H+ transporting 1 16kD 
Infantile malignant osteopetrosis 
T cell immune response cDNA 7 protein 
Osteoclastic proton pump 116 kDa subunit 
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Vacuolar proton translocating ATPase 116kDa 
Homologous to mouse chromosome 19 
Phenotype 
Osteopetrosis 
Gene ontology 
Transporter 
Plasma membrane 
Proton transport 
Cellular defence response 
Integral plasma membrane protein 
Positive control of cell proliferation 
Anti-pathogen response 
CHK (67,580, 852-67,609 ,331) 
Choline kinase, CK1 
Homologous to mouse chromosome 19 
Gene references into function 
Activity regulated by Ras proteins through Ral-GDS and PI-3 kinase; has 
role in malignant transformation 
Gene ontology 
Choline kinase 
Lipid transport 
Lipid metabolism 
Signal transduction 
FLJ20039 (67, 685, 737-67,687, 668) 
Hypothetical protein FLJ20039 
Gene ontology 
286 
Unknown 
CGI-85 (67, 694, 363-67,741, 898) 
CGI-85 protein 
Gene ontology 
Unknown 
C11orf24 (67, 789,962-67, 800, 576) 
DM4E3 
Homologous to mouse chromosome 19 
Gene ontology 
Unknown 
LRP5 (67, 841,286-67, 995, 925) 
HBM, LR3, LRP7, OPPG, BMND1 
Low density lipoprotein receptor-related protein 7 
Homologous to mouse chromosome 19 
Phenotype 
Bone mineral density variability 1 
Osteoporosis-pseudogl ioma syndrome 
Gene references into function 
Seven novel sequence variants/polymorphisms 
Mutation results in an autosomal dominant high-bone-mass trait 
LRP5V171 mutation causes high bone density by impairing the action of a 
normal antagonist of the Wnt pathway and thus increasing Wnt signalling 
Gene ontology 
LDL receptor 
Lipid metabolism 
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Signal transduction 
Integral membrane protein 
Positive control of cell proliferation 
Protein translocation 
Intercellular transport 
C11orf23 (68,038,431-68, 153, 845) 
SAPL, FLJ11058 
Sporulation-induced transcript 3-associated protein 
Homologous to mouse chromosome 19 
Gene ontology 
Unknown 
LOC51083 (68, 229 ,061-68, 229, 782) 
Galanin-related peptide 
MTL5 (68, 246,060-68, 289,040) 
M TL T, TESMIN, tesmin 
Homologous to mouse chromosome 19 
Gene ontology 
Anti-apoptosis 
Spermatogenesis 
Heavy metal binding 
Metal ion homeostasis 
Oxidative stress response 
Small molecule-binding protein 
CPTlA (68, 296, 227-68, 356, 254) 
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CPT1, CPT1-L, L-CPT1 
Homologous to mouse chromosome 19 
Phenotype 
CPT deficiency, hepatic, type I 
Gene ref er enc es into function 
Human CPT1A, CPT1B, CPT2, CROT and CRAT are knownto encode 
activate carnitine acyltransferases 
Gene ontology 
Mitochondrion 
Fatty-acid beta-oxidation 
Carniti ne O-pal mityltransf erase 
Energy generation 
Energy storage 
IGHMBP2 (68 , 381, 164-68,478, 692) 
HCSA, CATF1, SMARD1, SMUBP2 
Homologous to mouse chromosome 19 
Gene ontology 
DNA repair 
DNA helicase 
DNA replication 
DNA recombination 
Single-strand DNA binding 
CCND1 (69 , 061,641-69 , 075, 010) 
BCL1, PRAD1, U2 1B3 1, D115287E 
B-cell CLL/lymphoma 1 
Gl/5-specific cyclin Dl 
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Homologous to mouse chromosome 7 
Phenotype 
Centrocytic lymphoma 
Leukemia/lymphoma, B-cell, 1 
Multiple myeloma 
Parathyroid adenomatosis 1 
Gene references into function 
Expression is related to apoptosis in thymus 
Cyclin Dl play important roles in oesophageal carcinogenesis 
A/G polymorphism of CCND1 was associated with the susceptibility to 
NPC 
Endostatin causes Gl  arrest of endothelial cells through inhibition of 
cyclin Dl  
TGF-beta and PTHrP control chondrocyte proliferation by activating 
cyclin Dl  expression 
Analysis of expression improves differentiation of mantle cells from 
other lymphoma eel Is 
Cyclopentenone causes cell cycle arrest and represses cyclin Dl  
promoter activity in  MCF-7 breast cancer cells 
Over-expression of cyclin Dl  is found to be significantly correlated with 
increased chromosomal instability in patients with breast cancer 
Activation of cyclin Dl and D2 promoters by human T-cell leukemia virus 
type I tax protein is associated with IL-2 independent growth of T-cells 
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FGF19 (69, l i 8 ,n4-67, 124,874) 
Gene references into function 
FGF19 transgenic mice had a significant and specific reduction in fat 
mass that resulted from an increase in energy expenditure. FGF19 
transgenic mice did not become obese or diabetic on a high fat diet 
Gene ontology 
Neurogenesis 
Neuronal development 
Embryonic expression 
FGF4 (69, 193 , 565-69, 195, 939) 
HST, KFGF, HST-1, HSTF 1, K-FGF, HBGF-4 
Oncogene HST 
Kaposi sarcoma oncogene 
Transforming protein KS3 
Heparin secretory transforming protein 1 
Human stomach cancer, transforming factor from FGF-related oncogene 
Gene references into function 
Activation of human HST-1 gene in transgenic mice induces 
spermatogenesis and prevents Adriamycin-induced toxicity 
Gene ontology 
Oncogenes is 
Extracellular 
Growth factor 
Signal transduction 
Cell-cell signalling 
Positive control of cell proliferation 
Embryonic expression 
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FGF3 (69,230,492-69, 231, 225) 
INT2, HBGF-3 
INT-2 proto-oncogene protein precursor 
Murine mammary tumor virus integration site 2, mouse, included 
V-INT2 murine mammary tumor virus integration site oncogene homolog 
Homologous to mouse chromosome 7 
Gene ontology 
Oncogenesis 
Extracellular 
Growth factor 
Signal transduction 
Cell-cell signalling 
Histogenesis and organogenesis 
Embryogenesis and morphogenesis 
Embryonic expression 
FLJ10261 (69,420, 615-69,4n,950) 
Gene ontology 
Unknown 
FADD (69,492,036-69,496,058) 
MORT1 
Fas-associating protein with death domain 
Homologous to mouse chromosome 7 
Gene references into function 
Apoptosis and NF-kappa B: the FADD connection 
Binding of FADD and caspase-8 to mo/luscum contagiosum virus MC159 v­
FLIP is not sufficient for its anti-apoptotic function 
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Significant decrease in the percentage of FADD-immunoreactive 
dopaminergic (DA) neurons in the substantia nigra pars compacta of 
patients with Parkinson's disease 
Gene ontology 
Cytoplasm 
Oncogenesis 
Antimicrobial humoral response 
Death receptor associated factor 
Cell surface receptor linked signal transduction 
Induction of apoptosis via death domain receptors 
Anti-pathogen response 
PPFIA1 (69, 559 ,414-69 ,672, 161) 
LIP.1 
Homologous to mouse chromosome 7 
Gene references into function 
Physical and functional interactions between tyrosine phosphatase alpha, 
PI 3-kinase and PKCdelta 
Gene ontology 
Cytoplasm 
Cell adhesion 
Focal adhesion 
Signal transduction 
Cell-cell matrix adhesion 
Cell shape and cell size control 
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EMS1 (69 ,687, 248-69, 725, 279) 
Cttn, oncogene EMS1 
Homologous to mouse chromosome 13 
Gene references into function 
Substrate for caspase cleavage during apoptosis 
Primary arrest of circulating platelets of collagen phosphorylation of 
Syk, cortactin and focal adhesion kinase 
Gene ontology 
Cytoskeleton 
Soluble fraction 
Peripheral plasma membrane protein 
Acti n-cytoskeleton associated 
Cytoplasmic 
SHANK2 (69,756,543-67, 950, 362) 
SHANK, CORTBP1, ProSAPl, SPANK-3, KIAA1022 
Cortactin binding protein 1 
GKAP/SAPAP interacting protein 
Cortactin SH3 domain-binding protein 
Gene ontology 
Expressed in developing and adult brain 
FLJ10661 (70, 372, 551-70, 386, 250) 
Homology to chromosome 8 (2278350-2290754) 
Gene ontology 
Unknown 
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FLJl 1099 (70, 575,611-70, 582,609) 
Gene ontology 
Unknown 
IL18BP (70, 584, 0n-70, 588, 767) 
Gene References into Function 
Transcriptional activation & release of IL-18 binding protein in response 
to IFN-gamma 
Gene ontology 
Immune Response 
Soluble fraction 
Signal transduction 
NUMA 1 (70, 587,887 -70,665, 529) 
NUMA 
Phenotype 
Leukaemia, acute promueliocytic, NUMA/RARA type 
Gene ontology 
Spindle 
Nucleus 
Oncogenesis 
Mitotic anaphase 
Structural protein 
Spindle microtubule 
Nuclear organisation & biogenesis 
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FLJ20625 (70, 682, 310-70, 688, 287) 
Gene ontology 
Unknown 
DKFZP564M082 (70, 694, 600-70, 697,791) 
FOLR 
Phenotype 
Congenital abnormalities 
Gene Ontology 
Folate binding 
Membrane fraction 
Receptor Mediated endocytosis 
Tumor antigen 
Integral plasma membrane protein 
Folate transport 
Peripheral Membrane 
GPI-anchored membrane-bound receptor 
FOLR3 (70,720, 736 -70, 724,899) 
FR-G, FR-gamma, gamma-HFR 
Gene ontology 
Folate binding 
Folate transport 
Membrane binding 
GPI-anchored membrane-bound receptor 
Small molecule-binding protein 
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FOLR1 (70,774,567-70,781, 306) 
FOLR 
Gene ontology 
Folate binding 
Tumor antigen 
Folate transport 
Membrane fraction 
Receptor mediated endocytosis 
Integral plasma membrane protein 
GPI-anchored membrane-bound receptor 
FOLR2 (70,801,808-70, 806,954) 
FR-P3, FR-beta, FBP/PL-1, beta hFR 
Gene ontology 
Folate binding 
Folate transport 
Membrane fraction 
Unspecified membrane 
Post-translational membrane targeting 
Small molecule-binding protein 
INNPL1 (70,809, 790-70, 824, 114) 
SHIP2 
Gene ontology 
Phosphate metabolism 
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SKD3 (70, 877,434-71,019,o33) 
Gene ontology 
Known / inferred 
SDCCA628 (71, 167,031-71, 167,400) 
CGI-52 , NY-C0-28, Similar to phosphatidtcholine transfer protein 2 
Gene ontology 
Tumor antigen 
KIAA0769 (71, 210,90o-71,o16,193) 
Gene ontology 
Unknown 
P2RY6 (71,613, 248-71,610, 381) 
Pyrimidinergic receptor P2Y, G-protein coupled, 6 
P2Y6 
Gene references into function 
Expression profile in human peripheral tissues and brain regions using 
PCR 
Gene ontology 
G-protein signalling, linked to IP3 second messenger (phopholipase C 
activating) 
G-protein coupled receptor 
G-protein coupled receptor protein signalling pathway 
G-protein linked receptor 
G-protein linked receptor protein signal ling pathway 
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Integral plasma membrane protein 
Integral plasma membrane protein 
KIAA0337 (71 ,626, 609-71 , 685, 818) 
Gene ontology 
Unknown 
TNFRSF19L (71 , 693, 096-71,  71 3, 375) 
RELT, FLJ14993 
Gene ontology 
Unknown 
PHRETl (71 , 962,91 1 -71 ,9n, 586) 
KPL1, PHR1 
Gene ontology 
Phototransduction 
Integral plasma membrane protein 
Membrane fraction 
Signal transduction 
PME- 1 (72, 140, 165-72, 223,544) 
Gene ontology 
Protein demethylation 
Protein phosphatase inhibitor 
Hydro lase 
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DKFZP586N2124 (72,930, 425-72,  944, 986) 
Gene ontology 
Unknown 
FLJ22596 (72,932, 227-72,933,652) 
Gene ontology 
Unknown 
KIAA0102 (73 ,182 ,947-73 , 211, 393) 
Gene ontology 
Unknown 
NEU3 (73 , 221,793 -73 , 241, 353) 
SIAL3, neuraminidase 3 (membrane sialidase), neuraminidase 3 
(ganglioside sialidase) 
Gene ontology 
Enzyme 
Ganglioside 
Integral plasma membrane protein 
Hydro lase 
SLX21A9 (73 , 384,n5-73 ,439,911) 
OATPB, OATP-B, KIAA0880 
ARRBl (73 ,499,7n-73,521,035) 
ARRl 
Gene ontology 
Cytoplasm 
300 
Plasma membrane 
Soluble fraction 
Enzyme inhibitor 
Signal transduction 
Heterotrimeric G-protein complex 
Peripheral plasma membrane protein 
Inhibitor/repressor 
Protein translocation 
Complete assembly protein 
RPS3 (73 ,633, 188-73,639 , 347) 
405 Ribosomal protein S3 
Gene ontology 
Oncogenes is 
RNA binding 
Protein biosynthesis 
Structural protein of ribosome 
Cystol ic small ribosomal (40S) subunit 
PPl 665 (73 ,668, 299-73, 675, 453) 
Gene ontology 
Unknown 
SERPINH2 (73,795, 926-73, 806,445) 
CBP2, HSP47, col l igin-2, col lagen-binding protein 2 (co l lagen 2) 
Gene ontology 
Col lagen binding 
Heat shock protein 
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Endoplasmic reticulum 
FLJ22644 (73, 951 ,475-73, 962, 985) 
Gene ontology 
Unknown 
DGAT (74,021 , n8-74,035, 187) 
GS1999 full 
Gene ontology 
Expressed in liver, white adipose tissue (PMID 1 1481335) 
UVRAG (74,047,885-74, 376,860) 
Gene ontology 
Cytoplasm 
DNA repair 
Embryonic expression 
Axial asymmetry 
WNT1 1 (74,419,980-74,440, 184) 
HWNT11  
Gene ontology 
Embryogenesis and morphogenesis 
Signal transduction 
Cell-cell signalling 
Embryonic and foetal expression 
Expressed during development 
Embryonic expression of WNT14B in mice 
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PRKRIR (74,583, 614-74, 614,490) 
Inhibitor of protein kinase PKR 
Gene ontology 
Stress response 
Protein binding 
Signal transduction 
Translational regulation 
Negative control of cell proliferation 
Embryonic expression 
C11ORF30 (74,680, 593-74, 783, 885) 
GL002, EMSY protein, EMSY 
Gene ontology 
Unknown 
GARP (74, 891, 183-74, 903,592) 
D11S833E, garpin 
Gene ontology 
Integral plasma membrane protein 
Associated with UVRAG 
E2IG4 (75. 029. 256-75. 031, 796) 
DKFZP586E011, DKFZP586011 Protein 
Gene ontology 
Unknown 
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PHCA (75, 094, 572-75, 256, 521) 
APHC, FLIJ11238 
Alkaline phytoceramidase 
CAPN5 (75, 300, 663-75, 357,854) 
HTRA3, nCL-3 
Gene ontology 
Calpain 
Protease (other than proteasomal) 
Hydro lase 
Signal transduction 
Embryonic expression 
OMP (75, 336,495-75, 336, 986) 
Olfactory marker protein 
Gene ontology 
Olfaction 
Cytoplasm 
Signal transduction 
Synaptic transmission 
Chemosensation and response 
Foetal expression in rats 
Expressed during development in humas 
Foetal and embryonic expression in humans 
MYO7A (75, 361, 919-75,448, 892) 
DFNB2, NSRD2, VSHlB, DFNA 11, Myosin VIIA 
Deafness, autosomal dominant 11 
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Deafness, autosomal recessive 2 
Gene ontology 
Vision 
Hearing 
Myosin ATPase 
Cel I structure 
Hydro lase 
Motor protein 
Cytoskeletal 
Contains an internal repeat 
PAK1 (75, 556, 638-75, 707, 585) 
PAKalpha, P21/Cdc42/Rac1-activated kinase 1 (years Ste20-related) 
Gene ontology 
JNK cascade 
Protein kinase 
Protein phosphorylation 
Transferase 
Embryonic expression in mice 
HBXAP (75,849,807 -75,871,455) 
XAP8 
HBV pX associated protein-8 
Hepatitus B virus-associated protein 
ARIX (75, 883,451-75,887, 841) 
Gene ontology 
Regulate gene expression, morphogenesis & differentiation 
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Transciption factor 
Neurotansmitter synthesis & storage 
Transciption from Pol II promoter 
Neuronal development & Transmission 
DNA bind ing protein 
DNA associated (indirect/direct) 
Left-right asymmetry determination 
Associated with craniofacial abnormalities 
CLNSlA (75,889 ,882-75, 937,186 
CLC1, ICLN, ICLn, CLNS1B 
Gene ontology 
Vision 
Circulation 
Plasma membrane 
Small molecule transport 
Auxi l iary transport protein 
Photoreception 
Integral membrane 
Simi lar properties to UVRAG 
Al l  information obtained on each gene is adapted from LocusLink (NCBI website) - April 
2001 
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APPENDIX 13 
Patient Consent form for DNA banking and/or analysis 
(Printed on Ed ith Cowan University Letterhead) 
I, .. . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ... . . . . . . . . . .. . 
of . . . . . . . . . . . . . . . . . . .. . . . . .. . . . . . . . . . . . . . . . . . . . ... . . . . . . . . . . . . . . . .. . .. . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . .  . 
hereby consent to ... ... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . .. . . . . ... ... . . . . . . . . . . . . . . . . . . . . . . .  . 
being sampled from me/my .. . . . . . . . . .. ... . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . .. . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . .. . . . . .. . . . . . .  . 
for the purpose of DNA banking and/ or analysis. 
In add ition I consent to my genetic material (DNA) being used for the 
development of genetic tests for the disorder carried by myself or my family 
and consent to my DNA being used for research purposes, provided th is 
research is approved by the appropriate Hospital Ethics Committee. 
I understand that not al l attempts to establ ish immortal cel l  l ines are 
successfu l ,  and that it may be necessary to give a further sample. If such 
attempts are successfu l ,  then I understand that; 
1) My genetic material w i l l  be avai lable for repeated analyses for an 
indef inite period of time. 
2) My genetic material wi l l  be used for d iagnostic purposes for myself and 
for such members of my family in whom it may be of use and who desire 
such a d iagnostic service. My genetic material may also be used for 
research. 
3) Trad itional principles of med ical confidential ity shal l apply. 
4) If the genetic test I require is not currently avai lable, my genetic 
material may be suppl ied to another col laborating agency, after 
d iscussion with you. 
The purpose and nature of the above-mentioned procedure has been explained 
to me. 
Signature .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . .. . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . .. . 
Dated .. . . . . . . . . . . .. . . . . . . . . . . .. . .. . . . . . . . . . . . . . . . . . . . . . . .. . .. . . . . . . . . . . . . . . . . . . . .. . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . .  . 
Witness declaration: 
I, . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . .. . . . . .. . .. . . . . .. . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . .  . 
Have read over and explained to the consenting party the purpose and nature 
of the above-mentioned procedure, who stated they understood and affixed 
their s ignature in my presence. 
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APPENDIX 14 
UVRAG Exon 15 coding sequence 
ttagctcagacctaagtatgctgttccctgtctctggatccagaaggcttacactgagttctgaagt 
ccaaagtaacttcttgtttttgtttctcttctagTGACAGACATCACACCTCCAGTGCAA 
TCCCTGTTCCTAAGAGACAAAGCTCCATATTTGGGGGTGCAGATGTAGGC 
TTCTCTGGGGGGATCCCTTCACCAGACAAAGGACATCGAAAACGGGCCAGC 
TCTGAGAATGAGAGACTTCAGTACAAAACCCCTCCTCCCAGTTACAACTC 
AGCATTAGCCCAGCCTGTGACCACCGTCCCCTCCATGGGAGAGACCGAGAG 
AAAGATAACATCTCTATCCTCCTCCTTGGATACCTCCTTGGACTTCTCCAA 
AGAAAACAAGAAAAAAGGAGAGGATCTAGTTGGCAGCTTAAACGGAGGC 
CACGCGAATGTGCACCCTAGCCAAGAACAAGGAGAAGCCCTCTCCGGGCAC 
CGGGCCACAGTCAATGGCACTCTCCTACCCAGCGAGCAGGCCGGGTCCGCCA 
GTGTCCAGCTTCCAGGCGAGTTCCACCCAGTCTCAGAAGCTGAGCTCTGCT 
GTACTGTGGAGCAAGCAGAAGAAATCATCGGGCTGGAAGCCACAGGTTTC 
GCCTCAGGTGATCAGCTAGAAGCATTTAACTGCATCCCAGTGGACAGTGC 
TGTGGCAGTAGAGTGTGACGAACAAGTTCTGGGAGAATTTGAAGAGTTC 
TCCCGAAGGATCTATGCACTGAATGAAAACGTATCCAGCTTCCGCCGGCCG 
CGCAGGAGTTCCGATAAGTGAAGTGAGCAGGTCAACAGTAGGACTGGGGC 
AGAAGCTCTGCCTAAAATGAAGTGAAAGCTGCACTTAACCCTTTGTGATA 
ATGATGACACAAAATGAATATTAATGGAGGATATTCCTCGGAAAAACAG 
ACTTTGGGAATGAAGGAGGGACTCAGGATCATTGTTATCAGTGGGCCAAA 
GTTAGATTTTGCTTTCAAGATTTGCTTTTCGGGCCTGATGATTTTAAAGC 
AAAAATCACCCTCTAGTTGAAAGAGCTTACAGCTCGAGTCACCTTTTAGC 
TATTTGTCTGCTTTTTATTTACCCTTGTATGTTATCCTCAGAGGGAAGAT 
GATAATATATAAATAATATAATGAACACACCCTTAGTTTCTCATAAGCA 
TTTGCCCTCACCATGGTTTATAAAACTTTGGGAAAACGGAATATTCAGAA 
ATAGGTTTCCGCCATGTACTGAAAGGTCTGTGGCCATCTGTGAGGTAGAT 
GAAGAAGCAGCATAGTGGTCTCCTTACATCTAGGCCTAACTGTCCCTCTTC 
CTGCCCCCGGGTACCACAGTCCACCTTTAGACCCTACTGTCGCCCCATCTTC 
TCCGTGGATGGGCCATGCGTCCTGAAAACAGGACATCAGATTCACTGGTT 
CTGTAACCCAGTAGCTGTGACGTTCCATCTCTTCTAACCAGCCATGGCCTT 
CCCCTCCTCTGCCATACCCTTAATGCGGCCCTCAGATTAGATGAAAAACTT 
GCTCCTGGTGGATCCCAAGGGACCCTCAAGGACCTCGAGGTTACTGCAGTC 
AGATGCCATCTCATCCCCTGTGGGGGCCAAAGTTTTTATGTGGGCAGATG 
CTGTGGTCAGGAACTAGGCATGCTTTCTGGCAATGCACTCACCAGACAAA 
AATCCCTTGATGTAAATCCCATGTTAATTTATTAAATTTCAGTCAGAAGG 
TCAGCATTTACATGACAGAATGTATGTAGAGAGTTGGGGTGTCTGGTAG 
GCAAACTGCAAGGCAGTTGAGATAGTTGGATTAAGAGGCTAGACGAGAC 
ATAGAATACTATTGGTATGTGTGCAATTTCATGAATATTAAATTATGTT 
TCGAAGTCCAGTTGTCATTCCCGCATTCAGATTTCATTTGCTGTTGCTTTA 
310 
TACGTTACGTACCCAAGGACATTGCCTCAGGGTTGCAAACTCTTTAAAGG 
AAAATTTATCCATATATCCATGTATTATATAGAAGAATAAAAATTGAGT 
TTACTTC 
Upper case depicts exonic sequence 
Lower case depicts 100 intronic bases prior to start of exon 
Adapted from the Draft Human Genome, UCSC, 2002 
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APPENDIX 15 
Identification of mouse genes homologous to candidate HFM genes on chromosome 
11  
Candidate gene Human Gene Mouse chromosome cM Mouse gene 
llq12-q13 COXB 19 Cox8a 
llq12-q13 EMK1 19 3 Emk 
llq13 STIP1 19 Stipl 
llq13 KCNK4 19 4.5 Kcnk4 
llq12 ESRRA 19 3 Esrra 
llqll-q13 RPS6KA4 19 Rsp6ka4 
11  MGC13045 19 Pygm 
llq13 NRXN2 19 Nrxn2 
llq13 RASGRP2 19 Rasgrp2 
llq12-q13.2 PYGM 19 2 Pygm 
llq13 MAP4K2 19 Map4k2 
llq13 MEN! 19 Menl 
llq13 EHD1 19 2 Ehdl 
llq13 Cllorf5 19 ORF6 
11  POLA2 19 Pola2 
llq13 REQ 19 2 Req 
llq12 LTBP3 19 2 Ltbp3 
llq13 DOC-1R 19 5830466O2 lRi k 
11cen-q12.1 CHK 19 3 Chk 
llq13.4 LRP5 19 Lrp5 
llq13 Cllorf23 19 9130026N02Rik 
llq13.2-q13.3 MTL5 19 Mtl5 
llq13.1-q13.2 CPT1A 19 Cptla 
llq13.2-q13.4 IGHMBP2 19 0 Ighmbp2 
llq13.3 FGF4 7 72.4 Fgf4 
llq13 CCND1 7 72.3 CcndI 
llq13.3 FADD 7 70 Fadd 
llq13 EMS! 13 31 Cttn 
llq13.2-q13.5 DHCR7 7 Dhcr 
llq13.3-q14.1 FOLR1 7 Folrl 
11q13.3-q13.5 FOLR2 7 Folr2 
llq23 INPPL1 Inppll 
llq13 CGI-52 Pctpl 
11 SKD3 Skd3 
313 
Candidate gene Human Gene Mouse chromosome cM Mouse gene 
11q13.5-q14.1 P2RY2 P2ry2 
11q13.5 NEU3 7 Neu 3 
11q13 ARRBl 7 50 Arrbl 
11 SERPINHl 7 Sepinhl 
11q13.5 SERPINH2 7 Serpinh2 
11q13.5 WNT1 1 7 48b Wntll 
11q13.5 PRKRIR 7 2900052810Rik 
11q13.5-q14 GARP 7 46 Garp 
11q14 CAPN5 7 Capn5 
11q13.5 MYO7A 7 48.1 Myo7a 
11q13-q14 PAKl 7 46.5 Pakl 
11q13.5-q14 CLNSlA 7 50 Clcni 
Bold case depicts candidate genes identified in this project 
Chromosome 11 candidate genes not listed in this table have no homologous mouse 
gene 
Adapted from uses Human-Mouse homology Map 
http:/ /www.ncbi.nlm.nih.gov/Homology/view.cgi?map=ucsc_mgd&chr=11&tax_id=9606&mode=text 
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APPENDIX 16 
Markers for chromosome 14 l inkage region 
[)14S1142 (92, 880, 607-92, 880, 769) 
SYNONYMNS -
PRIMERS - 5' TTGCAGGGAGTCAGGTGT ATG 
3' GCATCACACAGAGACACGGAT 
[)14S1143 (93,119,794-93,119, 956) 
SYNONYMS -
PRIMERS - 5' ATACATATATACGTATACACAT 
3' GT AAGCAATGAGCAATGATT 
GATA 168F06 (93, 507,497 -93, 507, 718) 
SYNONYMS - CHLC.GATA168F06.P66298, D14S1434 
PRIMERS - 5' ACAATTCCAGAAACTTCCCC 
3' ATCAGTGAGCCAA TTCCTTG 
[)14S987 (95,080, 876-95,081, 183) 
SYNONYMS - stCP4371, 28967, D14S987, AFM161yd12, 251047, 
RH31328, 161yd12, HS161YD12, STS3601, SHGC-20885, DBSTS:28967, 
DBSTS:46779, AFM161YD12 
PRIMERS - 5' ACCATATAGGGTGACGATGA 
3' AGCTGAACT ATTTT AATTCAATTGT 
[)14S65 (96, 108,679-96, 108, 841 & 96, 108,697-96, 108 ,847) 
SYNONYMS - D14S65, 538, RH73259, RH49006, SHGC-707, SU884, 
RH800, RH12952, 216553, AFM093yg5 
PRIMERS - 5' GCTCCACCCCCTAAAGATC 
3' TCAA TACACCCTGTGGAAAG 
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[)145267 (97, 711, 801-97, 712, 038 & 97, 711, 831-97, 712, 043) 
SYNONYMS - 263wh9, RH84477, rh53507, RH3660, HS263WH9, 
STS29598, RH85839, gdb: 199593, SHGC-1405, STS59558, 223865, 
D14S267, 1797, DBSTS: 1797, AFM263WH9, AFM263wh9, RH9623, 
RH15357 
PRIMERS - 5' TTAATGCCCACTGAA TGCT 
3' AAGGCAGCCCTGGTTT 
Above information was taken from ENSEMBL database (June 2002) 
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APPENDIX 17 
Chromatograms of genes sequenced on chromosome 1 1  
In order of presentation: 
Gene 
UVRAG 
UVRAG 
UVRAG 
UVRAG 
UVRAG 
CLNSJA 
CLNSJA 
CLNSJA 
CLNSJA 
CLNSJA 
GARP 
GARP 
GARP 
GARP 
Exon Sequence direction 
exon 4 forward sequence 
exon 6 reverse sequence 
exon 7 reverse sequence 
exon 8 forward sequence 
exon 10 forward sequence 
exon 1 forward sequence 
exon 4 forward sequence 
exon 4 reverse sequence 
exon 5 forward sequence 
exon 6 forward sequence 
exon 1 forward sequence 
exon 2 forward sequence 
exon 3(ii) forward sequence 
exon 3(v) reverse sequence 
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C 
: IB•6(42)R_ 
le: 6 42 R 
Run Ended: Jan 1 7, 2003, 19:34:57 
Lane: 18 Base s acin 10.03 
Signal G:8 1 A:359 T:198 C : 108 
854 bases in 1 0693 scans 
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10 20 30 4 0  50 60 7 0  8 0  
G N , G N T C T C " N G G  N N G N T  C N N 1<F>. T A A  T T T  A A T C i· C T G T G C T ' C ' tt T T T T G • C G C T T G C C T A A 
T , G C T T G ' T 
; C N G N N . G 
: r G · T c c  
G 
' - ,\ 
C T C 
' G G G C T ' " G ' ' G T T T C T T  
- G • G 
2 3 0  
T T G C G .= c • c G 
T T T G "l ' T ' ' C C C T G n - T T  -
T T G c · c · ' T T  " T C '\ ' ' T ' T G • c T C T G ' G T ' T 
,-. G T G T A T A T C T G C C  . ., T G T .., T ,- G .• C T T T  C 
' T C T G C G T G G N • "'  
321  
�o �o �o ½ 
' N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N  
23-7(42)R 
pie: JR 
T T N G C N 
Run Ended: Oct 29, 2002, 22:58 : 15  Signal G:145 A:388 T:290 C: 1 1 1  
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C 
1 0  
T T  C C . T T C C  C T T C C . N N  TG G G C • ' C G N C N 
4 0  
T C G 
50 
T C C C G  G G G C G C T , G T T G T T C T T C C G  G G G T G C T G C C  
: T C C , G G G C G  G G C G  N T G T G T T G C -, C G  C T T G C T G T G C T C C • C T G C T G 
C G G G " G G G C C T C G G C C G G T G G G '!' T C C T G G T C C C C ' G C G C T G G C C ! C 
G C T T T C T " G G  
N N N C N N  N N " 
C G G G G C G G C C T G G  
G C G GG G N N N T N  N T N  N N N C N N N N N N N  N N A 
500 510 
N T C N N rl N T  N T C T N  C C C N T C C 
Ao no 2n000 a o- o Oen so sS e rxcc a 
325 
N T N  N I  
c l3•CLN4 42F 
aple: CLN4 42F 
Run Ended: Sep 5, 2003, 7 : 1 9 :4 1  
Lane: 1 3  Base spacing 10.27 
Signal G: 139 A:20 1 T: 197 C: 1 36 
628 bases in 8 1 06 scans 
GC C G  N 
10 
T N TC C " 
2 0  30  40  50 
G T T T T G T T T C C C  G N GGG C G T T T T G T G T l\C C C ' T T ' 
c c � G T C C T G � G G  T G C., G G  T T C .-, G - T G , C T 
Comment: Rebecca Watt, ECU 
Page 1 of2 
60 7 0  8 0  
T T T T T T G C C T GG T G G T T C T T T T 
T " T G A T G T G G " - G C 
T T ' C 
T 
3 4 0  
; N N N N N N N N N N N N N N N N N N N N  N N N N N N N N N N N N N N N N N N N N N N C N N 
390  
N N N N N N N N N  N 
4 00 4 10 4 2 0  4 30 4 4 0  4 50 4 60 
N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N  N N N N N N N N N N N 
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I N N N N N N N N N N N N N N N N N N N N T  N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N T T T T T N N N C C C C N T T T 
Cao Gr a = = 
3 2 6  
e: 14•CLN4 42 R 
111 le: CLN4 42 R 
1 0  
Run Ended: Sep 5 ,  2003, 7: 1 9:4 1  
Lane: 1 4  Base s acin 1 0.24 
2 0  
240  2 60 
30 
Signal G:74 A: 1 57 T:1 38  C : 1 23 
767 bases in 9780 scans 
4 0  
Comment: Rebecca Watt, ECU 
P e 1 of2 
50 
A • C • • · c c c 0 c T r r ;. ,  � · r e c  
60 
T T T C C T 
7 0  
'< C C r T G T G C T T c c · c 
T T ' T G G G T A C C • • " C G C C ;. C G T A. T T T -, C " A ' T C T G C C A A. i-. T T G T • ;:; G ,.,, T C .' T C T T G 
8 0  
T C " 
G 
320 340 350 370 380 39 
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327 
03•CLN5(1 )  430 F Run Ended: Jun 25, 2003, 2 1 : 1 9:0 1 Signal G: 1 49 A: 1 99 T: 188 C:144 Comment: Rebecca Watt, ECU 
le: CLN5 I 430 F Lane: 3 Base s acin 10 .99 799 bases in 10076 scans P e 1 of2 
1 0  20  3 0  40 50 60 7 0  80 
T T  G T TNT  C N • • G G • T ; G TT C C T C C C ' TG TT TG G C  C ,; G G C T G G C G  G C T CCi T ! T A T T , T T G • T T C C • T T T T G T T T T T T C T 
; T T  G T 
C G T C  • G T G G  
C " G C , G " G G C C  C .- C ' C T G G  
· c G G G G G :i. c · r c c c r 
G " T T ' G " 
37 0 380  390  4 ,  
N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N  
4 1 0  420  4 3 0  4 4 0  4 50 4 60 4 7 0  
N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N �  
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N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N  
3 28 
t 14•CLN6 43F Run Ended: Jun 9, 2003, 22:03:33 
le:  CLN6 43F Lane: 14  Base s acin 1 0.32 
Signal G:44 A:64 T:72 C:49 
897 bases in 1 2975 scans 
Comment: Rebecca Watt, ECU 
P e 1 of2 
1 0  20  30  4 0  50 60 7 0  8 0  
; N N GC T N  T C r,r G C C T G T C T T C C C  T N T T C T A G G G � T T G C T C G T " A T T N T T T T T T N G T T T " G ' T G G G ' T G G P G G T G G  
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' T C ,O T G 'I. I\ ;\ T C ·. T T G .,. i-; ' T G T T T C T ' C T T T T T ' 
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C - T , ;,, A i-.  T A N N N N N C N N N N N  N N N N 
3 2 0  330  340  
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370  380  
N N N C N N N N  C N C C N N N  N T N N N T 
A tS> a:::, etnr:A'}, OtO-o-A 
3 9 0  ezG:::Oc:a::, 4 g0 Br:ooeve,c,cr:, 0 4r0 nC 1'>oO :Ac aAs:?cf AAr0» C C -<>no Gara AAac00 470 E>:C:irn-@ e, 
N N N C C  C C C N C N N N N C N N C C C C N N N N N T C N N N N N N C C N TN N N N N C N N N N N N N C F N N N  T C N N N C 
oa00 <>z<>:c>-- <>: azo A o CO 0 
450 460  470  
� N G N N N  C N T N  N N N N N N T N  N N N N N  N N N 
zC sCr: 
4 8 0  
C N T N N N 
02S c«OmtAr::r::c: Cc a 
4 90 
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0 :ra::5) C:GrtDRo 
C C C N N C 
500 51(  
N N N N N N N N T T C T 
-A G& = econ m cf?ttrC 7 & ace G:Zib o C 1bz of\& <7St:casco C C 
3 29 
e: 33•GARP142QF 
m le: G1 42F 
Run Ended: May 13 ,  2003, 2 1 :23 :42 
Lane: 33 Base s acin -9.00 
Signal G:366 A:507 T:457 C :2 1 8  
8 l l  bases in 1 0364 scans 
Comment: Rebecca Watt, ECU 
P e 1 of2 
10 20 30  40 so 60  70 80 9 0  
G G G T CNC T C G GGC C ,T " C TG TG GC T G T C TG C C C TG C T C C TG C G TG T G GG G G T C G T TG G C G G G C T T " G G G "G G ' G C C T T G T T TG G T 
JO l l 0  130  
G T G G G  c r T T T G C T T TG G ' G .;c · G " T G ' ' C T G G  
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3 4 0  350 360 370 
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470  4 8 0  4 90 500 510  520 530 540  550 
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3 30 
�: 1 8•GARP2 42F Run Ended: Jun 9, 2003, 22 :03 :33 Signal G:6 1 A:70 T:7 1 C:83 Comment: Rebecca Watt, ECU 
mple: GARP2 42F Lane: 1 8  Base spacing 1 0.25 838 bases in 10905 scans Page l of l 
10 2 0  30 4 0  50 60 7 0  8 0  90 100  110  1 2 0  130  1 4 0  
GG,T CTCICA,-;g:;; Ci" TTT a: MGGG ""G'IGG3GG: � i'G'.IGGS IVGG O:CG1GGGCT'I,>C,-"'GTGT1CCCCTTTCCTCTCa;ccTTFCACG l'GCCATG -Grc ar; t\'lCCTGCTGCTCCIGGCCCTGCTG ;cccT: - - .-- .--
J /I 
I 
I' , A \ ' \ I U\ \ 
150 1 6 0  170  1 8 0  1 9 0  200  2 1 0  2 2 0  2 3 0  2 4 0  2 50 2 6 0  270  2 8 0  
;(;CTGGC TGCrcAAC -ce,- 'G: CN.4,fGCCCTGT' " G  "'l'GGTA,"G ',TGCTCTGCCC.- G llC. ' GGGTGJ{ ;G/lCCiCCCCCACCTCCCTGCCCT ;:a;GTGTGCT
T
\GTGCCCC-GCCCC.-'G'V H'.:CnG "GTT, G, "& GrC.-
290 300  310 320 330 3 4 0  350 3 6 0  370  3 8 0  390  4 0 0  4 1 0  4 2 0  
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>stAn::::se Acts Dee z ct nee ca&CtOOo a o/OATO:cto- c t  a e -JtOsa s sra:a<>Oe:t:32':?::ca O e m o:Oaod 
570 580  590 600  6 1 0  620  6 3 0  6 4 0  650 6 6 0  670  6 8 0  6 · 
� T N  T 1NTCTNN T 'IO!"  NN'ITJG NNN NNC N N  C N NQ\1NNNNTNNN NNNN1NN N CNNNNNN '.ltGTNNIC TNTNN NC N C NNC C TN T T NC CN TNTN NC NTN N NN  N "N CNN C NTT N T  "N TNN N NNNN J  
t00Are0£z,QOS, rAOO>Drcc en, ,  :9crfrooA:o:nM co6>o ean0>0trfM«>cotfr:f¥ t:n6½ne& ct A:n12:ofueeeeexs>e'.)crA0ao ecOe,d- Ctr cc 
l 7 0 0  7 1 0  720  7 3 0  7 4 0  7 50 7 6 0  7 7 0  7 8 0  7 9 0  8 0 0  8 1 0  
1NNNNTNNTA NCNT-c G'IWNGTNT TNC C NI\NN'J C T N l-rr N N '!N.- -Jlfll GN '.NNN MNNCTN N7 NNNN NN!INT NW N T  NN TNNNN T !INN;NNT NNNNT NC - v_-; JIN N  C G  JlN>ITr N C CN T'JQ:;NN'I 
•mets oAcereattOtC9dn e::e::::?A::rt' Crc c a  a Va&c?O f¼t:n:rnO:-x?:e:e ta - re «Ac,a,eAz SE?:8:c-An s t:nn ,o +c:CS?:t::ertrC a ,m-:xfh:a, -0::eorr::st 
820 8 3 0  
J:N 'IN: N TNr NII TNNNW - N CC 
33 1  
:: 2 I •GARP 3(ii) 42F 
n le: GARP 3 ii 42F 
Run Ended: Oct 7, 2003, 22:03 :47 
Lane: 2 1  Base s acin 10 .40 
Signal G:63 A:92 T:69 C:77 
875 bases in 1 1 234 scans 
Comment: Rebecca Watt, ECU 
P e 1 of2 
10 2 0  30 40 so 
G N N C T G G T N CG , ,c • C.' TA N T T N C G N TG T G T N N C • T T G ' T T T TC C N N '\C N '\ N C T N  T 
90  100  
G G  T G N c ;, N - G C C T ' N " T T C .�. - c C C " N 
190  200  2 1 0  
6 0  
' C G G ' C C T T  G T G C T T T T C C T G C C T C A G T G � C T G G " " T 
7 0  
T T T C T T T T T G T G G C T N . 
' N C ' G G T G 
0 2 50 2 6 0  27 0  2 8 0  2 90 300 310  
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T C C T 
T T T  C 
C T T T G G G C T T T T C � G · .� G T G T " C !\ C "· C ,.. C C A •. T C C C C C A T T C C C C T C N C T C C " G G C T " A C T T  G T T C T T C T G T , G 
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G T T C N G G T T T T C C C G • C G G N N  C . T C C C : G C N G G T C C . N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N I 
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33 2  
�: 3 I •G3 (v) 42QR 
mple: G3 (v) 42QR 
10 
Run Ended: Jun 9, 2003, 22:03:33 Signal G:4 1 A:49 T:45 C:46 Comment: Rebecca Watt, ECU 
Lane: 3 1  Base spacing l0 .40 870 bases in l 0233 scans Page I of2 
20  30 40 50 60 70 80 
: C C G T G G  T C T C C N G G G N T T C N T ' ,,, A " T G N G TG G C G GC C A C G T G G C T C T G C P G C C T C T C T C C T • C C � G C T G G G  G 
C T T G T G C T C 
180 
T C T G ,,  C l\ G G T C ;; ,- C ' T T A T T C T C G G C T G T C C C T G G C T G 
40 250 260 270  280  290  300 310  
c c c · G T G C " G C C C G G G  G G G G G T C C C C  C T G " T G C G C i G G C G G C " G G G G T G T C C T G G G C T G T T T T 
320 330 3 4 0  350 360 370 380  390 
G "• C C ' G �. G T T C T G G G " T C C C G G  T C C T G T G T G ' C C T T G G T C G TC C T C C T C T T  C T C T G T T" C T C ' N G C T C C  CC C 
4 0 0  4 10 420  430  4 4 0  450  4 6 0  4 7 0  4 8 0  
T G CC T "\· G " G T G T C T C C C G G C T T C T T T  " G C T T T  T T  C T G T T G G T T  " C TT C TTG C C G G N G G ::." C G C ' N C C  · c · N GG C GG N C 
4 90 500 510 520 530 540  550 560 570 
G C C T TGG T T G GGG ' - N G T T GG C : N CC C " C T N T GG . G G T G G G  T G " " T G TTG " " G G G T N G TG T ? N T T C N " N T C C C  C C C C  
333 
l 
APPENDIX 18 
Exons sequenced in chromosome 11 HFM candidate 
genes 
334 
I 
APPENDIX 18 
Exons sequenced in chromosome 11 HFM candidate genes 
Sequence Results for UVRAG and ARIX 
Region UVRAG Region ARIX 
EXON 1 No variation EXON 1 non definitive 
EXON 2 No variation EXON 2 non definitive 
EXON 3 No variation EXON 3 non definitive 
EXON 4 No variation 
EXON 5 No variation 
EXON 6 No variation 
EXON 7 No variation 
EXON 8 No variation 
EXON 9 No variation 
EXON 10 No variation 
EXON 11  No variation 
EXON 12 No variation 
EXON 13 No variation 
EXON 14 No variation 
EXON 15(i) non definitive 
EXON 15(ii) non definitive 
EXON 15(iii) non definitive 
EXON 15(iv) non definitive 
l 335 
Table Sequence Results for CLNSJA and GARP 
Region CLNSJA Region GARP 
EXON 1 No variation EXON 1 No variation 
EXON 2 No variation EXON 2 No variation 
EXON 3 No variation EXON 3(i) No variation 
EXON 4 No variation EXON 3(ii) non definitive 
EXON 5 No variation EXON 3(i i i) non definitive 
EXON 6 No variation EXON 3(iv) No variation 
EXON 7(i) non definitive EXON 3(v) No variation 
EXON ?(i i) non definitive EXON 3(vi) No variation 
EXON 3(vii) No variation 
EXON 3(vi i i)  No variation 
336 
